

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2015281155 B2**

(54) Title
Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on NAE inhibitory effect

(51) International Patent Classification(s)
C07D 487/04 (2006.01) **A61P 43/00** (2006.01)
A61K 31/519 (2006.01) **C07D 519/00** (2006.01)
A61P 35/00 (2006.01)

(21) Application No: **2015281155** (22) Date of Filing: **2015.06.24**

(87) WIPO No: **WO15/199136**

(30) Priority Data

(31) Number	(32) Date	(33) Country
2014-129740	2014.06.24	JP
2015-024785	2015.02.10	JP

(43) Publication Date: **2015.12.30**

(44) Accepted Journal Date: **2017.07.13**

(71) Applicant(s)
Taiho Pharmaceutical Co., Ltd.

(72) Inventor(s)
Mizutani, Takashi;Yoshimura, Chihoko;Kondo, Hitomi;Kitade, Makoto;Ohkubo, Shuichi

(74) Agent / Attorney
Griffith Hack, GPO Box 1285, Melbourne, VIC, 3001, AU

(56) Related Art
JP 2008-530027 A
WO 2013/108809 A1

(12) 特許協力条約に基づいて公開された国際出願

(19) 世界知的所有権機関
国際事務局

(43) 国際公開日
2015 年 12 月 30 日(30.12.2015)



(10) 国際公開番号
WO 2015/199136 A1

- (51) 国際特許分類:
C07D 487/04 (2006.01) *A61P 43/00* (2006.01)
A61K 31/519 (2006.01) *C07D 519/00* (2006.01)
A61P 35/00 (2006.01)
- (21) 国際出願番号: PCT/JP2015/068218
- (22) 国際出願日: 2015 年 6 月 24 日(24.06.2015)
- (25) 国際出願の言語: 日本語
- (26) 国際公開の言語: 日本語
- (30) 優先権データ:
特願 2014-129740 2014 年 6 月 24 日(24.06.2014) JP
特願 2015-024785 2015 年 2 月 10 日(10.02.2015) JP
- (71) 出願人: 大鵬薬品工業株式会社(TAIHO PHARMACEUTICAL CO., LTD.) [JP/JP]; 〒1018444 東京都千代田区神田錦町 1 丁目 2 7 番地 Tokyo (JP).
- (72) 発明者: 水谷 尊志(MIZUTANI, Takashi); 〒3002611 茨城県つくば市大久保 3 番地 大鵬薬品工業株式会社内 Ibaraki (JP). 吉村 千穂子(YOSHIMURA, Chihoko); 〒3002611 茨城県つくば市大久保 3 番地 大鵬薬品工業株式会社内 Ibaraki (JP). 近藤 ひとみ(KONDO, Hitomi); 〒3002611 茨城県つくば市大久保 3 番地 大鵬薬品工業株式会社内 Ibaraki (JP). 北出 誠(KITADE, Makoto); 〒3670241 埼玉県児玉郡神川町元原 2 0

0-22 大鵬薬品工業株式会社内 Saitama (JP). 大久保 秀一(OHKUBO, Shuichi); 〒3002611 茨城県つくば市大久保 3 番地 大鵬薬品工業株式会社内 Ibaraki (JP).

(74) 代理人: 特許業務法人三枝国際特許事務所(SAE-GUSA & PARTNERS); 〒5410045 大阪府大阪市中央区道修町 1-7-1 北浜 T N K ビル Osaka (JP).


(81) 指定国 (表示のない限り、全ての種類の国内保護が可能): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) 指定国 (表示のない限り、全ての種類の広域保護が可能): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), ユーラシア (AM, AZ, BY, KG, KZ, RU, TJ, TM), ヨーロッパ (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC,

[続葉有]

(54) Title: NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT

(54) 発明の名称: 新規ピロロピリミジン化合物又はその塩、及びこれを含む医薬組成物、特に N A E 阻害作用に基づく腫瘍等の予防剤及び／又は治療剤



(A)

(57) Abstract: The problem to be solved by the present invention is to provide a novel pyrrolopyrimidine compound or a salt thereof having an NAE inhibitory effect as well as a cell growth-suppressing effect. The present invention provides a compound represented by general formula (A) or a salt thereof, and a NAE inhibitor, pharmaceutical composition, and antitumor agent having this compound or a salt thereof as an active ingredient.

(57) 要約: 本発明が解決すべき課題は、N A E 阻害作用を有し、且つ細胞増殖抑制効果を有する新規なピロロピリミジン化合物又はその塩を提供することである。本発明は、一般式 (A) で表される化合物又はその塩、当該化合物又はその塩を有効成分とする N A E 阻害剤、医薬組成物及び抗腫瘍剤を提供する。



MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 添付公開書類:
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, — 国際調査報告 (条約第 21 条(3))
KM, ML, MR, NE, SN, TD, TG).

DESCRIPTION

Title of Invention: NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT
THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY
AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE
5 INHIBITORY EFFECT

Technical Field

[0001]

Cross Reference to Related Applications

10 The present application claims priority to the
specification of Japan Patent Application No. 2014-129740 filed
on June 24, 2014, and the specification of Japan Patent
Application No. 2015-024785 filed on February 10, 2015 (the
entire disclosure of these specifications is incorporated in the
15 present specification by reference). The present invention
relates to a novel pyrrolopyrimidine compound or a salt thereof,
and a pharmaceutical composition comprising the pyrrolopyrimidine
compound, in particular, a prophylactic agent and/or a
therapeutic agent for tumors etc. based on an NAE inhibitory
20 action.

Background Art

[0002]

25 A protein group called ubiquitin-like protein (Ubl),
typified by ubiquitin, binds to corresponding activating enzyme
E1 and transferase E2 to be added to a target protein through a
covalent bond, thereby exerting influences on various
characteristics such as target enzyme activity, stability,
intracellular localization, and the like (Non-patent Document 1).

30 [0003]

Nedd8, a kind of Ubl, is activated by APPBP1-UBA3
heterodimer, which is a Nedd8-activating enzyme (NAE), in an ATP-
dependent manner. The activated Nedd8 is subsequently transferred
to E2 (Ubc12), and is then added to a series of target proteins
35 called cullin. It is called neddylation that Nedd8 is conjugated

to a target protein. The neddylation with respect to cullin promotes the activity (ability to add ubiquitin to a ligase substrate) of cullin-RING ligases (CRL), which function by forming a complex with cullin family protein and adaptor protein.

5 The protein group ubiquitinated by CRL is degraded in the proteasome. Many proteins are known as CRL substrates that regulate cell cycles and conduct intracellular signal transduction, and that are reported to be decreased expression in tumors; examples of such proteins include p27, p21, and
10 phosphorylated I κ -B (Non-patent Documents 2 and 3). More specifically, NAE contributes to tumor cell growth and survival by facilitating ubiquitination and degradation by proteasome of the CRL substrate protein group through Nedd8 activation.
[0004]

15 Because of the physiological function of NAE, an NAE inhibitor has a characteristic property of simultaneously affecting a plurality of signaling pathways involved in the survival and growth of tumors. Thus, NAE inhibitors are expected to serve as a therapeutic agent having broad and effective
20 antitumor actions. N-[(1S)-1-indanyl]-7-[(1R)-3 α -hydroxy-4 α -(sulfamoyloxymethyl)cyclopentyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (hereinafter referred to as "MLN4924") and the like have been known as a compound that inhibits the Nedd8-activating function of NAE (Patent Document 1). MLN4924 is a compound having
25 a pyrrolopyrimidine skeleton, and is characterized by having a substituted amino group at 4-position. MLN4924 causes accumulation of the CRL substrate protein group through neddylation inhibition, thereby inducing cell growth arrest and apoptosis (Non-patent Document 4). Currently, the development of
30 MLN4924 as an antitumor agent has been advanced (Patent Document 2); and, in addition to the use of MLN4924 alone, tests using a combination of MLN4924 and other various anticancer drugs have also been conducted (Non-patent Documents 5 and 6). However, a great deal of the MLN4924 administered is transferred to red
35 blood cells in the blood; thus, an issue of decrease in plasma

concentration from the concentration required for ensuring the original medicinal effects of MLN4924 has been identified (Non-patent Document 6). Further, since MLN4924 inhibits carbonic anhydrase II, which is highly expressed even in normal organs, such as red blood cells, kidneys, brain, and eyes, there is a concern that MLN4924 induces side effects, specifically, electrolyte abnormality, hypotonia bulbi, metabolic acidosis, polyuria, urinary calculus, and dysesthesia (Non-patent Document 8). Under such circumstances, a new NAE inhibitor that ensures NAE inhibitory activity, but that has a smaller carbonic anhydrase II inhibitory effect, has been desired.

Citation List

Patent Documents

[0005]

Patent Document 1: International Publication No. WO2006084281

Patent Document 2: International Publication No. WO2012061551

Non-patent Documents

[0006]

Non-patent Document 1: Nature Rev Mol Cell Biol, 2009, 10 (5): 319-31.

Non-patent Document 2: Genes & Cancer, 2010; 1 (7): 690-699

Non-patent Document 3: Journal of Cellular Physiology, 2000, 183, 10-17

Non-patent Document 4: Nature, 2009, 9; 458 (7239): 732-6

Non-patent Document 5: Mol Cancer Ther, 2014, 13 (6): 1625-1635

Non-patent Document 6: Mol Cancer Ther, 2012, 11 (4): 942-951

Non-patent Document 7: 9th International ISSX Meeting Abstract, p. 108

Non-patent Document 8: Israel Medical Association Journal, 2003, 5, April, 260-263

Summary of Invention

Technical Problem

[0007]


It would be advantageous to provide a novel pyrrolopyrimidine compound or a salt thereof having NAE inhibitory action, a cell growth inhibitory effect, and attenuated carbonic anhydrase II inhibitory activity. It would also be advantageous to provide a pharmaceutical preparation useful for preventing and/or treating NAE-related diseases, particularly tumors, based on its NAE inhibitory action.

Solution to Problem

[0008]

The present inventors conducted extensive research on compounds having an NAE inhibitory action, and found that a novel compound represented by Formula (A) below, which is characterized by comprising a vinylene group, an ethynylene group, an arylene group, or a heteroarylene group at 5-position (R_3 in Formula (A)) of the pyrrolopyrimidine skeleton, or a salt thereof, has superior NAE inhibitory action as well as a superior cell growth inhibitory effect against tumor cell lines. The inventors further found that the compound or a salt thereof has attenuated carbonic anhydrase II inhibitory activity. With these findings, the inventors completed the present invention.

[0009]



[0010]

wherein:

[0011]

5

[0012]

is a single bond or a double bond;

X is -O-, -CH₂-, or -CH=;

Y is -NH- or -O-;

10

R₁ is hydrogen, fluorine, a hydroxy group, a cyano group, or an amino group;

R₂ is hydrogen, fluorine, a hydroxy group, a cyano group, or an amino group;

15 R₃ is a vinylene group, an ethynylene group, a C₆-C₁₄ arylene group, or a monocyclic or bicyclic heteroarylene group having at least one heteroatom selected from the group consisting of N, S and O;

R₄ is a bond, a methylene group, or a C₃-C₇ cycloalkylidene group;

20

R₅ is a C₃-C₇ saturated cycloalkyl group that may have one or more R₆, a C₆-C₁₀ unsaturated cycloalkyl group that may have one or more R₆, or a monocyclic or bicyclic unsaturated

heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more R₆;

R₆ is

- 5 halogen,
- a hydroxy group,
- a cyano group,
- a C1-C6 alkyl group that may have one or more phenoxy group as a substituent,
- 10 a carbamoyl group,
- a C1-C6 alkoxy carbonyl group,
- a monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S and O,
- 15 a monocyclic or bicyclic saturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have, one or more of either halogen, hydroxy group, carboxyl group, or C1-C6 alkyl group, as a substituent,
- 20 an amino group,
- a mono- or di-(C1-C4 alkyl) amino group that may have one or more hydroxy group or phenyl group as a substituent,
- a C1-C6 alkoxy group that may have one or more of either halogen, C3-C7 saturated cycloalkyl group, or monocyclic or bicyclic
- 25 unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S and O as a substituent,
- a benzyloxy group that may have one or more carbamoyl group as a substituent,
- a C1-C6 alkylthio group,
- 30 a C1-C6 alkylsulfonyl group, or
- an aminosulfonyl group,

when two or more R₆ are present, the plurality of R₆ may be the same or different.

35 Advantageous Effects of Invention

[0013]

The present invention provides a novel compound or a salt thereof represented by Formula (A) above. The novel compound is useful as an NAE inhibitor.

5 [0014]


It was clarified that the compound of the present invention or a salt thereof has superior NAE inhibitory activity, and inhibits growth of tumor cells. Further, since the carbonic anhydrase II inhibitory activity of the compound of the present invention or a salt thereof is attenuated, the effect of the decrease in plasma concentration due to the transfer to the red blood cells will not occur. Therefore, the compound of the present invention or a salt thereof is significantly useful as an agent for preventing and/or treating Tumors.

15 [0014a]

The present invention as claimed herein is described in the following Items 1 to 14:

[Item 1]

20 A compound or a salt thereof, represented by Formula (A) below:



wherein:

=====

is a single bond or a double bond;

X is -O-, -CH₂-, or -CH=;

5 Y is -NH- or -O-;

R₁ is hydrogen, fluorine, a hydroxy group, a cyano group, or an amino group;

R₂ is hydrogen, fluorine, a hydroxy group, a cyano group, or an amino group;

10 R₃ is a vinylene group, an ethynylene group, a C₆-C₁₄ arylene group, or a monocyclic or bicyclic heteroarylene group having at least one heteroatom selected from the group consisting of N, S, and O;

R₄ is a bond, a methylene group, or a C₃-C₇ cycloalkylidene group;

R₅ is a C₃-C₇ saturated cycloalkyl group that may have one or more R₆, a C₆-C₁₀ unsaturated cycloalkyl group that may have one or more R₆, or a monocyclic or bicyclic unsaturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more R₆;

R₆ is
halogen,
a hydroxy group,
25 a cyano group,
a C₁-C₆ alkyl group that may have one or more phenoxy group as a substituent,
a carbamoyl group,
a C₁-C₆ alkoxycarbonyl group,
30 a monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S, and O,
a monocyclic or bicyclic saturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of

N, S, and O, and that may have one or more of either halogen, hydroxy group, carboxyl group, or C1-C6 alkyl group as a substituent,

an amino group,

5 a mono- or di-(C1-C4 alkyl) amino group that may have one or more hydroxy group or phenyl group as a substituent,

a C1-C6 alkoxy group that may have one or more of either halogen, C3-C7 saturated cycloalkyl group, or monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom

10 selected from the group consisting of N, S, and O as a substituent,

a benzyloxy group that may have one or more carbamoyl group as a substituent,

a C1-C6 alkylthio group,

15 a C1-C6 alkylsulfonyl group, or
an aminosulfonyl group,

when two or more R_6 are present, the plurality of R_6 may be the same or different.

20 [Item 2]

The compound or a salt thereof according to Item 1, wherein in Formula (A), R_1 is hydrogen, fluorine, or a hydroxy group;

R_2 is hydrogen, fluorine, or a hydroxy group; and

25 R_3 is an ethynylene group, or a monocyclic or bicyclic heteroarylene group having 1 to 4 of at least one kind of heteroatom selected from the group consisting of N, S, and O.

[Item 3]

30 The compound or a salt thereof according to Item 1 or 2, wherein in Formula (A), R_1 is a hydroxy group;

R_2 is hydrogen or a hydroxy group;

R_3 is an ethynylene group, or a monocyclic heteroarylene group having 2 of at least one kind of heteroatom
35 selected from the group consisting of N, S and O;

R₅ is a C3-C7 saturated cycloalkyl group that may have one or more R₆, a C6-C10 unsaturated cycloalkyl group that may have one or more R₆, or a monocyclic or bicyclic unsaturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more R₆; and

R₆ is halogen; a hydroxy group; a cyano group; a C1-C6 alkyl group that may have one or more phenoxy group as a substituent; a carbamoyl group; a C1-C6 alkoxy carbonyl group; a monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S and O; a monocyclic or bicyclic saturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more of either halogen, hydroxy group, carboxyl group, or C1-C6 alkyl group as a substituent; an amino group; a mono- or di-(C1-C4 alkyl) amino group that may have one or more hydroxy group or phenyl group as a substituent; a C1-C6 alkoxy group that may have one or more of either halogen, C3-C7 saturated cycloalkyl group, or monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S, and O as a substituent; a benzyloxy group that may have one or more carbamoyl group as a substituent; a C1-C4 alkylthio group; a C1-C4 alkylsulfonyl group; or an aminosulfonyl group (when two or more R₆ are present, the plurality of R₆ may be the same or different).

[Item 4]

A compound or a salt thereof according to any one of Items 1 to 3, wherein, in Formula (A), R₁ is a hydroxy group; R₂ is hydrogen or a hydroxy group; R₃ is an ethynylene group, or a monocyclic heteroarylene group having 2 of at least one kind of heteroatom selected from the group consisting of N, S and O;

R_5 is a C3-C7 saturated cycloalkyl group that may have one or more R_6 ; a C6-C10 unsaturated cycloalkyl group that may have one or more R_6 , or a monocyclic or bicyclic unsaturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more R_6 ; and

R_6 is fluorine; chlorine; a hydroxy group; a cyano group; a C1-C6 alkyl group that may have one or more phenoxy group as a substituent; a carbamoyl group; a C1-C6 alkoxy carbonyl group; a pyridinyl group; an azetidiny group; a hydroxy azetidiny group; a thiomorpholinyl group; a dioxide thiomorpholinyl group; a methyl piperazinyl group; a hydroxy piperidinyl group; an oxopiperidinyl group; a piperidinyl group; a hydroxy pyrrolidinyl group; an oxopyrrolidinyl group; a pyrrolidinyl group; a carboxyl pyrrolidinyl group; a fluoro pyrrolidinyl group; a morpholinyl group; a 9-oxa-3-azabicyclo[3.3.1]nonan-3-yl group; a 3-oxa-8-azabicyclo[3.2.1]octan-8-yl group; an amino group; a methylamino group; an ethylamino group; an isopropylamino group; a hydroxyethylamino group; a dimethylamino group; a phenyl methylamino group; a C1-C6 alkoxy group that may have one or more of either halogen, C3-C7 saturated cycloalkyl group, or monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S, and O as a substituent; a benzyloxy group that may have one or more carbamoyl group as a substituent; a C1-C4 alkylthio group; a C1-C4 alkylsulfonyl group; or an aminosulfonyl group (when two or more R_6 are present, the plurality of R_6 may be the same or different).

[Item 5]

A compound or a salt thereof according to Items 1 to 4, wherein, in Formula (A), R_1 is a hydroxy group;

R_2 is a hydroxy group;

R_3 is an ethynylene group;

R₄ is a bond;

R₅ is a C₆-C₁₀ unsaturated cycloalkyl group that may have one or more R₆; or a monocyclic or bicyclic unsaturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more R₆; and

R₆ is fluorine; chlorine; a hydroxy group; a cyano group; a methyl group; a 3-fluoro pyrrolidinyl group; a morpholinyl group; a thiomorpholinyl group; a 3-hydroxy azetidiny group; an azetidiny group; an amino group; a N-methylamino group; a C₁-C₆ alkoxy group that may have one or more of either halogen or C₃-C₇ saturated cycloalkyl group as a substituent; or a C₁-C₄ alkylthio group (when two or more R₆ are present, the plurality of R₆ may be the same or different).

[Item 6]

A compound or a salt thereof according to Items 1 to 5, wherein in Formula (A), Y is -NH-;

R₁ is a hydroxy group;

R₂ is a hydroxy group;

R₃ is an ethynylene group;

R₄ is a bond;

R₅ is a phenyl group or a naphthyl group that may have one or more R₆; or a monocyclic or bicyclic unsaturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S and O, and that may have one or more R₆;

R₆ is fluorine; a methyl group; a 3-fluoro pyrrolidinyl; a 3-hydroxy azetidiny; azetidiny; an amino group; a N-methylamino group; a C₁-C₆ alkoxy group that may have one or more cyclopropyl group; or a C₁-C₄ alkylthio group (when two or more R₆ are present, the plurality of R₆ may be the same or different).

[Item 7]

The compound or a salt thereof according to any one of Items 1 to 6, wherein the compound or a salt thereof is at least one member selected from the group consisting of: 4-amino-5-[2-

5 (2,6-difluoro phenyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine;

4-amino-5-[2-(4-amino-2,6-difluoro-phenyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
10 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine;

4-amino-5-[2-[2,6-difluoro-4-(methylamino)phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
15 d]pyrimidine;

4-amino-5-[2-[2,6-difluoro-4-[(3R)-3-fluoro pyrrolidin-1-yl]phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
d]pyrimidine;

20 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-ethoxy-4,6-difluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;

4-amino-5-[2-[2,6-difluoro-4-(3-hydroxy azetidin-1-yl)phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
25 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine;

4-amino-5-[2-[4-(azetidin-1-yl)-2,6-difluoro-phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
30 d]pyrimidine;

4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-ethoxy-6-fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;

4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-fluoro-6-
 propoxy-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
 8-[2-[4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
 5 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
 d]pyrimidin-5-yl]ethynyl]-7-fluoro-4-methyl-2,3-dihydro-1,4-
 benzoxazine;
 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-
 10 ethylsulfanyl-6-fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
 4-amino-5-[2-[2-(cyclopropyl methoxy)-6-fluoro-phenyl]ethynyl]-7-
 [(2R,3R,4S,5R)-3,4-dihydroxy-5-
 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
 d]pyrimidine;
 15 4-amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
 [(sulfamoylamino)methyl]cyclopentyl]-5-[2-(2-fluoro-6-
 methylsulfanyl-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
 8-[2-[4-amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
 [(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidin-5-
 20 yl]ethynyl]-7-fluoro-4-methyl-2,3-dihydro-1,4-benzoxazine;
 4-amino-7-[(1R,4R,5S)-4,5-dihydroxy-3-
 [(sulfamoylamino)methyl]cyclopent-2-en-1-yl]-5-[2-(2-ethoxy-6-
 fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine; and
 4-amino-7-[(1R,4R,5S)-4,5-dihydroxy-3-
 25 [(sulfamoylamino)methyl]cyclopent-2-en-1-yl]-5-[2-(2-fluoro-6-
 methylsulfanyl-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine; and salts
 of these compounds.

[Item 8]

30 An NAE inhibitor comprising the compound or a salt
 thereof according to any one of Items 1 to 7, as an active
 ingredient.

[Item 9]

A pharmaceutical composition comprising the compound or a salt thereof according to any one of Items 1 to 7.

5 [Item 10]

An antitumor agent comprising the compound or a salt thereof according to any one of Items 1 to 7.

[Item 11]

10 A method of inhibiting NAE in a patient comprising administering the compound or a salt thereof according to any one of Items 1 to 7 to the patient.

[Item 12]

15 Use of the compound or a salt thereof according to any one of Items 1 to 7 in the preparation of a medicament for inhibiting NAE.

[Item 13]

20 A method for preventing or treating a tumor by inhibiting NAE in a patient comprising administering the compound or a salt thereof according to any one of Items 1 to 7 to the patient.

25 [Item 14]

Use of the compound or a salt thereof according to any one of Items 1 to 7 in the preparation of a medicament for preventing or treating a tumor by inhibiting NAE.

30 Brief Description of Drawings

[0015]

Fig. 1 shows the growth inhibitory effects of the compound obtained in Example 1 on HCT-116.

35 Fig. 2 shows the body weight change caused by the compound obtained in Example 1.

Fig. 3 shows the growth inhibitory effects of the compound obtained in Example 55 on HCT-116.

Fig. 4 shows the body weight change caused by the compound obtained in Example 55.

5 Fig. 5 shows the growth inhibitory effects of the compound obtained in Examples 122 and 64 on CCRF-CEM.

Fig. 6 shows the body weight change caused by the compound obtained in Examples 122 and 64.

10 Description of Embodiments

[0016]

The groups in the composition represented by Formula (A) are described below.

[0017]

15

In Formula (A), the "C6-C14 arylene group" represented by R₃ is a monocyclic or polycyclic bivalent aromatic hydrocarbon group having 6 to 14 carbon atoms. More specifically, examples of C6-C14 arylene group include phenylene group, naphthylene group, and tetrahydronaphthylene group. A phenylene group or naphthylene group is preferable.

[0018]

In Formula (A), "a monocyclic or bicyclic heteroarylene group having at least one heteroatom selected from the group consisting of N, S and O" represented by R₃ is a monocyclic or bicyclic heteroarylene group having 1 to 3 of at least one kind of heteroatom selected from the group consisting of N, S and O. Examples include thiazolylenegroup, pyrazolylenegroup, imidazolylenegroup, thienylenegroup, furylenegroup, pyrrolylenegroup, oxazolylenegroup, isoxazolylenegroup, isothiazolylenegroup, thiadiazolylenegroup, triazolylenegroup, tetrazolylenegroup, pyridylenegroup, pyrazolylenegroup, pyrimidinylengroup, pyridazinylengroup, indolylenegroup, isoindolylenegroup, indazolylenegroup, triazolopyridilengroup, benzimidazolilengroup, benzoxazolylenegroup, benzothiazolylenegroup, benzothienylenegroup, benzofuranylenegroup, purinylenegroup, quinolylenegroup, isoquinolylenegroup, quinazolinylengroup, quinoxalylenegroup, methylenedioxy phenylenegroup, ethylenedioxy phenylenegroup, dihydro benzofuranylenegroup, benzoxazinylengroup, dihydrobenzoxazinylengroup, chromanylenegroup, thiochromanylenegroup, 1,1-dioxythiochromanylenegroup, dihydro benzothienylenegroup, and 1,1-dioxydihydro benzothienylenegroup. Preferable examples include a monocyclic heteroarylene group having 1 to 3 of at least one kind of heteroatom selected from the group consisting of N, S, and O. More preferable examples include a monocyclic 5-membered heteroarylene group having 1 or 2 of at least one kind of heteroatom selected from the group consisting of N, S, and O. Particularly preferable examples include thiazolylenegroup, pyrazolylenegroup, imidazolylenegroup, thienylenegroup, and



oxazolylenes group.

[0019]

In Formula (A), the "C3-C7 cycloalkylidene group" is a monocyclic saturated alkylidene group having 3 to 7 carbon atoms.

5 Examples include the compounds below.

[0020]



10 .

[0021]

Preferable examples include a cyclopropylidene group.

[0022]

15 In the present specification, the "cycloalkyl group" refers to a saturated or unsaturated monovalent cyclic hydrocarbon group. Unless otherwise specified, the term "cycloalkyl" encompasses a monocyclic cycloalkyl, and a polycyclic cycloalkyl such as bicyclic or tricyclic cycloalkyl.

[0023]

20 In the present specification, the "heterocycloalkyl group" refers to a saturated or unsaturated monovalent heterocyclic group. Unless otherwise specified, the term "heterocycloalkyl" encompasses a monocyclic heterocycloalkyl, and a polycyclic heterocycloalkyl such as bicyclic or tricyclic
25 heterocycloalkyl.

[0024]

In Formula (A), the C3-C7 saturated cycloalkyl group

of the "C3-C7 saturated cycloalkyl group that may have one or more R₆" represented by R₅ refers to a cyclic saturated hydrocarbon group having 3 to 7 carbon atoms. Examples include cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, and cycloheptyl group. Preferable examples

[0025]

In Formula (A), the C6-C10 unsaturated cycloalkyl group of the "C6-C10 unsaturated cycloalkyl group that may have one or more R₆" represented by R₅ is a monocyclic or bicyclic unsaturated hydrocarbon group having 6 to 10 carbon atoms. Examples include phenyl group, naphthyl group, tetrahydronaphthyl group, and 2,3-dihydroindenyl group. Preferable examples include phenyl group, naphthyl group, and 2,3-dihydroindenyl group.

[0026]

In Formula (A), examples of the monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S, and O of the "monocyclic or bicyclic unsaturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more R₆" represented by R₅ include hexamethyleneimino group, imidazolyl group, thienyl group, furyl group, pyrrolyl group, oxazolyl group, isooxazolyl group, thiazolyl group, isothiazolyl group, pyrazolyl group, triazolyl group, tetrazolyl group, pyridyl group, pyrazyl group, pyrimidinyl group, pyridazinyl group, indolyl group, isoindolyl group, indazolyl group, methylenedioxy phenyl group, ethylene dioxyphenyl group, benzofuranyl group, dihydro benzofuranyl group, benzimidazolyl group, benzooxazolyl group, benzothiazolyl group, purinyl group, quinolyl group, isoquinolyl group, quinazolinyl group, quinoxalinyl group, 1H-pyrazolo[4,3-b]pyridin-5-yl group, 2,3-dihydro-1,4-benzoxazino group, 1,1-dioxo-3,4-dihydro-2H-thiochromen-8-yl group, 2,3-dihydro benzothiophen-7-yl group, and 1,1-dioxo-2,3-dihydro benzothiophen-7-yl group. Preferable examples include a monocyclic or bicyclic 5 to 10-membered

unsaturated heterocycloalkyl group having 1 to 3 of at least one kind of heteroatom selected from the group consisting of N, S, and O. More preferable examples include thienyl group, pyridyl group, pyrazyl group, quinolyl group, isoquinolyl group, 1H-pyrazolo[4,3-b]pyridin-5-yl group, 2,3-dihydro-1,4-benzoxazino group, 1,1-dioxo-3,4-dihydro-2H-thiochromen-8-yl group, 2,3-dihydro benzothiophen-7-yl group, and 1,1-dioxo-2,3-dihydro benzothiophen-7-yl group.

[0027]

10 In Formula (A), examples of the "halogen" represented by R₆ include fluorine, chlorine, bromine, and iodine. Preferable examples include fluorine and chlorine.

[0028]

15 In Formula (A), the C1-C6 alkyl group of the "C1-C6 alkyl group that may have one or more phenoxy group as a substituent" represented by R₆ refers to a linear or branched alkyl group having 1 to 6 carbon atoms. Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl. Methyl is preferable.

20 [0029]

 In Formula (A), the C1-C6 alkoxy group of the "C1-C6 alkoxy group that may have one or more of either halogen, C3-C7 saturated cycloalkyl group, or monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S, and O as a substituent" represented by R₆ refers to a linear or branched alkoxy group having 1 to 6 carbon atoms. Examples include methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butoxy group, isobutoxy group, and tert-butoxy group. Methoxy group, ethoxy group, n-propoxy group, and isopropoxy group are preferable.

[0030]

 In Formula (A), the halogen of the "C1-C6 alkoxy group that may have one or more of either halogen, C3-C7 saturated cycloalkyl group, or monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected

35

from the group consisting of N, S, and O as a substituent" represented by R₆ refers to the halogens listed above, and is preferably fluorine. The number of substituted halogens is 1 to 3, preferably 2 or 3.

5 [0031]

In Formula (A), the C3-C7 saturated cycloalkyl group of the "C1-C6 alkoxy group that may have one or more of either halogen, C3-C7 saturated cycloalkyl group, or monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one
10 heteroatom selected from the group consisting of N, S, and O, as a substituent" represented by R₆ refers to a saturated cycloalkyl group having 3 to 7 carbon atoms. Examples include cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, and cycloheptyl group. Cyclopropyl group is preferable. The number
15 of substituted saturated cycloalkyl groups is preferably 1.

[0032]

In Formula (A), the monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S, and O of the "C1-C6 alkoxy
20 group that may have one or more of either halogen, C3-C7 saturated cycloalkyl group, or monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S, and O, as a substituent" represented by R₆ refers to the unsaturated heterocycloalkyl group
25 described above. Preferable examples include a monocyclic unsaturated heterocycloalkyl group having 1 to 3 of at least one kind of heteroatom selected from the group consisting of N, S, and O. More preferable examples include a monocyclic 5 or 6-membered unsaturated heterocycloalkyl group having 1 or 2 of at
30 least one kind of heteroatom selected from the group consisting of N, S, and O. Particularly preferable examples include pyrazolyl group, triazolyl group, and pyridyl group. The number of substituted unsaturated heterocycloalkyl groups is preferably
1.

35 [0033]

In Formula (A), preferable examples of the "C1-C6 alkoxy group that may have one or more of either halogen, C3-C7 saturated cycloalkyl group, or monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S, and O, as a substituent" represented by R₆ include methoxy group, difluoro methoxy group, trifluoro methoxy group, cyclopropyl methoxy group, 3-pyridyl methoxy group, pyrazol-1-ylmethoxy group, ethoxy group, 2,2,2-trifluoro ethoxy group, n-propoxy group, and isopropoxy group.

10 [0034]

In Formula (A), preferable examples of the "benzyloxy group that may have one or more carbamoyl groups as a substituent" represented by R₆ include benzyloxy group, and 3-carbamoyl benzyloxy group.

15 [0035]

In Formula (A), the mono- or di-(C1-C4 alkyl) amino group of the "mono- or di-(C1-C4 alkyl) amino group that may have one or more hydroxy group or phenyl group as a substituent" represented by R₆ refers to, among the above C1-C6 alkyl groups, an amino group monosubstituted or disubstituted with a C1-C4 alkyl group. Examples include methylamino group, ethylamino group, diethylamino group, methylethylamino group, isopropylamino group, cyclobutylmethylamino group, and dimethylamino group. Preferably examples include methylamino group, ethylamino group, dimethylamino group, and isopropylamino group.

20
25
[0036]

In Formula (A), the "mono- or di-(C1-C4 alkyl) amino group that may have one or more hydroxy group or phenyl group as a substituent" represented by R₆ is preferably methylamino group, ethylamino group, isopropylamino group, hydroxyethylamino group, dimethylamino group, or phenylmethylamino group (benzylamino group).

30
[0037]

In Formula (A), the "C1-C6 alkoxy carbonyl group"

represented by R₆ refers to a carbonyl group substituted with the above alkoxy group. Examples include methoxycarbonyl group, ethoxycarbonyl group, n-propoxycarbonyl group, isopropoxycarbonyl group, 1-methylpropoxycarbonyl group, n-butoxycarbonyl group, isobutoxycarbonyl group, tert-butoxycarbonyl group, 2-methyl-butoxycarbonyl group, neopentyloxycarbonyl group, and pentan-2-yloxycarbonyl group. Methoxycarbonyl group is preferable.

[0038]

In Formula (A), the "monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S, and O" represented by R₆ refers to the unsaturated heterocycloalkyl group described above, preferably a monocyclic 5 or 6-membered unsaturated heterocycloalkyl group having 1 or 2 of at least one kind of heteroatom selected from the group consisting of N, S and O, and more preferably pyridyl group.

[0039]

In Formula (A), examples of the monocyclic or bicyclic saturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O of the "monocyclic or bicyclic saturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more of either halogen, hydroxy group, carboxyl group or C1-C6 alkyl group as a substituent" represented by R₆ include azetidiny group, pyrrolidinyl group, piperidinyl group, 2-oxo-1-pyrrolidinyl group, 4-oxo-1-piperidinyl group, piperazinyl group, hexamethyleneimino group, morpholino group, thiomorpholino group, 1,1-dioxo-thiomorpholino group, homopiperazinyl group, tetrahydrofuranyl group, tetrahydropyranyl group, 9-oxa-3-azabicyclo[3.3.1]nonan-3-yl group, and 3-oxa-8-azabicyclo[3.2.1]octan-8-yl group. Preferable examples include a monocyclic or bicyclic 5 to 10-membered saturated heterocycloalkyl group having 1 to 4 of at least one kind of heteroatom selected from the group consisting of N, S, and O. More preferable examples include azetidiny group,

pyrrolidinyl group, piperidinyl group, piperazinyl group, 2-oxo-1-pyrrolidinyl group, 4-oxo-1-piperidinyl group, morpholino group, thiomorpholino group, 1,1-dioxo-thiomorpholino group, 9-oxa-3-azabicyclo[3.3.1]nonan-3-yl group, and 3-oxa-8-azabicyclo[3.2.1]octan-8-yl group.
[0040]

In Formula (A), the halogen of the "monocyclic or bicyclic saturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more of either halogen, hydroxy group, carboxyl group or C1-C6 alkyl group as a substituent" represented by R₆ refers to the halogen listed above, preferably fluorine, chlorine, etc., and more preferably fluorine.
[0041]

In Formula (A), examples of the C1-C6 alkyl group of the "monocyclic or bicyclic saturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more of either halogen, hydroxy group, carboxyl group or C1-C6 alkyl group as a substituent" represented by R₆ include, among the above alkyl groups, an alkyl group having 1 to 6 carbon atoms, preferably a methyl group.
[0042]

In Formula (A), preferable examples of the "monocyclic or bicyclic saturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more of either halogen, hydroxy group, carboxyl group or C1-C6 alkyl group as a substituent" represented by R₆ include azetidiny group, 3-hydroxy azetidin-1-yl group, pyrrolidinyl group, 3-fluoropyrrolidin-1-yl group, 3-hydroxy pyrrolidin-1-yl group, 3-carboxy-1-pyrrolidin-1-yl group, piperidinyl group, 4-oxo-1-piperidinyl group, 3-hydroxy-1-piperidinyl group, piperazinyl group, 4-methyl piperazin-1-yl group, 4-oxo-1-piperidinyl group, morpholino group, thiomorpholino group, 1,1-dioxo-thiomorpholino group, 9-oxa-3-

azabicyclo[3.3.1]nonan-3-yl group, and 3-oxa-8-azabicyclo[3.2.1]octan-8-yl group.

[0043]

In Formula (A), the "C1-C6 alkylthio group" represented by R₆ refers to a thio group having the above C1-C6 alkyl group, preferably a C1-C4 alkylthio group, more preferably a methylthio group or an ethylthio group.

[0044]

In Formula (A), the "C1-C6 alkylsulfonyl group" represented by R₆ refers to a sulfonyl group having the above C1-C6 alkyl group, preferably a C1-C4 alkylsulfonyl group, more preferably a methyl sulfonyl group or an ethyl sulfonyl group.

[0045]

Y in Formula (A) is -NH- or -O-, preferably -NH-.

[0046]

R₁ in Formula (A) is hydrogen, fluorine, a hydroxy group, a cyano group or an amino group, preferably hydrogen, fluorine or a hydroxy group, further preferably a hydroxy group.

[0047]

R₂ in Formula (A) is hydrogen, fluorine, a hydroxy group, a cyano group or an amino group, preferably hydrogen, fluorine, or a hydroxy group, further preferably hydrogen or a hydroxy group, particularly preferably a hydroxy group.

[0048]

R₃ in Formula (A) is preferably an ethynylene group, or a monocyclic heteroarylene group having 2 of at least one kind of heteroatom selected from the group consisting of N, S, and O, more preferably an ethynylene group.

[0049]

R₄ in Formula (A) is preferably a bond.

[0050]

R₅ in Formula (A) is preferably a C3-C7 saturated cycloalkyl group that may have one or more R₆, a C6-C10 unsaturated cycloalkyl group that may have one or more R₆, or a monocyclic or bicyclic unsaturated heterocycloalkyl group that

has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more R₆.

More preferably, R₅ is a phenyl group or a naphthyl group that may be substituted with one or more R₆, or a monocyclic
5 or bicyclic unsaturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S and O, and that may have one or more R₆.

Further preferably, R₅ is a unsaturated heterocycloalkyl group or a phenyl group that may be substituted
10 with one or more R₆, particularly preferably a phenyl group, thienyl group, pyridyl group, pyrazyl group, quinolyl group, isoquinolyl group, 1H-pyrazolo[4,3-b]pyridin-5-yl group, 2,3-dihydro-1,4-benzoxazino group, 1,1-dioxo-3,4-dihydro-2H-thiochromen-8-yl group, 2,3-dihydro benzothiophen-7-yl group, or
15 1,1-dioxo-2,3-dihydro benzothiophen-7-yl group that may be substituted with one or more R₆.

[0051]

When R₅ is an unsaturated heterocycloalkyl group, R₅ is preferably a 2,3-dihydro-1,4-benzoxazinyl group, a 3,4-dihydro-
20 2H-thiochromen-8-yl group, a 2,3-dihydro benzothiophen-7-yl group or the like, more preferably a 2,3-dihydro-1,4-benzoxazinyl group. The unsaturated heterocycloalkyl groups listed above may be substituted with one or more R₆.

[0052]

25 When R₅ has R₆, the number of R₆ is, for example, 1 to 5, preferably 1 to 3.

[0053]

When R₅ has one or more R₆, R₆ is one of:

- (i-1) halogen,
- 30 (i-2) hydroxy group,
- (i-3) cyano group,
- (i-4) C1-C6 alkyl group that may have one or more phenoxy group as a substituent,
- (i-5) carbamoyl group,
- 35 (i-6) C1-C6 alkoxycarbonyl group,

(i-7) monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S, and O,

(i-8) monocyclic or bicyclic saturated heterocycloalkyl group
5 that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more of either halogen, hydroxy group, carboxyl group, or C1-C6 alkyl group as a substituent,

(i-9) amino group,

10 (i-10) mono- or di-(C1-C4 alkyl) amino group that may have one or more hydroxy group or phenyl group as a substituent,

(i-11) C1-6 alkoxy group that may have one or more of either halogen, C3-C7 saturated cycloalkyl group, or monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one
15 heteroatom selected from the group consisting of N, S, and O as a substituent,

(i-12) benzyloxy group that may have one or more carbamoyl group as a substituent,

(i-13) C1-C6 alkylthio group,

20 (i-14) C1-C6 alkylsulfonyl group,

(i-15) aminosulfonyl group.

[0054]

When R₅ has one or more R₆, R₆ in Formula (A) is more preferably one of:

25 (ii-1) halogen,

(ii-2) hydroxy group,

(ii-3) cyano group,

(ii-4) C1-C6 alkyl group that may have one or more phenoxy group as a substituent,

30 (ii-5) carbamoyl group,

(ii-6) C1-C6 alkoxy carbonyl group,

(ii-7) monocyclic 5 or 6-membered unsaturated heterocycloalkyl group having 1 or 2 of at least one kind of heteroatom selected from the group consisting of N, S, and O,

35 (ii-8) monocyclic or bicyclic 5 to 10-membered saturated

heterocycloalkyl group that has 1 to 4 of at least one kind of heteroatom selected from the group consisting of N, S, and O, and that may have one or more of either halogen, hydroxy group, carboxyl group, or C1-C6 alkyl group as a substituent,

5 (ii-9) amino group,

(ii-10) mono- or di-(C1-C4 alkyl) amino group that may have one or more hydroxy group or phenyl group, as a substituent,

(ii-11) C1-6 alkoxy group that may have one or more of either halogen, C3-C7 saturated cycloalkyl group, or monocyclic or

10 bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S, and O as a substituent,

(ii-12) benzyloxy group that may have one or more carbamoyl group as a substituent

15 (ii-13) C1-C4 alkylthio group,

(ii-14) C1-C4 alkylsulfonyl group, or

(ii-15) aminosulfonyl group.

[0055]

When R₅ has one or more R₆, R₆ in Formula (A) is more preferably one of:

(iii-1) fluorine, chlorine

(iii-2) hydroxy group,

(iii-3) cyano group,

25 (iii-4) C1-C6 alkyl group that may have one or more phenoxy group as a substituent,

(iii-5) carbamoyl group,

(iii-6) C1-C6 alkoxycarbonyl group,

(iii-7) pyridinyl group,

(iii-8) azetidiny group, hydroxy azetidiny group,

30 thiomorpholinyl group, dioxide thiomorpholinyl group, methyl piperazinyl group, hydroxy piperidinyl group, oxopiperidinyl group, piperidinyl group, hydroxy pyrrolidinyl group,

oxopyrrolidinyl group, pyrrolidinyl group, carboxyl pyrrolidinyl group, fluoro pyrrolidinyl group, morpholinyl group, 9-oxa-3-

35 azabicyclo[3.3.1]nonan-3-yl group, 3-oxa-8-

azabicyclo[3.2.1]octan-8-yl group,

(iii-9) amino group,

(iii-10) methylamino group, ethylamino group, isopropylamino group, hydroxyethylamino group, dimethylamino group, phenyl

5 methylamino group,

(iii-11) C1-C6 alkoxy group that may have one or more of either halogen, C3-C7 saturated cycloalkyl group, or monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S, and O as a
10 substituent,

(iii-12) benzyloxy group that may have one or more carbamoyl group as a substituent

(iii-13) C1-C4 alkylthio group,

(iii-14) C1-C4 alkylsulfonyl group, or

15 (iii-15) aminosulfonyl group.

[0056]

When R₅ has one or more R₆, R₆ in Formula (A) is more preferably one of:

(iv-1) fluorine, chlorine

20 (iv-2) hydroxy group,

(iv-3) cyano group,

(iv-4) methyl group,

(iv-7) 3-fluoro pyrrolidinyl group, morpholinyl group, thiomorpholinyl group, 3-hydroxy azetidiny group, azetidiny
25 group,

(iv-9) amino group,

(iv-10) methylamino group,

(iv-11) C1-C6 alkoxy group that may have one or more of either halogen or C3-C7 saturated cycloalkyl group as a substituent, or

30 (iv-13) C1-C4 alkylthio group.

[0057]

When R₅ has one or more R₆, R₆ in Formula (A) is more preferably one of:

(v-1) fluorine,

35 (v-4) methyl group,

(v-7) saturated heterocycloalkyl group selected from the group consisting of 3-fluoro pyrrolidinyl, 3-hydroxy azetidiny, and azetidiny,

(v-9) amino group,

5 (v-10) methylamino group,

(v-11) C1-C6 alkoxy group that may have one or more cyclopropyl group, or

(v-13) C1-C4 alkylthio group.

[0058]

10 When two or more R_6 are present, the plurality of R_6 may be the same or different.

[0059]

The compound represented by Formula (A) is preferably a compound having high enzyme inhibitory activity against NAE
15 that can generally be tested by a known method, more preferably, a compound such that the concentration (IC_{50}) of the compound by which 50% of the enzyme can be inhibited is 0.03 μM or less, further preferably a compound having an IC_{50} of 0.01 μM or less, particularly preferably a compound having an IC_{50} of 0.003 μM or
20 less.

[0060]

The compound represented by Formula (A) is preferably a compound having high tumor growth inhibitory activity that can generally be tested by a known method, more preferably, a
25 compound such that the concentration (IC_{50}) of the compound by which 50% of tumor growth can be inhibited is 0.01 μM or less, particularly preferably a compound having an IC_{50} of 0.003 μM or less.

[0061]

30 The compound represented by Formula (A) is preferably a compound having a weak enzyme inhibitory activity against carbonic anhydrase II, and said activity can generally be tested by a known method. More preferably, the compound represented by Formula (A) is such that the concentration (IC_{50}) of the compound
35 by which 50% of the enzyme is inhibited is 0.03 μM or more,

further preferably a compound having an IC₅₀ of 0.1 µM or more, further more preferably a compound having an IC₅₀ of 0.3 µM or more, and particular preferably a compound having IC₅₀ of 1.0 µM or more.

5 [0062]

Further preferable examples of the compound of the present invention include a compound wherein in Formula (A),

R₁ is hydrogen, fluorine, or a hydroxy group;

R₂ is hydrogen, fluorine, or a hydroxy group; and

10 R₃ is an ethynylene group, or a monocyclic or bicyclic heteroarylene group having 1 to 4 of at least one kind of heteroatom selected from the group consisting of N, S, and O, or a salt thereof.

[0063]

15 Further preferable examples of the compound of the present invention include a compound wherein in Formula (A),

R₁ is a hydroxy group;

R₂ is hydrogen or a hydroxy group;

20 R₃ is an ethynylene group, or a monocyclic heteroarylene group having 2 of at least one kind of heteroatom selected from the group consisting of N, S and O;

R₅ is a C3-C7 saturated cycloalkyl group that may have one or more R₆; a C6-C10 unsaturated cycloalkyl group that may have one or more R₆; or a monocyclic or bicyclic unsaturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S and O, and that may be substituted with one or more R₆;

25 R₆ is
halogen,
30 a hydroxy group,
a cyano group,
a C1-C6 alkyl group that may have one or more phenoxy group as a substituent,

a carbamoyl group,
35 a C1-C6 alkoxy carbonyl group,

a monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S and O,

a monocyclic or bicyclic saturated heterocycloalkyl group that

5 has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more of either halogen, hydroxy group, carboxyl group, or C1-C6 alkyl group as a substituent,

an amino group,

10 a mono- or di-(C1-C4 alkyl) amino group that may have one or more hydroxy group or phenyl group,

a C1-6 alkoxy group that may have, as a substituent, one or more of either halogen, C3-C7 saturated cycloalkyl group, or

monocyclic or bicyclic unsaturated heterocycloalkyl group having
15 at least one heteroatom selected from the group consisting of N, S, and O as a substituent,,

a benzyloxy group that may have one or more carbamoyl group as a substituent,

a C1-C4 alkylthio group,

20 a C1-C4 alkylsulfonyl group, or
an aminosulfonyl group,

(when two or more R₆ are present, the plurality of R₆ may be the same or different), or a salt thereof.

[0064]

25 Further preferable examples of the compound of the present invention include a compound wherein, in Formula (A), R₁ is a hydroxy group;

R₂ is hydrogen or a hydroxy group;

R₃ is an ethynylene group, or a monocyclic heteroarylene group

30 having 2 of at least one kind of heteroatom selected from the group consisting of N, S, and O;

R₅ is a C3-C7 saturated cycloalkyl group that may have one or more R₆; a C6-C10 unsaturated cycloalkyl group that may have one or more R₆; or a monocyclic or bicyclic unsaturated heterocycloalkyl

35 group that has at least one heteroatom selected from the group

consisting of N, S, and O, and that may have one or more R₆;
R₆ is fluorine, chlorine, a hydroxy group, a cyano group,
a C1-C6 alkyl group that may have one or more phenoxy group as a
substituent,

- 5 a carbamoyl group, a C1-C6 alkoxy carbonyl group,
a pyridinyl group that may have at least one substituent selected
from the group consisting of halogen, hydroxy group, and C1-C4
alkyl group,
a saturated heterocycloalkyl group selected from the group
10 consisting of azetidiny l group, hydroxy azetidiny l group,
thiomorpholinyl group, dioxide thiomorpholinyl group, methyl
piperazinyl group, hydroxy piperidinyl group, oxopiperidinyl
group, piperidinyl group, hydroxy pyrrolidinyl group,
oxopyrrolidinyl group, pyrrolidinyl group, carboxyl pyrrolidinyl
15 group, fluoro pyrrolidinyl group and morpholinyl group,
amino group, methylamino group, ethylamino group, isopropylamino
group, hydroxyethylamino group, dimethylamino group, phenyl
methylamino group,
9-oxa-3-azabicyclo[3.3.1]nonan-3-yl group,
20 3-oxa-8-azabicyclo[3.2.1]octan-8-yl group,
a C1-C6 alkoxy group that may have one or more of either halogen,
C3-C7 saturated cycloalkyl group, or monocyclic or bicyclic
unsaturated heterocycloalkyl group having at least one heteroatom
selected from the group consisting of N, S, and O, as a
25 substituent,
a benzyloxy group that may have one or more carbamoyl group as a
substituent,
a C1-C4 alkylthio group,
a C1-C4 alkylsulfonyl group, or
30 an aminosulfonyl group
(when two or more R₆ are present, the plurality of R₆ may be the
same or different), or a salt thereof.

[0065]

Further preferable examples of the compound of the
35 present invention include a compound wherein in Formula (A),

R₁ is a hydroxy group;

R₂ is a hydroxy group;

R₃ is an ethynylene group;

R₄ is a bond;

5 R₅ is a C₆-C₁₀ unsaturated cycloalkyl group that may have one or more R₆, or

a monocyclic or bicyclic unsaturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S and O, and that may have one or more R₆; and

10 R₆ is

fluorine,

chlorine,

a hydroxy group,

a cyano group,

15 a methyl group,

a 3-fluoro pyrrolidinyl group,

a morpholinyl group,

a thiomorpholinyl group,

a 3-hydroxy azetidiny group,

20 an azetidiny group,

an amino group,

a methylamino group,

a C₁-C₆ alkoxy group that may have one or more of either halogen, C₃-C₇ saturated cycloalkyl group, or

25 a C₁-C₄ alkylthio group as a substituent

(when two or more R₆ are present, the plurality of R₆ may be the same or different), or a salt thereof.

[0066]

Further preferable examples of the compound of the
30 present invention include a compound wherein, in Formula (A), Y is -NH-;

R₁ is a hydroxy group;

R₂ is a hydroxy group;

R₃ is an ethynylene group;

35 R₄ is a bond;

R₅ is a phenyl group or a naphthyl group having one or more R₆, or a monocyclic or bicyclic unsaturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more R₆; and R₆ is

- 5 fluorine,
 a methyl group,
 3-fluoro pyrrolidinyl,
 3-hydroxy azetidiny,
 azetidiny,
10 an amino group,
 a methylamino group,
 a C1-C6 alkoxy group that may have a cyclopropyl group, or
 a C1-C4 alkylthio group
 (when two or more R₆ are present, the plurality of R₆ may be the
15 same or different), or a salt thereof.
 [0067]

Specifically, preferable examples of the compound of the present invention include:

- 4-amino-5-[2-(2,6-difluoro phenyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-
20 dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-
 yl]pyrrolo[2,3-d]pyrimidine;
4-amino-5-[2-(4-amino-2,6-difluoro-phenyl)ethynyl]-7-
 [(2R,3R,4S,5R)-3,4-dihydroxy-5-
 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
25 d]pyrimidine;
4-amino-5-[2-[2,6-difluoro-4-(methylamino)phenyl]ethynyl]-7-
 [(2R,3R,4S,5R)-3,4-dihydroxy-5-
 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
30 d]pyrimidine;
4-amino-5-[2-[2,6-difluoro-4-[(3R)-3-fluoro pyrrolidin-1-
 yl]phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
 d]pyrimidine;
4-[4-[2-[4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
35 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-

d]pyrimidin-5-yl]ethynyl]-3-ethoxy-5-fluoro-phenyl]morpholine;
4-amino-7-[(2R, 3R, 4S, 5R) -3, 4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-ethoxy-4, 6-
difluoro-phenyl)ethynyl]pyrrolo[2, 3-d]pyrimidine;
5 4-[4-[2-[4-amino-7-[(2R, 3R, 4S, 5R) -3, 4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2, 3-
d]pyrimidin-5-yl]ethynyl]-3, 5-difluoro-phenyl]thio morpholine;
4-amino-5-[2-[2, 6-difluoro-4-(3-hydroxy azetidin-1-
yl)phenyl]ethynyl]-7-[(2R, 3R, 4S, 5R) -3, 4-dihydroxy-5-
10 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2, 3-
d]pyrimidine;
4-amino-5-[2-[4-(azetidin-1-yl)-2, 6-difluoro-phenyl]ethynyl]-7-
[(1R, 2S, 3R, 4R) -2, 3-dihydroxy-4-
[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2, 3-d]pyrimidine;
15 4-amino-7-[(2R, 3R, 4S, 5R) -3, 4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-ethoxy-6-
fluoro-phenyl)ethynyl]pyrrolo[2, 3-d]pyrimidine;
4-amino-7-[(2R, 3R, 4S, 5R) -3, 4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-fluoro-6-
20 propoxy-phenyl)ethynyl]pyrrolo[2, 3-d]pyrimidine;
4-amino-7-[(2R, 3R, 4S, 5R) -3, 4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-[2-fluoro-6-
(2, 2, 2-trifluoro ethoxy)phenyl]ethynyl]pyrrolo[2, 3-d]pyrimidine;
8-[2-[4-amino-7-[(2R, 3R, 4S, 5R) -3, 4-dihydroxy-5-
25 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2, 3-
d]pyrimidin-5-yl]ethynyl]-7-fluoro-4-methyl-2, 3-dihydro-1, 4-
benzoxazine;
4-amino-7-[(2R, 3R, 4S, 5R) -3, 4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-
30 ethylsulfanyl-6-fluoro-phenyl)ethynyl]pyrrolo[2, 3-d]pyrimidine;
4-amino-5-[2-[2-(cyclopropyl methoxy)-6-fluoro-phenyl]ethynyl]-7-
[(2R, 3R, 4S, 5R) -3, 4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2, 3-
d]pyrimidine;
35 4-amino-7-[(1R, 2S, 3R, 4R) -2, 3-dihydroxy-4-

[(sulfamoylamino)methyl]cyclopentyl]-5-[2-(2-ethoxy-6-fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
4-amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
[(sulfamoylamino)methyl]cyclopentyl]-5-[2-(2-fluoro-6-
5 methylsulfanyl-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
8-[2-[4-amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-7-fluoro-4-methyl-2,3-dihydro-1,4-benzoxazine;
4-amino-7-[(1R,4R,5S)-4,5-dihydroxy-3-
10 [(sulfamoylamino)methyl]cyclopent-2-en-1-yl]-5-[2-(2-ethoxy-6-fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
4-amino-7-[(1R,4R,5S)-4,5-dihydroxy-3-
[(sulfamoylamino)methyl]cyclopent-2-en-1-yl]-5-[2-(2-fluoro-6-methylsulfanyl-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
15 [(2R,3S,4R,5R)-5-[4-amino-5-[2-(2,6-difluoro phenyl)ethynyl]pyrrolo[2,3-d]pyrimidin-7-yl]-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl sulfamate; and salts of these compounds,
further preferably,
20 4-amino-5-[2-(2,6-difluoro phenyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine;
4-amino-5-[2-(4-amino-2,6-difluoro-phenyl)ethynyl]-7-
[(2R,3R,4S,5R)-3,4-dihydroxy-5-
25 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine;
4-amino-5-[2-[2,6-difluoro-4-(methylamino)phenyl]ethynyl]-7-
[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
30 d]pyrimidine;
4-amino-5-[2-[2,6-difluoro-4-[(3R)-3-fluoro pyrrolidin-1-yl]phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
d]pyrimidine;
35 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-

[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-ethoxy-4,6-difluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
4-amino-5-[2-[2,6-difluoro-4-(3-hydroxy azetidin-1-yl)phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
5 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine;
4-amino-5-[2-[4-(azetidin-1-yl)-2,6-difluoro-phenyl]ethynyl]-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidine;
10 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-ethoxy-6-fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-fluoro-6-
15 propoxy-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
8-[2-[4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-7-fluoro-4-methyl-2,3-dihydro-1,4-benzoxazine;
20 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-ethylsulfanyl-6-fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
4-amino-5-[2-[2-(cyclopropyl methoxy)-6-fluoro-phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine;
25 4-amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
[(sulfamoylamino)methyl]cyclopentyl]-5-[2-(2-fluoro-6-methylsulfanyl-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
8-[2-[4-amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-7-fluoro-4-methyl-2,3-dihydro-1,4-benzoxazine;
4-amino-7-[(1R,4R,5S)-4,5-dihydroxy-3-
[(sulfamoylamino)methyl]cyclopent-2-en-1-yl]-5-[2-(2-ethoxy-6-
35 fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;

4-amino-7-[(1R,4R,5S)-4,5-dihydroxy-3-
[(sulfamoylamino)methyl]cyclopent-2-en-1-yl]-5-[2-(2-fluoro-6-
methylsulfanyl-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine; and salts
of these compounds.

5 [0068]


The method for producing the compound of the present
invention is described below.

The compounds of the present invention may be produced,
for example, through the production methods below or the methods
10 described in the Examples. However, the method for producing the
compounds of the present invention is not limited to these
reaction examples.

[0069]

Production Method A

15 [0070]



[0071]

In the formula, Z¹ and Z² are the same or different,
and each represents hydrogen, fluorine, a hydroxy group, an amino
20 group, a cyano group or a protector thereof.

P₁ is a protecting group of an amino group.

R₃ represents a vinylene group, an ethynylene group, a C6-C14
arylene group, or a monocyclic or bicyclic heteroarylene group
having at least one heteroatom selected from the group consisting
25 of N, S, and O.

R₄ represents a single bond, a methylene group, or a C3-C7

cycloalkylidene.

R₅ is a C3-C7 saturated cycloalkyl group that may be substituted with one or more R₆;

a C6-C10 unsaturated cycloalkyl group that may be substituted

5 with one or more R₆; or

a monocyclic or bicyclic unsaturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, O, and that may be substituted with one or more R₆.

R₆ is

10 halogen;

a hydroxy group;

a cyano group;

a C1-C6 alkyl group that may have one or more phenoxy group as a substituent;

15 a carbamoyl group, a C1-C6 alkoxy carbonyl group;

a C4-C7 unsaturated cycloalkyl group that may have one or more of either halogen, hydroxy group, C1-C4 alkyl group, or carbamoyl group as a substituent;

a monocyclic or bicyclic unsaturated heterocycloalkyl group

20 having at least one heteroatom selected from the group consisting of N, S, and O;

a monocyclic or bicyclic saturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more of either halogen,

25 hydroxy group, oxo group, carboxyl group, dioxide group, or C1-C6 alkyl group as a substituent;

an amino group;

a mono- or di-(C1-C4 alkyl) amino group that may have one or more hydroxy group or phenyl group as a substituent;

30 a C1-C6 alkoxy group having one or more of either halogen, C3-C7 saturated cycloalkyl group, or monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S, and O as a substituent;

35 a benzyloxy group that may have one or more carbamoyl group as a substituent;

a C1-C4 alkylthio group;
a C1-C4 alkylsulfonyl group; or
an aminosulfonyl group.

when two or more R_6 are present, the plurality of R_6
5 may be the same or different.

[0072]



[0073]

represents -O-, -CH₂- or =CH.


10 Step 1

This step produces Compound (2) using a compound
represented by Formula (1) (in this specification, the compound
represented by Formula (1) may be simply referred to as Compound
(1); similarly, compounds represented by Formulas 2 to 30 may be
15 simply referred to as Compounds (2) to (30)) as a raw material,
through a Mitsunobu reaction using a nitrogen nucleophile, and a
subsequent deprotection reaction.

[0074]

In Compound (1), when Z^1 and/or Z^2 represents a
20 protector of a hydroxy group, examples of the protector include
dimethyl acetal group, benzylidene acetal group, benzoyl group,
and tert-butyl dimethyl silyloxy group. Z^1 and Z^2 may form the
structure below, or the like,

[0075]



25

[0076]

(wherein R_a are the same or different, and each
represents hydrogen, methyl, ethyl, phenyl, cyclohexyl or

cyclopentyl)

together with the carbon atoms bound thereto. Examples of
nitrogen nucleophile include phthalimide. When phthalimide is
5 used as a nitrogen nucleophile, the amount of phthalimide used is
1 to 10 moles, preferably 1 to 5 moles, per mole of Compound (1).
[0077]

The Mitsunobu reaction can generally be performed by a
known method, such as, for example, the method described in
10 Synthesis, p. 1 (1981); or a similar method.
[0078]

Examples of azodicarboxylic acid esters used for the
Mitsunobu reaction include diethyl azodicarboxylate and
diisopropyl azodicarboxylate. Such an azodicarboxylic acid ester
15 can be used in an amount of 1 to 10 moles, and preferably 1 to 5
moles, per mole of Compound (1).
[0079]

Examples of phosphine compounds used in the Mitsunobu
reaction include triphenylphosphine and tributylphosphine, and
20 the amount of phosphine compound used is 1 to 10 moles,
preferably 1 to 5 moles, per mole of Compound (1).
[0080]

Examples of the solvent include tetrahydrofuran, 1,2-
dimethoxyethane, 1,4-dioxane, toluene, N,N-dimethyl formamide,
25 N,N-dimethylacetamide, dimethyl sulfoxide, and N-
methylpyrrolidin-2-one. These solvents may be used alone, or in a
mixture. The reaction time ranges from 0.1 to 100 hours,
preferably 0.1 to 24 hours. The reaction temperature ranges from
0°C to the boiling temperature of the solvent, preferably 0°C to
30 100°C. The removal of the protecting group of a nitrogen
nucleophile can generally be performed by a known method, such as
the method described in Protective Groups in Organic Synthesis,
T.W. Greene, John Wiley & Sons (1981); or a similar method.
[0081]

35 The removal of the phthalimide group can be performed

by using an isolated phthalimide intermediate or by directly using the Mitsunobu reaction solution, with hydrazine, hydroxylamine, methylamine, ethylamine, n-butylamine, etc., as a deprotection reagent. The amount of the deprotection reagent is typically an equimolar to excessive molar amount per mole of Compound (1).

[0082]

Examples of the solvent include alcohol solvents (ethanol, methanol, etc.), acetonitrile, dichloromethane, chloroform, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and N-methylpyrrolidin-2-one. These solvents may be used alone, or in a mixture. The reaction time ranges from 0.1 to 100 hours, preferably 0.1 to 24 hours. The reaction temperature ranges from 0°C to the boiling temperature of the solvent, preferably 0°C to 100°C.

[0083]

Step 2

This step produces Compound (3) by reacting a sulfamoyl-introducing reagent with Compound (2).

[0084]

The sulfamoyl-introducing reagent can be obtained from commercial suppliers, or can be produced through a known method using, for example, sulfamoyl chloride, 1-aza-4-azoniabicyclo [2.2.2]octane -4-ylsulphonyl(tert-butoxycarbonyl)azanide or the like. The amount of the sulfamoyl-introducing reagent used is 1 to 10 moles, preferably 1 to 5 moles, per mole of Compound (2).

[0085]

Examples of the protecting group of an amino group include C1-C6 alkyl group, tert-butoxycarbonyl group, benzyloxycarbonyl group, acetyl group, and propionyl group.

[0086]

Examples of bases include triethylamine, diisopropylethylamine, pyridine, imidazole, and DBU. When a base is used, the amount of the base is generally 1 to 30 moles,

preferably 1 to 10 moles, per mole of Compound (2).

[0087]

Examples of the solvent include acetonitrile, dichloromethane, chloroform, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, toluene, N,N-dimethyl formamide, N,N-dimethylacetamide, and N-methylpyrrolidin-2-one. These solvents may be used alone, or in a mixture. The reaction time ranges from 0.1 to 100 hours, preferably 0.1 to 24 hours. The reaction temperature ranges from 0°C to the boiling temperature of the solvent, and preferably from 0°C to 100°C.

[0088]

Step 3

Using Compound (3) as a raw material, this step produces Compound (4) through a coupling reaction (Sonogashira coupling, Suzuki-Miyaura coupling, etc.). This step may be performed through multiple steps as necessary, and may suitably be combined with a protection reaction, a deprotection reaction.

[0089]

For example, among various Compounds (4), a compound in which R₃ has an alkynylene group may be obtained through a coupling (Sonogashira) reaction, using Compound (3) and a compound: H-C≡C-R₄-R₅ (wherein R₄ and R₅ are as defined above).

[0090]

In this case, the compound: H-C≡C-R₄-R₅ (wherein R₄ and R₅ are as defined above) can be obtained from commercial suppliers, or can be produced through a known method. The amount of this compound is 1 to 10 mole, preferably 1 to 3 mole, per mole of Compound (3).

[0091]

This step can generally be performed by a known method, for example, the method disclosed in Chemical Reviews, Vol. 107, p. 874 (2007). For example, this step can be performed in the presence of a transition metal catalyst and a base in a solvent that does not adversely affect the reaction.

[0092]

Examples of transition metal catalyst usable in this step include palladium catalysts (e.g., palladium acetate, tris(dibenzylideneacetone)dipalladium, 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride-dichloromethane complex, etc.). As necessary, a ligand (e.g., triphenylphosphine, tri-tert-butylphosphine, etc.) is added, and a copper reagent (e.g., copper iodide, copper acetate, etc.) is used as a cocatalyst. The amount of the transition metal catalyst varies depending on the type of catalyst. For example, the amount of the transition metal catalyst used is generally 0.0001 to 1 mole, preferably 0.01 to 0.5 moles, per mole of Compound (4). The amount of the ligand used is generally 0.0001 to 4 moles, preferably 0.01 to 2 moles, per mole of Compound (4). The amount of the cocatalyst used is generally 0.0001 to 4 moles, preferably 0.001 to 2 moles, per mole of Compound (4).
[0093]

Further, a base may be added during the above reaction as necessary. Examples of bases include organic bases such as triethylamine, diisopropylethylamine, pyridine, lutidine, collidine, 4-dimethylaminopyridine, potassium tert-butyrate, sodium tert-butyrate, sodium methoxide, sodium ethoxide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, or butyl lithium; and inorganic bases such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, and sodium hydride. Among these, organic bases such as triethylamine and diisopropylethylamine are preferable. The amount of the base used is generally 0.1 to 50 moles, and preferably 1 to 20 moles, per mole of Compound (4).
[0094]

The reaction solvent is not particularly limited, and any solvent that does not adversely affect the reaction can be used. Examples of the solvent include hydrocarbons (e.g., benzene, toluene, and xylene), nitriles (e.g., acetonitrile), ethers (e.g., dimethoxyethane, tetrahydrofuran, 1,4-dioxane, etc.), alcohols

(e.g., methanol, ethanol, etc.), aprotic polar solvents (e.g., dimethylformamide, dimethylsulfoxide, hexamethyl phosphoramidate, etc.), water, and mixtures thereof. The reaction time ranges from 0.1 to 100 hours, preferably 0.5 to 24 hours. The reaction temperature ranges from 0°C to the boiling temperature of the solvent, preferably 0 to 150°C.

[0095]

Further, this step may also be performed through Suzuki-Miyaura coupling using Compound (3) and an organic boron compound (boric-acid compound, boric-acid ester, etc.) having a substituent -R₃-R₄-R₅ (wherein R₃, R₄, and R₅ are as defined above).

[0096]

In this method, the organic boron compound can be obtained from commercial suppliers, or can be produced through a known method. The amount of the organic boron compound used is 1 to 10 moles, preferably 1 to 3 moles, per mole of Compound (3).

[0097]

In this method, the Suzuki-Miyaura coupling can generally be performed by a known method, such as the method described in Chemical Reviews, Vol. 95, p. 2457 (1995); or a similar method.

[0098]

Examples of reaction catalyst used for the Suzuki-Miyaura coupling include tetrakis triphenylphosphine palladium (0), bis (triphenylphosphine)palladium(II) dichloride, and 1,1'-bis (diphenyl phosphino)ferrocene-palladium(II) dichloride-dichloromethane complex. The amount of the reaction catalyst used depends on the type of the catalyst. The amount of the catalyst used is generally 0.0001 to 1 mole, preferably 0.01 to 0.5 moles, per mole of Compound (3).

[0099]

Examples of the solvent include hydrocarbons (e.g., benzene, toluene, and xylene), nitriles (e.g., acetonitrile), ethers (e.g., dimethoxyethane, tetrahydrofuran, 1,4-dioxane, etc.), alcohols (e.g., methanol, ethanol, etc.), aprotic polar

solvents (e.g., dimethylformamide, dimethylsulfoxide, etc.), and water. These solvents may be used alone, or in a mixture. The reaction time ranges from 0.1 to 100 hours, preferably 0.1 to 24 hours. The reaction temperature ranges from 0°C to the boiling temperature of the solvent, preferably 0°C to 100°C.

[0100]

Step 4

This step produces Compound (5) by deprotecting the protected amino group of Compound (4). The deprotection can generally be performed by a known method, such as the method described in Protective Groups in Organic Synthesis, T.W. Greene, John Wiley & Sons (1981); or a similar method. An example of the protecting group is tert-butyloxycarbonyl. When a tert-butyl oxycarbonyl group is used as a protecting group, the deprotection is preferably performed under acidic conditions. Examples of acids that can be used include hydrochloric acid, acetic acid, trifluoroacetic acid, sulfuric acid, methanesulfonic acid, tosic acid, and the like. The amount of the acid used is preferably 1 to 100 moles per mole of Compound (4).

[0101]

Any solvent that does not adversely affect the reaction may be used for the reaction. Examples of the solvent include alcohols (e.g., methanol), hydrocarbons (e.g., benzene, toluene, and xylene), halogenated hydrocarbons (e.g., methylene chloride, chloroform, 1,2-dichloroethane, etc.), nitriles (e.g., acetonitrile), ethers (e.g., dimethoxyethane, tetrahydrofuran, etc.), aprotic polar solvents (e.g., N,N-dimethylformamide, dimethylsulfoxide, hexamethyl phosphoramide, etc.), and mixtures thereof. The reaction time ranges 0.1 to 100 hours, preferably 0.5 to 24 hours. The reaction temperature ranges from 0 to 120°C, preferably 0 to 90°C.


[0102]

Compound (1) used as a raw material in Production Method A can be obtained from commercial suppliers, or can be produced through a known method. For example, Compound (7) in

which Z^1 and Z^2 in Formula 1 represent a specific protector of a hydroxy group may be produced through Production Method B below.
[0103]

5 Production Method B

[0104]



[0105]

wherein Ra are the same or different, and each
10 represents hydrogen, methyl, ethyl, phenyl, cyclohexyl, or cyclopentyl.

Step 5

This step produces Compound (7) by protecting two
15 hydroxy groups among the hydroxy groups of Compound (6). Examples of the protection reagent include dialkoxy alkane and the like. The amount of the protection reagent used is 1 to 100 moles, preferably 1 to 10 moles, per mole of Compound (6).

[0106]

20 The protection can generally be performed by a known method, such as the method described in Protective Groups in Organic Synthesis, T.W. Greene, John Wiley & Sons (1981); or a similar method.

[0107]

25 Examples of the reaction catalyst include p-toluenesulfonic acid, methanesulfonic acid, pyridinium p-toluenesulfonates, perchloric acid, and sulfuric acid. When a reaction catalyst is used, the amount of the reaction catalyst

depends on the type of the catalyst. For example, the amount of the reaction catalyst is generally 0.0001 to 1 mole, preferably 0.01 to 0.5 moles, per mole of Compound (6).

[0108]

5 Examples of the solvent include acetonitrile, dichloromethane, chloroform, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and N-methylpyrrolidin-2-one. These solvents may be used alone, or in a mixture. The reaction time ranges from
10 0.1 to 100 hours, preferably 0.1 to 24 hours. The reaction temperature ranges from 0°C to the boiling temperature of the solvent, preferably 0°C to 100°C.


[0109]

15 Further, Compound (15) in which Z¹ and Z² in Formula 1 represent a specific protector of a hydroxy group may be produced through Production Method C below.

[0110]

Production Method C

[0111]



20

[0112]

wherein P₂ is a protecting group of a hydroxy group.
Ra is as defined above.

Step 6

5 This step produces Compound (9) by protecting two hydroxy groups among the hydroxy groups of Compound (8). The protection reaction may be performed in the same manner as in Step 5.

[0113]

10 Step 7

 This step produces an isomer mixture of Compound (10), which is a pyrrolopyrimidine compound, by reacting an isomer mixture of Compound (9) and 2-(4,6-dichloro pyrimidin-5-yl)acetaldehyde in the presence of a base.

15 [0114]

 The amount of the 2-(4,6-dichloro pyrimidin-5-yl)acetaldehyde is 1 to 10 moles, preferably 1 to 3 moles, per mole of Compound (9).

[0115]

20 The reaction can generally be performed by a known method, for example, the method disclosed in Tetrahedron Letters, 26 (16), 2001-2 (1985).

[0116]

 Examples of bases include triethylamine, diisopropylethylamine, pyridine, lutidine, collidine, and DBU. When a base is used, the amount of the base is generally 1 to 100 moles, preferably 1 to 20 moles, per mole of Compound (9).

[0117]

 Examples of the solvent include ethanol, 2-propanol, 2-butanol, acetonitrile, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, N,N-dimethylformamide, N,N-dimethylacetamide, and N-methylpyrrolidin-2-one. These solvents may be used alone, or in a mixture. The reaction time ranges from 0.1 to 100 hours, preferably 0.1 to 24 hours. The reaction temperature ranges from 35 0°C to the boiling temperature of the solvent, preferably 0°C to

100°C.

[0118]

Step 8

This step converts the isomer mixture of Compound (10)
5 into Compound (11) consisting of only one of the isomers, in the
presence of an acid catalyst.

[0119]

Examples of acids include p-toluenesulfonic acid,
methanesulfonic acid, pyridinium p-toluene sulfonate, perchloric
10 acid, and sulfuric acid. The amount of the acid is generally
0.001 to 10 moles, preferably 0.01 to 2 moles, per mole of
Compound (10).

[0120]

Examples of the solvent include acetone, 2-butanone,
15 acetonitrile, dichloromethane, chloroform, tetrahydrofuran, 1,2-
dimethoxyethane, 1,4-dioxane, toluene, N,N-dimethylformamide,
N,N-dimethylacetamide, and N-methylpyrrolidin-2-one. These
solvents may be used alone, or in a mixture. The reaction time
ranges from 0.1 to 100 hours, preferably 1 to 48 hours. The
20 reaction temperature ranges from 0°C to the boiling temperature
of the solvent, preferably 0°C to 100°C.

[0121]

Step 9

This step protects the hydroxy group of Compound (11)
25 using Compound P₂-Cl (wherein P₂ is a protecting group of a
hydroxy group).

[0122]

The reaction can generally be performed by a known
method, such as the method described in Protective Groups in
30 Organic Synthesis, T.W. Greene, John Wiley & Sons (1981); or a
similar method.

[0123]

The protecting group of a hydroxy group represented by
P₂ in Compound P₂-Cl is not particularly limited insofar as it has
35 a protecting function. Examples include lower alkyl groups such

as methyl, ethyl, propyl, isopropyl, and tert-butyl; lower alkylsilyl groups such as trimethylsilyl and tert-butyl dimethylsilyl; lower alkoxyethyl groups such as methoxyethyl and 2-methoxyethoxyethyl; tetrahydropyranyl; 5 trimethylsilylethoxyethyl; aralkyl groups such as benzyl, p-methoxybenzyl, 2,3-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, and trityl; and acyl groups such as formyl, acetyl, and trifluoroacetyl. In particular, methyl, methoxyethyl, tetrahydropyranyl, trimethylsilylethoxyethyl, tert-10 butyl dimethylsilyl, and acetyl are preferable.

[0124]

The compound can be obtained from commercial suppliers, or can be produced through a known method. The amount of the compound is 1 to 20 moles, preferably 1 to 5 moles, per mole of 15 Compound (11).

[0125]

Examples of the base include triethylamine, diisopropylethylamine, pyridine, lutidine, collidine, and DBU. The amount of the base is generally 1 to 20 moles, preferably 1 20 to 5 moles, per mole of Compound (11).

[0126]

Examples of the solvent include acetonitrile, dichloromethane, chloroform, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, toluene, N,N-dimethylformamide, N,N-25 dimethylacetamide, and N-methylpyrrolidin-2-one. These solvents may be used alone, or in a mixture. The reaction time ranges from 0.1 to 100 hours, preferably 0.1 to 24 hours. The reaction temperature ranges from 0°C to the boiling temperature of the solvent, preferably 0°C to 100°C.

30 [0127]

Step 10

This step produces Compound (13) by reacting Compound (12) with iodosuccinimide, thereby introducing an iodine atom.

[0128]

35 The iodination may be performed according to the

method disclosed in International Publication WO2006/102079, or a similar method. The amount of the iodosuccinimide is 1 to 20 moles, preferably 1 to 5 moles, per mole of Compound (12).

[0129]

5 Examples of the solvent include acetone, acetonitrile, ethyl acetate, dichloromethane, chloroform, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and N-methylpyrrolidin-2-one. These solvents may be used alone, or in a mixture. The reaction time
10 ranges from 0.1 to 100 hours, preferably 0.1 to 24 hours. The reaction temperature ranges from 0°C to the boiling temperature of the solvent, preferably 0°C to 100°C.

[0130]

Step 11

15 This step produces Compound (14) by deprotecting the protected hydroxy group of Compound (13).

[0131]

 The deprotection can generally be performed by a known method, such as the method described in Protective Groups in
20 Organic Synthesis, T.W. Greene, John Wiley & Sons (1981); or a similar method.

[0132]

 When a tert-butyl dimethylsilyl group is used as a protecting group, tetrabutylammonium fluoride, for example, is
25 used as a deprotection reagent. The amount of the reagent is preferably 1 to 10 moles, per mole of Compound (13).

[0133]

 Any solvent that does not adversely affect the reaction may be used for the reaction. Examples of the solvent
30 include ethers (e.g., 1,2-dimethoxyethane, tetrahydrofuran, etc.), aprotic polar solvents (e.g., N,N-dimethylformamide, dimethylsulfoxide, hexamethyl phosphoryl amide), etc.), and mixtures thereof. The reaction time ranges from 0.1 to 100 hours, preferably 0.5 to 24 hours. The reaction temperature ranges from
35 0 to 80°C, preferably 0 to 50°C.

[0134]

Step 12

This step produces Compound (15) by reacting Compound (14) with ammonia or a salt thereof.

5 [0135]

The amount of the ammonia or a salt thereof used in this step is typically an equimolar to excessive molar amount per mole of Compound (14).

[0136]

10 The reaction solvent is not particularly limited, and any solvent that does not adversely affect the reaction can be used. Examples of the solvent include water, methanol, ethanol, isopropanol, tert-butyl alcohol, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, N,N-dimethylformamide, N-methylpyrrolidin-2-one, dimethylsulfoxide, and mixtures thereof.

[0137]


The reaction temperature is generally 0°C to 200°C, preferably from room temperature to 150°C. The reaction time is generally 5 minutes to 7 days, preferably 30 minutes to 72 hours.

20 [0138]

Production Method D

Further, Compound (19), which is a compound in which Z¹ in Formula 1 is a hydroxy group, Z² is hydrogen, and X is CH₂, may be produced through Production Method D below.

[0139]



[0140]

Step 13

30 This step reacts Compound (16) with 2-(4,6-dichloro pyrimidin-5-yl)acetaldehyde. This reaction may be performed in

the same manner as in Step 7.

[0141]

Step 14

This step reacts the reaction product obtained in Step 13 with iodosuccinimide, thereby introducing an iodine atom. This reaction may be performed in the same manner as in Step 10.

[0142]

Step 15


This step produces Compound (19) by reacting the reaction product obtained in Step 14 with ammonia or a salt thereof. This reaction may be performed in the same manner as in Step 12.

[0143]

Compound (20)

Further, Compound (20), which is a compound in which Z^1 in Formula 1 is a hydroxy group, Z^2 is hydrogen, and X is O, is a publicly known compound.

[0144]



[0145]

Production Method E

Further, among the compounds of the present invention, Compound (27) in which R_1 and R_2 are hydroxy groups, and


[0146]



[0147]

is =CH- may be produced through Production Method E below.

[0148]



[0149]

wherein R₃, R₄, and R₅ are as defined above.

Step 16

This step produces Compound (22) by reducing the
5 carboxyl group of Compound (21). This step is performed in the
presence of a reducing agent. In this step, the amount of the
reducing agent is 1 to 20 moles, preferably 1 to 5 moles, per
mole of Compound (21). Examples of the reducing agent include
10 (e.g., diborane), and diisobutylaluminum hydride.

[0150]

Examples of the solvent include methanol, ethanol,
diethylether, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane,
15 and toluene. These solvents may be used alone, or in a mixture.
The reaction time ranges from 0.1 to 100 hours, preferably 0.1 to
24 hours. The reaction temperature ranges from 0°C to the boiling
temperature of the solvent, preferably 0°C to 100°C.

[0151]

20 Step 17

This step produces Compound (23) through a Mitsunobu
reaction using Compound (22) as a raw material, and 4-chloro-5-
iodo-7H-pyrrolo[2,3-d]pyrimidine as a nucleophilic agent.

[0152]

25 This reaction may be performed in the same manner as
in Step 1.

[0153]

Step 18

This step produces Compound (24) by reacting Compound
30 (23) with ammonia or a salt thereof. This reaction may be
performed in the same manner as in Step 12.

[0154]

Step 19

This step produces Compound (25) by deprotecting the
35 protected hydroxy group of Compound (24). This reaction may be

performed in the same manner as in Step 11.

[0155]

Step 20

This step produces Compound (26) through a Mitsunobu
5 reaction using Compound (25) as a raw material, and tert-butyl
sulfamoyl carbamate as a nucleophilic agent.

[0156]

This reaction may be performed in the same manner as
in Step 1.

10 [0157]

Step 21


This step produces Compound (27) using Compound (26)
as a raw material, by deprotecting the protected amino group
after a coupling reaction (Sonogashira coupling, Suzuki-Miyaura
15 coupling, etc.). This reaction may be performed in the same
manner as in Step 3 and Step 4.

[0158]

Production Method F

20 Further, among the compounds of the present invention,
Compound (29) in which R_1 and R_2 are the same or different, and
each represent hydrogen, fluorine, a hydroxy group, an amino
group, a cyano group, or a protector thereof may be produced
through Production Method F below.

25 [0159]



[0160]

wherein X, R_3 , R_4 , R_5 , Z^1 , and Z^2 are as defined above.

30

Step 22

This step produces Compound (28) through a coupling reaction (Sonogashira coupling, Suzuki-Miyaura coupling, etc.) using Compound (1) as a raw material. This reaction may be performed in the same manner as in Step 3.

[0161]

Step 23

This step produces Compound (29) by reacting Compound (28) with a sulfamoyl-introducing reagent.

[0162]


This reaction may be performed in the same manner as in Step 2. This step may be performed through multiple steps as necessary, and may suitably be combined with a deprotection reaction.

[0163]

Production Method G

Further, among the compounds of the present invention, Compound (32) may be produced through Production Method G below.

[0164]



[0165]

wherein P₁, Z¹, and Z² are as defined above.

R_b is the same as R₆ above. R_c represents a substituted or unsubstituted alkyl group.

[0166]

Step 24

This step produces Compound (31) by oxidizing Compound

(30). This step is performed in the presence of an oxidant. The amount of the oxidant used in this step is 1 to 20 moles, preferably 1 to 5 moles, per mole of Compound (30). Examples of the oxidant include oxone, m-chloroperbenzoic acid, hydrogen
5 peroxide, and potassium permanganate.

[0167]

Examples of the solvent include water, acetone, 2-butanone, acetonitrile, ethyl acetate, dichloromethane, chloroform, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane,
10 toluene, N,N-dimethylformamide, N,N-dimethylacetamide, and N-methylpyrrolidin-2-one. These solvents may be used alone, or in a mixture. The reaction time ranges from 0.1 to 100 hours, preferably 0.1 to 24 hours. The reaction temperature ranges from 0°C to the boiling temperature of the solvent, preferably 0°C to
15 100°C.

[0168]

Step 25

This step produces Compound (32) by deprotecting the protected amino group of Compound (31). This reaction may be
20 performed in the same manner as in Step 4.

[0169]

The compounds thus-obtained through Production Methods A to G can be subjected to the subsequent step after or without isolation and purification by known separation and purification
25 means, such as concentration, vacuum concentration, crystallization, solvent extraction, reprecipitation, and chromatography.

[0170]

When the compound of the present invention has isomers
30 such as optical isomers, stereoisomers, regioisomers, and rotational isomers, any of the isomers and mixtures thereof is included within the scope of the compound of the present invention. For example, when the compound has optical isomers, the optical isomer separated from a racemic mixture is also
35 included within the scope of the compound of the present

invention. Each of such isomers can be obtained as a single compound by known synthesis and separation means (e.g., concentration, solvent extraction, column chromatography, recrystallization, etc.).

5 [0171]

The compound of the present invention can be isolated and purified by usual isolation and purification means. Examples of such means include solvent extraction, recrystallization, preparative reversed-phase high-performance liquid chromatography, column chromatography, preparative thin-layer chromatography, and the like.

[0172]

The compound or a salt thereof of the present invention may be in the form of crystals. Single crystals and polymorphic mixtures are included within the scope of the compound or a salt thereof of the present invention. Such crystals can be produced by crystallization according to a crystallization method known *per se* in the art. The compound or a salt thereof of the present invention may be a solvate (e.g., a hydrate) or a non-solvate. Any of such forms are included within the scope of the compound or a salt thereof of the present invention. Compounds labeled with an isotope (e.g., ³H, ¹⁴C, ³⁵S, ¹²⁵I) are also included within the scope of the compound or a salt thereof of the present invention.

25 [0173]

A prodrug of the compound of the present invention or of a salt thereof refers to a compound that can be converted to the compound or a salt thereof of the present invention through a reaction with an enzyme, gastric acid, or the like, under physiological conditions *in vivo*, i.e., a compound that can be converted to the compound or a salt thereof of the present invention by enzymatic oxidation, reduction, hydrolysis, or the like; or a compound that can be converted to the compound or a salt thereof of the present invention by hydrolysis with gastric acid or the like. Further, the prodrug of the compound or a salt

thereof of the present invention may be compounds that can be converted to the compound or a salt thereof of the present invention under physiological conditions, such as those described in "*Iyakuhin no Kaihatsu* [Development of Pharmaceuticals]," Vol. 7, Molecular Design, published in 1990 by Hirokawa Shoten Co., pp. 163-198.

[0174]

The salt of the compound of the present invention refers to a common salt used in the field of organic chemistry. Examples of such salts include base addition salts to carboxyl group when the compound has carboxyl group, and acid addition salts to an amino or basic heterocycloalkyl group when the compound has an amino or basic heterocycloalkyl group.

[0175]

Examples of base addition salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; ammonium salts; and organic amine salts such as trimethylamine salts, triethylamine salts, dicyclohexylamine salts, ethanolamine salts, diethanolamine salts, triethanolamine salts, procaine salts, and N,N'-dibenzylethylenediamine salts.

[0176]

Examples of acid addition salts include inorganic acid salts such as hydrochlorides, sulfates, nitrates, phosphates, and perchlorates; organic acid salts such as acetates, formates, maleates, fumarates, tartrates, citrates, ascorbates, and trifluoroacetates; and sulfonates such as methanesulfonates, isethionates, benzenesulfonates, and p-toluenesulfonates. Hydrochlorides are preferable.

[0177]

The compound or a salt thereof of the present invention has superior NAE inhibitory activity and is useful as an antitumor agent. The type of malignant tumor to be treated by the compound or a salt thereof of the present invention is not particularly limited. Examples of malignant tumors include

epithelial cancers (e.g., respiratory system cancers, digestive system cancers, reproductive system cancers, secretion system cancers, and the like), sarcomas, hematopoietic tumors, central nervous system tumors, and peripheral nerve tumors.

5 Preferable examples include epithelial cancers, sarcomas, and hematopoietic tumors. More preferable examples include digestive system cancers, sarcomas, and hematopoietic tumors. Further, the organ from which the tumor is developed is not particularly limited. Examples include head and neck cancers,
10 esophagus cancer, gastric cancer, colon cancer, rectum cancer, liver cancer, gallbladder cancer, cholangiocarcinoma, biliary tract cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, renal cancer, bladder cancer, prostate cancer, testicular tumor, osteosarcoma,
15 soft-tissue sarcoma, multiple myeloma, skin cancer, brain tumor, and mesothelioma. Preferably, the target cancer is colon cancer, rectum cancer, pancreatic cancer, lung cancer, prostate cancer, breast cancer, osteosarcoma, soft-tissue sarcoma, or skin cancer.
[0178]

20 Further, examples of hematopoietic tumors include bone marrow tumors (e.g., lymphocytic leukemia, myelogenous leukemia, acute leukemia, chronic leukemia, and the like), and lymphoid tumors.
[0179]

25 Examples of bone marrow tumors include myeloproliferative neoplasm (MPN), acute myelogenous leukemia (AML), related precursor neoplasm, acute lymphocytic leukemia, chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS). Preferable examples include acute leukemia. Particularly
30 preferable examples include acute myelogenous leukemia.
[0180]

 Examples of lymphoid tumors include precursor lymphoid tumor, mature B-cell tumor, mature T-cell tumor and NK-cell tumor, and Hodgkin's lymphoma. Preferable examples include precursor
35 lymphoid tumors, mature B-cell tumor, mature T-cell tumor and NK-

cell tumor. Lymphoid tumors that are not regarded as Hodgkin's lymphoma may be collectively referred to as non-Hodgkin's lymphoma.

[0181]

5 Examples of precursor lymphoid tumors include B-lymphoblastic leukemia/lymphoma, T-lymphoblastic leukemia/lymphoma (ALL), blastic NK-cell lymphoma, and like blastic lymphoma. T-lymphoblastic leukemia/lymphoma is preferable.

[0182]

10 Examples of mature B-cell tumor include chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), B-cell prolymphocytic leukemia (B-PLL), splenic marginal zone lymphoma (SMZL), hairy cell leukemia (HCL), Waldenstrom's macroglobulinemia (WM), plasma cell tumor, MALT lymphoma,
15 follicular lymphoma, mantle cell lymphoma (MCL), B-cell lymphoma (diffuse large B-cell lymphoma (DLBCL), and Burkitt's lymphoma). Plasma cell tumor and B-cell lymphoma are preferable.

[0183]

 Preferable examples of plasma cell tumor include
20 multiple myeloma.

[0184]

 Examples of mature T-cell tumor and NK-cell tumor include T-cell prolymphocytic leukemia (T-PLL), aggressive NK-cell leukemia/lymphoma, adult T-cell leukemia/lymphoma, and
25 peripheral T-cell lymphoma not otherwise specified (PTCL-NOS).

[0185]

 Examples of Hodgkin's lymphoma include nodular lymphocyte-predominant Hodgkin's lymphoma, classical Hodgkin's lymphoma, nodular sclerosis classical Hodgkin's lymphoma, and
30 mixed cellularity classical Hodgkin's lymphoma.

[0186]

 FAB classification has been hitherto known for use in the diagnosis and classification of hematopoietic tumors. In recent years, WHO classification has also been used. The compound
35 of the present invention or a salt thereof is useful for the

various hematopoietic tumors classified by both FAB classification and WHO classification.

[0187]

When the compound or a salt thereof of the present invention is used as a pharmaceutical preparation, a pharmaceutical carrier can be added, if required, thereby forming a suitable dosage form according to prevention and treatment purposes. Examples of the dosage form include oral preparations, injections, suppositories, ointments, patches, eye-drops, and the like. Of these, injections (intravenous injections etc.) are preferable. Such dosage forms can be formed by methods conventionally known to persons skilled in the art.

[0188]

As the pharmaceutical carrier, various conventional organic or inorganic carrier materials used as preparation materials may be blended as an excipient, binder, disintegrant, lubricant, or coating agent in solid preparations; or as a solvent, solubilizing agent, suspending agent, isotonicizing agent, pH adjuster/buffer, or soothing agent in liquid preparations. Moreover, pharmaceutical preparation additives, such as antiseptics, antioxidants, colorants, sweeteners, and stabilizers, may also be used, if required.

[0189]

When a liquid preparation for oral administration is prepared, a taste-masking agent, a buffer, a stabilizer, a flavoring agent, and the like, may be added to the compound of the present invention; and the resulting mixture may be formulated into an oral liquid preparation, syrup, elixir, etc., according to an ordinary method.

[0190]

When a suppository is prepared, pharmaceutically acceptable carriers known in the art, such as polyethylene glycol, lanolin, cacao butter, and fatty acid triglyceride; and as necessary, surfactants such as Tween 80®, may be added to the compound of the present invention, and the resulting mixture may

be formulated into a suppository according to an ordinary method.
[0191]

When an ointment is prepared, a commonly used base, stabilizer, wetting agent, preservative, and the like, may be
5 blended into the compound of the present invention, as necessary; and the obtained mixture may be mixed and formulated into an ointment according to an ordinary method.
[0192]

Examples of the base include liquid paraffin, white
10 petrolatum, white beeswax, octyl dodecyl alcohol, paraffin, and the like.
[0193]

Examples of excipients include lactose, sucrose, D-mannitol, starch, crystalline cellulose, calcium silicate, and
15 the like.
[0194]

Examples of binders include hydroxypropyl cellulose, methyl cellulose, polyvinylpyrrolidone, candy powder, hypromellose, and the like.
20 [0195]

Examples of disintegrators include sodium starch glycolate, carmellose calcium, croscarmellose sodium, crospovidon, low-substituted hydroxy propyl cellulose, partially pregelatinized starch, and the like.
25 [0196]

Examples of lubricants include talc, magnesium stearate, sucrose fatty acid ester, stearic acid, sodium stearyl fumarate, and the like.
[0197]

Examples of coating agents include ethyl cellulose, aminoalkyl methacrylate copolymer RS, hypromellose, sucrose, and the like.
30 [0198]

Examples of solvents include water, propylene glycol, physiological saline, and the like.
35

[0199]

Examples of solubilizing agents include polyethylene glycol, ethanol, α -cyclodextrin, macrogol 400, polysorbate 80, and the like.

5 [0200]

Examples of suspending agents include carrageenan, crystalline cellulose/carmellose sodium, polyoxyethylene hydrogenated castor oil, and the like.

[0201]

10 Examples of isotonizing agents include sodium chloride, glycerin, potassium chloride, and the like.

[0202]

Examples of pH adjuster/buffer include sodium citrate, hydrochloric acid, lactic acid, phosphoric acid, sodium
15 dihydrogen phosphate, and the like.

[0203]

Examples of soothing agents include procaine hydrochloride, lidocaine, and the like.

[0204]

20 Examples of antiseptics include ethyl parahydroxybenzoate, cresol, benzalkonium chloride, and the like.

[0205]

Examples of antioxidants include sodium sulfite, ascorbic acid, natural vitamin E, and the like.

25 [0206]

Examples of coloring agents include titanium oxide, iron sesquioxide, Food Blue No. 1, copper chlorophyll, and the like.

[0207]

30 Examples of sweeteners include aspartame, saccharins, sucralose, l-menthol, mint flavor, and the like.

[0208]

Examples of stabilizers include sodium pyrosulfite, edetate sodium, erythorbic acid, magnesium oxide,
35 dibutylhydroxytoluene, and the like.

[0209]

Examples of preservatives include methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, and the like.

5 [0210]

When a patch is prepared, the above-described ointment, cream, gel, paste, or the like, may be applied to an ordinary substrate according to an ordinary method.

[0211]

10 As the substrate, woven fabrics or non-woven fabrics comprising cotton, staple fibers, or chemical fibers; and films or foam sheets of soft vinyl chloride, polyethylene, polyurethane, etc., are suitable.

[0212]

15 The amount of the compound of the present invention to be incorporated in each of such dosage unit forms depends on the condition of the patient to whom the compound is administered, the dosage form, etc. In general, in the case of an oral agent, an injection, and a suppository, the amount of the compound of
20 the present invention is preferably 10 mg/m² to 1000 mg/m² per dosage unit form.

[0213]

The daily dose of the medicine in such a dosage form depends on the condition, body weight, age, gender, etc., of the
25 patient, and cannot be generalized. For example, the daily dose of the compound of the present invention for an adult (body weight: 50 kg) may be generally 13.9 to 1500 mg, and preferably 50 to 1000 mg; and is preferably administered in one dose, or in two to three divided doses, per day.

30

Examples

[0214]

The following describes the present invention in more detail with reference to Examples. However, the scope of the
35 present invention is not limited to these Examples.

[0215]

Commercially available reagents were used in the Examples, unless otherwise specified.

[0216]

5 For silica gel column chromatography, Purif-Pack (registered trademark) SI produced by Moritex Corp., KP-Sil (registered trademark) Silica preppacked column produced by Biotage, or HP-Sil (registered trademark) Silica preppacked column produced by Biotage was used.

10 [0217]

For basic silica gel column chromatography, Purif-Pack (registered trademark) NH produced by Moritex Corp or KP-NH (registered trademark) preppacked column produced by Biotage was used.

15 [0218]

For preparative thin-layer chromatography, Kieselgel TM 60F 254, Art. 5744 produced by Merck or NH₂ Silica Gel 60F254 Plate produced by Wako was used.

[0219]

20 NMR spectra were measured by using AL400 (400 MHz; produced by JEOL), Mercury 400 (400 MHz; produced by Agilent Technologies, Inc.) model spectrometer, or Inova 400 (400 MHz; produced by Agilent Technologies, Inc.) model spectrometer equipped with an OMNMR probe (produced by Protasis). The
25 measurement was carried out using tetramethylsilane as an internal standard when tetramethylsilane was contained in a deuterated solvent; otherwise, an NMR solvent was used as an internal standard. All the δ values are shown by ppm.

[0220]

30 The microwave reaction was performed using Discover S-class produced by CEM Corporation, or Initiator produced by Biotage.

[0221]

LCMS spectra were measured using an Acquity SQD
35 (quadrupole) produced by Waters Corporation under the following

conditions.

Column: YMC-Triart C18, 2.0 x 50 mm, 1.9 µm (produced by YMC)

MS detection: ESI positive

UV detection: 254 and 210 nm

5 Column flow rate: 0.5 mL/min

Mobile phase: Water/acetonitrile (0.1% formic acid)

Injection volume: 1 µL

Gradient (Table 1)

Time (min) Water (%) Acetonitrile (%)

10	0	95	5
	0.1	95	5
	2.1	5	95
	3.0	STOP	

[0222]

15 Preparative reversed-phase HPLC purification was performed using a preparative separation system available from Waters Corporation.

Column: Connected YMC-Actus Triart C18, 20 x 50 mm, 5 µm (produced by YMC) and YMC-Actus Triart C18, 20 x 10 mm, 5 µm

20 (produced by YMC)

UV detection: 254 nm

MS detection: ESI positive

Column flow rate: 25 mL/min

Mobile phase: Water/acetonitrile (0.1% formic acid)

25 Injection volume: 0.1 to 0.5 mL

Abbreviations

s: Singlet

d: Doublet

30 t: Triplet

q: Quartet

m: Multiplet

brs: Broad Singlet

brm: Broad Multiplet

35 dd: Double Doublet

dt: Double Triplet

dq: Double Quartet

ddd: Double Double Doublet

DMSO-d₆: Deuterated dimethyl sulfoxide

5 CDCl₃: Deuterated chloroform

CD₃OD: Deuterated methanol

PdCl₂ (dppf) CH₂Cl₂: 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride-dichloromethane complex

n-butyllithium: normal butyl lithium

10 [0223]

Example 1

4-Amino-5-[2-(2,6-difluorophenyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

15 Step 1: Synthesis of [(3aR,4R,6R,6aR)-4-(4-amino-5-iodo-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol

(2R,3R,4S,5R)-2-(4-Amino-5-iodo-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (15 g, 20 34.8 mmol) was suspended at room temperature in acetone (120 mL) and 2,2-dimethoxypropane (24.4 mL). Thereafter, boron trifluoride diethyl etherate (27.8 mL, 6.3 eq) was added thereto dropwise in an ice bath with stirring so as to keep the internal temperature at 10°C or lower. The obtained mixture was stirred for 75 minutes in an ice bath, and a 5 M aqueous sodium hydroxide solution (60 25 mL) was then slowly added thereto dropwise so as to keep the internal temperature at 15°C or lower. After acetone was distilled off under reduced pressure, chloroform and water were added thereto, followed by stirring for about 5 minutes. The reaction solution was filtered through a celite bed to remove the 30 generated insoluble matter. Thereafter, the aqueous layer was separated and extracted twice with chloroform. All of the organic layers were combined, washed with water and saturated saline, and dried over sodium sulfate, followed by distilling off the solvent. 35 The brown oil residue was suspended in hexane (50 mL), and

stirred for 2 hours. The formed solid was then collected by filtration, followed by drying, thereby obtaining the title compound (10.7 g, 71%) as a light-brown solid.

[0224]

5 ¹H-NMR (CDCl₃) δ: 8.23 (1H, s), 7.12 (1H, s), 6.40 (1H, d, J = 11.5 Hz), 5.76-5.74 (2H, brs), 5.69 (1H, d, J = 5.1 Hz), 5.24-5.22 (1H, m), 5.10-5.08 (1H, m), 4.49 (1H, s), 3.97-3.94 (1H, m), 3.78 (1H, t, J = 11.5 Hz), 1.63 (3H, s), 1.36 (3H, s). LCMS (ESI) m/z 433 [M+H]⁺

10

Step 2: Synthesis of 7-((3aR,4R,6R,6aR)-6-(aminomethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-amine

15 [(3aR,4R,6R,6aR)-4-(4-Amino-5-iodo-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol (3.2 g, 7.4 mmol) and phthalimide (2.18 g, 14.8 mmol) were dissolved in tetrahydrofuran (30 mL), and triphenylphosphine (2.9 g, 11.1 mmol) was added thereto with stirring under ice-cooling. After triphenylphosphine was
20 dissolved, diisopropyl azodicarboxylate (2.2 mL, 11.1 mmol) was added thereto dropwise with stirring under ice-cooling. After the reaction solution was stirred for 1.5 h under ice-cooling, the reaction solution was distilled off under reduced pressure, and ethanol (30 mL), water (9 mL), and hydrazine monohydrate (1.2 mL,
25 24.7 mmol) were added at room temperature to the residue. After being stirred under reflux overnight, the reaction solution was distilled off under reduced pressure. The residue was partitioned between ethyl acetate and saturated sodium bicarbonate solution. Then, the aqueous layer was separated and extracted with ethyl
30 acetate. All of the organic layers were combined and dried over sodium sulfate, followed by distilling off the solvent. The residue was then purified by basic silica gel column chromatography (developing solvent: methanol/chloroform), thereby obtaining the title compound (3.23 g, quantitative) as a yellow
35 solid.

[0225]

¹H-NMR (CDCl₃) δ: 8.28 (1H, s), 7.19 (1H, s), 6.13 (1H, d, J = 3.2 Hz), 5.65-5.63 (2H, brs), 5.23 (1H, dd, J = 6.7, 3.2 Hz), 4.93 (1H, dd, J = 6.7, 4.0 Hz), 4.18-4.14 (1H, m), 3.04 (1H, dd, J = 13.4, 4.3 Hz), 2.93 (1H, dd, J = 13.4, 5.9 Hz), 1.61 (3H, s), 1.37 (3H, s). LCMS (ESI) m/z 432 [M+H]⁺

Step 3: Synthesis of tert-butyl N-(((3aR,4R,6R,6aR)-6-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfamoyl carbamate

7-((3aR,4R,6R,6aR)-6-(Aminomethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-amine (3.23 g) was dissolved in chloroform (40 mL), and 1-aza-4-azoniabicyclo[2.2.2]octan-4-ylsulfonyl(tert-butoxycarbonyl)azanido: 1,4-diazabicyclo[2.2.2]octane monohydrochloride (Reference: Organic Letters, 2012, 10, 2626-2629) (6.2 g, 14.1 mmol) was added thereto at room temperature. After the reaction solution was stirred for 2 hours at room temperature, the precipitate was filtered off and washed with chloroform. After the filtrate was concentrated, the residue was purified by silica gel column chromatography (developing solvent: chloroform/methanol), thereby obtaining the title compound (4.0 g, 88%) as a milky-white solid.

[0226]

¹H-NMR (CDCl₃) δ: 9.27-9.25 (1H, brs), 8.50 (1H, s), 7.08 (1H, s), 6.04-6.02 (2H, brs), 5.65 (1H, d, J = 4.7 Hz), 5.28 (1H, dd, J = 6.3, 4.7 Hz), 5.07 (1H, dd, J = 6.3, 2.2 Hz), 4.50 (1H, d, J = 2.2 Hz), 3.63-3.49 (2H, m), 1.61 (3H, s), 1.44 (9H, s), 1.35 (3H, s). LCMS (ESI) m/z 611 [M+H]⁺

Step 4: Synthesis of example compound 1

tert-Butyl N-(((3aR,4R,6R,6aR)-6-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfamoyl carbamate (20 mg, 0.033 mmol),

2-ethynyl-1,3-difluorobenzene (9.0 mg, 0.066 mmol),
bis(triphenylphosphine)palladium (II) dichloride (3 mg, 0.0043
mmol), copper iodide (1 mg, 0.0053 mmol), and
diisopropylethylamine (0.011 mL, 0.066 mmol) were suspended in
5 tetrahydrofuran (0.20 mL). After the reaction solution was
stirred at 70°C for 2 hours, a mixed solution (0.60 mL) of
trifluoroacetic acid/water = 4/1 was added thereto at room
temperature, followed by stirring at room temperature overnight.
After the solvent was distilled off, the residue was purified by
10 basic silica gel column chromatography (developing solvent:
methanol/chloroform), thereby obtaining the title compound (14 mg,
91%) as a yellow powder.

[0227]

¹H-NMR (CD₃OD) δ: 8.25 (1H, s), 7.68 (1H, s), 7.45-7.37 (1H, m),
15 7.10-7.04 (2H, m), 5.86 (1H, d, J = 7.3 Hz), 4.86-4.81 (1H, m),
4.31-4.29 (1H, m), 4.27-4.25 (1H, m), 3.40-3.35 (2H, m). LCMS
(ESI) m/z 481 [M+H]⁺

Step 5: Synthesis of 4-amino-5-[2-(2,6-difluorophenyl)ethynyl]-7-
20 [(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]
pyrimidine hydrochloride

tert-Butyl N-(((3aR,4R,6R,6aR)-6-(4-amino-5-((2,6-
difluorophenyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl-2,2-
25 dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfamoyl
carbamate (8.05 g, 12.9 mmol) was dissolved in acetonitrile (120
mL), and concentrated hydrochloric acid (10.8 mL, 129 mmol) was
added thereto at room temperature. After the mixture was stirred
at room temperature for 6 hours, acetonitrile (80 mL) was added
30 thereto, followed by stirring at room temperature overnight. The
precipitate was collected by filtration and washed with
acetonitrile (80 mL), followed by drying, thereby obtaining the
title compound hydrochloride (5.93 g, 88%) as a white solid.

[0228]

35 ¹H-NMR (DMSO-D₆) δ: 8.42 (1H, s), 8.25 (1H, s), 7.55 (1H, tt, J =

8.1, 7.7 Hz), 7.28 (2H, dd, J = 8.4, 8.1 Hz), 7.02 (1H, brs),
6.61 (1H, brs), 6.03 (1H, d, J = 6.6 Hz), 4.48 (1H, dd, J = 6.6,
5.1 Hz), 4.12-4.10 (1H, m), 4.06-4.03 (1H, m), 3.22 (1H, dd, J =
13.9, 5.5 Hz), 3.12 (1H, dd, J = 13.2, 5.5 Hz). LCMS (ESI) m/z
5 481 [M+H]⁺.

[0229]

Example 2

4-[4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
10 d]pyrimidin-5-yl]-2-(o-tolyl)thiazole

tert-Butyl N-(((3aR,4R,6R,6aR)-6-(4-amino-5-iodo-7H-
pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-
d][1,3]dioxol-4-yl)methyl)sulfamoyl carbamate (300 mg, 0.491
mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium (II)
15 dichloride-dichloromethane complex (40.1 mg, 0.049 mmol), and 4-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(o-tolyl)thiazole
(295 mg, 0.982 mmol) were suspended in a 2 M aqueous sodium
carbonate solution (1.23 mL) and dimethoxyethane (5 mL), followed
by stirring at 70°C for 17 hours. The reaction solution was
20 partitioned between ethyl acetate and water, and the organic
layer was washed with water and concentrated. The residue was
dissolved in acetonitrile (1 mL), trifluoroacetic acid (0.5 mL),
and water (0.1 mL), followed by stirring at room temperature
overnight. After the reaction liquid was concentrated, the
25 residue was purified by basic silica gel column chromatography
(developing solvent: methanol/chloroform), thereby obtaining the
target product (110 mg, 43%) as a yellowish white solid.

¹H-NMR (DMSO-D₆) δ: 8.10 (1H, s), 8.08 (1H, s), 8.06 (1H, s), 7.70
(1H, d, J = 7.3 Hz), 7.46-7.35 (3H, m), 6.60 (2H, s), 5.97 (1H, d,
30 J = 6.6 Hz), 5.40 (1H, d, J = 6.6 Hz), 5.20 (1H, d, J = 4.8 Hz),
4.60 (1H, dt, J = 6.6, 5.5 Hz), 4.14-4.11 (1H, m), 4.08-4.04 (1H,
m), 2.53 (3H, s). LCMS (ESI) m/z 518 [M+H]⁺.

[0230]

Example 3

35 4-Amino-5-[2-(4-benzyloxyphenyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-

dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example 1, except that 1-(benzyloxy)-4-ethynylbenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0231]

¹H-NMR (CDCl₃) δ: 8.29 (1H, s), 7.44-7.27 (8H, m), 6.96 (2H, d, J = 8.8 Hz), 5.69 (1H, d, J = 6.8 Hz), 5.10 (2H, s), 4.87-4.84 (1H, m), 4.36-4.33 (2H, m), 3.46-3.40 (4H, m). LCMS (ESI) m/z 551

[M+H]⁺.

[0232]

Example 4

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-[5-(2-pyridyl)-2-thienyl]ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example 1, except that 2-(5-ethynylthiophen-2-yl)pyridine was used in place of 2-ethynyl-1,3-difluorobenzene.

[0233]

¹H-NMR (CD₃OD) δ: 8.49 (1H, d, J = 5.1 Hz), 8.25 (1H, s), 7.84-7.82 (2H, m), 7.64 (1H, s), 7.64 (1H, d, J = 4.1 Hz), 7.35 (1H, d, J = 4.1 Hz), 7.30-7.27 (1H, m), 5.87 (1H, d, J = 6.8 Hz), 4.87-4.84 (1H, m), 4.32-4.30 (1H, m), 4.28-4.25 (1H, m), 3.39-3.30 (2H, m). LCMS (ESI) m/z 528 [M+H]⁺.

[0234]

Example 5

4-[4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidin-5-yl]-2-(2-methoxyphenyl)thiazole

The title compound was obtained as in Example 2, except that 2-(2-methoxyphenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole was used in place of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(o-tolyl)thiazole.

[0235]

¹H-NMR (CD₃OD) δ: 8.20 (1H, s), 8.17 (1H, dd, J = 7.7, 1.8 Hz),

7.88 (1H, s), 7.84 (1H, s), 7.49 (1H, dt, J = 1.1, 8.8 Hz), 7.24 (1H, d, J = 8.8 Hz), 7.15 (1H, t, J = 7.7 Hz), 5.98 (1H, d, J = 6.6 Hz), 4.84-4.80 (1H, m), 4.36 (1H, dd, J = 5.5, 2.9 Hz), 4.29-4.26 (1H, m), 4.08 (3H, s), 3.47-3.37 (2H, m). LCMS (ESI) m/z 534 [M+H]⁺.

[0236]

Example 6

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(1-naphthyl)ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example 1, except that 1-ethynylnaphthalene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0237]

¹H-NMR (CD₃OD) δ: 8.36 (1H, d, J = 8.0 Hz), 8.26 (1H, s), 7.93-7.90 (2H, m), 7.77 (1H, d, J = 7.6 Hz), 7.73 (1H, s), 7.64-7.47 (3H, m), 5.90 (1H, d, J = 6.8 Hz), 4.87-4.84 (1H, m), 4.34-4.32 (1H, m), 4.30-4.25 (1H, m), 3.39-3.30 (2H, m). LCMS (ESI) m/z 495 [M+H]⁺.

[0238]

Example 7

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-(3-phenylprop-1-ynyl)pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example 1, except that prop-2-yn-1-yl benzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0239]

¹H-NMR (CD₃OD) δ: 8.18 (1H, s), 7.43 (1H, s), 7.40 (2H, d, J = 7.6 Hz), 7.33 (2H, dd, J = 7.6, 7.3 Hz), 7.24 (1H, t, J = 7.3 Hz), 5.80 (1H, d, J = 6.8 Hz), 4.87-4.80 (1H, m), 4.30-4.25 (1H, m), 4.24-4.20 (1H, m), 3.88 (2H, s), 3.39-3.30 (2H, m). LCMS (ESI) m/z 459 [M+H]⁺.

[0240]

Example 8

4-[2-[4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
d]pyrimidin-5-yl]ethynyl]quinoline

The title compound was obtained as in step 4 of Example
5 1, except that 4-ethynylquinoline was used in place of 2-ethynyl-
1,3-difluorobenzene.

[0241]

¹H-NMR (CD₃OD) δ: 8.83 (1H, d, J = 4.4 Hz), 8.40 (1H, d, J = 9.5
Hz), 8.28 (1H, s), 8.06 (1H, d, J = 8.0 Hz), 7.91 (1H, s), 7.84
10 (1H, dd, J = 8.8, 8.0 Hz), 7.76-7.73 (2H, m), 5.93 (1H, d, J =
6.6 Hz), 4.87-4.80 (1H, m), 4.35-4.30 (1H, m), 4.29-4.26 (1H, m),
3.40-3.30 (2H, m). LCMS (ESI) m/z 496 [M+H]⁺.

[0242]

Example 9

15 4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-[4-
(phenoxymethyl)phenyl]ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example
1, except that 1-ethynyl-4-(phenoxymethyl)benzene was used in
20 place of 2-ethynyl-1,3-difluorobenzene.

[0243]

¹H-NMR (CD₃OD) δ: 8.25 (1H, s), 7.61 (1H, s), 7.57 (2H, d, J = 8.3
Hz), 7.49 (2H, d, J = 8.3 Hz), 7.28 (2H, dd, J = 8.0, 7.8 Hz),
7.00 (2H, d, J = 7.8 Hz), 6.94 (1H, t, J = 8.0 Hz), 5.86 (1H, d,
25 J = 6.8 Hz), 5.12 (2H, s), 4.85-4.75 (1H, m), 4.35-4.30 (1H, m),
4.28-4.25 (1H, m), 3.40-3.30 (2H, m). LCMS (ESI) m/z 551 [M+H]⁺.

[0244]

Example 10

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
30 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(1-
phenylcyclopropyl)ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example
1, except that (1-ethynylcyclopropyl)benzene was used in place of
2-ethynyl-1,3-difluorobenzene.

35 [0245]

¹H-NMR (CD₃OD) δ: 8.21 (1H, s), 7.46 (1H, s), 7.43-7.40 (2H, m), 7.32 (2H, d, J = 8.0 Hz), 7.23-7.19 (1H, m), 5.82 (1H, d, J = 6.8 Hz), 4.82-4.79 (1H, m), 4.30-4.28 (1H, m), 4.25-4.21 (1H, m), 3.37-3.34 (2H, m), 1.54-1.50 (2H, m), 1.40-1.37 (2H, m). LCMS (ESI) m/z 485 [M+H]⁺.

[0246]

Example 11

1-[2-[4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
d]pyrimidin-5-yl]ethynyl]isoquinoline

The title compound was obtained as in step 4 of Example 1, except that 1-ethynylisoquinoline was used in place of 2-ethynyl-1,3-difluorobenzene.

[0247]

¹H-NMR (DMSO-D₆) δ: 8.56 (1H, d, J = 8.0 Hz), 8.45 (1H, d, J = 8.0 Hz), 8.23 (1H, s), 8.19 (1H, s), 8.07 (1H, d, J = 8.0 Hz), 7.90 (1H, d, J = 8.0 Hz), 7.88-7.78 (2H, m), 7.38-7.34 (1H, brs), 6.64 (2H, s), 5.99 (1H, d, J = 6.8 Hz), 5.48-5.46 (1H, brs), 5.29-5.25 (1H, brs), 4.63-4.59 (1H, m), 4.15-4.11 (1H, m), 4.10-4.06 (1H, m), 3.25-3.21 (1H, m), 3.18-3.12 (1H, m). LCMS (ESI) m/z 496 [M+H]⁺.

[0248]

Example 12

4-[4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
d]pyrimidin-5-yl]-2-phenyl-oxazol

The title compound was obtained as in Example 2, except that 2-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxazol was used in place of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(o-tolyl)thiazole.

[0249]

¹H-NMR (CD₃OD) δ: 8.28 (1H, s), 8.07-8.00 (2H, m), 7.93 (1H, s), 7.51-7.49 (3H, m), 7.48 (1H, s), 6.05 (1H, d, J = 6.3 Hz), 4.77-4.71 (2H, m), 4.33 (1H, dd, J = 5.4, 3.2 Hz), 4.26-4.22 (1H, m), 3.45-3.35 (2H, m). LCMS (ESI) m/z 488 [M+H]⁺.

[0250]

Example 13

5- $[2-[4\text{-Amino-}7-[(2R,3R,4S,5R)\text{-}3,4\text{-dihydroxy-}5\text{-}[(\text{sulfamoylamino})\text{methyl}]\text{tetrahydrofuran-}2\text{-yl}]\text{pyrrolo}[2,3\text{-}d]\text{pyrimidin-}5\text{-yl}]\text{ethynyl}]\text{quinoline}$

The title compound was obtained as in step 4 of Example 1, except that 5-ethynylquinoline was used in place of 2-ethynyl-1,3-difluorobenzene.

[0251]

10 $^1\text{H-NMR}$ (CD_3OD) δ : 8.91 (1H, dd, $J = 4.4, 1.7$ Hz), 8.84-8.78 (1H, m), 8.26 (1H, s), 8.04 (1H, d, $J = 8.5$ Hz), 7.89 (1H, dd, $J = 7.9, 1.1$ Hz), 7.81 (1H, s), 7.80-7.76 (1H, m), 7.67 (1H, dd, $J = 8.5, 4.4$ Hz), 5.92 (1H, d, $J = 6.8$ Hz), 4.87-4.82 (1H, m), 4.35-4.33 (1H, m), 4.29-4.26 (1H, m), 3.45-3.36 (2H, m). LCMS (ESI) m/z 496
15 $[\text{M}+\text{H}]^+$.

[0252]

Example 14

4-Amino-7- $[(2R,3R,4S,5R)\text{-}3,4\text{-dihydroxy-}5\text{-}[(\text{sulfamoylamino})\text{methyl}]\text{tetrahydrofuran-}2\text{-yl}]\text{-}5\text{-}[2-[2\text{-}(\text{trifluoromethoxy})\text{phenyl}]\text{ethynyl}]\text{pyrrolo}[2,3\text{-}d]\text{pyrimidine}$

The title compound was obtained as in step 4 of Example 1, except that 1-ethynyl-2-(trifluoromethoxy)benzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0253]

25 $^1\text{H-NMR}$ (CD_3OD) δ : 8.26 (1H, s), 7.68-7.62 (1H, m), 7.65 (1H, s), 7.50-7.46 (1H, m), 7.42-7.38 (2H, m), 5.86 (1H, d, $J = 7.1$ Hz), 4.86-4.81 (1H, m), 4.31-4.29 (1H, m), 4.27-4.25 (1H, m), 3.40-3.35 (2H, m). LCMS (ESI) m/z 529 $[\text{M}+\text{H}]^+$.

[0254]

30 Example 15

4-Amino-7- $[(2R,3R,4S,5R)\text{-}3,4\text{-dihydroxy-}5\text{-}[(\text{sulfamoylamino})\text{methyl}]\text{tetrahydrofuran-}2\text{-yl}]\text{-}5\text{-}[2-(2\text{-methoxy-}1\text{-naphthyl})\text{ethynyl}]\text{pyrrolo}[2,3\text{-}d]\text{pyrimidine}$

The title compound was obtained as in step 4 of Example 1, except that 1-ethynyl-2-methoxynaphthalene was used in place

of 2-ethynyl-1,3-difluorobenzene.

[0255]

¹H-NMR (CD₃OD) δ: 8.23 (1H, s), 7.89-7.80 (2H, m), 7.66-7.57 (1H, m), 7.64 (1H, s), 7.58-7.54 (1H, m), 7.42-7.36 (2H, m), 5.90 (1H, d, J = 8.0 Hz), 4.83-4.81 (1H, m), 4.37-4.33 (1H, m), 4.27-4.25 (1H, m), 4.06 (3H, s), 3.40-3.35 (2H, m). LCMS (ESI) m/z 525 [M+H]⁺.

[0256]

Example 16

10 4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2,6-
dimethoxyphenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example 1, except that 2-ethynyl-1,3-dimethoxybenzene was used in place
15 of 2-ethynyl-1,3-difluorobenzene.

[0257]

¹H-NMR (CD₃OD) δ: 8.22 (1H, s), 7.50 (1H, s), 7.28 (1H, t, J = 8.5 Hz), 6.69 (2H, d, J = 8.5 Hz), 5.86 (1H, d, J = 6.8 Hz), 4.83-4.81 (1H, m), 4.32-4.30 (1H, m), 4.27-4.25 (1H, m), 3.91 (6H, s),
20 3.40-3.35 (2H, m). LCMS (ESI) m/z 505 [M+H]⁺.

[0258]

Example 17

8-[2-[4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
25 d]pyrimidin-5-yl]ethynyl]quinoline

The title compound was obtained as in step 4 of Example 1, except that 8-ethynylquinoline was used in place of 2-ethynyl-1,3-difluorobenzene.

[0259]

¹H-NMR (CD₃OD) δ: 8.99 (1H, dd, 4.1, 1.7 Hz), 8.33 (1H, dd, 8.5, 1.7 Hz), 8.22 (1H, s), 7.91 (1H, s), 7.90-7.82 (2H, m), 7.58-7.52 (2H, m), 5.86 (1H, d, J = 6.8 Hz), 4.87-4.85 (1H, m), 4.32-4.30 (1H, m), 4.27-4.25 (1H, m), 3.40-3.35 (2H, m). LCMS (ESI) m/z 496 [M+H]⁺.

35 [0260]

Example 18

4-Amino-5-[2-[2-(difluoromethoxy)phenyl]ethynyl]-7-
[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
5 d]pyrimidine

The title compound was obtained as in step 4 of Example 1, except that 1-(difluoromethoxy)-2-ethynylbenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0261]

10 ¹H-NMR (CD₃OD) δ: 8.24 (1H, s), 7.62 (1H, s), 7.58 (1H, d, J = 7.8, 1.7 Hz), 7.43-7.39 (1H, m), 7.28-7.23 (2H, m), 7.01 (1H, t, J = 7.2 Hz), 5.86 (1H, d, J = 6.8 Hz), 4.87-4.85 (1H, m), 4.32-4.30 (1H, m), 4.27-4.25 (1H, m), 3.40-3.35 (2H, m). LCMS (ESI) m/z 511 [M+H]⁺.

15 [0262]

Example 19

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(1H-
pyrazolo[4,3-b]pyridin-5-yl)ethynyl]pyrrolo[2,3-d]pyrimidine

20 The title compound was obtained as in step 4 of Example 1, except that 5-ethynyl-1H-pyrazolo[4,3-b]pyridine was used in place of 2-ethynyl-1,3-difluorobenzene.

[0263]

¹H-NMR (CD₃OD) δ: 8.25 (1H, s), 8.23 (1H, s), 8.06 (1H, d, J = 8.8 Hz), 7.75 (1H, s), 7.64 (1H, d, J = 8.8 Hz), 5.89 (1H, d, J = 6.8 Hz), 4.87-4.85 (1H, m), 4.34-4.30 (1H, m), 4.27-4.25 (1H, m), 3.40-3.35 (2H, m). LCMS (ESI) m/z 486 [M+H]⁺.

[0264]

Example 20

30 4-Amino-5-[2-(4-amino-2-fluoro-phenyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example 1, except that 4-ethynyl-3-fluoroaniline was used in place of 2-
35 ethynyl-1,3-difluorobenzene.

[0265]

¹H-NMR (CD₃OD) δ: 8.22 (1H, s), 7.48 (1H, s), 7.21-7.17 (1H, m),
6.46-6.41 (2H, m), 5.84 (1H, d, J = 6.8 Hz), 4.87-4.85 (1H, m),
4.32-4.28 (1H, m), 4.27-4.24 (1H, m), 3.40-3.35 (2H, m). LCMS
5 (ESI) m/z 478 [M+H]⁺.

[0266]

Example 21

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-(2-indan-1-
10 ylethynyl)pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example
1, except that 1-ethynyl-2,3-dihydro-1H-indene was used in place
of 2-ethynyl-1,3-difluorobenzene.

[0267]

15 ¹H-NMR (CD₃OD) δ: 8.19 (1H, s), 7.42 (1H, s), 7.42-7.38 (1H, m),
7.26-7.18 (3H, m), 5.81 (1H, d, J = 7.1 Hz), 4.84-4.79 (1H, m),
4.30-4.18 (3H, m), 3.40-3.35 (2H, m), 3.04-2.91 (2H, m), 2.62-
2.54 (1H, m), 2.19-2.11 (1H, m). LCMS (ESI) m/z 485 [M+H]⁺.

[0268]

20 Example 22

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-
methylsulfonylphenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example
25 1, except that 1-ethynyl-2-(methylsulfonyl)benzene was used in
place of 2-ethynyl-1,3-difluorobenzene.

[0269]

¹H-NMR (CD₃OD) δ: 8.24 (1H, s), 8.07 (1H, dd, J = 7.7, 1.3 Hz),
7.79 (1H, dd, J = 7.7, 1.3 Hz), 7.77 (1H, s), 7.75-7.70 (1H, m),
30 7.62-7.57 (1H, m), 5.89 (1H, d, J = 6.8 Hz), 4.85-4.81 (1H, m),
4.33-4.29 (1H, m), 4.28-4.24 (1H, m), 3.40-3.35 (2H, m), 3.30 (3H,
s). LCMS (ESI) m/z 523 [M+H]⁺.

[0270]

Example 23

35 4-[4-[2-[4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-

[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-3,5-difluoro-phenyl)morpholine

Step 1: Synthesis of 4-(4-ethynyl-3,5-difluorophenyl)morpholine

2-Ethynyl-1,3,5-trifluorobenzene (52 mg, 0.33 mmol) and cesium carbonate (163 mg, 0.50 mmol) were dissolved in N,N-dimethylformamide (0.50 mL). Morpholine (0.044 mL, 0.50 mmol) was added thereto at room temperature, followed by stirring at 80°C overnight. After the resulting mixture was air-cooled to room temperature, ethyl acetate (2.0 mL) and a saturated aqueous ammonium chloride solution (1.0 mL) were sequentially added thereto, and the mixture was partitioned into an aqueous layer and an organic layer. The organic layer was then sequentially washed with water and saturated saline, and dried over anhydrous sodium sulfate, followed by distilling off the solvent. The residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining 4-(4-ethynyl-3,5-difluorophenyl)morpholine (40 mg, 54%) as a white solid.

[0271]

¹H-NMR (CDCl₃) δ: 6.37 (2H, d, J = 10.7 Hz), 3.83 (4H, dd, J = 5.7, 4.2 Hz), 3.40 (1H, s), 3.19 (4H, dd, J = 5.7, 4.2 Hz). LCMS (ESI) m/z 224 [M+H]⁺

Step 2: Synthesis of example compound 23

The title compound was obtained as in step 4 of Example 1, except that 4-(4-ethynyl-3,5-difluorophenyl)morpholine was used in place of 2-ethynyl-1,3-difluorobenzene.

[0272]

¹H-NMR (CD₃OD) δ: 8.23 (1H, s), 7.56 (1H, s), 6.63 (2H, d, J = 11.5 Hz), 5.85 (1H, d, J = 7.1 Hz), 4.85-4.79 (1H, m), 4.30 (1H, dd, J = 5.6, 2.4 Hz), 4.27-4.23 (1H, m), 3.80 (4H, t, J = 4.9 Hz), 3.42-3.32 (2H, m), 3.27-3.22 (4H, m). LCMS (ESI) m/z 566 [M+H]⁺.

[0273]

Example 24

4-Amino-5-[2-(4-amino-2,6-difluoro-phenyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-

[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example 1, except that 4-ethynyl-3,5-difluoroaniline was used in place of 2-ethynyl-1,3-difluorobenzene.

[0274]

¹H-NMR (CD₃OD) δ: 8.23 (1H, s), 7.52 (1H, s), 6.26 (2H, d, J = 10.2 Hz), 5.85 (1H, d, J = 6.8 Hz), 4.85-4.81 (1H, m), 4.33-4.29 (1H, m), 4.26-4.23 (1H, m), 3.40-3.34 (2H, m). LCMS (ESI) m/z 496 [M+H]⁺.

[0275]

Example 25

4-Amino-5-[2-[2,6-difluoro-4-(methylamino)phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 4-ethynyl-3,5-difluoro-N-methylaniline

The title compound was obtained as in step 1 of Example 23, except that methylamine was used in place of morpholine.

[0276]

¹H-NMR (CDCl₃) δ: 6.11 (2H, d, J = 10.6 Hz), 4.22-4.14 (1H, brm), 3.39 (1H, s), 2.84 (3H, s). LRMS (ESI) m/z 168 [M+H]⁺

Step 2: Synthesis of example compound 25

The title compound was obtained as in step 4 of Example 1, except that 4-ethynyl-3,5-difluoro-N-methylaniline was used in place of 2-ethynyl-1,3-difluorobenzene.

[0277]

¹H-NMR (CD₃OD) δ: 8.24 (1H, s), 8.18 (1H, brs), 8.03 (1H, dd, J = 7.7, 1.1 Hz), 7.53 (1H, s), 7.48 (1H, t, J = 7.7 Hz), 6.22 (2H, d, J = 11.0 Hz), 5.86 (1H, d, J = 7.0 Hz), 4.86-4.81 (1H, m), 4.32 (1H, dd, J = 5.5, 2.2 Hz), 4.27-4.25 (1H, m), 3.43-3.34 (2H, m), 2.79 (3H, s). LCMS (ESI) m/z 510 [M+H]⁺.

[0278]

Example 26

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-

[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-[4-(ethylamino)-2,6-difluoro-phenyl]ethynyl]pyrrolo[2,3-d]pyrimidine
Step 1: Synthesis of N-ethyl-4-ethynyl-3,5-difluoroaniline

The title compound was obtained as in step 1 of Example 23, except that ethylamine was used in place of morpholine.

[0279]

¹H-NMR (CDCl₃) δ: 6.10 (2H, d, J = 10.3 Hz), 4.07-4.00 (1H, brm), 3.38 (1H, s), 3.18-3.11 (2H, m), 1.27 (5H, t, J = 7.3 Hz). LRMS (ESI) m/z 182 [M+H]⁺

Step 2: Synthesis of example compound 26

The title compound was obtained as in step 4 of Example 1, except that N-ethyl-4-ethynyl-3,5-difluoroaniline was used in place of 2-ethynyl-1,3-difluorobenzene.

[0280]

¹H-NMR (CD₃OD) δ: 8.24 (1H, s), 8.07-8.00 (1H, m), 7.59-7.45 (1H, m), 7.57 (1H, s), 6.23 (2H, d, J = 11.0 Hz), 5.89 (1H, d, J = 7.0 Hz), 4.80 (1H, dd, J = 7.0, 5.5 Hz), 4.32 (1H, dd, J = 5.5, 2.6 Hz), 4.26 (1H, ddd, J = 4.0, 3.7, 2.6 Hz), 3.41 (1H, dd, J = 13.2, 3.7 Hz), 3.36 (1H, dd, J = 13.2, 4.0 Hz), 3.13 (2H, q, J = 7.3 Hz), 1.25 (3H, t, J = 7.3 Hz). LCMS (ESI) m/z 524 [M+H]⁺

Example 27

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-[3-(isopropylamino)phenyl]ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example 1, except that 3-ethynyl-N-isopropylaniline was used in place of 2-ethynyl-1,3-difluorobenzene.

[0281]

¹H-NMR (CD₃OD) δ: 8.24 (1H, s), 7.55 (1H, s), 7.11 (1H, t, J = 8.3 Hz), 6.79-6.76 (2H, m), 6.67-6.65 (1H, m), 5.86 (1H, d, J = 6.8 Hz), 4.84-4.79 (1H, m), 4.31 (1H, dd, J = 5.6, 2.4 Hz), 4.25 (1H, q, J = 3.2 Hz), 3.67-3.54 (1H, m), 3.39-3.35 (2H, m), 1.20 (6H, d, J = 6.3 Hz). LCMS (ESI) m/z 502 [M+H]⁺.

[0282]

Example 28

4-Amino-5-[2-(5-amino-2-fluoro-phenyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example 1, except that 3-ethynyl-4-fluoroaniline was used in place of 2-ethynyl-1,3-difluorobenzene.

[0283]

¹H-NMR (DMSO-D₆) δ: 8.18 (1H, s), 7.90 (1H, s), 7.38-7.33 (1H, m), 6.99 (1H, t, J = 9.3 Hz), 6.70 (1H, dd, J = 6.1, 2.9 Hz), 6.62-6.56 (3H, m), 5.92 (1H, d, J = 7.1 Hz), 5.40 (1H, d, J = 6.3 Hz), 5.23 (1H, d, J = 4.4 Hz), 5.16 (2H, s), 4.57 (1H, dd, J = 12.1, 6.7 Hz), 4.12-4.08 (1H, m), 4.07-4.03 (1H, m), 3.24-3.08 (2H, m). LCMS (ESI) m/z 478 [M+H]⁺.

[0284]

Example 29

4-Amino-5-[2-[2,6-difluoro-4-[(3R)-3-fluoropyrrolidin-1-yl]phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of (3R)-1-(4-ethynyl-3,5-difluorophenyl)-3-fluoropyrrolidine

The title compound was obtained as in step 1 of Example 23, except that (R)-3-fluoropyrrolidine was used in place of morpholine.

[0285]

¹H-NMR (CDCl₃) δ: 6.07 (2H, d, J = 10.3 Hz), 5.38 (1H, d, J = 52.8 Hz), 3.59-3.38 (5H, m), 2.47-2.36 (1H, m), 2.27-2.06 (1H, m). LCMS (ESI) m/z 226 [M+H]⁺

Step 2: Synthesis of example compound 29

The title compound was obtained as in step 4 of Example 1, except that (3R)-1-(4-ethynyl-3,5-difluorophenyl)-3-fluoropyrrolidine was used in place of 2-ethynyl-1,3-difluorobenzene.

[0286]

¹H-NMR (DMSO-D₆) δ: 8.16 (1H, s), 7.84 (1H, s), 7.35-7.30 (1H, m),

6.58 (2H, s), 6.42 (2H, d, J = 11.2 Hz), 5.91 (1H, d, J = 7.1 Hz),
5.45 (1H, d, J = 52.7 Hz), 5.37 (1H, d, J = 6.3 Hz), 5.20 (1H, d,
J = 4.4 Hz), 4.56 (1H, dd, J = 12.1, 6.7 Hz), 4.11-4.07 (1H, m),
4.06-4.01 (1H, m), 3.61-3.45 (3H, m), 3.41-3.33 (1H, m), 3.24-
5 3.16 (1H, m), 3.14-3.06 (1H, m), 2.30-2.10 (2H, m). LCMS (ESI)
m/z 568 [M+H]⁺.

[0287]

Example 30

4-Amino-5-[2-[2,6-difluoro-4-[(3R)-3-hydroxypyrrolidin-1-
10 yl]phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
d]pyrimidine

Step 1: Synthesis of (3R)-1-(4-ethynyl-3,5-difluorophenyl)-
pyrrolidin-3-ol

15 The title compound was obtained as in step 1 of Example
23, except that (R)-pyrrolidin-3-ol was used in place of
morpholine.

[0288]

¹H-NMR (CDCl₃) δ: 6.02 (2H, d, J = 10.5 Hz), 4.63-4.60 (1H, m),
20 3.50-3.43 (2H, m), 3.40-3.38 (1H, m), 3.33 (1H, dt, J = 3.3, 9.0
Hz), 3.22 (1H, d, J = 10.7 Hz), 2.22-2.11 (1H, m), 2.11-2.06 (1H,
m). LCMS (ESI) m/z 224 [M+H]⁺

Step 2: Synthesis of example compound 30

The title compound was obtained as in step 4 of Example
25 1, except that (3R)-1-(4-ethynyl-3,5-difluorophenyl)-pyrrolidin-
3-ol was used in place of 2-ethynyl-1,3-difluorobenzene.

[0289]

¹H-NMR (DMSO-D₆) δ: 8.17 (1H, s), 7.85 (1H, s), 7.36 (1H, dd, J =
7.7, 4.8 Hz), 6.60 (2H, s), 6.35 (2H, d, J = 11.0 Hz), 5.91 (1H,
30 d, J = 7.0 Hz), 5.39 (1H, d, J = 6.2 Hz), 5.23 (1H, d, J = 4.4
Hz), 5.06 (1H, d, J = 3.7 Hz), 4.60-4.55 (1H, m), 4.42-4.37 (1H,
m), 4.11-4.07 (1H, m), 4.06-4.02 (1H, m), 3.45-3.37 (2H, m),
3.24-3.18 (1H, m), 3.16-3.09 (2H, m), 2.07-1.99 (1H, m), 1.94-
1.86 (1H, m). LCMS (ESI) m/z 566.3 [M+H]⁺.

35 [0290]

Example 31

4-Amino-5-[3-(2,6-difluorophenyl)prop-1-ynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

5 The title compound was obtained as in step 4 of Example 1, except that 1,3-difluoro-2-(prop-2-yn-1-yl)benzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0291]

¹H-NMR (CD₃OD) δ: 8.20 (1H, s), 7.40 (1H, s), 7.36-7.30 (1H, m),
10 7.04-6.99 (2H, m), 5.79 (1H, d, J = 6.8 Hz), 4.80-4.69 (1H, m),
4.28-4.25 (1H, m), 4.22-4.20 (1H, m), 3.88 (2H, s), 3.39-3.32 (2H, m). LCMS (ESI) m/z 495 [M+H].

[0292]

Example 32

15 4-Amino-5-[2-[2,6-difluoro-4-(2-hydroxyethylamino)phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

 2-((4-Ethynyl-3,5-difluorophenyl)amino)ethanol was
20 obtained as in step 1 of Example 23, except that 2-aminoethanol was used in place of morpholine, and the title compound was then obtained as in step 4 of Example 1, except that the thus-obtained 2-((4-ethynyl-3,5-difluorophenyl)amino)ethanol was used in place of 2-ethynyl-1,3-difluorobenzene.

25 [0293]

¹H-NMR (DMSO-D₆) δ: 8.20 (1H, s), 7.91 (1H, s), 7.38 (1H, s), 7.03
(2H, t, J = 9.5 Hz), 6.61 (2H, brs), 5.93 (1H, d, J = 6.6 Hz),
5.47-5.36 (1H, m), 5.34-5.18 (1H, m), 4.60 (1H, t, J = 10.0 Hz),
4.13-4.08 (1H, m), 4.08-4.04 (1H, m), 3.26-3.19 (1H, m), 3.16-
30 3.08 (1H, m), 2.55 (2H, s). LCMS (ESI) m/z 540.3 [M+H]⁺.

[0294]

Example 33

4-Amino-5-[2-[2,6-difluoro-4-(2-oxopyrrolidin-1-yl)phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
35 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-

d]pyrimidine

Step 1: Synthesis of 1-(4-ethynyl-3,5-difluorophenyl)pyrrolidin-2-one

The title compound was obtained as in step 1 of Example 23, except that pyrrolidin-2-one was used in place of morpholine. [0295]

¹H-NMR (CDCl₃) δ: 7.35 (2H, d, J = 10.0 Hz), 3.82 (2H, t, J = 7.2 Hz), 3.47 (1H, s), 2.65 (2H, t, J = 8.2 Hz), 2.23-2.15 (2H, m).

LCMS (ESI) m/z 222 [M+H]⁺

Step 2: Synthesis of example compound 33

The title compound was obtained as in step 4 of Example 1, except that 1-(4-ethynyl-3,5-difluorophenyl)pyrrolidin-2-one was used in place of 2-ethynyl-1,3-difluorobenzene.

[0296]

¹H-NMR (DMSO-D₆) δ: 8.18 (1H, s), 7.97 (1H, s), 7.64 (2H, d, J = 10.5 Hz), 7.33-7.30 (1H, brs), 6.58 (2H, s), 5.92 (1H, d, J = 7.3 Hz), 5.38 (1H, d, J = 6.8 Hz), 5.21 (1H, d, J = 4.1 Hz), 4.60-4.54 (1H, m), 4.08-4.07 (1H, m), 4.05-4.02 (1H, m), 3.84 (2H, t, J = 7.2 Hz), 3.27-3.18 (1H, m), 3.15-3.08 (1H, m), 2.56 (2H, t, J = 8.2 Hz), 2.10-2.02 (2H, m). LCMS (ESI) m/z 564 [M+H].

[0297]

Example 34

4-[4-[2-[4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-((sulfamoylamino)methyl)tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-3-ethoxy-5-fluoro-phenyl]morpholine

Step 1: Synthesis of 4-(3-ethoxy-4-ethynyl-5-fluorophenyl)morpholine

4-(4-ethynyl-3,5-difluorophenyl)morpholine (100 mg, 0.448 mmol) was dissolved in ethanol (3 mL). Sodium ethoxide (a 21 wt% ethanol solution, 0.168 mL, 0.448 mmol) was added thereto, followed by stirring for 0.5 hours in a sealed container at 160°C. After the resulting mixture was air-cooled to room temperature, ethyl acetate (5.0 mL) and a saturated ammonium chloride solution (2.0 mL) were sequentially added thereto, and the mixture was

partitioned into an aqueous layer and an organic layer. The organic layer was then sequentially washed with water and saturated saline, and dried over anhydrous sodium sulfate, followed by distilling off the solvent. The residue was purified by silica gel column chromatography (developing solvent: hexane/ethyl acetate), thereby obtaining 4-(3-ethoxy-4-ethynyl-5-fluorophenyl)morpholine (60 mg, 54%) as a green solid.

[0298]

¹H-NMR (CDCl₃) δ: 6.20 (1H, dd, J = 12.1, 2.2 Hz), 6.13 (1H, s), 4.12-4.07 (2H, m), 3.85-3.82 (4H, m), 3.41 (1H, s), 3.20-3.15 (4H, m), 1.46 (3H, t, J = 7.1 Hz). LCMS (ESI) m/z 250 [M+H]⁺

Step 2: Synthesis of example compound 34

The title compound was obtained as in Example 1, except that 4-(3-ethoxy-4-ethynyl-5-fluorophenyl)morpholine was used in place of 2-ethynyl-1,3-difluorobenzene.

[0299]

¹H-NMR (DMSO-D₆) δ: 8.17 (1H, s), 7.77 (1H, s), 7.41-7.36 (1H, m), 6.60 (2H, s), 6.48 (1H, d, J = 13.6 Hz), 6.42 (1H, s), 5.90 (1H, d, J = 7.0 Hz), 5.37 (1H, d, J = 6.6 Hz), 5.21 (1H, d, J = 4.4 Hz), 4.60-4.55 (1H, m), 4.20 (2H, q, J = 7.0 Hz), 4.12-4.07 (1H, m), 4.06-4.02 (1H, m), 3.74-3.69 (4H, m), 3.27-3.05 (6H, m), 1.36 (3H, t, J = 7.0 Hz). LCMS (ESI) m/z 592 [M+H]⁺.

[0300]

Example 35

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-ethoxy-4,6-difluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 1-ethoxy-2-ethynyl-3,5-difluorobenzene

The title compound was obtained as in step 1 of Example 34, except that 2-ethynyl-1,3,5-trifluorobenzene was used in place of 4-(4-ethynyl-3,5-difluorophenyl)morpholine.

[0301]

¹H-NMR (CDCl₃) δ: 6.48-6.39 (2H, m), 4.09 (2H, q, J = 7.0 Hz), 3.45 (1H, s), 1.47 (3H, t, J = 7.0 Hz).

Step 2: Synthesis of example compound 35

The title compound was obtained as in Example 1, except that 1-ethoxy-2-ethynyl-3,5-difluorobenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0302]

5 ¹H-NMR (DMSO-D₆) δ: 8.18 (1H, s), 7.90 (1H, s), 7.36 (1H, s), 7.02-6.97 (2H, m), 6.61-6.58 (2H, m), 5.92 (1H, d, J = 7.1 Hz), 5.41-5.36 (1H, m), 5.24-5.21 (1H, m), 4.61-4.55 (1H, m), 4.24 (2H, q, J = 7.0 Hz), 4.11-4.08 (1H, m), 4.07-4.03 (1H, m), 3.25-3.07 (2H, m), 1.38 (3H, t, J = 7.0 Hz). LCMS (ESI) m/z 525 [M+H]⁺.

10 [0303]

Example 36

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[3-(2-
fluorophenyl)prop-1-ynyl]pyrrolo[2,3-d]pyrimidine

15 The title compound was obtained as in Example 1, except that 1-fluoro-2-(prop-2-yn-1-yl)benzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0304]

20 ¹H-NMR (CD₃OD) δ: 8.20 (1H, s), 7.54 (1H, t, J = 8.0 Hz), 7.45 (1H, s), 7.33-7.25 (1H, m), 7.20-7.16 (1H, m), 7.13-7.08 (1H, m), 5.82 (1H, d, J = 6.8 Hz), 4.80-4.77 (1H, m), 4.30-4.28 (1H, m), 4.24-4.23 (1H, m), 3.90 (2H, s), 3.40-3.31 (2H, m). LCMS (ESI) m/z 477 [M+H].

[0305]

25 Example 37

4-[4-[2-[4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
d]pyrimidin-5-yl]ethynyl]-3,5-difluoro-phenyl]thiomorpholine
Step 1: Synthesis of 4-(4-ethynyl-3,5-
30 difluorophenyl)thiomorpholine

The title compound was obtained as in step 1 of Example 23, except that thiomorpholine was used in place of morpholine.

[0306]

35 ¹H-NMR (CDCl₃) δ: 6.32 (2H, d, J = 11.0 Hz), 3.69-3.66 (4H, m), 3.38 (1H, s), 2.69-2.66 (4H, m). LCMS (ESI) m/z 240 [M+H]⁺

Step 2: Synthesis of example compound 37

The title compound was obtained as in Example 1, except that 4-(4-ethynyl-3,5-difluorophenyl)thiomorpholine was used in place of 2-ethynyl-1,3-difluorobenzene.

5 [0307]

¹H-NMR (DMSO-D₆) δ: 8.18 (1H, s), 7.87 (1H, s), 7.36-7.32 (1H, m), 6.78 (2H, d, J = 12.1 Hz), 6.59 (2H, s), 5.92 (1H, d, J = 7.0 Hz), 5.46-5.32 (1H, m), 5.30-5.16 (1H, m), 4.59-4.55 (1H, m), 4.11-4.07 (1H, m), 4.06-4.02 (1H, m), 3.78-3.72 (4H, m), 3.24-3.06 (2H, m), 2.63-2.58 (4H, m). LCMS (ESI) m/z 582 [M+H]⁺.

[0308]

Example 38

4-Amino-5-[2-[2,6-difluoro-4-(3-hydroxy-1-piperidyl)phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
15 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 1-(4-ethynyl-3,5-difluorophenyl)piperidin-3-ol

The title compound was obtained as in step 1 of Example 20 23, except that piperidin-3-ol was used in place of morpholine.

[0309]

¹H-NMR (CDCl₃) δ: 6.39 (2H, dt, J = 17.2, 3.2 Hz), 3.91-3.83 (1H, m), 3.49 (1H, dd, J = 12.7, 3.4 Hz), 3.38 (1H, s), 3.31-3.28 (1H, m), 3.12-3.00 (2H, m), 1.98-1.82 (3H, m), 1.68-1.56 (2H, m). LCMS
25 (ESI) m/z 238 [M+H]⁺

Step 2: Synthesis of example compound 38

The title compound was obtained as in Example 1, except that 1-(4-ethynyl-3,5-difluorophenyl)piperidin-3-ol was used in place of 2-ethynyl-1,3-difluorobenzene.

30 [0310]

¹H-NMR (DMSO-D₆) δ: 8.20 (1H, s), 7.86 (1H, s), 7.36-7.32 (1H, m), 6.72 (2H, d, J = 12.1 Hz), 6.59 (2H, s), 5.92 (1H, d, J = 7.0 Hz), 5.38 (1H, d, J = 6.2 Hz), 5.22 (1H, d, J = 3.3 Hz), 4.88-4.83 (1H, m), 4.60-4.54 (1H, m), 4.11-4.08 (1H, m), 4.06-4.03 (1H, m),
35 3.68-3.51 (3H, m), 3.25-3.17 (1H, m), 3.15-3.07 (1H, m), 3.01-

2.94 (1H, m), 2.84 (1H, dd, J = 12.6, 8.6 Hz), 1.89-1.83 (1H, m), 1.75-1.69 (1H, m), 1.48-1.34 (2H, m). LCMS (ESI) m/z 580 [M+H]⁺.
[0311]

Example 39

5 4-Amino-5-[2-[2,6-difluoro-4-(3-hydroxyazetidin-1-yl)phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 1-(4-ethynyl-3,5-difluorophenyl)azetidin-3-ol
10 ol

The title compound was obtained as in step 1 of Example 23, except that azetidin-3-ol was used in place of morpholine.
[0312]

¹H-NMR (CDCl₃) δ: 5.90 (2H, dq, J = 19.2, 3.4 Hz), 4.83-4.76 (1H, m),
15 m), 4.17 (2H, dd, J = 8.4, 7.0 Hz), 3.75 (2H, dd, J = 8.4, 4.2 Hz), 3.38 (1H, s), 2.21 (1H, d, J = 6.2 Hz). LCMS (ESI) m/z 210 [M+H]⁺

Step 2: Synthesis of example compound 39

The title compound was obtained as in Example 1, except
20 that 1-(4-ethynyl-3,5-difluorophenyl)azetidin-3-ol was used in place of 2-ethynyl-1,3-difluorobenzene.

[0313]

¹H-NMR (DMSO-D₆) δ: 8.17 (1H, s), 7.85 (1H, s), 7.37-7.32 (1H, m), 6.59 (2H, s), 6.24 (2H, d, J = 9.9 Hz), 5.91 (1H, d, J = 7.0 Hz),
25 5.75 (1H, d, J = 6.6 Hz), 5.38 (1H, d, J = 6.6 Hz), 5.22 (1H, d, J = 4.4 Hz), 4.60-4.54 (2H, m), 4.16-4.07 (3H, m), 4.06-4.02 (1H, m), 3.64 (2H, dd, J = 8.6, 4.6 Hz), 3.25-3.17 (1H, m), 3.14-3.05 (1H, m). LCMS (ESI) m/z 552 [M+H]⁺.

[0314]

30 Example 40

4-Amino-5-[2-[2,6-difluoro-4-[(3R)-3-hydroxy-1-piperidyl]phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

35 Step 1: Synthesis of (3R)-1-(4-ethynyl-3,5-

difluorophenyl)piperidin-3-ol

The title compound was obtained as in step 1 of Example 23, except that (R)-piperidin-3-ol was used in place of morpholine.

5 [0315]

¹H-NMR (CDCl₃) δ: 6.39 (2H, d, J = 11.0 Hz), 3.91-3.84 (1H, m), 3.49 (1H, dd, J = 12.5, 3.3 Hz), 3.38 (1H, s), 3.33-3.27 (1H, m), 3.12-3.01 (2H, m), 1.98-1.85 (2H, m), 1.80 (1H, d, J = 6.2 Hz), 1.69-1.60 (1H, m). LCMS (ESI) m/z 238 [M+H]⁺

10 Step 2: Synthesis of example compound 40

The title compound was obtained as in Example 1, except that (3R)-1-(4-ethynyl-3,5-difluorophenyl)piperidin-3-ol was used in place of 2-ethynyl-1,3-difluorobenzene.

[0316]

15 ¹H-NMR (DMSO-D₆) δ: 8.17 (1H, s), 7.86 (1H, s), 7.36-7.32 (1H, m), 6.72 (2H, d, J = 12.1 Hz), 6.59 (2H, s), 5.92 (1H, d, J = 7.0 Hz), 5.38 (1H, d, J = 6.6 Hz), 5.22 (1H, d, J = 4.4 Hz), 4.86 (1H, d, J = 4.4 Hz), 4.57 (1H, dd, J = 12.3, 6.8 Hz), 4.11-4.08 (1H, m), 4.06-4.03 (1H, m), 3.68-3.50 (3H, m), 3.23-3.18 (1H, m), 3.15-
20 3.07 (1H, m), 3.01-2.94 (1H, m), 2.84 (1H, dd, J = 12.6, 8.6 Hz), 1.89-1.83 (1H, m), 1.75-1.69 (1H, m), 1.47-1.37 (2H, m). LCMS (ESI) m/z 580 [M+H]⁺.

[0317]

Example 41

25 1-[4-[2-[4-amino-7-[(2R,3R,4S,5R)]-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidin-yl]ethynyl]-3,5-difluoro-phenyl]pyrrolidine-3-carboxylic acid

Step 1: Synthesis of 1-(4-ethynyl-3,5-difluorophenyl)pyrrolidine-30 3-carboxylic acid

The title compound was obtained as in step 1 of Example 23, except that pyrrolidine-3-carboxylic acid was used in place of morpholine.

[0318]

35 ¹H-NMR (CDCl₃) δ: 6.06 (2H, d, J = 10.3 Hz), 3.61-3.52 (2H, m),

-87A-

3.46-3.25 (4H, m), 2.38-2.33 (2H, m). LCMS (ESI) m/z 252 [M+H]⁺

Step 2: Synthesis of example compound 41

The title compound was obtained as in step 4 of Example 1, except that 1-(4-ethynyl-3,5-difluorophenyl)pyrrolidine-3-carboxylic acid was used in place of 2-ethynyl-1,3-

5 difluorobenzene.

[0319]

¹H-NMR (DMSO-D₆) δ: 12.59 (1H, s), 8.17 (1H, s), 7.85 (1H, s), 7.36-7.32 (1H, m), 6.59 (2H, s), 6.39 (2H, d, J = 11.0 Hz), 5.91 (1H, d, J = 7.0 Hz), 5.38 (1H, d, J = 6.2 Hz), 5.22 (1H, d, J = 10 4.4 Hz), 4.59-4.55 (1H, m), 4.12-4.08 (1H, m), 4.06-4.02 (1H, m), 3.54-3.42 (2H, m), 3.24-3.07 (5H, m), 2.27-2.11 (2H, m). LCMS (ESI) m/z 594 [M+H]⁺.

[0320]

Example 42

15 4-Amino-5-[2-[2,6-difluoro-4-(4-oxo-1-piperidyl)phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 1-(4-ethynyl-3,5-difluorophenyl)piperidin-4-one
20 one

The title compound was obtained as in step 1 of Example 23, except that piperidin-4-one was used in place of morpholine.

[0321]

¹H-NMR (CDCl₃) δ: 6.40 (2H, d, J = 11.0 Hz), 3.66 (4H, t, J = 6.0 25 Hz), 3.41 (1H, s), 2.57 (4H, t, J = 6.0 Hz). LCMS (ESI) m/z 236 [M+H]⁺

Step 2: Synthesis of example compound 42

The title compound was obtained as in step 4 of Example 1, except that 1-(4-ethynyl-3,5-difluorophenyl)piperidin-4-one 30 was used in place of 2-ethynyl-1,3-difluorobenzene.

[0322]

¹H-NMR (DMSO-D₆) δ: 8.18 (1H, s), 7.88 (1H, s), 7.37-7.32 (1H, m), 6.86 (2H, d, J = 11.7 Hz), 6.60 (2H, s), 5.92 (1H, d, J = 7.0 Hz), 5.40 (1H, d, J = 6.2 Hz), 5.24 (1H, d, J = 4.0 Hz), 4.60-4.55 (1H, 35 m), 4.11-4.08 (1H, m), 4.06-4.03 (1H, m), 3.73 (4H, t, J = 5.9

7.5 Hz), 7.74-7.68 (2H, m), 7.52 (1H, dt, $J = 1.4, 7.5$ Hz), 7.29 (1H, m), 6.53 (2H, s), 5.87 (1H, d, $J = 6.8$ Hz), 5.40 (1H, brs), 5.23 (1H, brs), 4.53 (1H, t, $J = 5.5$ Hz), 4.04 (2H, dd, $J = 5.5, 2.7$ Hz), 4.01-3.98 (2H, brm), 3.19-3.03 (2H, m). LCMS (ESI) m/z 470 $[M+H]^+$.

[0338]

Example 50

4-Amino-5-(3-cyclohexylprop-1-ynyl)-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example 1, except that prop-2-yn-1-yl cyclohexane was used in place of 2-ethynyl-1,3-difluorobenzene.

[0339]

$^1\text{H-NMR}$ (DMSO- D_6) δ : 8.05 (1H, s), 7.56 (1H, s), 7.27 (1H, dd, $J = 7.5, 4.1$ Hz), 6.51 (2H, s), 5.79 (1H, d, $J = 6.8$ Hz), 4.46 (1H, dd, $J = 6.8, 5.5$ Hz), 4.01 (1H, dd, $J = 5.5, 2.1$ Hz), 3.97-3.94 (1H, brm), 3.17-2.99 (2H, m), 2.32 (2H, d, $J = 6.2$ Hz), 1.76-1.72 (2H, brm), 1.65-1.60 (2H, brm), 1.58-1.54 (1H, brm), 1.49-1.41 (1H, brm), 1.23-0.93 (5H, m). LCMS (ESI) m/z 465 $[M+H]^+$.

[0340]

Example 51

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-fluoro-6-methoxy-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 2-ethynyl-1-fluoro-3-methoxybenzene

2-Fluoro-6-methoxybenzaldehyde (2.0 g, 13 mmol) was dissolved in methanol (20 mL). Then, potassium carbonate (3.6 g, 26 mmol) was added thereto at room temperature, and dimethyl(1-diazo-2-oxopropyl)phosphonate (2.3 mL, 16 mmol) was added thereto under ice-cooling, followed by stirring under ice-cooling for 1 hour and at room temperature for another 1 hour. The reaction solution was partitioned with the addition of ethyl acetate, a saturated aqueous sodium hydrogen carbonate solution, and water, and the organic layer was washed with saturated saline. After

7.28 (1H, dd, J = 7.6, 5.1 Hz), 6.53 (2H, s), 5.86 (1H, d, J = 7.0 Hz), 4.52 (1H, dd, J = 7.0, 5.7 Hz), 4.04 (1H, dd, J = 5.1, 2.5 Hz), 4.01-3.97 (1H, brm), 3.18-3.02 (2H, m). LCMS (ESI) m/z 446 [M+H]⁺.

5 [0328]

Example 45

4-Amino-5-[2-(2-chlorophenyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

10 The title compound was obtained as in step 4 of Example 1, except that 1-chloro-2-ethynylbenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0329]

¹H-NMR (DMSO-D₆) δ: 8.12 (1H, s), 7.88 (1H, s), 7.63-7.52 (1H, m),
15 7.54-7.53 (1H, m), 7.38-7.32 (2H, m), 7.27 (1H, dd, J = 7.6, 5.1 Hz), 6.53 (2H, s), 5.86 (1H, d, J = 7.0 Hz), 4.51 (1H, dd, J = 7.0, 5.1 Hz), 4.03 (1H, dd, J = 5.1, 2.5 Hz), 4.00-3.97 (1H, brm), 3.19-3.02 (2H, m). LCMS (ESI) m/z 479 [M+H]⁺.

[0330]

20 Example 46

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-fluorophenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

25 The title compound was obtained as in step 4 of Example 1, except that 1-ethynyl-2-fluorobenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0331]

¹H-NMR (DMSO-D₆) δ: 8.11 (1H, s), 7.86 (1H, s), 7.58 (1H, t, J = 7.6 Hz), 7.43-7.37 (1H, m), 7.30-7.26 (2H, m), 7.21 (1H, t, J =
30 7.6 Hz), 6.52 (2H, s), 5.86 (1H, d, J = 7.0 Hz), 4.51 (1H, dd, J = 7.0, 5.1 Hz), 4.03 (1H, t, J = 2.5 Hz), 4.00-3.97 (1H, m), 3.17-3.02 (2H, m). LCMS (ESI) m/z 463 [M+H]⁺.

[0332]

Example 47

35 4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-

[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-methoxyphenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example 1, except that 1-ethynyl-2-methoxybenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0333]

¹H-NMR (DMSO-D₆) δ: 8.10 (1H, s), 7.73 (1H, s), 7.36-7.29 (3H, m), 7.04 (1H, d, J = 8.2 Hz), 6.92 (1H, t, J = 7.6 Hz), 6.53 (2H, s), 5.84 (1H, d, J = 7.0 Hz), 4.50 (1H, dd, J = 7.0, 5.1 Hz), 4.03 (1H, dd, J = 5.1, 2.5 Hz), 3.84-3.84 (1H, brm), 4.00 (3H, s), 3.21-3.01 (2H, m). LCMS (ESI) m/z 475 [M+H]⁺.

[0334]

Example 48

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-

[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(4-dimethylaminophenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example 1, except that 4-ethynyl-N,N-dimethylaniline was used in place of 2-ethynyl-1,3-difluorobenzene.

[0335]

¹H-NMR (DMSO-D₆) δ: 8.10 (1H, s), 7.73 (1H, s), 7.36-7.29 (3H, m), 7.04 (1H, d, J = 8.2 Hz), 6.92 (1H, t, J = 7.6 Hz), 6.53 (2H, s), 5.84 (1H, d, J = 7.0 Hz), 4.50 (1H, dd, J = 7.0, 5.1 Hz), 4.03 (1H, dd, J = 5.1, 2.5 Hz), 3.84-3.84 (1H, brm), 4.00 (3H, s), 3.21-3.01 (2H, m). LCMS (ESI) m/z 475 [M+H]⁺.

[0336]

Example 49

4-Amino-5-[2-(2-cyanophenyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example 1, except that 2-ethynylbenzonitrile was used in place of 2-ethynyl-1,3-difluorobenzene.

[0337]

¹H-NMR (DMSO-D₆) δ: 8.12 (1H, s), 7.93 (1H, s), 7.87 (1H, d, J =

7.5 Hz), 7.74-7.68 (2H, m), 7.52 (1H, dt, $J = 1.4, 7.5$ Hz), 7.29 (1H, m), 6.53 (2H, s), 5.87 (1H, d, $J = 6.8$ Hz), 5.40 (1H, brs), 5.23 (1H, brs), 4.53 (1H, t, $J = 5.5$ Hz), 4.04 (2H, dd, $J = 5.5, 2.7$ Hz), 4.01-3.98 (2H, brm), 3.19-3.03 (2H, m). LCMS (ESI) m/z 470 $[M+H]^+$.

[0338]

Example 50

4-Amino-5-(3-cyclohexylprop-1-ynyl)-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 4 of Example 1, except that prop-2-yn-1-yl cyclohexane was used in place of 2-ethynyl-1,3-difluorobenzene.

[0339]

$^1\text{H-NMR}$ (DMSO- D_6) δ : 8.05 (1H, s), 7.56 (1H, s), 7.27 (1H, dd, $J = 7.5, 4.1$ Hz), 6.51 (2H, s), 5.79 (1H, d, $J = 6.8$ Hz), 4.46 (1H, dd, $J = 6.8, 5.5$ Hz), 4.01 (1H, dd, $J = 5.5, 2.1$ Hz), 3.97-3.94 (1H, brm), 3.17-2.99 (2H, m), 2.32 (2H, d, $J = 6.2$ Hz), 1.76-1.72 (2H, brm), 1.65-1.60 (2H, brm), 1.58-1.54 (1H, brm), 1.49-1.41 (1H, brm), 1.23-0.93 (5H, m). LCMS (ESI) m/z 465 $[M+H]^+$.

[0340]

Example 51

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-fluoro-6-methoxy-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 2-ethynyl-1-fluoro-3-methoxybenzene

2-Fluoro-6-methoxybenzaldehyde (2.0 g, 13 mmol) was dissolved in methanol (20 mL). Then, potassium carbonate (3.6 g, 26 mmol) was added thereto at room temperature, and dimethyl(1-diazo-2-oxopropyl)phosphonate (2.3 mL, 16 mmol) was added thereto under ice-cooling, followed by stirring under ice-cooling for 1 hour and at room temperature for another 1 hour. The reaction solution was partitioned with the addition of ethyl acetate, a saturated aqueous sodium hydrogen carbonate solution, and water, and the organic layer was washed with saturated saline. After

being dried over sodium sulfate, the resulting product was filtered and concentrated, and the residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining 2-ethynyl-1-fluoro-3-methoxybenzene (1.6 g, 11 mmol, 81%) as a reddish brown solid.

[0341]

¹H-NMR (CDCl₃) δ: 7.31-7.22 (1H, m), 6.76-6.65 (2H, m), 3.92 (3H, s), 3.53 (1H, s).

Step 2: Synthesis of example compound 51

The title compound was obtained as in step 4 of Example 1, except that 2-ethynyl-1-fluoro-3-methoxybenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0342]

¹H-NMR (CD₃OD) δ: 8.23 (1H, s), 7.57 (1H, s), 7.37-7.30 (1H, m), 6.90 (1H, d, J = 8.5 Hz), 6.82-6.78 (1H, m), 5.86 (1H, d, J = 6.8 Hz), 4.87-4.85 (1H, m), 4.32-4.27 (1H, m), 4.26-4.24 (1H, m), 3.97 (3H, s), 3.40-3.35 (2H, m). LCMS (ESI) m/z 493 [M+H]⁺.

[0343]

Example 52

4-Amino-5-[2-(5-benzyloxy-2-pyridyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 5-(benzyloxy)-2-ethynylpyridine

The title compound was obtained as in step 1 of Example 51, except that 5-(benzyloxy)picolinaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

[0344]

¹H-NMR (CDCl₃) δ: 8.36 (1H, d, J = 2.9 Hz), 7.44-7.34 (5H, m), 7.20 (2H, dd, 8.8, 2.9 Hz), 5.13 (2H, s), 3.07 (1H, s). LCMS (ESI) m/z 210 [M+H]⁺

Step 2: Synthesis of example compound 52

The title compound was obtained as in step 4 of Example 1, except that 5-(benzyloxy)-2-ethynylpyridine was used in place of 2-ethynyl-1,3-difluorobenzene.

[0345]

¹H-NMR (CD₃OD) δ: 8.29 (1H, d, J = 2.9 Hz), 8.22 (1H, s), 7.65 (1H, s), 7.56 (1H, d, J = 8.0 Hz), 7.50-7.30 (6H, m), 5.86 (1H, d, J = 6.8 Hz), 5.20 (2H, s), 4.85-4.75 (1H, m), 4.35-4.20 (2H, m), 3.40-3.30 (2H, m). LCMS (ESI) m/z 552 [M+H]⁺.

5 [0346]

Example 53

4-Amino-5-[2-(4-benzyloxy-2-methoxy-phenyl)ethynyl]-7-
[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
10 d]pyrimidine

Step 1: Synthesis of 4-(benzyloxy)-1-ethynyl-2-methoxybenzene

The title compound was obtained as in step 1 of Example 51, except that 4-(benzyloxy)-2-methoxybenzaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

15 [0347]

¹H-NMR (CDCl₃) δ: 7.48-7.32 (6H, m), 6.50-6.55 (2H, m), 5.07 (2H, s), 3.87 (3H, s), 3.24 (1H, s). LCMS (ESI) m/z 239 [M+H]⁺

Step 2: Synthesis of example compound 53

The title compound was obtained as in step 4 of Example 1, except that 4-(benzyloxy)-1-ethynyl-2-methoxybenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

20 [0348]

¹H-NMR (DMSO-D₆) δ: 8.16 (1H, s), 7.74 (1H, s), 7.46-7.32 (7H, m), 6.78-6.76 (1H, brs), 6.67 (1H, d, J = 8.0 Hz), 6.63-6.59 (2H, brs), 5.90 (1H, d, J = 6.3 Hz), 5.39 (1H, d, J = 6.1 Hz), 5.23 (1H, d, J = 4.1 Hz), 5.16 (2H, s), 4.61-4.55 (1H, m), 4.12-4.08 (1H, m), 4.06-4.04 (1H, m), 3.89 (3H, s), 3.26-3.15 (1H, m), 3.15-3.03 (1H, m). LCMS (ESI) m/z 581 [M+H]⁺.

[0349]

30 Example 54

4-Amino-5-[2-(2,6-difluoro-4-hydroxy-phenyl)ethynyl]-7-
[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
d]pyrimidine

35 Step 1: Synthesis of 4-ethynyl-3,5-difluorophenol

The title compound was obtained as in step 1 of Example 51, except that 2,6-difluoro-4-hydroxybenzaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

[0350]

5 $^1\text{H-NMR}$ (CDCl_3) δ : 6.43 (2H, d, $J = 8.0$ Hz), 5.60-5.40 (1H, brs.), 3.42 (1H, s).

Step 2: Synthesis of example compound 54

The title compound was obtained as in step 4 of Example 1, except that 4-ethynyl-3,5-difluorophenol was used in place of
10 2-ethynyl-1,3-difluorobenzene.

[0351]

$^1\text{H-NMR}$ (CD_3OD) δ : 8.23 (1H, s), 7.58 (1H, s), 6.48 (2H, d, $J = 9.5$ Hz), 5.86 (1H, d, $J = 6.8$ Hz), 4.85-4.81 (1H, m), 4.33-4.29 (1H, m), 4.26-4.23 (1H, m), 3.40-3.34 (2H, m). LCMS (ESI) m/z 497
15 $[\text{M}+\text{H}]^+$.

[0352]

Example 55

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-ethoxy-6-
20 fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 2-ethoxy-6-fluorobenzaldehyde

2-Fluoro-6-hydroxybenzaldehyde (50 g, 360 mmol) was dissolved in N,N-dimethylformamide (500 mL), and potassium carbonate (74 g, 540 mmol) and iodoethane (86 mL, 1.1 mol) were
25 added thereto at room temperature, followed by stirring at room temperature overnight. The reaction solution was partitioned with the addition of ethyl acetate and water, and extracted with ethyl acetate. The organic layer was washed with water and brine and dried over sodium sulfate, followed by filtration and
30 concentration. The residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining 2-ethoxy-6-fluorobenzaldehyde (59 g, 98%) as a white solid.

[0353]

35 $^1\text{H-NMR}$ (CDCl_3) δ : 10.47 (1H, s), 7.50-7.41 (1H, m), 6.77-6.67 (2H,

m), 4.16 (2H, q, $J = 6.8$ Hz), 1.48 (3H, t, $J = 6.8$ Hz). LCMS (ESI) m/z 169 $[M+H]^+$

Step 2: Synthesis of 1-ethoxy-2-ethynyl-3-fluorobenzene

The title compound was obtained as in step 1 of Example 51, except that 2-ethoxy-6-fluorobenzaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

[0354]

$^1\text{H-NMR}$ (CDCl_3) δ : 7.28-7.20 (1H, m), 6.74-6.63 (2H, m), 4.13 (2H, q, $J = 7.1$ Hz), 3.50 (1H, s), 1.47 (3H, t, $J = 7.1$ Hz).

Step 3: Synthesis of example compound 55

The title compound was obtained as in step 4 of Example 1, except that 1-ethoxy-2-ethynyl-3-fluorobenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0355]

$^1\text{H-NMR}$ (CD_3OD) δ : 8.24 (1H, s), 7.58 (1H, s), 7.34-7.28 (1H, m), 6.88 (1H, d, $J = 8.0$ Hz), 6.82-6.74 (1H, m), 5.86 (1H, d, $J = 7.0$ Hz), 4.85-4.81 (1H, m), 4.33-4.29 (1H, m), 4.27-4.21 (3H, m), 3.40-3.34 (2H, m), 1.47 (3H, t, $J = 7.0$ Hz). LCMS (ESI) m/z 507 $[M+H]^+$.

Step 4: Synthesis of 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-ethoxy-6-fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine hydrochloride

The title compound hydrochloride was obtained as in step 5 of Example 1.

$^1\text{H-NMR}$ (DMSO-D_6) δ : 8.38 (1H, s), 8.13 (1H, s), 7.44-7.38 (1H, m), 7.01-6.91 (3H, m), 6.80-6.40 (1H, brs), 6.01 (1H, d, $J = 6.8$ Hz), 4.51-4.48 (1H, m), 4.24 (2H, q, $J = 7.0$ Hz), 4.11-4.09 (1H, m), 4.06-4.02 (1H, m), 3.24-3.19 (1H, m), 3.14-3.09 (1H, m), 1.38 (3H, t, $J = 7.0$ Hz). LCMS (ESI) m/z 507 $[M+H]^+$

30

Example 56

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-fluoro-6-isopropoxy-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 2-fluoro-6-isopropoxybenzaldehyde

The title compound was obtained as in step 1 of Example 55, except that 2-iodopropane was used in place of iodoethane.

[0356]

¹H-NMR (CDCl₃) δ: 10.44 (1H, s), 7.44 (1H, dt, J = 6.3, 8.5 Hz),
5 6.77 (1H, d, J = 8.5 Hz), 6.68 (1H, dd, J = 10.2, 8.5 Hz), 4.72-
4.62 (1H, m), 1.41 (6H, d, J = 6.1 Hz).

Step 2: Synthesis of 2-ethynyl-1-fluoro-3-isopropoxybenzene

The title compound was obtained as in step 1 of Example 51, except that 2-fluoro-6-isopropoxybenzaldehyde was used in
10 place of 2-fluoro-6-methoxybenzaldehyde.

[0357]

¹H-NMR (CDCl₃) δ: 7.22 (1H, dt, J = 6.6, 8.4 Hz), 6.71-6.65 (2H, m), 4.64-4.56 (1H, m), 3.47 (1H, s), 1.39 (6H, d, J = 6.2 Hz).

Step 3: Synthesis of example compound 56

15 The title compound was obtained as in step 4 of Example 1, except that 2-ethynyl-1-fluoro-3-isopropoxybenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0358]

¹H-NMR (CD₃OD) δ: 8.24 (1H, s), 7.57 (1H, s), 7.32-7.26 (1H, m),
20 6.89 (1H, d, J = 9.0 Hz), 6.78-6.73 (1H, m), 5.87 (1H, d, J = 6.8 Hz), 4.85-4.81 (1H, m), 4.79-4.71 (1H, m), 4.33-4.31 (1H, m), 4.27-4.24 (1H, m), 3.42-3.33 (2H, m), 1.41 (6H, d, J = 5.9 Hz).
LCMS (ESI) m/z 521 [M+H]⁺.

[0359]

25 Example 57

4-Amino-5-[2-(4-cyano-2,6-difluoro-phenyl)ethynyl]-7-
[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
d]pyrimidine

30 Step 1: Synthesis of 4-ethynyl-3,5-difluorobenzonitrile

The title compound was obtained as in step 1 of Example 51, except that 3,5-difluoro-4-formylbenzonitrile was used in place of 2-fluoro-6-methoxybenzaldehyde.

[0360]

35 ¹H-NMR (CDCl₃) δ: 7.25 (2H, d, J = 8.0 Hz), 3.73 (1H, s).

Step 2: Synthesis of example compound 57

The title compound was obtained as in step 4 of Example 1, except that 4-ethynyl-3,5-difluorobenzonitrile was used in place of 2-ethynyl-1,3-difluorobenzene.

5 [0361]

¹H-NMR (CD₃OD) δ: 8.26 (1H, s), 7.78 (1H, s), 7.58 (2H, d, J = 7.1 Hz), 5.88 (1H, d, J = 6.8 Hz), 4.85-4.78 (1H, m), 4.33-4.30 (1H, m), 4.27-4.24 (1H, m), 3.42-3.33 (2H, m). LCMS (ESI) m/z 506 [M+H]⁺.

10 [0362]

Example 58

Methyl 4-[2-[4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-3,5-difluoro-benzoate

15 Step 1: Synthesis of methyl 4-ethynyl-3,5-difluorobenzimidate

3,5-Difluoro-4-formylbenzonitrile (200 mg, 1.2 mmol) was dissolved in methanol (3 mL). Then, potassium carbonate (331 mg, 24 mmol) was added thereto at room temperature, and dimethyl(1-diazo-2-oxopropyl)phosphonate (0.22 mL, 1.4 mmol) was added thereto under ice-cooling, followed by stirring under ice-cooling for 30 minutes and at room temperature for additional 2 hours and 30 minutes. The reaction solution was partitioned with the addition of ethyl acetate, a saturated aqueous sodium hydrogen carbonate solution, and water, and the organic layer was washed with saturated saline. After being dried over sodium sulfate, the resulting product was filtered and concentrated, and the residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining methyl 4-ethynyl-3,5-difluorobenzimidate (172 mg).

30 [0363]

LCMS (ESI) m/z 196 [M+H]⁺

Step 2: Synthesis of example compound 58

The title compound was obtained as in step 4 of Example 1, except that methyl 4-ethynyl-3,5-difluorobenzimidate was used in place of 2-ethynyl-1,3-difluorobenzene.

[0364]

¹H-NMR (CD₃OD) δ: 8.27 (1H, s), 7.76 (1H, s), 7.69 (2H, d, J = 7.8 Hz), 5.88 (1H, d, J = 6.6 Hz), 4.85-4.78 (1H, m), 4.33-4.31 (1H, m), 4.27-4.24 (1H, m), 3.94 (3H, s), 3.42-3.33 (2H, m). LCMS

5 (ESI) m/z 539 [M+H]⁺.

[0365]

Example 59

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-fluoro-6-
10 methylsulfanyl-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of (2-ethynyl-3-fluorophenyl)(methyl)sulfane

The title compound was obtained as in step 1 of Example 51, except that 2-fluoro-6-(methylthio)benzaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

15 [0366]

¹H-NMR (CDCl₃) δ: 7.32-7.25 (1H, m), 6.94 (1H, d, J = 8.1 Hz), 6.89-6.64 (1H, m), 3.70 (1H, s), 2.51 (3H, s).

Step 2: Synthesis of example compound 59

The title compound was obtained as in step 4 of Example 20 1, except that (2-ethynyl-3-fluorophenyl)(methyl)sulfane was used in place of 2-ethynyl-1,3-difluorobenzene.

[0367]

¹H-NMR (CD₃OD) δ: 8.24 (1H, s), 7.65 (1H, s), 7.37-7.31 (1H, m), 7.11 (1H, d, J = 8.0 Hz), 6.99-6.94 (1H, m), 5.88 (1H, d, J = 6.8
25 Hz), 4.85-4.78 (1H, m), 4.33-4.31 (1H, m), 4.27-4.24 (1H, m), 3.42-3.33 (2H, m), 2.56 (3H, s). LCMS (ESI) m/z 509 [M+H]⁺.

[0368]

Example 60

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
30 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-fluoro-6-propoxy-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 2-fluoro-6-propoxybenzaldehyde

The title compound was obtained as in step 1 of Example 55, except that 1-iodopropane was used in place of iodoethane.

35 [0369]

¹H-NMR (CDCl₃) δ: 10.48 (1H, s), 7.46 (1H, dt, J = 6.3, 8.5 Hz), 6.76 (1H, d, J = 8.5 Hz), 6.71 (1H, dd, J = 10.4, 8.5 Hz), 4.04 (2H, t, J = 6.3 Hz), 1.93-1.83 (2H, m), 1.56 (1H, s), 1.07 (3H, t, J = 7.3 Hz). LCMS (ESI) m/z 183 [M+H]⁺

5 Step 2: Synthesis of 2-ethynyl-1-fluoro-3-propoxybenzene

The title compound was obtained as in step 1 of Example 51, except that 2-fluoro-6-propoxybenzaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

[0370]

10 ¹H-NMR (CDCl₃) δ: 7.27-7.20 (1H, m), 6.72-6.63 (2H, m), 4.01 (2H, t, J = 6.5 Hz), 3.49 (1H, s), 1.81-1.91 (2H, m), 1.07 (3H, t, J = 8.0 Hz).

Step 3: Synthesis of example compound 60

15 The title compound was obtained as in step 4 of Example 1, except that 2-ethynyl-1-fluoro-3-propoxybenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0371]

20 ¹H-NMR (CD₃OD) δ: 8.24 (1H, s), 7.57 (1H, s), 7.34-7.28 (1H, m), 6.88 (1H, d, J = 8.0 Hz), 6.80-6.74 (1H, m), 5.86 (1H, d, J = 6.8 Hz), 4.85-4.78 (1H, m), 4.33-4.31 (1H, m), 4.27-4.24 (1H, m), 4.13 (2H, t, J = 6.7 Hz), 3.42-3.33 (2H, m), 1.92-1.82 (2H, m), 1.07 (3H, t, 7.4 Hz). LCMS (ESI) m/z 521 [M+H]⁺.

[0372]

Example 61

25 4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-[2-fluoro-6-(2,2,2-trifluoroethoxy)phenyl]ethynyl]pyrrolo[2,3-d]pyrimidine
Step 1: Synthesis of 2-fluoro-6-(2,2,2-trifluoroethoxy)benzaldehyde

30 The title compound was obtained as in step 1 of Example 55, except that 1,1,1-trifluoro-2-iodoethane was used in place of iodoethane.

[0373]

35 ¹H-NMR (CDCl₃) δ: 10.45 (1H, s), 7.53 (1H, dt, J = 6.1, 8.6 Hz), 6.89 (1H, dd, J = 9.8, 8.6 Hz), 6.77 (1H, d, J = 8.6 Hz), 4.48

(2H, q, J = 8.0 Hz). LCMS (ESI) m/z 223 [M+H]⁺

Step 2: Synthesis of 2-ethynyl-1-fluoro-3-(2,2,2-trifluoroethoxy)benzene

The title compound was obtained as in step 1 of Example 51, except that 2-fluoro-6-(2,2,2-trifluoroethoxy)benzaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

[0374]

¹H-NMR (CDCl₃) δ: 7.32-7.24 (1H, m), 6.88-6.81 (1H, m), 6.72 (1H, d, J = 8.0 Hz), 4.45 (2H, q, J = 8.0 Hz), 3.53 (1H, s).

Step 3: Synthesis of example compound 61

The title compound was obtained as in step 4 of Example 1, except that 2-ethynyl-1-fluoro-3-(2,2,2-trifluoroethoxy)benzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0375]

¹H-NMR (CD₃OD) δ: 8.24 (1H, s), 7.60 (1H, s), 7.39-7.33 (1H, m), 6.98 (1H, d, J = 8.5 Hz), 6.93-6.89 (1H, m), 5.86 (1H, d, J = 7.1 Hz), 4.84-4.82 (1H, m), 4.76 (2H, q, J = 8.4 Hz), 4.33-4.29 (1H, m), 4.27-4.25 (1H, m), 3.40-3.37 (2H, m). LCMS (ESI) m/z 561

[M+H]⁺.

[0376]

Example 62

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-ethoxy-6-methoxy-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 2-ethoxy-6-methoxybenzaldehyde

The title compound was obtained as in step 1 of Example 55, except that 2-hydroxy-6-methoxybenzaldehyde was used in place of 2-fluoro-6-hydroxybenzaldehyde.

[0377]

¹H-NMR (CDCl₃) δ: 10.53 (1H, s), 7.42 (1H, t, J = 8.5 Hz), 6.56 (2H, d, J = 8.5 Hz), 4.15-4.08 (2H, q, J = 7.0 Hz), 3.90 (3H, s), 1.46 (3H, t, J = 7.0 Hz). LCMS (ESI) m/z 181 [M+H]⁺

Step 2: Synthesis of 1-ethoxy-2-ethynyl-3-methoxybenzene

The title compound was obtained as in step 1 of Example

51, except that 2-ethoxy-6-methoxybenzaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

[0378]

¹H-NMR (CDCl₃) δ: 7.23 (1H, t, J = 8.4 Hz), 6.55-6.50 (2H, m),

5 4.12 (2H, q, J = 7.0 Hz), 3.90 (3H, s), 3.53 (1H, s), 1.46 (3H, t, J = 7.0 Hz). LCMS (ESI) m/z 177 [M+H]⁺

Step 3: Synthesis of example compound 62

The title compound was obtained as in step 4 of Example 1, except that 1-ethoxy-2-ethynyl-3-methoxybenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0379]

¹H-NMR (CD₃OD) δ: 8.22 (1H, s), 7.48 (1H, s), 7.27-7.23 (1H, m), 6.67-6.64 (2H, m), 5.85 (1H, d, J = 6.5 Hz), 4.88-4.80 (1H, m), 4.32-4.30 (1H, m), 4.26-4.23 (1H, m), 4.18 (2H, q, J = 7.0 Hz), 15 3.91 (3H, s), 3.42-3.31 (2H, m), 1.45 (3H, t, J = 7.0 Hz). LCMS (ESI) m/z 519 [M+H]⁺.

[0380]

Example 63

8-[2-[4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-

20 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2.3-d]pyrimidin-5-yl]ethynyl]-7-methoxyquinoline

Step 1: Synthesis of 8-ethynyl-7-methoxyquinoline

The title compound was obtained as in step 1 of Example 51, except that 7-methoxyquinoline-8-carbaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

[0381]

¹H-NMR (CDCl₃) δ: 9.03 (1H, dd, J = 4.2, 1.8 Hz), 8.12 (1H, dd, J = 8.3, 1.8 Hz), 7.83 (1H, d, J = 9.2 Hz), 7.35 (1H, d, J = 9.2 Hz), 7.33 (1H, dd, J = 8.3, 4.2 Hz), 4.10 (3H, s), 3.87 (1H, s).

30 LCMS (ESI) m/z 184 [M+H]⁺

Step 2: Synthesis of example compound 63

The title compound was obtained as in step 4 of Example 1, except that 8-ethynyl-7-methoxyquinoline was used in place of 2-ethynyl-1,3-difluorobenzene.

35 [0382]

¹H-NMR (CD₃OD) δ: 8.92 (1H, dd, J = 4.3, 1.7 Hz), 8.29 (1H, dd, J = 8.3, 1.7 Hz), 8.22 (1H, s), 7.92 (1H, d, J = 9.0 Hz), 7.59 (1H, s), 7.54 (1H, d, J = 9.0 Hz), 7.43 (1H, dd, J = 8.3, 4.3 Hz), 5.89 (1H, d, J = 6.8 Hz), 4.61-4.59 (1H, m), 4.33 (1H, dd, J = 5.4, 2.7 Hz), 4.29-4.26 (1H, m), 4.11 (3H, s), 3.44-3.34 (2H, m).
LCMS (ESI) m/z 526 [M+H]⁺.

[0383]

Example 64

8-[2-[4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
10 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
d]pyrimidin-5-yl]ethynyl]-7-fluoro-4-methyl-2,3-dihydro-1,4-
benzoxazine

Step 1: Synthesis of 7-fluoro-4-methyl-2,3-dihydro-1,4-
benzoxazine

15 7-Fluoro-2,3-dihydro-1,4-benzoxazine (1.50 g, 9.79
mmol) was dissolved in N,N-dimethylformamide (15 mL), and
potassium carbonate (2.98 g, 21.5 mmol) and methyl iodide (1.67 g,
11.8 mmol) were added thereto at room temperature. After the
resulting mixture was stirred at room temperature for 3 days,
20 water (60 mL) and ethyl acetate (60 mL) were sequentially added
thereto to partition the mixture into an aqueous layer and an
organic layer, followed by separation of each layer. The aqueous
layer was extracted with ethyl acetate (60 mL), and the obtained
organic layers were combined. The combined organic layer was
25 sequentially washed with water (60 mL) and saturated saline (60
mL), and dried over anhydrous sodium sulfate, followed by
distilling off the solvent. The residue was purified by silica
gel column chromatography (developing solvent: ethyl
acetate/hexane), thereby obtaining 7-fluoro-4-methyl-2,3-dihydro-
30 1,4-benzoxazine (1.09 g) as a light-yellow oil.

[0384]

¹H-NMR (CDCl₃) δ: 6.58-6.51 (3H, m), 4.31 (2H, t, J = 4.4 Hz),
3.20 (2H, t, J = 4.4 Hz), 2.84 (3H, s). LCMS (ESI) m/z 168.1
[M+H]⁺

35 Step 2: Synthesis of 7-fluoro-4-methyl-2,3-dihydro-1,4-

benzoxazine-8-carbaldehyde

7-Fluoro-4-methyl-2,3-dihydro-1,4-benzoxazine (1.07 g, 6.40 mmol) was dissolved in tetrahydrofuran (17.1 mL), and n-butyllithium (a 1.6 M hexane solution, 4.83 mL) was added thereto dropwise with stirring at -78°C. After the mixture was stirred at -78°C for 3 hours, N,N-dimethylformamide (702 mg, 9.60 mmol) was added thereto dropwise, and the temperature was increased to 0°C. A saturated aqueous ammonium chloride solution (40 mL) and ethyl acetate (40 mL) were sequentially added thereto, followed by separation of each layer. The aqueous layer was extracted twice with ethyl acetate (40 mL), and the obtained organic layers were combined. The combined organic layer was sequentially washed with a saturated aqueous ammonium chloride solution (100 mL), water (100 mL), and saturated saline (100 mL), and dried over anhydrous sodium sulfate, followed by distilling off the solvent. The residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining 7-fluoro-4-methyl-2,3-dihydro-1,4-benzoxazine-8-carbaldehyde (1.13 g) as a bright yellow solid.

[0385]

¹H-NMR (CDCl₃) δ: 10.38 (1H, d, J = 2.2 Hz), 6.78-6.73 (1H, m), 6.62-6.57 (1H, m), 4.45-4.42 (2H, m), 3.28-3.25 (2H, m), 2.87 (3H, d, J = 1.8 Hz). LCMS (ESI) m/z 196.2 [M+H]⁺

Step 3: Synthesis of 8-ethynyl-7-fluoro-4-methyl-2,3-dihydro-1,4-benzoxazine

The title compound was obtained as in step 1 of Example 51, except that 7-fluoro-4-methyl-2,3-dihydro-1,4-benzoxazine-8-carbaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde. [0386]

¹H-NMR (CDCl₃) δ: 6.59-6.56 (2H, m), 4.43 (2H, t, J = 4.4 Hz), 3.49 (1H, s), 3.22 (2H, t, J = 4.4 Hz), 2.84 (3H, s). LCMS (ESI) m/z 192.4 [M+H]⁺

Step 4: Synthesis of example compound 64

The title compound was obtained as in step 4 of Example 1, except that 8-ethynyl-7-fluoro-4-methyl-2,3-dihydro-1,4-

benzoxazine was used in place of 2-ethynyl-1,3-difluorobenzene.
[0387]

¹H-NMR (DMSO-D₆) δ: 8.17 (1H, s), 7.88 (1H, s), 7.38 (1H, dd, J =
7.3, 4.8 Hz), 6.78-6.69 (2H, m), 6.60 (2H, s), 5.91 (1H, d, J =
5 7.3 Hz), 5.40 (1H, s), 5.24 (1H, s), 4.58 (1H, t, J = 6.2 Hz),
4.43 (2H, t, J = 4.2 Hz), 4.12-4.07 (1H, m), 4.07-4.02 (1H, m),
3.26 (2H, t, J = 4.2 Hz), 3.23-3.16 (1H, m), 3.15-3.07 (1H, m),
2.82 (3H, s). LCMS (ESI) m/z 534.3 [M+H]⁺.

Step 5: Synthesis of 8-[2-[4-amino-7-[(2R,3R,4S,5R)-3,4-
10 dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-
yl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-7-fluoro-4-methyl-2,3-
dihydro-1,4-benzoxazine hydrochloride

The title compound hydrochloride was obtained as in
step 5 of Example 1.

15 ¹H-NMR (DMSO-D₆) δ: 8.47 (1H, s), 8.23 (1H, s), 6.82-6.76 (2H, m),
6.06 (1H, d, J = 6.8 Hz), 4.49-4.45 (3H, m), 4.12 (1H, dd, J =
5.2, 2.8 Hz), 4.05 (1H, dt, J = 5.6, 2.8 Hz), 3.28 (2H, t, J =
4.4 Hz), 3.23 (1H, dd, J = 14.0, 6.0 Hz), 3.13 (1H, dd, J = 14.0,
6.0 Hz), 2.84 (3H, s). LCMS (ESI) m/z 534.3 [M+H]⁺

20 [0388]

Example 65

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2,4-
dimethoxy-3-pyridyl)ethynyl]pyrrolo[2,3-d]pyrimidine

25 Step 1: Synthesis of 3-ethynyl-2,4-dimethoxypyridine

The title compound was obtained as in step 1 of Example
51, except that 2,4-dimethoxynicotinaldehyde was used in place of
2-fluoro-6-methoxybenzaldehyde.

[0389]

30 ¹H-NMR (CDCl₃) δ: 8.05 (1H, d, J = 6.1 Hz), 6.54 (1H, d, J = 6.1
Hz), 4.02 (3H, s), 3.95 (3H, s), 3.58 (1H, s). LCMS (ESI) m/z 164
[M+H]⁺

Step 2: Synthesis of example compound 65

The title compound was obtained as in step 4 of Example
35 1, except that 3-ethynyl-2,4-dimethoxypyridine was used in place

of 2-ethynyl-1,3-difluorobenzene.

[0390]

¹H-NMR (DMSO-D₆) δ: 8.18 (1H, s), 8.08 (1H, d, J = 6.1 Hz), 7.85 (1H, d, J = 2.0 Hz), 7.35 (1H, s), 6.89 (1H, d, J = 6.1 Hz), 6.59 (2H, s), 5.91 (1H, d, J = 7.1 Hz), 4.58 (1H, t, J = 5.7 Hz), 4.11-4.08 (1H, m), 4.06-4.03 (1H, m), 3.95 (6H, d, J = 2.7 Hz), 3.35 (2H, s), 3.22-3.10 (2H, m). LCMS (ESI) m/z 506 [M+H]⁺.

[0391]

Example 66

10 4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-
ethylsulfanyl-6-fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine
Step 1: Synthesis of 2-(ethylthio)-6-fluorobenzaldehyde

Ethyl (3-fluorophenyl)sulfane (2.0 g, 12.8 mmol) was
15 dissolved in tetrahydrofuran (30 mL), and n-butyllithium (a 2.69
M hexane solution, 5.71 mL) was added thereto dropwise while
being stirred with cooling at -78°C. After the resulting mixture
was stirred at -78°C for 30 minute, N,N-dimethylformamide (2.95
mL, 38.4 mmol) was added thereto, followed by stirring for 1 hour.
20 A saturated aqueous ammonium chloride solution was added to the
reaction liquid, followed by extraction with ethyl acetate.
After the solvent was distilled off, the residue was purified by
column chromatography (developing solvent: hexane/ethyl acetate),
thereby obtaining 2-(ethylthio)-6-fluorobenzaldehyde (430 mg,
25 18%) as a light-yellow solid.

¹H-NMR (CDCl₃) δ: 10.52 (1H, s), 7.51-7.46 (1H, m), 7.13 (1H, d, J = 8.8 Hz), 6.91 (1H, t, J = 8.8 Hz), 2.99 (2H, q, J = 7.3 Hz), 1.42 (3H, t, J = 7.3 Hz).

Step 2: Synthesis of ethyl(2-ethynyl-3-fluorophenyl)sulfane

30 The title compound was obtained as in step 1 of Example
51, except that 2-(ethylthio)-6-fluorobenzaldehyde was used in
place of 2-fluoro-6-methoxybenzaldehyde.

[0393]

¹H-NMR (CDCl₃) δ: 7.30-7.24 (1H, m), 7.03 (1H, d, J = 8.1 Hz),
35 6.89 (1H, dd, J = 8.8, 8.1 Hz), 3.71 (1H, s), 3.03 (2H, q, J =

7.3 Hz), 1.40 (3H, t, J = 7.3 Hz).

Step 3: Synthesis of example compound 66

The title compound was obtained as in step 4 of Example 1, except that ethyl (2-ethynyl-3-fluorophenyl)sulfane was used in place of 2-ethynyl-1,3-difluorobenzene.

[0394]

¹H-NMR (DMSO-D₆) δ: 8.16 (1H, s), 7.95 (1H, s), 7.91 (1H, d, J = 7.0 Hz), 7.46 (1H, t, J = 7.7 Hz), 7.41-7.32 (2H, m), 7.22 (1H, d, J = 8.1 Hz), 7.12 (1H, t, J = 8.8 Hz), 6.57 (2H, s), 5.91 (1H, d, J = 7.0 Hz), 5.37 (1H, brs), 5.21 (1H, brs), 4.57 (1H, brs), 4.09-4.06 (1H, brm), 4.04-4.01 (1H, brm), 3.23-3.05 (2H, m), 1.28 (3H, t, J = 7.0 Hz). LCMS (ESI) m/z 523 [M+H]⁺.

[0395]

Example 67

4-Amino-5-[2-[2,6-difluoro-4-(triazol-2-ylmethoxy)phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 4-((2H-1,2,3-triazol-2-yl)methoxy)-2,6-difluorobenzaldehyde

The title compound was obtained as in step 1 of Example 55, except that 2,6-difluoro-4-hydroxybenzaldehyde was used in place of 2-fluoro-6-hydroxybenzaldehyde, and that 2-(chloromethyl)triazole was used in place of iodoethane.

[0396]

¹H-NMR (CDCl₃) δ: 10.21 (1H, s), 7.76 (2H, s), 6.88 (2H, d, J = 10.0 Hz), 6.30 (2H, s). LCMS (ESI) m/z 240 [M+H]⁺

Step 2: Synthesis of 2-((4-ethynyl-3,5-difluorophenoxy)methyl)-2H-1,2,3-triazole

The title compound was obtained as in step 1 of Example 51, except that 4-((2H-1,2,3-triazol-2-yl)methoxy)-2,6-difluorobenzaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

[0397]

¹H-NMR (CDCl₃) δ: 7.74 (2H, s), 7.26 (2H, s), 6.82 (1H, d, J = 8.5

Hz), 6.24 (1H, s), 3.43 (1H, s). LCMS (ESI) m/z 236 [M+H]⁺

Step 3: Synthesis of example compound 67

The title compound was obtained as in step 4 of Example 1, except that 2-((4-ethynyl-3,5-difluorophenoxy)methyl)-2H-1,2,3-triazole was used in place of 2-ethynyl-1,3-difluorobenzene. [0398]

¹H-NMR (DMSO-D₆) δ: 8.17 (1H, s), 7.99 (2H, s), 7.96 (1H, s), 7.36-7.31 (1H, brs), 7.19 (2H, d, J = 9.5 Hz), 6.61-6.57 (2H, s), 6.52 (2H, s), 5.91 (1H, d, J = 7.1 Hz), 5.40 (1H, d, J = 6.6 Hz), 5.23 (1H, d, J = 4.1 Hz), 4.59-4.54 (1H, m), 4.10-4.06 (1H, m), 4.05-4.02 (1H, m), 3.22-3.16 (1H, m), 3.10-3.06 (1H, m). LCMS (ESI) m/z 578 [M+H]⁺. [0399]

Example 68

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-[2-(ethylamino)-6-fluoro-phenyl]ethynyl]pyrrolo[2,3-d]pyrimidine
Step 1: Synthesis of 2-(ethylamino)-6-fluorobenzaldehyde

The title compound was obtained as in step 1 of Example 23, except that 2,6-difluorobenzaldehyde and ethylamine were used in place of 2-ethynyl-1,3,5-trifluorobenzene and morpholine. [0400]

¹H-NMR (CDCl₃) δ: 10.28 (1H, s), 8.66 (1H, brs), 7.35-7.29 (1H, m), 6.45 (1H, d, J = 8.1 Hz), 6.27 (1H, dd, J = 11.4, 8.1 Hz), 3.32-3.25 (2H, m), 1.33 (3H, t, J = 7.3 Hz). LRMS (ESI) m/z 168 [M+H]⁺
Step 2: Synthesis of N-ethyl-2-ethynyl-3-fluoroaniline

The title compound was obtained as in step 1 of Example 51, except that 2-(ethylamino)-6-fluorobenzaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde. [0401]

¹H-NMR (CDCl₃) δ: 7.13 (1H, dd, J = 14.7, 7.7 Hz), 6.38-6.34 (2H, m), 4.62-4.56 (1H, brm), 3.62 (1H, s), 3.21 (2H, dq, J = 7.3, 6.6 Hz), 1.29 (3H, t, J = 7.3 Hz). LRMS (ESI) m/z 164 [M+H]⁺

Step 3: Synthesis of example compound 68

The title compound was obtained as in step 4 of Example

1, except that N-ethyl-2-ethynyl-3-fluoroaniline was used in place of 2-ethynyl-1,3-difluorobenzene.

[0402]

¹H-NMR (CD₃OD) δ: 8.22 (1H, s), 7.55 (1H, s), 7.26 (1H, ddd, J = 8.4, 8.4, 7.0 Hz), 6.82 (1H, d, J = 8.4 Hz), 6.74 (1H, t, J = 8.4 Hz), 5.87 (1H, d, J = 6.6 Hz), 4.79 (1H, t, J = 6.6 Hz), 4.30 (1H, dd, J = 5.5, 2.6 Hz), 4.23-4.17 (2H, m), 4.19 (1H, q, J = 7.0 Hz), 3.56-3.54 (2H, m), 1.46 (3H, t, J = 7.0 Hz). LCMS (ESI) m/z 506 [M+H]⁺.

[0403]

Example 69

4-Amino-5-[2-(2,4-difluoro-3-pyridyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 3-ethynyl-2,4-difluoropyridine

The title compound was obtained as in step 1 of Example 51, except that 2,4-difluoronicotinaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

[0404]

¹H-NMR (ACETONE-D₆) δ: 8.38 (1H, dd, J = 8.2, 5.7 Hz), 7.44-7.40 (1H, m), 4.46 (1H, s). LCMS (ESI) m/z 140 [M+H]⁺

Step 2: Synthesis of example compound 69

The title compound was obtained as in step 4 of Example 1, except that 3-ethynyl-2,4-difluoropyridine was used in place of 2-ethynyl-1,3-difluorobenzene.

[0405]

¹H-NMR (CD₃OD) δ: 8.25 (1H, s), 8.18 (1H, dd, J = 8.2, 5.8 Hz), 7.73 (1H, s), 7.27 (1H, dd, J = 8.2, 5.8 Hz), 5.87 (1H, d, J = 6.6 Hz), 4.82 (1H, d, J = 5.9 Hz), 4.32 (1H, dd, J = 5.5, 2.6 Hz), 4.26 (1H, q, J = 3.1 Hz), 3.43-3.33 (2H, m). LCMS (ESI) m/z 482 [M+H]⁺.

[0406]

Example 70

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-

ethylsulfonyl-6-fluoro-4-pyrrolidin-1-yl-
phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 2,6-difluoro-4-(pyrrolidin-1-yl)benzaldehyde

The title compound was obtained as in step 1 of Example
5 23, except that 2,4,6-trifluorobenzaldehyde and pyrrolidine were
used in place of 2-ethynyl-1,3,5-trifluorobenzene and morpholine.
[0407]

¹H-NMR (CDCl₃) δ: 10.04 (1H, s), 6.01 (2H, d, J = 12.8 Hz), 3.35-
3.32 (4H, m), 2.07-2.03 (4H, m). LCMS (ESI) m/z 212 [M+H]⁺

10 Step 2: Synthesis of 2-(ethylthio)-6-fluoro-4-(pyrrolidin-1-
yl)benzaldehyde

2,6-Difluoro-4-(pyrrolidin-1-yl)benzaldehyde (3.7 g, 18
mmol) was dissolved in N,N-dimethylformamide (37 mL), and sodium
ethanethiolate (1.6 g, 18 mmol) was added thereto, followed by
15 stirring at room temperature for 30 minutes. Ethyl acetate, water,
and a saturated aqueous sodium hydrogen carbonate solution were
added to the reaction solution, and the aqueous layer was
extracted with ethyl acetate. The organic layer was washed with
water and a saturated sodium chloride aqueous solution, and dried
20 over sodium sulfate, followed by distilling off the solvent. The
residue was purified by silica gel column chromatography
(developing solvent: chloroform), thereby obtaining 2-
(ethylthio)-6-fluoro-4-(pyrrolidin-1-yl)benzaldehyde (4.4 g) as a
white solid.

25 [0408]

¹H-NMR (CDCl₃) δ: 10.18 (1H, s), 6.10 (1H, d, J = 2.0 Hz), 5.98
(1H, dd, J = 14.3, 2.0 Hz), 3.39-3.35 (4H, m), 2.91 (2H, q, J =
7.3 Hz), 2.07-2.04 (4H, m), 1.41 (3H, t, J = 7.3 Hz). LCMS (ESI)
m/z 254 [M+H]⁺

30 Step 3: Synthesis of 2-(ethylsulfonyl)-6-fluoro-4-(pyrrolidin-1-
yl)benzaldehyde

2-(Ethylthio)-6-fluoro-4-(pyrrolidin-1-yl)benzaldehyde
(79 mg, 0.31 mmol) was dissolved in dichloromethane (1.6 mL), and
3-chloroperbenzoic acid (110 mg, 0.65 mmol) was added thereto in
35 an ice bath, followed by stirring for 2 hours in an ice bath. 3-

chloroperbenzoic acid (56 mg, 0.32 mmol) was added to the resulting mixture in an ice bath, followed by stirring for 1 hour in an ice bath. Thereafter, 3-chloroperbenzoic acid (10 mg, 0.058 mmol) was further added thereto in an ice bath, followed by
5 stirring for 30 minutes in an ice bath. Chloroform, water, and a saturated aqueous sodium hydrogen carbonate solution were added in an ice bath to the reaction solution, and the aqueous solution was extracted with chloroform. The organic layer was washed with a saturated sodium chloride aqueous solution, and dried over
10 sodium sulfate, followed by distilling off the solvent. The residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining 2-(ethylsulfonyl)-6-fluoro-4-(pyrrolidin-1-yl)benzaldehyde (54 mg, 0.19 mmol, 62%) as a yellow solid.

15 [0409]

¹H-NMR (CDCl₃) δ: 10.28 (1H, s), 7.19 (1H, d, J = 2.6 Hz), 6.33 (1H, dd, J = 13.9, 2.6 Hz), 3.62 (2H, q, J = 7.5 Hz), 3.50-3.40 (4H, m), 2.11-2.08 (4H, m), 1.31 (3H, t, J = 7.5 Hz). LCMS (ESI) m/z 286 [M+H]⁺

20 Step 4: Synthesis of 1-(3-(ethylsulfonyl)-4-ethynyl-5-fluorophenyl)pyrrolidine

The title compound was obtained as in step 1 of Example 51, except that 2-(ethylsulfonyl)-6-fluoro-4-(pyrrolidin-1-yl)benzaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.
25

[0410]

¹H-NMR (CDCl₃) δ: 7.01 (1H, d, J = 2.3 Hz), 6.38 (1H, dd, J = 11.9, 2.3 Hz), 3.63 (1H, s), 3.49 (2H, q, J = 7.4 Hz), 3.36-3.32 (4H, m), 2.07-2.04 (4H, m), 1.27 (3H, t, J = 7.4 Hz). LCMS (ESI) m/z
30 282 [M+H]⁺

Step 5: Synthesis of example compound 70

The title compound was obtained as in step 4 of Example 1, except that 1-(3-(ethylsulfonyl)-4-ethynyl-5-fluorophenyl)pyrrolidine was used in place of 2-ethynyl-1,3-difluorobenzene.
35

[0411]

¹H-NMR (CD₃OD) δ: 8.22 (1H, s), 7.61 (1H, s), 7.01 (1H, d, J = 2.3 Hz), 6.66 (1H, dd, J = 12.4, 2.3 Hz), 5.86 (1H, d, J = 7.1 Hz), 4.85-4.81 (1H, m), 4.32-4.30 (1H, m), 4.27-4.24 (1H, m), 3.49 (2H, q, J = 7.3 Hz), 3.40-3.36 (4H, m), 3.31-3.30 (2H, m), 2.10-2.07 (4H, m), 1.25 (3H, t, J = 7.3 Hz). LCMS (ESI) m/z 624 [M+H].

[0412]

Example 71

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-

[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(3-fluoro-5-methoxy-4-pyridyl)ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 4-ethynyl-3-fluoro-5-methoxypyridine

The title compound was obtained as in step 1 of Example 51, except that 3-fluoro-5-methoxyisonicotinaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

[0413]

¹H-NMR (CDCl₃) δ: 8.21-8.17 (2H, m), 4.03 (3H, s), 3.69 (1H, s). LCMS (ESI) m/z 152 [M+H]⁺

Step 2: Synthesis of example compound 71

The title compound was obtained as in step 4 of Example 1, except that 4-ethynyl-3-fluoro-5-methoxypyridine was used in place of 2-ethynyl-1,3-difluorobenzene.

[0414]

¹H-NMR (DMSO-D₆) δ: 8.38 (1H, d, J = 7.8 Hz), 8.37 (1H, s), 8.20 (1H, s), 8.05 (1H, s), 7.32-7.29 (1H, brs), 6.58 (2H, s), 5.93 (1H, d, J = 6.8 Hz), 5.41-5.38 (1H, brs), 5.23-5.21 (1H, brs), 4.59-4.57 (1H, m), 4.08-4.04 (2H, m), 4.07 (3H, s), 3.22-3.18 (1H, m), 3.12-3.08 (1H, m). LCMS (ESI) m/z 494 [M+H].

[0415]

Example 72

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-

[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-[2-ethylsulfonyl-6-fluoro-4-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 2,6-difluoro-4-[(3R)-3-hydroxypyrrolidin-1-

yl]benzaldehyde

The title compound was obtained as in step 1 of Example 23, except that 2,4,6-trifluorobenzaldehyde and (R)-pyrrolidin-3-ol were used in place of 2-ethynyl-1,3,5-trifluorobenzene and morpholine.

[0416]

¹H-NMR (CDCl₃) δ: 10.05 (1H, s), 6.03 (2H, d, J = 12.4 Hz), 4.70-4.66 (1H, m), 3.60-3.53 (2H, m), 3.48-3.42 (1H, m), 3.36-3.31 (1H, m), 2.21-2.12 (2H, m), 1.79 (1H, d, J = 3.9 Hz). LCMS (ESI) m/z 228 [M+H]⁺

Step 2: Synthesis of 2-ethylsulfanyl-6-fluoro-4-[(3R)-3-hydroxypyrrolidin-1-yl]benzaldehyde

The title compound was obtained as in step 2 of Example 70, except that 2,6-difluoro-4-[(3R)-3-hydroxypyrrolidin-1-yl]benzaldehyde was used in place of 2,6-difluoro-4-(pyrrolidin-1-yl)benzaldehyde.

[0417]

¹H-NMR (CDCl₃) δ: 10.19 (1H, s), 6.11 (1H, d, J = 2.2 Hz), 6.00 (1H, dd, J = 14.1, 2.2 Hz), 4.69-4.66 (1H, m), 3.63-3.57 (2H, m), 3.50-3.45 (1H, m), 3.41-3.35 (1H, m), 2.91 (2H, q, J = 7.4 Hz), 2.21-2.14 (2H, m), 1.77 (1H, d, J = 4.1 Hz), 1.41 (3H, t, J = 7.4 Hz). LCMS (ESI) m/z 270 [M+H]⁺

Step 3: Synthesis of 2-ethylsulfonyl-6-fluoro-4-[(3R)-3-hydroxypyrrolidin-1-yl]benzaldehyde

The title compound was obtained as in step 3 of Example 70, except that 2-ethylsulfanyl-6-fluoro-4-[(3R)-3-hydroxypyrrolidin-1-yl]benzaldehyde was used in place of 2-(ethylthio)-6-fluoro-4-(pyrrolidin-1-yl)benzaldehyde.

[0418]

¹H-NMR (CDCl₃) δ: 10.30 (1H, s), 7.20 (1H, d, J = 2.4 Hz), 6.36 (1H, dd, J = 14.0, 2.4 Hz), 4.73-4.71 (1H, m), 3.67-3.42 (4H, m), 3.46-3.42 (1H, m), 3.35-3.32 (1H, m), 2.21-2.17 (2H, m), 1.76 (1H,

d, $J = 3.4$ Hz), 1.32 (3H, t, $J = 7.6$ Hz). LCMS (ESI) m/z 302 [M+H]⁺

Step 4: Synthesis of (3R)-1-(3-(ethylsulfonyl)-4-ethynyl-5-fluorophenyl)pyrrolidin-3-ol

5 The title compound was obtained as in step 1 of Example 51, except that 2-ethylsulfonyl-6-fluoro-4-[(3R)-3-hydroxypyrrolidin-1-yl]benzaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

[0419]

10 ¹H-NMR (CDCl₃) δ : 7.03 (1H, d, $J = 2.4$ Hz), 6.41 (1H, dd, $J = 11.7, 2.4$ Hz), 4.69-4.67 (1H, m), 3.65 (1H, s), 3.61-3.43 (5H, m), 3.35 (1H, d, $J = 11.0$ Hz), 2.23-2.12 (2H, m), 1.69 (1H, d, $J = 3.7$ Hz), 1.27 (3H, t, $J = 7.4$ Hz). LCMS (ESI) m/z 298 [M+H]⁺

Step 5: Synthesis of example compound 72

15 The title compound was obtained as in step 4 of Example 1, except that (3R)-1-(3-(ethylsulfonyl)-4-ethynyl-5-fluorophenyl)pyrrolidin-3-ol was used in place of 2-ethynyl-1,3-difluorobenzene.

[0420]

20 ¹H-NMR (CD₃OD) δ : 8.23 (1H, s), 7.62 (1H, s), 7.01 (1H, d, $J = 2.3$ Hz), 6.67 (1H, dd, $J = 12.2, 2.3$ Hz), 5.87 (1H, d, $J = 7.1$ Hz), 4.85-4.79 (1H, m), 4.58-4.54 (1H, m), 4.32-4.30 (1H, m), 4.26-4.24 (1H, m), 3.58-3.43 (6H, m), 3.42-3.33 (2H, m), 2.22-2.14 (1H, m), 2.12-2.05 (1H, m), 1.25 (3H, t, $J = 7.4$ Hz). LCMS (ESI) m/z

25 640 [M+H].

[0421]

Example 73

4-Amino-5-[2-(2-chloro-6-fluoro-phenyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

30

Step 1: Synthesis of 1-chloro-2-ethynyl-3-fluorobenzene

 The title compound was obtained as in step 1 of Example 51, except that 2-chloro-6-fluorobenzaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

35 [0422]

¹H-NMR (CDCl₃) δ: 7.29-7.21 (2H, m), 7.05-7.00 (1H, m), 3.61 (1H, s).

Step 2: Synthesis of example compound 73

The title compound was obtained as in step 4 of Example 1, except that 1-chloro-2-ethynyl-3-fluorobenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0423]

¹H-NMR (CD₃OD) δ: 8.23 (1H, s), 7.67 (1H, s), 7.37-7.30 (2H, m), 7.18-7.13 (1H, m), 5.87 (1H, d, J = 7.1 Hz), 4.85-4.82 (1H, m), 4.33-4.31 (1H, m), 4.27-4.25 (1H, m), 3.43-3.34 (2H, m). LCMS (ESI) m/z 497 [M+H].

[0424]

Example 74

4-[4-[2-[4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-3,5-difluoro-phenyl]-1,1-dioxo-1,4-thiazinane

Step 1: Synthesis of 4-(4-ethynyl-3,5-difluorophenyl)thiomorpholine-1,1-dioxide

The title compound was obtained as in step 3 of Example 70, except that 4-(4-ethynyl-3,5-difluorophenyl)thiomorpholine was used in place of 2-(ethylthio)-6-fluoro-4-(pyrrolidin-1-yl)benzaldehyde.

¹H-NMR (CDCl₃) δ: 6.40 (2H, d, J = 10.2 Hz), 3.92-3.88 (4H, m), 3.42 (1H, s), 3.11-3.06 (4H, m). LCMS (ESI) m/z 272 [M+H]⁺

Step 2: Synthesis of example compound 74

The title compound was obtained as in step 4 of Example 1, except that 4-(4-ethynyl-3,5-difluorophenyl)thiomorpholine-1,1-dioxide was used in place of 2-ethynyl-1,3-difluorobenzene.

[0425]

¹H-NMR (DMSO-D₆) δ: 8.18 (1H, s), 7.90 (1H, s), 7.36-7.32 (1H, m), 6.95 (2H, d, J = 11.4 Hz), 6.60 (2H, s), 5.92 (1H, d, J = 7.0 Hz), 5.39 (1H, d, J = 6.2 Hz), 5.24-5.22 (1H, m), 4.60-4.55 (1H, m), 4.12-4.08 (1H, m), 4.06-4.03 (1H, m), 3.95-3.89 (4H, m), 3.25-3.17 (1H, m), 3.17-3.09 (5H, m). LCMS (ESI) m/z 614 [M+H]⁺.

[0426]

Example 75

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-[2-
5 ethylsulfonyl-6-fluoro-4-[(3R)-3-fluoropyrrolidin-1-
yl]phenyl]ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 2,6-difluoro-4-[(3R)-fluoropyrrolidin-1-
yl]benzaldehyde

The title compound was obtained as in step 1 of Example
10 23, except that 2,4,6-trifluorobenzaldehyde and (R)-3-
fluoropyrrolidine were used in place of 2-ethynyl-1,3,5-
trifluorobenzene and morpholine.

[0427]

¹H-NMR (CDCl₃) δ: 10.07 (1H, s), 6.04 (2H, d, J = 12.5 Hz), 5.47-
15 5.32 (1H, m), 3.64-3.51 (4H, m), 2.50-2.41 (1H, m), 2.28-2.08 (1H,
m). LCMS (ESI) m/z 230 [M+H]⁺

Step 2: Synthesis of 2-(ethylthio)-6-fluoro-4-[(3R)-3-
fluoropyrrolidin-1-yl]benzaldehyde

The title compound was obtained as in step 2 of Example
20 70, except that 2,6-difluoro-4-[(3R)-fluoropyrrolidin-1-
yl]benzaldehyde was used in place of 2,6-difluoro-4-(pyrrolidin-
1-yl)benzaldehyde.

[0428]

¹H-NMR (CDCl₃) δ: 10.21 (1H, s), 6.11 (1H, d, J = 1.8 Hz), 6.01
25 (1H, dd, J = 13.9, 1.8 Hz), 5.47-5.33 (1H, m), 3.70-3.52 (4H, m),
2.92 (2H, q, J = 7.3 Hz), 2.49-2.40 (1H, m), 2.28-2.09 (1H, m),
1.41 (3H, t, J = 7.3 Hz). LCMS (ESI) m/z 272 [M+H]⁺

Step 3: Synthesis of 2-(ethylsulfonyl)-6-fluoro-4-[(3R)-3-
fluoropyrrolidin-1-yl]benzaldehyde

The title compound was obtained as in step 3 of Example
30 70, except that 2-(ethylthio)-6-fluoro-4-[(3R)-3-
fluoropyrrolidin-1-yl]benzaldehyde was used in place of 2-
(ethylthio)-6-fluoro-4-(pyrrolidin-1-yl)benzaldehyde.

[0429]

35 ¹H-NMR (CDCl₃) δ: 10.31 (1H, s), 7.21 (1H, d, J = 2.3 Hz), 6.38

(1H, dd, J = 13.7, 2.3 Hz), 5.51-5.35 (1H, m), 3.74-3.60 (6H, m), 2.53-2.45 (1H, m), 2.29-2.14 (1H, m), 1.32 (3H, t, J = 7.3 Hz).

LCMS (ESI) m/z 304 [M+H]⁺

Step 4: Synthesis of (3R)-1-(3-ethylsulfonyl-4-ethynyl-5-fluoro-phenyl)-3-fluoro-pyrrolidine

The title compound was obtained as in step 1 of Example 51, except that 2-(ethylsulfonyl)-6-fluoro-4-[(3R)-3-fluoropyrrolidin-1-yl]benzaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

[0430]

¹H-NMR (CDCl₃) δ: 7.03 (1H, d, J = 2.4 Hz), 6.42 (1H, dd, J = 11.7, 2.4 Hz), 5.47-5.33 (1H, m), 3.66-3.64 (2H, m), 3.61-3.46 (5H, m), 2.49-2.40 (1H, m), 2.29-2.11 (1H, m), 1.27 (3H, t, J = 7.5 Hz).

LCMS (ESI) m/z 300 [M+H]⁺

Step 5: Synthesis of example compound 75

The title compound was obtained as in step 4 of Example 1, except that (3R)-1-(3-ethylsulfonyl-4-ethynyl-5-fluoro-phenyl)-3-fluoro-pyrrolidine was used in place of 2-ethynyl-1,3-difluorobenzene.

¹H-NMR (CD₃OD) δ: 8.20 (1H, s), 7.60 (1H, s), 6.99 (1H, d, J = 2.6 Hz), 6.66 (1H, dd, J = 12, 2.6 Hz), 5.86 (1H, d, J = 7.0 Hz), 5.47-5.34 (1H, m), 4.81-4.78 (1H, m), 4.31-4.29 (1H, m), 4.25-4.23 (1H, m), 3.70-3.44 (6H, m), 3.41-3.32 (2H, m), 2.42-2.15 (2H, m), 1.24 (3H, t, J = 7.3 Hz). LCMS (ESI) m/z 642 [M+H].

[0431]

Example 76

4-Amino-5-[2-(5-benzyloxypyrimidin-2-yl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 5-(benzyloxy)-2-bromopyrimidine

2-Bromopyrimidin-5-ol (200 mg, 1.1 mmol) was dissolved in a liquid mixture of tetrahydrofuran (1 mL) and N,N-dimethylformamide (1 mL). Then, potassium carbonate (170 mg, 1.3 mmol) and benzyl bromide (0.15 mL, 1.3 mmol) were added thereto

at room temperature, followed by stirring at room temperature for 6 hours. The reaction solution was partitioned with ethyl acetate and water, and the organic layer was washed with water and saturated saline. The resulting product was dried over sodium sulfate, followed by filtration and concentration, and the residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining 5-(benzyloxy)-2-bromopyrimidine (200 mg, 0.75 mmol, 66%) as a white powder.

10 [0432]

$^1\text{H-NMR}$ (CDCl_3) δ : 8.31 (2H, s), 7.45-7.36 (5H, m), 5.15 (2H, s).

LCMS (ESI) m/z 265 $[\text{M}+\text{H}]^+$

Step 2: Synthesis of 5-(benzyloxy)-2-
((triisopropylsilyl)ethynyl)pyrimidine

15 5-(Benzyloxy)-2-bromopyrimidine (200 mg, 0.75 mmol), ethynyltriisopropylsilane (0.34 mL, 1.5 mmol), bis(triphenylphosphine)palladium (II) dichloride (53 mg, 0.075 mmol), copper iodide (14 mg, 0.075 mmol), and diisopropylethylamine (0.26 mL, 1.5 mmol) were suspended in tetrahydrofuran (2 mL). The reaction solution was stirred at 70°C for 1 hour and 30 minutes, and filtered through a celite bed, followed by distilling off the solvent. The residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining 5-(benzyloxy)-2-
20 ((triisopropylsilyl)ethynyl)pyrimidine (120 mg, 0.32 mmol, 43%) as a yellow oil.

[0433]

$^1\text{H-NMR}$ (CDCl_3) δ : 8.42 (2H, s), 7.43-7.36 (5H, m), 5.18 (2H, s), 1.17-1.13 (21H, m). LCMS (ESI) m/z 367 $[\text{M}+\text{H}]^+$

30 Step 3: Synthesis of 5-(benzyloxy)-2-ethynylpyrimidine

5-(Benzyloxy)-2-((triisopropylsilyl)ethynyl)pyrimidine (120 mg, 0.32 mmol) was dissolved in tetrahydrofuran (1 mL), and a tetrabutylammonium fluoride solution (1 M tetrahydrofuran solution, 0.38 mL, 0.38 mmol) was added thereto at room
35 temperature, followed by stirring at room temperature for 30

minutes.

After the solvent was distilled off, the residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining 5-(benzyloxy)-2-

5 ethynylpyrimidine (45 mg, 0.21 mmol, 67%) as a yellow powder.
[0434]

¹H-NMR (CDCl₃) δ: 8.43 (2H, s), 7.44-7.38 (5H, m), 5.19 (2H, s), 3.04 (1H, s). LCMS (ESI) m/z 211 [M+H]⁺

Step 4: Synthesis of example compound 76

10 The title compound was obtained as in step 4 of Example 1, except that 5-(benzyloxy)-2-ethynylpyrimidine was used in place of 2-ethynyl-1,3-difluorobenzene.

[0435]

¹H-NMR (CD₃OD) δ: 8.57 (2H, s), 8.26 (1H, s), 7.75 (1H, s), 7.49-
15 7.33 (5H, m), 5.87 (1H, d, J = 6.8 Hz), 5.30 (2H, s), 4.84-4.79 (1H, m), 4.32-4.27 (1H, m), 4.26-4.24 (1H, m), 3.40-3.35 (2H, m).
LCMS (ESI) m/z 553 [M+H]⁺.

[0436]

Example 77

20 4-Amino-5-[2-(4-benzyloxy-2-fluoro-phenyl)ethynyl]-7-
[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
d]pyrimidine

Step 1: Synthesis of ((4-(benzyloxy)-2-
25 fluorophenyl)ethynyl)trimethylsilane

The title compound was obtained as in step 2 of Example 76, except that 4-(benzyloxy)-2-fluoro-1-iodobenzene and ethynyltrimethylsilane were used in place of 5-(benzyloxy)-2-bromopyrimidine and ethynyltriisopropylsilane.

30 ¹H-NMR (CDCl₃) δ: 7.43-7.33 (6H, m), 6.77 (1H, dd, J = 10.4, 2.8 Hz), 6.70-6.67 (1H, m), 5.04 (2H, s), 0.25 (9H, s).

Step 2: Synthesis of 4-(benzyloxy)-1-ethynyl-2-fluorobenzene

The title compound was obtained as in step 3 of Example 76, except that 4((4-(benzyloxy)-2-
35 fluorophenyl)ethynyl)trimethylsilane was used in place of 5-

(benzyloxy)-2-((triisopropylsilyl)ethynyl)pyrimidine.

[0437]

¹H-NMR (CDCl₃) δ: 7.43-7.29 (6H, m), 6.66-6.79 (2H, m), 5.04 (2H, s), 3.25 (1H, s).

5 Step 3: Synthesis of example compound 77

The title compound was obtained as in step 4 of Example 1, except that 4-(benzyloxy)-1-ethynyl-2-fluorobenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0438]

10 ¹H-NMR (CD₃OD) δ: 8.22 (1H, s), 7.56 (1H, s), 7.40-7.26 (6H, m), 6.87-6.84 (2H, m), 5.85 (1H, d, J = 6.8 Hz), 5.12 (2H, s), 4.83-4.81 (1H, m), 4.33-4.29 (1H, m), 4.27-4.25 (1H, m), 3.40-3.35 (2H, m). LCMS (ESI) m/z 569 [M+H]⁺.

[0439]

15 Example 78

4-Amino-5-[2-[4-(benzylamino)phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of N-benzyl-4-

20 ((triisopropylsilyl)ethynyl)aniline

The title compound was obtained as in step 2 of Example 76, except that N-benzyl-4-iodoaniline and ethynyltriisopropylsilane were used in place of 5-(benzyloxy)-2-bromopyrimidine and ethynyltriisopropylsilane.

25 [0440]

¹H-NMR (CDCl₃) δ: 7.37-7.25 (7H, m), 6.53 (2H, d, J = 8.8 Hz), 4.34 (2H, s), 1.12-1.05 (21H, m). LCMS (ESI) m/z 364 [M+H]⁺

Step 2: Synthesis of N-benzyl-4-ethynylaniline

30 The title compound was obtained as in step 3 of Example 76, except that N-benzyl-4-((triisopropylsilyl)ethynyl)aniline was used in place of 5-(benzyloxy)-2-((triisopropylsilyl)ethynyl)pyrimidine.

[0441]

¹H-NMR (CDCl₃) δ: 7.39-7.25 (7H, m), 6.55 (2H, d, J = 8.0 Hz), 4.35 (2H, s), 4.28-4.19 (1H, brs), 2.96 (1H, s). LCMS (ESI) m/z

208 [M+H]⁺

Step 3: Synthesis of example compound 78

The title compound was obtained as in step 4 of Example 1, except that N-benzyl-4-ethynylaniline was used in place of 2-ethynyl-1,3-difluorobenzene.

[0442]

¹H-NMR (CD₃OD) δ: 8.25 (1H, s), 7.60 (1H, s), 7.36-7.20 (7H, m), 6.60 (2H, d, J = 8.8 Hz), 5.93 (1H, d, J = 6.6 Hz), 4.73-4.70 (1H, m), 4.35 (2H, s), 4.31-4.29 (1H, m), 4.25-4.22 (1H, m), 3.40-3.35 (2H, m). LCMS (ESI) m/z 550 [M+H]⁺.

[0443]

Example 79

2-[2-[4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-3-fluorobenzamide

Step 1: Synthesis of 3-fluoro-2-

((trimethylsilyl)ethynyl)benzamide

The title compound was obtained as in step 2 of Example 76, except that 3-fluoro-2-iodobenzamide and ethynyltrimethylsilane were used in place of 5-(benzyloxy)-2-bromopyrimidine and ethynyltriisopropylsilane.

[0444]

¹H-NMR (CDCl₃) δ: 7.96 (1H, d, J = 7.8 Hz), 7.83-7.55 (1H, brs), 7.45-7.40 (1H, m), 7.28-7.22 (1H, m), 6.19-5.72 (1H, brs), 0.31 (9H, s). LCMS (ESI) m/z 236 [M+H]⁺

Step 2: Synthesis of 2-ethynyl-3-fluorobenzamide

The title compound was obtained as in step 3 of Example 76, except that 3-fluoro-2-((trimethylsilyl)ethynyl)benzamide was used in place of 5-(benzyloxy)-2-

((triisopropylsilyl)ethynyl)pyrimidine.

[0445]

¹H-NMR (CDCl₃) δ: 7.89-7.86 (1H, m), 7.46 (1H, dt, J = 5.4, 8.0 Hz), 7.30-7.21 (2H, m), 6.29-5.45 (1H, brs), 3.77 (1H, s). LCMS (ESI) m/z 164 [M+H]⁺

Step 3: Synthesis of example compound 79

The title compound was obtained as in step 4 of Example 1, except that 2-ethynyl-3-fluorobenzamide was used in place of 2-ethynyl-1,3-difluorobenzene.

[0446]

5 ¹H-NMR (CD₃OD) δ: 8.23 (1H, s), 7.66 (1H, s), 7.47-7.41 (2H, m), 7.35-7.30 (1H, m), 5.87 (1H, d, J = 6.8 Hz), 4.82-4.75 (1H, m), 4.32-4.29 (1H, m), 4.26-4.24 (1H, m), 3.40-3.35 (2H, m). LCMS (ESI) m/z 506 [M+H]⁺.

[0447]

10 Example 80

4-Amino-5-[2-(3,5-difluoro-2-methoxy-4-pyridyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

15 Step 1: Synthesis of 4-ethynyl-3,5-difluoro-2-methoxypyridine

2,3,5-Trifluoro-4-iodopyridine (500 mg, 1.93 mmol) was dissolved in methanol (3 mL), and sodium methoxide (a 5 M methanol solution, 1.15 mL) was added thereto at room temperature, followed by stirring at room temperature overnight. The reaction solution was partitioned between ethyl acetate and water, and the organic layer was separated and sequentially washed with water and brine. The solvent was distilled off, and the residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining the target product (376 mg) as an oil mixture of 4-ethynyl-3,5-difluoro-2-methoxypyridine and 4-ethynyl-3-fluoro-2,5-dimethoxypyridine.

[0448]

The synthesis was performed as in steps 2 and 3 of Example 76 by using the obtained mixture, followed by separation and purification by silica gel column chromatography (developing solvent: ethyl acetate/hexane) to give the title compound.

[0449]

¹H-NMR (CDCl₃) δ: 7.87 (1H, s), 4.02 (3H, s), 3.73 (1H, s).

Step 2: Synthesis of example compound 80

35 The title compound was obtained as in step 4 of Example

1, except that 4-ethynyl-3,5-difluoro-2-methoxypyridine was used in place of 2-ethynyl-1,3-difluorobenzene.

[0450]

¹H-NMR (DMSO-D₆) δ: 8.20 (1H, s), 8.19 (1H, s), 8.14 (1H, s),

5 7.32-7.29 (1H, m), 6.59 (2H, s), 5.94 (1H, d, J = 6.6 Hz), 5.41 (1H, d, J = 6.6 Hz), 5.24 (1H, d, J = 4.4 Hz), 4.58 (1H, ddd, J = 7.3, 6.2, 4.4 Hz), 4.11-4.04 (2H, m), 3.96 (3H, s). LCMS (ESI) m/z 512 [M+H]⁺.

[0451]

10 Example 81

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-

[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(3-fluoro-2,5-dimethoxy-4-pyridyl)ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 4-ethynyl-3-fluoro-2,5-dimethoxypyridine

15 In accordance with step 1 of Example 80, the title compound was obtained.

[0452]

¹H-NMR (CDCl₃) δ: 7.76 (1H, s), 4.01 (3H, s), 3.97 (3H, s), 3.66 (1H, s).

20 Step 2: Synthesis of example compound 81

The title compound was obtained as in step 4 of Example 1, except that 4-ethynyl-3-fluoro-2,5-dimethoxypyridine was used in place of 2-ethynyl-1,3-difluorobenzene.

[0453]

25 ¹H-NMR (CD₃OD) δ: 8.26 (1H, s), 7.83 (1H, s), 7.75 (1H, s), 5.89 (1H, d, J = 6.6 Hz), 4.85-4.82 (3H, m), 4.34-4.32 (1H, m), 4.29-4.26 (1H, m), 4.04 (3H, s), 3.99 (3H, s), 3.70-3.67 (1H, m), 3.58-3.56 (1H, m), 3.42 (1H, dd, J = 12.5, 4.4 Hz), 3.37 (1H, dd, J = 12.5, 3.7 Hz). LCMS (ESI) m/z 524 [M+H]⁺.

30 [0454]

Example 82

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-

[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-ethylsulfanyphenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

35 Step 1: Synthesis of 1-ethylsulfanyl-2-ethynyl-benzene

The title compound was obtained as in step 2 and step 3 of Example 76, except that 1-bromo-2-ethylsulfanyl-benzene was used in place of 5-(benzyloxy)-2-bromopyrimidine.

[0455]

5 ¹H-NMR (CDCl₃) δ: 7.49 (1H, dd, J = 7.5, 1.3 Hz), 7.33-7.25 (2H, m), 7.12 (1H, dt, J = 1.5, 7.3 Hz), 3.47 (1H, s), 3.01 (2H, q, J = 7.5 Hz), 1.37 (3H, dd, J = 9.5, 5.1 Hz).

Step 2: Synthesis of example compound 82

10 The title compound was obtained as in step 4 of Example 1, except that 1-ethylsulfanyl-2-ethynyl-benzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0456]

¹H-NMR (DMSO-D₆) δ: 8.18 (1H, s), 7.91 (1H, s), 7.52 (1H, dd, J = 7.7, 1.1 Hz), 7.44-7.36 (3H, m), 7.23 (1H, dt, J = 1.5, 7.3 Hz),
15 6.61 (2H, s), 5.93 (1H, d, J = 7.0 Hz), 5.41 (1H, d, J = 6.6 Hz), 5.25 (1H, d, J = 4.4 Hz), 4.59 (1H, q, J = 6.2 Hz), 4.12-4.03 (2H, m), 3.23-3.19 (1H, m), 3.13 (1H, dd, J = 8.1, 5.1 Hz), 3.05 (2H, q, J = 7.5 Hz), 1.29 (3H, t, J = 7.3 Hz). LCMS (ESI) m/z 505.3 [M+H]⁺.

20 [0457]

Example 83

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(1,1-dioxo-
3,4-dihydro-2H-thiochromen-8-yl)ethynyl]pyrrolo[2,3-d]pyrimidine
25 Step 1: Synthesis of triisopropyl(thiochroman-8-ylethynyl)silane

The title compound was obtained as in step 2 of Example 76, except that 8-iodothiochroman was used in place of 5-(benzyloxy)-2-bromopyrimidine.

[0458]

30 ¹H-NMR (CDCl₃) δ: 7.27-7.25 (1H, m), 6.97-6.93 (1H, m), 6.89 (1H, t, J = 7.6 Hz), 3.07-3.04 (2H, m), 2.80 (2H, t, J = 6.1 Hz), 2.12-2.06 (2H, m), 1.26-1.04 (21H, m).

Step 2: Synthesis of 8-ethynyl thiochroman

35 The title compound was obtained as in step 3 of Example 76, except that triisopropyl(thiochroman-8-ylethynyl)silane was

used in place of 5-(benzyloxy)-2-
((triisopropylsilyl)ethynyl)pyrimidine.

[0459]

¹H-NMR (CDCl₃) δ: 7.31-7.26 (1H, m), 7.02-6.98 (1H, m), 6.92 (1H,
5 t, J = 7.6 Hz), 3.45 (1H, s), 3.09-3.06 (2H, m), 2.82 (2H, t, J =
6.1 Hz), 2.13-2.07 (2H, m).

Step 3: Synthesis of 8-ethynyl thiochroman 1,1-dioxide

1,4-Dioxane (1 mL) and water (0.50 mL) were added to 8-
ethynyl thiochroman (59 mg, 0.34 mmol). Then, oxone (420 mg, 0.68
10 mmol) was added thereto under ice-cooling, and the resulting
mixture was allowed to warm to room temperature overnight. The
reaction solution was partitioned at room temperature with the
addition of ethyl acetate, a saturated aqueous sodium hydrogen
carbonate solution, and water, and the aqueous layer was
15 extracted with ethyl acetate. The organic layer was washed with
saturated saline, and dried over sodium sulfate, followed by
filtration and concentration. The residue was purified by silica
gel column chromatography (developing solvent: ethyl
acetate/hexane), thereby obtaining the title compound (51 mg,
20 0.25 mmol, 73%) as a white solid.

[0460]

¹H-NMR (CDCl₃) δ: 7.55 (1H, d, J = 7.8 Hz), 7.38 (1H, t, J = 7.8
Hz), 7.21 (1H, dd, J = 7.8, 1.0 Hz), 3.59 (1H, s), 3.44-3.41 (2H,
m), 3.01 (2H, t, J = 6.2 Hz), 2.48-2.42 (2H, m). LCMS (ESI) m/z
25 207 [M+H]⁺

Step 4: Synthesis of example compound 83

The title compound was obtained as in step 4 of Example
1, except that 8-ethynyl thiochroman 1,1-dioxide was used in
place of 2-ethynyl-1,3-difluorobenzene.

30 [0461]

¹H-NMR (CD₃OD) δ: 8.22 (1H, s), 7.69 (1H, s), 7.57 (1H, d, J = 7.6
Hz), 7.48 (1H, t, J = 7.6 Hz), 7.30 (1H, d, J = 7.6 Hz), 5.87 (1H,
d, J = 6.8 Hz), 4.83-4.79 (1H, m), 4.32-4.30 (1H, m), 4.27-4.25
(1H, m), 3.54-3.51 (2H, m), 3.43-3.33 (2H, m), 3.07 (2H, t, J =
35 6.0 Hz), 2.43-2.38 (2H, m). LCMS (ESI) m/z 549 [M+H].

[0462]

Example 84

2-[2-[4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
5 d]pyrimidin-5-yl]ethynyl]-3-fluoro-benzenesulfonamide

Step 1: Synthesis of 3-fluoro-2-

((trimethylsilyl)ethynyl)benzenesulfonamide

The title compound was obtained as in step 2 of Example
76, except that 3-fluoro-2-iodobenzenesulfonamide and
10 ethynyltrimethylsilane were used in place of 5-(benzyloxy)-2-
bromopyrimidine and ethynyltriisopropylsilane.

[0463]

¹H-NMR (CDCl₃) δ: 7.85 (1H, d, J = 7.8 Hz), 7.45-7.41 (1H, m),
7.31-7.27 (1H, m), 5.24 (2H, s), 0.33 (9H, s). LCMS (ESI) m/z 272
15 [M+H]⁺

Step 2: Synthesis of 2-ethynyl-3-fluorobenzenesulfonamide

The title compound was obtained as in step 3 of Example
76, except that 3-fluoro-2-
((trimethylsilyl)ethynyl)benzenesulfonamide was used in place of
20 5-(benzyloxy)-2-((triisopropylsilyl)ethynyl)pyrimidine.

[0464]

¹H-NMR (CDCl₃) δ: 7.88 (1H, d, J = 7.8 Hz), 7.52-7.47 (1H, m),
7.37-7.31 (1H, m), 5.21 (2H, s), 3.90 (1H, s). LCMS (ESI) m/z 200
[M+H]⁺

25 Step 3: Synthesis of example compound 84

The title compound was obtained as in step 4 of Example
1, except that 2-ethynyl-3-fluorobenzenesulfonamide was used in
place of 2-ethynyl-1,3-difluorobenzene.

[0465]

30 ¹H-NMR (CD₃OD) δ: 8.30 (1H, s), 7.85 (1H, d, J = 7.8 Hz), 7.74 (1H,
s), 7.54-7.49 (1H, m), 7.46-7.41 (1H, m), 5.88 (1H, d, J = 6.8
Hz), 4.84-4.81 (1H, m), 4.33-4.30 (1H, m), 4.27-4.25 (1H, m),
3.43-3.33 (2H, m). LCMS (ESI) m/z 542 [M+H].

[0466]

35 Example 85

4-Amino-5-[2-(2-cyano-6-fluoro-phenyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 3-fluoro-2-

5 ((trimethylsilyl)ethynyl)benzonitrile

The title compound was obtained as in step 2 of Example 76, except that 3-fluoro-2-iodobenzonitrile and ethynyltrimethylsilane were used in place of 5-(benzyloxy)-2-bromopyrimidine and ethynyltriisopropylsilane.

10 [0467]

¹H-NMR (CDCl₃) δ: 7.46-7.44 (1H, m), 7.41-7.35 (1H, m), 7.33-7.29 (1H, m), 0.31 (9H, s). LCMS (ESI) m/z 218 [M+H]⁺

Step 2: Synthesis of 2-ethynyl-3-fluorobenzonitrile

The title compound was obtained as in step 3 of Example 15 76, except that 3-fluoro-2-((trimethylsilyl)ethynyl)benzonitrile was used in place of 5-(benzyloxy)-2-((triisopropylsilyl)ethynyl)pyrimidine.

[0468]

¹H-NMR (CDCl₃) δ: 7.51 (1H, dd, J = 7.7, 1.5 Hz), 7.49-7.44 (1H, m), 20 m), 7.39-7.35 (1H, m), 3.72 (1H, s).

Step 3: Synthesis of example compound 85

The title compound was obtained as in step 4 of Example 1, except that 2-ethynyl-3-fluorobenzonitrile was used in place of 2-ethynyl-1,3-difluorobenzene.

25 [0469]

¹H-NMR (CD₃OD) δ: 8.27 (1H, s), 7.79 (1H, s), 7.66-7.64 (1H, m), 7.57-7.53 (2H, m), 5.88 (1H, d, J = 6.8 Hz), 4.84-4.80 (1H, m), 4.33-4.31 (1H, m), 4.28-4.26 (1H, m), 3.45-3.35 (2H, m). LCMS (ESI) m/z 488 [M+H].

30 [0470]

Example 86

4-Amino-5-[2-[2-(cyclopropylmethoxy)-6-fluoro-phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
35 d]pyrimidine

Step 1: Synthesis of 1-(cyclopropylmethoxy)-3-fluoro-2-iodobenzene

3-Fluoro-2-iodophenol (200 mg, 0.84 mmol) was dissolved in tetrahydrofuran (2 mL). Then, cyclopropylmethanol (0.14 mL, 1.7 mmol) and triphenylphosphine (440 mg, 1.7 mmol) were added thereto at room temperature, and diisopropyl azodicarboxylate (0.33 mL, 1.7 mmol) was added thereto in an ice bath, followed by stirring for 2 hours in an ice bath. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining 1-(cyclopropylmethoxy)-3-fluoro-2-iodobenzene (192 mg) as a yellow oil.

[0471]

¹H-NMR (CDCl₃) δ: 7.26-7.19 (1H, m), 6.72-6.67 (1H, m), 6.57 (1H, d, J = 8.3 Hz), 3.91 (2H, d, J = 6.6 Hz), 1.33-1.28 (1H, m), 0.68-0.63 (2H, m), 0.44-0.41 (2H, m).

Step 2: Synthesis of ((2-(cyclopropylmethoxy)-6-fluorophenyl)ethynyl)trimethylsilane

The title compound was obtained as in step 2 of Example 76, except that 1-(cyclopropylmethoxy)-3-fluoro-2-iodobenzene and ethynyltrimethylsilane were used in place of 5-(benzyloxy)-2-bromopyrimidine and ethynyltriisopropylsilane.

[0472]

¹H-NMR (CDCl₃) δ: 7.17 (1H, dt, J = 6.6, 8.4 Hz), 6.69-6.64 (1H, m), 6.61 (1H, d, J = 8.5 Hz), 3.91 (2H, d, J = 6.3 Hz), 1.31-1.24 (1H, m), 0.64-0.60 (2H, m), 0.45-0.41 (2H, m), 0.28 (9H, s).

Step 3: Synthesis of 1-(cyclopropylmethoxy)-2-ethynyl-3-fluorobenzene

The title compound was obtained as in step 3 of Example 76, except that ((2-(cyclopropylmethoxy)-6-fluorophenyl)ethynyl)trimethylsilane was used in place of 5-(benzyloxy)-2-((triisopropylsilyl)ethynyl)pyrimidine.

[0473]

¹H-NMR (CDCl₃) δ: 7.24 (1H, dt, J = 6.6, 8.4 Hz), 6.72 (1H, t, J = 8.4 Hz), 6.67 (1H, J = 8.4 Hz), 3.93 (2H, d, J = 6.6 Hz), 3.52

(1H, s), 1.36-1.30 (1H, m), 0.68-0.63 (2H, m), 0.43-0.39 (2H, m).

Step 4: Synthesis of example compound 86

The title compound was obtained as in step 4 of Example 1, except that 1-(cyclopropylmethoxy)-2-ethynyl-3-fluorobenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0474]

¹H-NMR (CD₃OD) δ: 8.25 (1H, s), 7.59 (1H, s), 7.33-7.27 (1H, m), 6.88 (1H, d, J = 8.5 Hz), 6.79 (1H, t, J = 8.5 Hz), 5.88 (1H, d, J = 7.0 Hz), 4.86-4.83 (1H, m), 4.34-4.32 (1H, m), 4.28-4.26 (1H, m), 4.01 (2H, d, J = 7.0 Hz), 3.44-3.34 (2H, m), 1.40-1.32 (1H, m), 0.73-0.68 (2H, m), 0.43 (2H, m). LCMS (ESI) m/z 533 [M+H].

[0475]

Example 87

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-

[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-[4-(3-pyridylmethoxy)phenyl]ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of tert-butyl N-(((3aR,4R,6R,6aR)-6-(4-amino-5-((trimethylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfamoyl carbamate

tert-Butyl N-(((3aR,4R,6R,6aR)-6-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfamoyl carbamate (500 mg, 0.82 mmol), ethynyltrimethylsilane (240 mg, 2.5 mmol), bis(triphenylphosphine)palladium (II) dichloride (58 mg, 0.082 mmol), copper iodide (16 mg, 0.082 mmol), and diisopropylethylamine (0.28 mL, 1.6 mmol) were suspended in tetrahydrofuran (5 mL). The reaction solution was stirred at 70°C overnight and filtered through a celite bed, followed by distilling off the solvent. The residue was purified by silica gel column chromatography (developing solvent: methanol/chloroform), thereby obtaining the title compound (339 mg, 0.58 mmol, 71%) as a yellow amorphous substance.

[0476]

¹H-NMR (CDCl₃) δ: 9.41 (1H, brs), 8.50 (1H, s), 7.16 (1H, s), 5.98

(2H, brs), 5.63 (1H, d, $J = 4.6$ Hz), 5.25-5.21 (1H, m), 5.07-5.03 (1H, m), 4.51-4.49 (1H, m), 3.59-3.50 (2H, m), 1.59 (3H, s), 1.43 (9H, s), 1.34 (3H, s), 0.26 (9H, s). LCMS (ESI) m/z 581 $[M+H]^+$

Step 2: Synthesis of tert-butyl N-(((3aR,4R,6R,6aR)-6-(4-amino-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfamoyl carbamate

tert-Butyl N-(((3aR,4R,6R,6aR)-6-(4-amino-5-((trimethylsilyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfamoyl carbamate (339 mg, 0.58 mmol) was dissolved in tetrahydrofuran (6.8 mL), and a tetrabutylammonium fluoride solution (1 M tetrahydrofuran solution, 0.70 mL, 0.70 mmol) was added thereto at room temperature, followed by stirring at room temperature for 25 minutes. After the solvent was distilled off, the residue was purified by silica gel column chromatography (developing solvent: methanol/chloroform), thereby obtaining the title compound (260 mg, 0.51 mmol, 88%) as a yellow powder.

[0477]

$^1\text{H-NMR}$ (CDCl_3) δ : 9.25 (1H, brs), 8.51 (1H, s), 7.20 (1H, s), 6.11 (2H, brs), 5.65 (1H, d, $J = 4.6$ Hz), 5.29-5.25 (1H, m), 5.10-5.06 (1H, m), 4.52-4.49 (1H, m), 3.66-3.53 (2H, m), 3.25 (1H, s), 1.61 (3H, s), 1.44 (9H, s), 1.35 (3H, s). LCMS (ESI) m/z 509 $[M+H]^+$

Step 3: Synthesis of example compound 87

tert-Butyl N-(((3aR,4R,6R,6aR)-6-(4-amino-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfamoyl carbamate (20 mg, 0.039 mmol), 3-((4-iodophenoxy)methyl)pyridine (24 mg, 0.079 mmol), bis(triphenylphosphine)palladium (II) dichloride (3 mg, 0.0043 mmol), copper iodide (1 mg, 0.0053 mmol), and diisopropylethylamine (0.013 mL, 0.079 mmol) were suspended in tetrahydrofuran (0.30 mL). The reaction solution was stirred at 70°C overnight, and a mixed solution (0.60 mL) of trifluoroacetic acid/water = 4/1 was added thereto at room temperature, followed by stirring at room temperature overnight. After the solvent was

distilled off, the residue was purified by basic silica gel column chromatography (developing solvent: methanol/chloroform), thereby obtaining the title compound (2.1 mg, 0.0039 mmol, 10%) as a yellow powder.

5 [0478]

¹H-NMR (CD₃OD) δ: 8.65-8.60 (1H, m), 8.55-8.50 (1H, m), 8.24 (1H, s), 7.95-7.90 (1H, m), 7.50-7.40 (4H, m), 7.05-7.00 (2H, brs), 5.84-5.82 (1H, brs), 5.19 (2H, s), 4.80-4.70 (1H, m), 4.35-4.20 (2H, m), 3.40-3.30 (2H, m). LCMS (ESI) m/z 552 [M+H]⁺.

10 [0479]

Example 88

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(3-fluoro-2-
pyridyl)ethynyl]pyrrolo[2,3-d]pyrimidine

15 The title compound was obtained as in step 3 of Example 87, except that 3-fluoro-2-iodopyridine was used in place of 3-((4-iodophenoxy)methyl)pyridine.

[0480]

¹H-NMR (CD₃OD) δ: 8.43-8.39 (1H, m), 8.26 (1H, s), 7.78 (1H, s),
20 7.78-7.71 (1H, m), 7.50-7.46 (1H, m), 5.88 (1H, d, J = 7.1 Hz),
4.90-4.60 (1H, m), 4.33-4.31 (1H, m), 4.28-4.25 (1H, m), 3.40-
3.31 (2H, m). LCMS (ESI) m/z 464 [M+H]⁺.

[0481]

Example 89

25 4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-
methylsulfanylphenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 3 of Example 87, except that (2-iodophenyl)(methyl)sulfane was used in place
30 of 3-((4-iodophenoxy)methyl)pyridine.

[0482]

¹H-NMR (CD₃OD) δ: 8.24 (1H, s), 7.62 (1H, s), 7.48-7.46 (1H, m),
7.37-7.34 (2H, m), 7.22-7.16 (1H, m), 5.86 (1H, d, J = 8.0 Hz),
4.83-4.81 (1H, m), 4.33-4.29 (1H, m), 4.27-4.25 (1H, m), 3.40-
35 3.35 (2H, m), 2.55 (3H, s). LCMS (ESI) m/z 491 [M+H]⁺.

[0483]

Example 90

2-[2-[4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
5 d]pyrimidin-5-yl]ethynyl]benzenesulfonamide

The title compound was obtained as in step 3 of Example 87, except that 2-iodobenzenesulfonamide was used in place of 3-((4-iodophenoxy)methyl)pyridine.

[0484]

10 ¹H-NMR (CD₃OD) δ: 8.23 (1H, s), 8.02 (1H, dd, J = 8.0, 4.0 Hz), 7.74 (1H, dd, J = 7.8, 4.0 Hz), 7.71 (1H, s), 7.85-7.56 (1H, m), 7.53-7.49 (1H, m), 5.87 (1H, d, J = 6.8 Hz), 4.83-4.81 (1H, m), 4.33-4.29 (1H, m), 4.27-4.25 (1H, m), 3.40-3.35 (2H, m). LCMS (ESI) m/z 524 [M+H]⁺.

15 [0485]

Example 91

3-[[4-[2-[4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
d]pyrimidin-5-yl]ethynyl]phenoxy]methyl]benzamide

20 The title compound was obtained as in step 3 of Example 87, except that 3-((4-iodophenoxy)methyl)benzamide was used in place of 3-((4-iodophenoxy)methyl)pyridine.

[0486]

25 ¹H-NMR (CD₃OD) δ: 8.23 (1H, s), 7.98 (1H, s), 7.84 (1H, d, J = 8.1 Hz), 7.65 (1H, d, J = 8.0 Hz), 7.54 (1H, s), 7.54-7.49 (1H, m), 7.48 (2H, d, J = 8.0 Hz), 7.05 (2H, d, J = 8.0 Hz), 5.85 (1H, d, J = 7.1 Hz), 5.19 (2H, s), 4.83-4.81 (1H, m), 4.33-4.29 (1H, m), 4.27-4.25 (1H, m), 3.40-3.35 (2H, m). LCMS (ESI) m/z 594 [M+H]⁺.

[0487]

30 Example 92

4-[2-[4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
d]pyrimidin-5-yl]ethynyl]isoquinoline

35 The title compound was obtained as in step 3 of Example 87, except that 4-iodoisoquinoline was used in place of 3-((4-

iodophenoxy)methyl)pyridine.

[0488]

¹H-NMR (CD₃OD) δ: 9.20 (1H, s), 8.69 (1H, s), 8.34 (1H, d, J = 8.3 Hz), 8.26 (1H, s), 8.16 (1H, d, J = 8.3 Hz), 7.95-7.90 (1H, m),
5 7.81 (1H, s), 7.80-7.74 (1H, m), 5.92 (1H, d, J = 6.8 Hz), 4.87-
4.81 (1H, m), 4.36-4.33 (1H, m), 4.29-4.25 (1H, m), 3.43-3.39 (2H, m). LCMS (ESI) m/z 496 [M+H]⁺.

[0489]

Example 93

10 4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
[(sulfamoylamino)methyl]cyclopentyl]-5-[2-(1-
naphthyl)ethynyl]pyrrolo[2,3-d]pyrimidine
Step 1: Synthesis of ((3aR,4R,6R,6aS)-6-amino-2,2-
dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol and
15 (4aR,6R,7S,7aR)-6-amino-2,2-
dimethylhexahydrocyclopenta[d][1,3]dioxin-7-ol

(1R,2S,3R,5R)-3-Amino-5-(hydroxymethyl)cyclopentane-
1,2-diol hydrochloride (40 g, 218 mmol) was dissolved at room
temperature in methanol (400 mL) and 2,2-dimethoxypropane (54 mL,
20 436 mmol), and methanesulfonic acid(14 mL, 218 mmol) was added
thereto dropwise in an ice bath with stirring so as to keep the
internal temperature at 7°C or lower. After the mixture was
stirred in an ice bath for 5 minutes and at room temperature
overnight, triethylamine (122 mL, 872 mmol) was added thereto
25 dropwise in an ice bath so as to keep the internal temperature at
10°C or lower. After the mixture was stirred in an ice bath for 5
minutes and at room temperature for 30 minutes, the solvent was
distilled off under reduced pressure, thereby obtaining the title
compound as a crude isomeric mixture (102 g).

30 [0490]

LCMS (ESI) m/z 188 [M+H]⁺

Step 2: Synthesis of ((3aR,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-
d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-3aH-
cyclopenta[d][1,3]dioxol-4-yl)methanol and (4aR,6R,7S,7aR)-6-(4-
35 chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-

dimethylhexahydrocyclopenta[d][1,3]dioxin-7-ol

The crude isomeric mixture (102 g) of ((3aR,4R,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol and (4aR,6R,7S,7aR)-6-amino-2,2-

5 dimethylhexahydrocyclopenta[d][1,3]dioxin-7-ol obtained in step 1 of Example 93, and 2-(4,6-dichloropyrimidin-5-yl)acetaldehyde (46 g, 240 mmol) was suspended in 2-butanol (400 mL). Then, triethylamine (61 mL, 436 mmol) was added thereto at room temperature, and the reaction solution was stirred at 80°C
10 overnight. After the reaction solvent was distilled off under reduced pressure, the residue was partitioned with the addition of ethyl acetate and an aqueous sodium hydrogen carbonate solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, and dried over sodium
15 sulfate, followed by distilling off the solvent, thereby obtaining the title compound as a crude isomeric mixture (72 g).
[0491]

LCMS (ESI) m/z 324 [M+H]⁺

Step 3: Synthesis of ((3aR,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-3aH-
20 cyclopenta[d][1,3]dioxol-4-yl)methanol

The crude isomeric mixture (72 g) of ((3aR,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol and
25 (4aR,6R,7S,7aR)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethylhexahydrocyclopenta[d][1,3]dioxin-7-ol, obtained in step 2 of Example 93, was suspended in acetone (720 mL), and methanesulfonic acid (14.2 mL, 218 mmol) was added thereto in an ice bath. After the reaction solution was stirred in an ice bath
30 for 40 minutes and at room temperature overnight, triethylamine (122 mL, 872 mmol) was added thereto dropwise in an ice bath so as to keep the internal temperature at 10°C or lower. After the mixture was stirred in an ice bath for 10 minutes and at room temperature for 30 minutes, the solvent was distilled off under
35 reduced pressure. The residue was partitioned with the addition

of ethyl acetate and a sodium bicarbonate solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, and dried over sodium sulfate. The solvent was distilled off, thereby giving a crude product of the title

5 compound (77 g) as a brown oil.

[0492]

¹H-NMR (CDCl₃) δ: 8.63 (1H, s), 7.33 (1H, d, J = 3.7 Hz), 6.63 (1H, d, J = 3.7 Hz), 5.03-4.95 (2H, m), 4.73-4.70 (1H, m), 3.90-3.86 (1H, m), 3.83-3.78 (1H, m), 2.52-2.43 (2H, m), 2.38-2.32 (1H, m),
10 2.18-2.16 (1H, m), 1.60 (3H, s), 1.32 (3H, s). LCMS (ESI) m/z 324 [M+H]⁺

Step 4: Synthesis of 7-((3aS,4R,6R,6aR)-6-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)-4-chloro-7H-pyrrolo[2,3-d]pyrimidine
15

The crude product (77 g), i.e., ((3aR,4R,6R,6aS)-6-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol, obtained in step 3 of Example 93 was dissolved in N,N-dimethylformamide (770 mL). Then,
20 imidazole (37 g, 545 mmol) was added thereto at room temperature, and tert-butyldimethylchlorosilane (58 g, 382 mmol) was added in a water bath (25°C), followed by stirring for 40 minutes in a water bath (29°C). The reaction solution was partitioned with the addition of ethyl acetate (800 mL) and water (800 mL) in an ice
25 bath, and the organic layer was washed with water (400 mL). After the aqueous layer (about 300 mL) was removed, saturated saline (100 mL) was added to the organic layer and washed, followed by further washing with saturated saline (400 mL). After the resulting product was dried over sodium sulfate, the solvent was
30 distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining the title compound (79 g, four steps: 83%) as a yellow oil.

[0493]

35 ¹H-NMR (CDCl₃) δ: 8.62 (1H, s), 7.31 (1H, d, J = 3.7 Hz), 6.63 (1H,

d, J = 3.7 Hz), 5.09-5.04 (1H, m), 4.88 (1H, t, J = 6.3 Hz), 4.67-4.64 (1H, m), 3.82-3.74 (2H, m), 2.39-2.37 (3H, m), 1.59 (3H, s), 1.31 (3H, s), 0.93 (9H, s), 0.087 (3H, s), 0.074 (3H, s).

LCMS (ESI) m/z 438 [M+H]⁺

5 Step 5: Synthesis of 7-((3aS,4R,6R,6aR)-6-(((tert-butyl)dimethylsilyl)oxy)methyl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)-4-chloro-5-iodo-7H-pyrrolo [2,3-d]pyrimidine

7-((3aS,4R,6R,6aR)-6-(((tert-butyl)dimethylsilyl)oxy)methyl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)-4-chloro-7H-pyrrolo[2,3-d]pyrimidine (79 g, 180 mmol) was dissolved in N,N-dimethylformamide (790 mL), and N-iodosuccinimide (45 g, 198 mmol) was added thereto at room temperature, followed by stirring
15 at 50°C for 11 hours and at room temperature for 12 hours. Ethyl acetate (600 mL), a saturated sodium hydrogen sulphite solution (300 mL), and water (600 mL) were added in an ice bath to the reaction solution, followed by stirring at room temperature for 10 minutes. After partition, the organic layer was sequentially
20 washed with a liquid mixture of water (600 mL) and saturated saline (100 mL), and saturated saline (500 mL). After the resulting product was dried over sodium sulfate, the solvent was distilled off under reduced pressure, thereby giving a crude product of the title compound (95 g) as a brown oil.

25 [0494]

¹H-NMR (CDCl₃) δ: 8.61 (1H, s), 7.46 (1H, s), 5.08-5.04 (1H, m), 4.85 (1H, t, J = 6.3 Hz), 4.64-4.62 (1H, m), 3.81-3.73 (2H, m), 2.42-2.32 (3H, m), 1.58 (3H, s), 1.30 (3H, s), 0.94 (9H, s), 0.095 (3H, s), 0.082 (3H, s). LCMS (ESI) m/z 564 [M+H]⁺

30 Step 6: Synthesis of ((3aR,4R,6R,6aS)-6-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol

The crude product (95 g), i.e., 7-((3aS,4R,6R,6aR)-6-(((tert-butyl)dimethylsilyl)oxy)methyl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)-4-chloro-5-iodo-7H-

35

pyrrolo[2,3-d]pyrimidine, obtained in step 5 of Example 93 was dissolved in tetrahydrofuran (950 mL), and a tetrabutylammonium fluoride solution (1 M tetrahydrofuran solution, 180 mL) was added thereto at room temperature, followed by stirring at room temperature for 1 hour. The resulting mixture was partitioned in an ice bath with the addition of ethyl acetate (500 mL), water (500 mL), and a saturated sodium bicarbonate solution (300 mL), and the aqueous layer was extracted with ethyl acetate (500 mL). The organic layer was washed with saturated saline (500 mL), and dried over sodium sulfate, followed by distilling off the solvent under reduced pressure. The residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining the title compound (70 g, two steps: 86%) as a light-green amorphous substance.

[0495]

¹H-NMR (CDCl₃) δ: 8.62 (1H, s), 7.48 (1H, s), 5.05-4.99 (1H, m), 4.91 (1H, t, J = 6.5 Hz), 4.71-4.68 (1H, m), 3.89-3.85 (1H, m), 3.82-3.78 (1H, m), 2.50-2.45 (2H, m), 2.31-2.27 (1H, m), 1.90-1.88 (1H, m), 1.59 (3H, s), 1.31 (3H, s). LCMS (ESI) m/z 450

[M+H]⁺

Step 7: Synthesis of ((3aR,4R,6R,6aS)-6-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol

((3aR,4R,6R,6aS)-6-(4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol (70 g) was dissolved in 1,4-dioxane (350 mL), and 28% aqueous ammonia (350 mL) was added thereto at room temperature, followed by stirring at 100°C overnight in a pressure-resistant container. After the solvent was distilled off under reduced pressure, the resulting product was suspended in water (700 mL), followed by stirring at room temperature overnight. The precipitate was collected by filtration and washed with water (420 mL), followed by drying to give the title compound (67 g, 99%) as a light-brown powder.

[0496]

¹H-NMR (CDCl₃) δ: 8.26 (1H, s), 7.12 (1H, s), 5.69-5.67 (2H, brs), 4.94 (1H, t, J = 6.2 Hz), 4.90-4.84 (1H, m), 4.72-4.70 (1H, m), 3.89-3.85 (1H, m), 3.81-3.77 (1H, m), 3.06-3.04 (1H, brs), 2.58-2.46 (2H, m), 2.35-2.27 (1H, m), 1.59 (3H, s), 1.33 (3H, s) LCMS
5 (ESI) m/z 431 [M+H]⁺.

Step 8: Synthesis of 7-((3aS,4R,6R,6aR)-6-(aminomethyl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-amine

((3aR,4R,6R,6aS)-6-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol (51 g, 118 mmol) and phthalimide (35 g, 236 mmol) were dissolved in tetrahydrofuran (1000 mL). Then, triphenylphosphine (93 g, 354 mmol) was added thereto with stirring under ice-cooling. After triphenylphosphine
15 was dissolved, diisopropyl azodicarboxylate (70 mL, 354 mmol) was added thereto dropwise with stirring under ice-cooling. After the reaction solution was stirred for 30 minutes under ice-cooling, the resulting product was stirred at room temperature for 90 minutes, and the reaction solution was distilled off under
20 reduced pressure. Ethanol (750 mL), hydrazine monohydrate (25 mL, 519 mmol), and water (150 mL) were added to the residue, followed by stirring at 80°C overnight. After the solvent was distilled off under reduced pressure, the resulting product was partitioned with the addition of chloroform, water, and a saturated aqueous
25 sodium hydrogen carbonate solution. The aqueous layer was then separated and extracted with chloroform. All of the organic layers were combined and dried over sodium sulfate, followed by distilling off the solvent. The residue was purified by basic silica gel column chromatography (developing solvent:
30 methanol/chloroform), thereby obtaining the title compound (52 g, 89 wt%) as a yellow amorphous substance.

[0497]

¹H-NMR (CDCl₃) δ: 8.27 (1H, s), 7.13 (1H, s), 5.62-5.60 (2H, brs), 4.96-4.90 (2H, m), 4.56 (1H, t, J = 6.0 Hz), 2.90 (2H, d, J = 6.6
35 Hz), 2.46-2.40 (1H, m), 2.27-2.21 (1H, m), 2.17-2.08 (1H, m),

1.58 (3H, s), 1.32 (3H, s). LCMS (ESI) m/z 430 [M+H]⁺.

Step 9: Synthesis of tert-butyl N-(((3aR,4R,6R,6aS)-6-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methyl)sulfamoyl carbamate

5 7-((3aS,4R,6R,6aR)-6-(Aminomethyl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-amine (51.5 g, 89 wt%, ca. 107 mmol) obtained in step 8 of Example 93 was dissolved in acetonitrile (515 mL). Then, 1-aza-4-azoniabicyclo[2.2.2]octan-4-ylsulfonyl(tert-butoxycarbonyl)azanido: 1,4-diazabicyclo[2.2.2]octane monohydrochloride (Reference: Organic Letters, 2012, 10, 2626-2629) (70.5 g, 160 mmol) was added thereto at room temperature. After the reaction solution was stirred at room temperature for 30 minutes, water (1030 mL) and a saturated aqueous ammonium chloride solution (258 mL) were added to the reaction solution, followed by stirring at room temperature for 5 hours. The precipitate was collected by filtration and washed with water (1545 mL), followed by drying to give the title compound (57.1 g, 88%) as a yellowish white powder.

20 [0498]

¹H-NMR (CDCl₃) δ: 8.33 (1H, s), 7.05 (1H, s), 6.62-6.60 (1H, brs), 5.73-5.71 (2H, brs), 4.99 (1H, t, J = 5.9 Hz), 4.78-4.72 (1H, m), 4.64-4.62 (1H, m), 3.36-3.32 (1H, m), 3.24-3.25 (1H, m), 2.57-2.46 (2H, m), 2.38-2.32 (1H, m), 1.56 (3H, s), 1.48 (9H, s), 1.29 (3H, s). LCMS (ESI) m/z 609 [M+H]⁺.

25 Step 10: Synthesis of example compound 93

tert-Butyl N-(((3aR,4R,6R,6aS)-6-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methyl)sulfamoyl carbamate (20 mg, 0.033 mmol), 1-ethynylnaphthalene (10 mg, 0.066 mmol), bis(triphenylphosphine)palladium (II) dichloride (3 mg, 0.0043 mmol), copper iodide (1 mg, 0.0053 mmol), and diisopropylethylamine (0.011 mL, 0.066 mmol) were suspended in tetrahydrofuran (0.30 mL). After the reaction solution was stirred at 70°C for 1 hour, a mixed solution (0.60 mL) of

35

trifluoroacetic acid/water = 4/1 was added thereto at room temperature, followed by stirring at room temperature overnight. After the solvent was distilled off, the residue was purified by silica gel column chromatography (developing solvent:

5 methanol/chloroform), thereby obtaining the title compound (8.2 mg, 50%) as a yellow powder.

[0499]

¹H-NMR (CD₃OD) δ: 8.36 (1H, d, J = 8.5 Hz), 8.17 (1H, s), 7.93-7.89 (2H, m), 7.78-7.75 (1H, m), 7.74 (1H, s), 7.64-7.47 (3H, m),
10 5.02-4.95 (1H, m), 4.47-4.44 (1H, m), 4.05-4.03 (1H, m), 3.30-3.16 (2H, m), 2.52-2.44 (1H, m), 2.37-2.28 (1H, m), 1.90-1.82 (1H, m). LCMS (ESI) m/z 493 [M+H]⁺.

[0500]

Example 94

15 4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]-5-[2-(2,6-dimethoxyphenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 10 of Example 93, except that 2-ethynyl-1,3-dimethoxybenzene was used
20 in place of 1-ethynylnaphthalene.

[0501]

¹H-NMR (CD₃OD) δ: 8.12 (1H, s), 7.52 (1H, s), 7.27 (1H, t, J = 8.5 Hz), 6.68 (2H, d, J = 8.5 Hz), 4.95-4.86 (1H, m), 4.40-4.35 (1H, m), 4.05-3.95 (1H, m), 3.91 (6H, s), 3.30-3.13 (2H, m), 2.50-2.40
25 (1H, m), 2.34-2.28 (1H, m), 1.85-1.73 (1H, m). LCMS (ESI) m/z 503 [M+H]⁺.

[0502]

Example 95

4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]-5-[2-(2-fluoro-6-methoxyphenyl)ethynyl]pyrrolo[2,3-d]pyrimidine
30

The title compound was obtained as in step 10 of Example 93, except that 2-ethynyl-1-fluoro-3-methoxybenzene was used in place of 1-ethynylnaphthalene.

35 [0503]

¹H-NMR (CD₃OD) δ: 8.13 (1H, s), 7.59 (1H, s), 7.34-7.28 (1H, m), 6.88 (1H, d, J = 8.5 Hz), 6.78-6.74 (1H, m), 4.97-4.86 (1H, m), 4.43-4.39 (1H, m), 4.03-4.00 (1H, m), 3.96 (3H, s), 3.30-3.23 (1H, m), 3.22-3.14 (1H, m), 2.50-2.40 (1H, m), 2.34-2.28 (1H, m), 1.85-1.73 (1H, m). LCMS (ESI) m/z 491 [M+H]⁺.

[0504]

Example 96

8-[2-[4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]quinoline

The title compound was obtained as in step 10 of Example 93, except that 8-ethynylquinoline was used in place of 1-ethynylnaphthalene.

[0505]

¹H-NMR (CD₃OD) δ: 9.04-9.02 (1H, m), 8.40-8.35 (1H, m), 8.16 (1H, s), 7.94-7.85 (2H, m), 7.63 (1H, s), 7.61-7.57 (2H, m), 5.00-4.91 (1H, m), 4.46-4.42 (1H, m), 4.05-4.00 (1H, m), 3.30-3.14 (2H, m), 2.50-2.38 (1H, m), 2.34-2.28 (1H, m), 1.87-1.81 (1H, m). LCMS (ESI) m/z 494 [M+H]⁺.

[0506]

Example 97

4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]-5-[2-(2-ethoxy-6-fluorophenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: The title compound was obtained as in step 10 of Example 93, except that 1-ethoxy-2-ethynyl-3-fluorobenzene was used in place of 1-ethynylnaphthalene.

[0507]

¹H-NMR (CD₃OD) δ: 8.14 (1H, s), 7.60 (1H, s), 7.32-7.26 (1H, m), 6.86 (1H, d, J = 8.5 Hz), 6.79-6.74 (1H, m), 5.00-4.91 (1H, m), 4.45-4.42 (1H, m), 4.23 (2H, q, J = 7.1 Hz), 4.05-4.00 (1H, m), 3.30-3.24 (1H, m), 3.21-3.15 (1H, m), 2.50-2.40 (1H, m), 2.34-2.28 (1H, m), 1.87-1.81 (1H, m), 1.47 (3H, t, J = 7.1 Hz). LCMS (ESI) m/z 505 [M+H]⁺.

Step 2: Synthesis of 4-amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-

[(sulfamoylamino)methyl]cyclopentyl]-5-[2-(2-ethoxy-6-fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine hydrochloride

The title compound hydrochloride was obtained in accordance with step 5 of Example 1.

5 ¹H-NMR (CD₃OD) δ: 8.32 (1H, s), 7.95 (1H, s), 7.38-7.34 (1H, m), 6.93 (1H, d, J = 8.5 Hz), 6.84-6.80 (1H, m), 5.13-5.09 (1H, m), 4.41-4.37 (1H, m), 4.27 (2H, q, J = 7.0 Hz), 4.02-4.00 (1H, m), 3.28-3.23 (1H, m), 3.19-3.13 (1H, m), 2.47-2.42 (1H, m), 2.32-2.80 (1H, m), 1.87-1.79 (1H, m), 1.48 (3H, t, J = 7.0 Hz). LCMS
10 (ESI) m/z 505 [M+H]⁺

[0508]

Example 98

4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]-5-[2-(2-fluoro-6-
15 methylsulfanyl-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 10 of Example 93, except that 2-ethynyl-1-fluoro-3-methylsulfanyl-benzene was used in place of 1-ethynylnaphthalene.

[0509]

20 ¹H-NMR (CD₃OD) δ: 8.15 (1H, s), 7.67 (1H, s), 7.35-7.30 (1H, m), 7.10 (1H, d, J = 7.8 Hz), 6.98-6.92 (1H, m), 5.00-4.91 (1H, m), 4.45-4.40 (1H, m), 4.05-4.00 (1H, m), 3.30-3.24 (1H, m), 3.21-3.15 (1H, m), 2.56 (3H, s), 2.50-2.41 (1H, m), 2.34-2.28 (1H, m), 1.87-1.78 (1H, m). LCMS (ESI) m/z 507 [M+H]⁺.

25 [0510]

Example 99

4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]-5-[2-(2-ethylsulfanyl-6-
fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

30 The title compound was obtained as in step 10 of Example 93, except that 1-ethylsulfanyl-2-ethynyl-3-fluoro-benzene was used in place of 1-ethynylnaphthalene.

[0511]

¹H-NMR (DMSO-D₆) δ: 8.15 (1H, s), 7.93 (1H, s), 7.42-7.36 (1H, m),
35 7.23 (1H, d, J = 8.8 Hz), 7.13 (1H, t, J = 8.8 Hz), 6.65 (1H, dd,

J = 6.6, 5.9 Hz), 6.53 (2H, brs), 4.90 (1H, ddd, J = 10.3, 9.9, 8.4 Hz), 4.71 (1H, brs), 4.24 (1H, dd, J = 8.8, 5.5 Hz), 3.79 (1H, dd, J = 5.5, 3.7 Hz), 3.10-3.05 (1H, m), 3.09 (2H, q, J = 7.3 Hz), 2.96-2.89 (1H, m), 2.22 (1H, dt, J = 13.2, 8.1 Hz), 2.15-2.06 (1H, m), 1.61-1.53 (1H, m), 1.30 (3H, t, J = 7.3 Hz). LCMS (ESI) m/z 521 [M+H]⁺.

[0512]

Example 100

4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
10 [(sulfamoylamino)methyl]cyclopentyl]-5-[2-(2-ethoxy-6-methoxy-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 10 of Example 93, except that 1-ethoxy-2-ethynyl-3-methoxybenzene was used in place of 1-ethynylnaphthalene.

15 [0513]

¹H-NMR (DMSO-D₆) δ: 8.12 (1H, s), 7.72 (1H, s), 7.27 (1H, t, J = 8.4 Hz), 6.72-6.65 (3H, m), 6.53 (2H, s), 4.92-4.85 (2H, m), 4.68 (1H, d, J = 4.4 Hz), 4.25-4.20 (1H, m), 4.16 (2H, q, J = 7.0 Hz), 3.87 (3H, s), 3.82-3.78 (1H, m), 3.12-3.06 (1H, m), 2.96-2.90 (1H, m), 2.23-2.18 (1H, m), 2.15-2.07 (1H, m), 1.61-1.53 (1H, m), 1.37 (3H, t, J = 7.0 Hz). LCMS (ESI) m/z 517.3 [M+H]⁺.

[0514]

Example 101

4-[4-[2-[4-amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
25 [(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-3,5-difluoro-phenyl]morpholine

The title compound was obtained as in step 10 of Example 93, except that 4-(4-ethynyl-3,5-difluorophenyl)morpholine was used in place of 1-ethynylnaphthalene.

30 [0515]

¹H-NMR (CD₃OD) δ: 8.14 (1H, s), 7.59 (1H, s), 6.63 (2H, d, J = 11.5 Hz), 4.97-4.93 (1H, m), 4.41 (1H, dd, J = 8.4, 5.7 Hz), 4.01 (1H, dd, J = 5.7, 3.8 Hz), 3.80 (4H, t, J = 4.9 Hz), 3.27-3.11 (6H, m), 2.48-2.40 (1H, m), 2.35-2.25 (1H, m), 1.84-1.76 (1H, m).

LCMS (ESI) m/z 564 [M+H]⁺.

[0516]

Example 102

4-Amino-5-[2-[2,6-difluoro-4-(1-piperidyl)phenyl]ethynyl]-7-

5 [(1R,2S,3R,4R)-2,3-dihydroxy-4-

[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 1-(4-ethynyl-3,5-difluorophenyl)piperidine

The title compound was obtained as in step 1 of Example 23, except that piperidine was used in place of morpholine.

10 [0517]

¹H-NMR (CDCl₃) δ: 6.34 (2H, d, J = 11.4 Hz), 3.37 (1H, s), 3.26-3.20 (4H, m), 1.68-1.60 (6H, m). LCMS (ESI) m/z 222 [M+H]⁺

Step 2: Synthesis of example compound 102

15 The title compound was obtained as in step 10 of Example 93, except that 1-(4-ethynyl-3,5-difluorophenyl)piperidine was used in place of 1-ethynylnaphthalene.

[0518]

20 ¹H-NMR (CD₃OD) δ: 8.13 (1H, s), 7.57 (1H, s), 6.54 (2H, d, J = 11.7 Hz), 4.98-4.91 (1H, m), 4.40 (1H, dd, J = 8.4, 5.6 Hz), 4.01 (1H, dd, J = 5.6, 3.8 Hz), 3.31-3.30 (4H, m), 3.28-3.14 (2H, m), 2.48-2.39 (1H, m), 2.35-2.26 (1H, m), 1.85-1.75 (1H, m), 1.70-1.63 (6H, m). LCMS (ESI) m/z 562 [M+H]⁺.

[0519]

25 Example 103

4-Amino-5-[2-[2,6-difluoro-4-(4-methylpiperazin-1-

yl)phenyl]ethynyl]-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-

[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidine

30 Step 1: Synthesis of 1-(4-ethynyl-3,5-difluorophenyl)-4-methylpiperazine

The title compound was obtained as in step 1 of Example 23, except that 4-methylpiperazine was used in place of morpholine.

[0520]

35 ¹H-NMR (CDCl₃) δ: 6.36 (2H, d, J = 11.0 Hz), 3.39 (1H, s), 3.27-

3.23 (4H, m), 2.54-2.50 (4H, m), 2.34 (3H, s). LCMS (ESI) m/z 237 [M+H]⁺

Step 2: Synthesis of example compound 103

The title compound was obtained as in step 10 of Example 93, except that 1-(4-ethynyl-3,5-difluorophenyl)-4-methylpiperazine was used in place of 1-ethynylnaphthalene. [0521]

¹H-NMR (CD₃OD) δ: 8.23 (1H, s), 7.76 (1H, s), 6.76 (2H, d, J = 10.6 Hz), 5.06-4.97 (1H, m), 4.40 (1H, dd, J = 8.6, 5.6 Hz), 4.01 (1H, dd, J = 5.6, 3.7 Hz), 3.49-3.11 (10H, m), 2.97 (3H, s), 2.48-2.40 (1H, m), 2.34-2.26 (1H, m), 1.87-1.77 (1H, m). LCMS (ESI) m/z 577 [M+H]⁺.

[0522]

Example 104

4-Amino-5-[2-[2,6-difluoro-4-(pyrazol-1-ylmethoxy)phenyl]ethynyl]-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidine
Step 1: Synthesis of 4-((1H-pyrazol-1-yl)methoxy)-2,6-difluorobenzaldehyde

The title compound was obtained as in step 1 of Example 55, except that 2,6-difluoro-4-hydroxybenzaldehyde and 1-(chloromethyl)pyrazole hydrochloride were used in place of 2-fluoro-6-hydroxybenzaldehyde and iodoethane.

[0523]

¹H-NMR (CDCl₃) δ: 10.20 (1H, s), 7.65-7.62 (2H, m), 6.81 (2H, d, J = 10.0 Hz), 6.39 (1H, t, J = 2.1 Hz), 6.05 (2H, s). LCMS (ESI) m/z 239 [M+H]⁺

Step 2: Synthesis of 1-((4-ethynyl-3,5-difluorophenoxy)methyl)-1H-pyrazole

The title compound was obtained as in step 1 of Example 51, except that 4-((1H-pyrazol-1-yl)methoxy)-2,6-difluorobenzaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

[0524]

¹H-NMR (CDCl₃) δ: 7.64-7.60 (2H, m), 6.73 (2H, d, J = 8.8 Hz),

6.37 (1H, t, J = 2.2 Hz), 5.99 (2H, s), 3.42 (1H, s). LCMS (ESI) m/z 235 [M+H]⁺

Step 3: Synthesis of example compound 104

The title compound was obtained as in step 10 of
5 Example 93, except that 1-((4-ethynyl-3,5-difluorophenoxy)methyl)-1H-pyrazole was used in place of 1-ethynylnaphthalene.

[0525]

¹H-NMR (DMSO-D₆) δ: 8.14 (1H, s), 8.04 (1H, d, J = 2.0 Hz), 7.91
10 (1H, s), 7.61 (1H, d, J = 1.5 Hz), 7.15 (2H, d, J = 9.5 Hz), 6.64 (1H, t, J = 6.3 Hz), 6.51 (2H, s), 6.37-6.36 (1H, m), 6.18 (2H, s), 4.91-4.86 (2H, m), 4.69-4.66 (1H, brs), 4.23-4.19 (1H, m), 3.80-3.77 (1H, brs), 3.09-3.04 (1H, m), 2.95-2.88 (1H, m), 2.26-2.18 (1H, m), 2.14-2.10 (1H, m), 1.59-1.51 (1H, m). LCMS (ESI)
15 m/z 575 [M+H]⁺.

[0526]

Example 105

4-Amino-5-[2-(2,6-difluoro-4-pyrrolidin-1-yl-phenyl)ethynyl]-7-
[(1R,2S,3R,4R)-2,3-dihydroxy-4-
20 [(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidine
Step 1: Synthesis of 1-(4-ethynyl-3,5-difluorophenyl)pyrrolidine

The title compound was obtained as in step 1 of Example 23, except that pyrrolidine was used in place of morpholine.

[0527]

¹H-NMR (CDCl₃) δ: 6.02 (2H, d, J = 10.6 Hz), 3.38 (1H, s), 3.28-3.22 (4H, m), 2.04-2.00 (4H, m). LCMS (ESI) m/z 208 [M+H]⁺

Step 2: Synthesis of example compound 105

The title compound was obtained as in step 10 of
Example 93, except that 1-(4-ethynyl-3,5-difluorophenyl)pyrrolidine was used in place of 1-ethynylnaphthalene.
30

[0528]

¹H-NMR (CD₃OD) δ: 8.13 (1H, s), 7.54 (1H, s), 6.21 (2H, d, J = 11.0 Hz), 4.40 (1H, dd, J = 8.6, 5.7 Hz), 4.00 (1H, t, J = 4.6
35 Hz), 3.67-3.62 (1H, m), 3.29-3.05 (6H, m), 2.48-2.39 (1H, m),

2.35-2.25 (1H, m), 2.08-2.02 (4H, m), 1.85-1.75 (1H, m). LCMS (ESI) m/z 548 [M+H]⁺.

[0529]

Example 106

5 4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
[(sulfamoylamino)methyl]cyclopentyl]-5-[2-[2-ethoxy-6-fluoro-4-(1-piperidyl)phenyl]ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 1-(3-ethoxy-4-ethynyl-5-fluorophenyl)piperidine

10 The title compound was obtained as in step 1 of Example 34, except that 1-(4-ethynyl-3,5-difluorophenyl)piperidine was used in place of 4-(4-ethynyl-3,5-difluorophenyl)morpholine.

[0530]

¹H-NMR (CDCl₃) δ: 6.24 (1H, dd, J = 12.8, 2.2 Hz), 6.18-6.16 (1H, m), 4.12 (2H, q, J = 7.0 Hz), 3.42 (1H, s), 3.27-3.22 (4H, m), 1.73-1.60 (6H, m), 1.48 (3H, t, J = 7.0 Hz). LCMS (ESI) m/z 248 [M+H]⁺

Step 2: Synthesis of example compound 106

20 The title compound was obtained as in step 10 of Example 93, except that 1-(3-ethoxy-4-ethynyl-5-fluorophenyl)piperidine was used in place of 1-ethynylnaphthalene.

[0531]

¹H-NMR (CD₃OD) δ: 8.13 (1H, s), 7.50 (1H, s), 6.33-6.30 (2H, m), 4.97-4.90 (1H, m), 4.39 (1H, dd, J = 8.4, 5.5 Hz), 4.17 (2H, q, J = 7.1 Hz), 4.00 (1H, dd, J = 5.7, 3.8 Hz), 3.29-3.13 (6H, m), 2.47-2.40 (1H, m), 2.34-2.26 (1H, m), 1.84-1.75 (1H, m), 1.71-1.61 (6H, m), 1.45 (3H, t, J = 7.1 Hz). LCMS (ESI) m/z 588 [M+H]⁺.

[0532]

Example 107

30 4-Amino-5-[2-(4-benzyloxy-2,6-difluoro-phenyl)ethynyl]-7-
[(1R,2S,3R,4R)-2,3-dihydroxy-4-
[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidine
Step 1: Synthesis of 4-(benzyloxy)-2,6-difluorobenzaldehyde

35 The title compound was obtained as in step 1 of Example 55, except that 2,6-difluoro-4-hydroxybenzaldehyde and

benzylbromide were used in place of 2-fluoro-6-hydroxybenzaldehyde and iodoethane.

[0533]

¹H-NMR (CDCl₃) δ: 10.20 (1H, s), 7.49-7.36 (5H, m), 6.57 (2H, d, J = 10.5 Hz), 5.11 (2H, s). LCMS (ESI) m/z 249 [M+H]⁺

Step 2: Synthesis of 5-(benzyloxy)-2-ethynyl-1,3-difluorobenzene

The title compound was obtained as in step 1 of Example 51, except that 4-(benzyloxy)-2,6-difluorobenzaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

10 [0534]

¹H-NMR (CDCl₃) δ: 7.41-7.36 (5H, m), 6.54 (2H, d, J = 9.0 Hz), 5.04 (2H, s), 3.42 (1H, s). LCMS (ESI) m/z 245 [M+H]⁺

Step 3: Synthesis of example compound 107

15 The title compound was obtained as in step 10 of Example 93, except that 5-(benzyloxy)-2-ethynyl-1,3-difluorobenzene was used in place of 1-ethynylnaphthalene.

[0535]

20 ¹H-NMR (CD₃OD) δ: 8.15 (1H, s), 7.63 (1H, s), 7.45-7.34 (5H, m), 6.78 (2H, d, J = 9.5 Hz), 5.13 (2H, s), 4.92-4.88 (1H, m), 4.43-4.40 (1H, m), 4.02-3.98 (1H, m), 3.30-3.13 (2H, m), 2.46-2.40 (1H, m), 2.31-2.28 (1H, m), 1.83-1.78 (1H, m). LCMS (ESI) m/z 585 [M+H]⁺.

[0536]

Example 108

25 3-[4-[2-[4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-3-ethoxy-5-fluoro-phenyl]-8-oxa-3-azabicyclo[3,2,1]octane

30 Step 1: Synthesis of 3-(4-ethynyl-3,5-difluorophenyl)-8-oxa-3-azabicyclo[3.2.1]octane

The title compound was obtained as in step 1 of Example 23, except that 8-oxa-3-azabicyclo[3.2.1]octane was used in place of morpholine.

[0537]

35 ¹H-NMR (CDCl₃) δ: 6.28 (2H, dd, J = 13.9, 2.9 Hz), 4.52-4.49 (2H,

m), 3.40 (1H, s), 3.26 (2H, d, J = 11.3 Hz), 3.08 (2H, dd, J = 11.3, 2.7 Hz), 2.04-1.96 (2H, m), 1.89-1.82 (2H, m). LCMS (ESI) m/z 250 [M+H]⁺

Step 2: Synthesis of 3-(3-ethoxy-4-ethynyl-5-fluorophenyl)-8-oxa-3-azabicyclo[3.2.1]octane

The title compound was obtained as in step 1 of Example 34, except that 3-(4-ethynyl-3,5-difluorophenyl)-8-oxa-3-azabicyclo[3.2.1]octane was used in place of 4-(4-ethynyl-3,5-difluorophenyl)morpholine.

[0538]

¹H-NMR (CDCl₃) δ: 6.12 (1H, dd, J = 12.6, 2.4 Hz), 6.03 (1H, s), 4.51-4.47 (2H, m), 4.09 (2H, q, J = 7.0 Hz), 3.40 (1H, s), 3.28 (2H, d, J = 11.3 Hz), 3.06 (2H, dd, J = 11.3, 2.7 Hz), 2.03-1.92 (2H, m), 1.92-1.84 (2H, m), 1.46 (3H, t, J = 7.0 Hz). LCMS (ESI) m/z 276 [M+H]⁺

Step 3: Synthesis of example compound 108

The title compound was obtained as in step 10 of Example 93, except that 3-(3-ethoxy-4-ethynyl-5-fluorophenyl)-8-oxa-3-azabicyclo[3.2.1]octane was used in place of 1-ethynylnaphthalene.

[0539]

¹H-NMR (CD₃OD) δ: 8.12 (1H, s), 7.49 (1H, s), 6.29 (1H, d, J = 1.8 Hz), 6.25 (1H, s), 4.94-4.90 (1H, m), 4.47 (2H, s), 4.39 (1H, dd, J = 8.4, 5.9 Hz), 4.18 (2H, q, J = 7.1 Hz), 4.00 (1H, dd, J = 5.7, 3.8 Hz), 3.45 (2H, d, J = 11.0 Hz), 3.26 (1H, dd, J = 12.8, 6.2 Hz), 3.17 (1H, dd, J = 12.6, 6.8 Hz), 2.97 (2H, dd, J = 11.5, 2.4 Hz), 2.48-2.39 (1H, m), 2.35-2.25 (1H, m), 2.00-1.87 (4H, m), 1.84-1.74 (1H, m), 1.45 (3H, t, J = 7.0 Hz). LCMS (ESI) m/z 616 [M+H]⁺.

[0540]

Example 109

4-Amino-5-[2-(2,3-dihydrobenzothiophen-7-yl)ethynyl]-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-

[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 2,3-dihydrobenzo[b]thiophene-7-carbaldehyde

7-Bromo-2,3-dihydrobenzo[b]thiophene (200 mg, 0.93 mmol) was dissolved in tetrahydrofuran (2 mL), and an n-butyllithium solution (1.6 M hexane solution, 1.4 mL, 2.2 mmol) was added thereto at -78°C, followed by stirring at -78°C for 30 minutes. Thereafter, N,N-dimethylformamide (0.22 mL, 2.8 mmol) was added thereto at -78 °C, followed by stirring at -78°C for 20 minutes and at room temperature for 1 hour. A saturated aqueous ammonium chloride solution, water, and ethyl acetate were added to the reaction solution, and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with a saturated sodium chloride aqueous solution, and dried over sodium sulfate, followed by distilling off the solvent. The residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining the title compound (74 mg, 49%) as a yellow oil.

[0541]

¹H-NMR (CDCl₃) δ: 10.05 (1H, s), 7.62 (1H, d, J = 7.5 Hz), 7.39 (1H, dd, J = 7.5, 1.0 Hz), 7.18 (1H, t, J = 7.5 Hz), 3.42-3.37 (2H, m), 3.31 (2H, t, J = 7.6 Hz). LCMS (ESI) m/z 165 [M+H]⁺

Step 2: Synthesis of 7-ethynyl-2,3-dihydrobenzo[b]thiophene

The title compound was obtained as in step 1 of Example 51, except that 2,3-dihydrobenzo[b]thiophene-7-carbaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

[0542]

¹H-NMR (CDCl₃) δ: 7.25 (1H, d, J = 7.6 Hz), 7.15 (1H, dd, J = 7.6, 1.0 Hz), 6.96 (1H, t, J = 7.6 Hz), 3.40-3.31 (5H, m).

Step 3: Synthesis of example compound 109

The title compound was obtained as in step 10 of Example 93, except that 7-ethynyl-2,3-dihydrobenzo[b]thiophene was used in place of 1-ethynyl-naphthalene.

[0543]

¹H-NMR (CD₃OD) δ: 8.15 (1H, s), 7.60 (1H, s), 7.23 (1H, d, J = 7.6 Hz), 7.20-7.17 (1H, m), 7.02 (1H, dd, J = 7.6, 7.6 Hz), 4.97-4.88 (1H, m), 4.43-4.40 (1H, m), 4.02-4.00 (1H, m), 3.44-3.34 (4H, m), 3.29-3.23 (1H, m), 3.20-3.15 (1H, m), 2.48-2.41 (1H, m), 2.32-

2.28 (1H, m), 1.86-1.78 (1H, m). LCMS (ESI) m/z 501 [M+H].

[0544]

Example 110

8-[4-[2-[4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-

5 [(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidin-5-
yl]ethynyl]-3-ethoxy-5-fluoro-phenyl]-3-oxa-8-
azabicyclo[3,2,1]octane

Step 1: Synthesis of 8-(4-ethynyl-3,5-difluorophenyl)-3-oxa-8-
azabicyclo[3.2.1]octane

10 The title compound was obtained as in step 1 of Example
23, except that 3-oxa-8-azabicyclo[3.2.1]octane was used in place
of morpholine.

[0545]

¹H-NMR (CDCl₃) δ: 6.23 (2H, dd, J = 13.6, 3.3 Hz), 4.01-3.98 (2H,
15 m), 3.81 (2H, d, J = 11.2 Hz), 3.53 (2H, d, J = 11.2 Hz), 3.39
(1H, s), 2.16-2.01 (4H, m). LCMS (ESI) m/z 250 [M+H]⁺

Step 2: Synthesis of 8-(3-ethoxy-4-ethynyl-5-fluorophenyl)-3-oxa-
8-azabicyclo[3.2.1]octane

The title compound was obtained as in step 1 of Example
20 34, except that 8-(4-ethynyl-3,5-difluorophenyl)-3-oxa-8-
azabicyclo[3.2.1]octane was used in place of 4-(4-ethynyl-3,5-
difluorophenyl)morpholine.

[0546]

¹H-NMR (CDCl₃) δ: 6.08 (1H, dd, J = 12.1, 2.2 Hz), 6.00 (1H, s),
25 4.08 (2H, q, J = 7.0 Hz), 4.01 (2H, d, J = 2.6 Hz), 3.85 (2H, d,
J = 11.0 Hz), 3.52 (2H, d, J = 11.0 Hz), 3.39 (1H, d, J = 5.9 Hz),
2.13-2.00 (4H, m), 1.45 (3H, t, J = 7.0 Hz). LCMS (ESI) m/z 276
[M+H]⁺

Step 3: Synthesis of example compound 110

30 The title compound was obtained as in step 10 of
Example 93, except that 8-(3-ethoxy-4-ethynyl-5-fluorophenyl)-3-
oxa-8-azabicyclo[3.2.1]octane was used in place of 1-
ethynylnaphthalene.

[0547]

35 ¹H-NMR (CD₃OD) δ: 8.13 (1H, s), 7.50 (1H, s), 6.29 (1H, d, J = 2.2

Hz), 6.25 (1H, d, J = 2.2 Hz), 4.97-4.92 (1H, m), 4.39 (1H, dd, J = 8.4, 5.8 Hz), 4.21-4.14 (4H, m), 4.01 (1H, dd, J = 5.8, 3.8 Hz), 3.83 (2H, d, J = 10.8 Hz), 3.52 (2H, d, J = 10.8 Hz), 3.30-3.12 (2H, m), 2.49-2.39 (1H, m), 2.35-2.26 (1H, m), 2.10-1.99 (4H, m),
5 1.85-1.75 (1H, m), 1.45 (3H, t, J = 7.0 Hz). LCMS (ESI) m/z 616 [M+H]⁺.

[0548]

Example 111

4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-

10 [(sulfamoylamino)methyl]cyclopentyl]-5-[2-[2-methylsulfanyl-4-(1-piperidyl)phenyl]ethynyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 4-fluoro-2-(methylthio)benzaldehyde

Sodium thiomethoxide (680 mg, 9.6 mmol) was suspended in toluene (10 mL), and 2,4-difluorobenzaldehyde (1 g, 7.0 mmol)
15 was added thereto, followed by stirring at 80°C for 2 days. Ethyl acetate and water were added to the reaction solution. Then, the organic layer was washed with a saturated aqueous sodium hydrogen carbonate solution and saturated saline, and dried over sodium sulfate, followed by distilling off the solvent. The residue was
20 purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining the title compound (499 mg, 42%) as a white solid.

[0549]

¹H-NMR (CDCl₃) δ: 10.15 (1H, s), 7.82 (1H, dd, J = 8.3, 6.1 Hz),
25 7.01 (1H, dd, J = 10.1, 2.3 Hz), 6.95 (1H, dt, J = 2.3, 8.3 Hz), 2.49 (3H, s). LCMS (ESI) m/z 171 [M+H]⁺

Step 2: Synthesis of 2-(methylthio)-4-(piperidin-1-yl)benzaldehyde

4-Fluoro-2-(methylthio)benzaldehyde (200 mg, 1.2 mmol)
30 and potassium carbonate (220 mg, 1.6 mmol) were suspended in dimethylsulfoxide (2 mL), and piperidine (0.16 mL, 1.6 mmol) was added thereto at room temperature, followed by stirring at 80°C for 2 hours and 30 minutes. Ethyl acetate and water were added at room temperature to the reaction solution, and the aqueous layer
35 was extracted with ethyl acetate. The organic layer was washed

with a saturated sodium chloride aqueous solution, and dried over sodium sulfate, followed by distilling off the solvent. The residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining the
5 title compound (345 mg) as a yellow oil.

[0550]

¹H-NMR (CDCl₃) δ: 9.99 (1H, s), 7.64 (1H, d, J = 8.7 Hz), 6.68 (1H, dd, J = 8.7, 2.3 Hz), 6.64 (1H, d, J = 2.3 Hz), 3.43-3.40 (4H, m), 2.47 (3H, s), 1.80-1.70 (6H, m). LCMS (ESI) m/z 236 [M+H]⁺

10 Step 3: Synthesis of 1-(4-ethynyl-3-(methylthio)phenyl)piperidine

The title compound was obtained as in step 1 of Example 51, except that 2-(methylthio)-4-(piperidin-1-yl)benzaldehyde was used in place of 2-fluoro-6-methoxybenzaldehyde.

[0551]

15 ¹H-NMR (CDCl₃) δ: 7.32 (1H, d, J = 8.6 Hz), 6.68 (1H, d, J = 2.5 Hz), 6.63 (1H, dd, J = 8.6, 2.5 Hz), 3.35 (1H, s), 3.24-3.21 (4H, m), 2.49 (3H, s), 1.72-1.58 (6H, m). LCMS (ESI) m/z 232 [M+H]⁺

Step 4: Synthesis of example compound 111

The title compound was obtained as in step 10 of
20 Example 93, except that 1-(4-ethynyl-3-(methylthio)phenyl)piperidine was used in place of 1-ethynylnaphthalene.

[0552]

¹H-NMR (CD₃OD) δ: 8.13 (1H, s), 7.53 (1H, s), 7.29 (1H, d, J = 8.8 Hz), 6.81 (1H, d, J = 2.3 Hz), 6.75 (1H, dd, J = 8.8, 2.3 Hz), 4.96-4.87 (1H, m), 4.42-4.38 (1H, m), 4.02-4.00 (1H, m), 3.29-3.15 (6H, m), 2.52 (3H, s), 2.48-2.40 (1H, m), 2.28-2.32 (1H, m), 1.85-1.77 (1H, m), 1.72-1.61 (6H, m). LCMS (ESI) m/z 572 [M+H].

[0553]

30 Example 112

4-[4-[2-[4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-3-ethoxy-5-fluoro-phenyl]morpholine

The title compound was obtained as in step 10 of
35 Example 93, except that 4-(3-ethoxy-4-ethynyl-5-

fluorophenyl)morpholine was used in place of 1-ethynyl-naphthalene.
[0554]

¹H-NMR (DMSO-D₆) δ: 8.12 (1H, s), 7.73 (1H, s), 6.65 (1H, t, J =
6.0 Hz), 6.56-6.39 (4H, m), 4.91-4.84 (2H, m), 4.69 (1H, d, J =
5 4.4 Hz), 4.23-4.16 (2H, m), 3.79 (1H, dd, J = 8.4, 4.4 Hz), 3.74-
3.68 (4H, m), 3.26-3.21 (4H, m), 3.12-3.04 (1H, m), 2.98-2.88 (1H,
m), 2.27-2.17 (1H, m), 2.15-2.07 (2H, m), 1.60-1.51 (1H, m), 1.36
(3H, t, J = 7.0 Hz). LCMS (ESI) m/z 590 [M+H]⁺.

[0555]

10 Example 113

4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
[(sulfamoylamino)methyl]cyclopentyl]-5-[2-(4-methoxy-2-
methylsulfonyl-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine
Step 1: Synthesis of triisopropyl((4-methoxy-2-
15 (methylsulfonyl)phenyl)ethynyl)silane

The title compound was obtained as in step 2 of Example
76, except that 1-bromo-2-methanesulfonyl-4-methoxybenzene was
used in place of 5-(benzyloxy)-2-bromopyrimidine.

[0556]

20 ¹H-NMR (CDCl₃) δ: 7.61-7.59 (2H, m), 7.06 (1H, dd, J = 8.5, 2.7
Hz), 3.88 (3H, s), 3.33 (3H, s), 1.19-1.12 (21H, m). LCMS (ESI)
m/z 367 [M+H]⁺

Step 2: Synthesis of 1-ethynyl-4-methoxy-2-
(methylsulfonyl)benzene

25 The title compound was obtained as in step 3 of Example
76, except that triisopropyl((4-methoxy-2-
(methylsulfonyl)phenyl)ethynyl)silane was used in place of 5-
(benzyloxy)-2-((triisopropylsilyl)ethynyl)pyrimidine.

[0557]

30 ¹H-NMR (CDCl₃) δ: 7.64-7.62 (2H, m), 7.09 (1H, dd, J = 8.5, 2.7
Hz), 3.90 (3H, s), 3.53 (1H, s), 3.31 (3H, s). LCMS (ESI) m/z 211
[M+H]⁺

Step 3: Synthesis of example compound 113

The title compound was obtained as in step 10 of
35 Example 93, except that 1-ethynyl-4-methoxy-2-

(methylsulfonyl)benzene was used in place of 1-ethynylnaphthalene.
[0558]

¹H-NMR (CD₃OD) δ: 8.16 (1H, s), 7.72 (1H, s), 7.70 (1H, d, J = 8.6 Hz), 7.57 (1H, d, J = 2.8 Hz), 7.26 (1H, dd, J = 8.6, 2.8 Hz),
5 4.99-4.91 (1H, m), 4.44-4.40 (1H, m), 4.03-4.01 (1H, m), 3.91 (3H, s), 3.30 (3H, s), 3.39-3.24 (1H, m), 3.21-3.16 (1H, m), 2.50-2.42 (1H, m), 2.35-2.28 (1H, m), 1.87-1.79 (1H, m). LCMS (ESI) m/z 551 [M+H].

[0559]

10 Example 114

4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
[(sulfamoylamino)methyl]cyclopentyl]-5-[2-(2-ethylsulfonyl-6-
fluoro-4-pyrrolidin-1-yl-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 10 of
15 Example 93, except that 1-(3-(ethylsulfonyl)-4-ethynyl-5-
fluorophenyl)pyrrolidine was used in place of 1-
ethynylnaphthalene.

[0560]

¹H-NMR (CD₃OD) δ: 8.13 (1H, s), 7.62 (1H, s), 6.99 (1H, d, J = 2.6
20 Hz), 6.64 (1H, dd, J = 12.4, 2.6 Hz), 4.98-4.90 (1H, m), 4.43-
4.39 (1H, m), 4.02-4.00 (1H, m), 3.49 (2H, q, J = 7.4 Hz), 3.39-
3.34 (4H, m), 3.28-3.24 (1H, m), 3.20-3.15 (1H, m), 2.48-2.40 (1H, m), 2.34-2.28 (1H, m), 2.09-2.06 (4H, m), 1.85-1.77 (1H, m), 1.24 (3H, t, J = 7.4 Hz). LCMS (ESI) m/z 622 [M+H].

25 [0561]

Example 115

4-Amino-5-[2-[2,6-difluoro-4-[(3R)-3-fluoropyrrolidin-1-
yl]phenyl]ethynyl]-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 10 of
30 Example 93, except that (3R)-1-(4-ethynyl-3,5-difluorophenyl)-3-
fluoropyrrolidine was used in place of 1-ethynylnaphthalene.

[0562]

¹H-NMR (CD₃OD) δ: 8.12 (1H, s), 7.54 (1H, s), 6.25 (2H, d, J =
35 10.6 Hz), 5.38 (1H, d, J = 53.2 Hz), 5.04-4.95 (1H, m), 4.40 (1H,

dd, $J = 8.4, 5.9$ Hz), 4.01 (1H, dd, $J = 5.5, 3.7$ Hz), 3.64-3.10 (6H, m), 2.49-2.38 (1H, m), 2.37-2.26 (2H, m), 2.22-2.12 (1H, m), 1.84-1.75 (1H, m). LCMS (ESI) m/z 566 $[M+H]^+$.

[0563]

5 Example 116

4-Amino-5-[2-[2,6-difluoro-4-[(3S)-3-fluoropyrrolidin-1-yl]phenyl]ethynyl]-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidine
Step 1: Synthesis of (3S)-1-(4-ethynyl-3,5-difluorophenyl)-3-fluoropyrrolidine
10 fluoropyrrolidine

The title compound was obtained as in step 1 of Example 23, except that (S)-3-fluoropyrrolidine was used in place of morpholine.

[0564]

15 $^1\text{H-NMR}$ (CDCl_3) δ : 6.06 (2H, d, $J = 10.3$ Hz), 5.38 (1H, d, $J = 53.5$ Hz), 3.62-3.39 (5H, m), 2.47-2.36 (1H, m), 2.28-2.07 (1H, m).

LCMS (ESI) m/z 226 $[M+H]^+$

Step 2: Synthesis of example compound 116

The title compound was obtained as in step 10 of Example 93, except that (3S)-1-(4-ethynyl-3,5-difluorophenyl)-3-fluoropyrrolidine was used in place of 1-ethynyl-naphthalene.

[0565]

$^1\text{H-NMR}$ (CD_3OD) δ : 8.11 (1H, s), 7.53 (1H, s), 6.22 (2H, d, $J = 10.6$ Hz), 5.38 (1H, d, $J = 53.2$ Hz), 4.93-4.90 (1H, m), 4.42-4.37 (1H, m), 4.01 (1H, dd, $J = 5.5, 4.0$ Hz), 3.62-3.15 (6H, m), 2.49-2.40 (1H, m), 2.34-2.27 (2H, m), 2.22-2.08 (1H, m), 1.84-1.76 (1H, m). LCMS (ESI) m/z 566 $[M+H]^+$.

[0566]

Example 117

30 4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]-5-[2-(1,1-dioxo-2,3-dihydrobenzothiophen-7-yl)ethynyl]pyrrolo[2,3-d]pyrimidine
Step 1: Synthesis of 7-ethynyl-2,3-dihydrobenzo[b]thiophene 1,1-dioxide

35 The title compound was obtained as in step 3 of Example

70, except that 7-ethynyl-2,3-dihydrobenzo[b]thiophene was used in place of 2-(ethylthio)-6-fluoro-4-(pyrrolidin-1-yl)benzaldehyde.

[0567]

5 ¹H-NMR (CDCl₃) δ: 7.57-7.51 (2H, m), 7.36 (1H, d, J = 7.1 Hz), 3.57-3.52 (3H, m), 3.35 (2H, t, J = 7.2 Hz). LCMS (ESI) m/z 193 [M+H]⁺

Step 2: Synthesis of example compound 117

The title compound was obtained as in step 10 of
10 Example 93, except that 7-ethynyl-2,3-dihydrobenzo[b]thiophene 1,1-dioxide was used in place of 1-ethynylnaphthalene.

[0568]

¹H-NMR (CD₃OD) δ: 8.15 (1H, s), 7.74 (1H, s), 7.64 (1H, t, J = 7.6 Hz), 7.58 (1H, d, J = 7.6 Hz), 7.45 (1H, d, J = 7.6 Hz), 5.00-
15 4.89 (1H, m), 4.44-4.40 (1H, m), 4.03-4.00 (1H, m), 3.62 (2H, t, J = 7.1 Hz), 3.41 (2H, t, J = 7.1 Hz), 3.22-3.11 (2H, m), 2.48-2.42 (1H, m), 2.32-2.26 (1H, m), 1.87-1.77 (1H, m). LCMS (ESI) m/z 533 [M+H].

[0569]

20 Example 118

4-Amino-5-[2-[4-(azetidin-1-yl)-2,6-difluoro-phenyl]ethynyl]-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 10 of
25 Example 93, except that 1-(4-ethynyl-3,5-difluorophenyl)azetidine was used in place of 1-ethynylnaphthalene.

[0570]

¹H-NMR (CD₃OD) δ: 8.14 (1H, s), 7.56 (1H, s), 6.03 (2H, d, J = 10.0 Hz), 4.99-4.89 (1H, m), 4.40 (1H, dd, J = 8.5, 5.6 Hz), 4.01
30 (1H, dd, J = 5.6, 3.7 Hz), 3.94 (4H, t, J = 7.4 Hz), 3.28-3.09 (2H, m), 2.46-2.36 (3H, m), 2.34-2.24 (1H, m), 1.85-1.72 (1H, m). LCMS (ESI) m/z 534 [M+H]⁺.

[0571]

Example 119

35 4-Amino-5-[2-[2,6-difluoro-4-(4-hydroxy-1-

piperidyl]phenyl]ethynyl]-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidine

Step 1: Synthesis of 1-(4-ethynyl-3,5-difluorophenyl)piperidin-4-
ol

5 The title compound was obtained as in step 1 of Example
23, except that piperidin-4-ol was used in place of morpholine.
[0572]

¹H-NMR (CDCl₃) δ: 6.36 (2H, d, J = 11.2 Hz), 3.93-3.87 (1H, m),
3.58 (2H, dt, J = 13.0, 4.9 Hz), 3.40 (1H, s), 3.06-3.00 (2H, m),
10 2.21-2.10 (1H, m), 1.99-1.91 (2H, m), 1.65-1.55 (2H, m). LCMS
(ESI) m/z 238 [M+H]⁺

Step 2: Synthesis of example compound 119

 The title compound was obtained as in step 10 of
Example 93, except that 1-(4-ethynyl-3,5-
15 difluorophenyl)piperidin-4-ol was used in place of 1-
ethynylnaphthalene.

[0573]

¹H-NMR (CD₃OD) δ: 8.19 (1H, s), 7.57 (1H, s), 6.57 (2H, d, J =
11.5 Hz), 4.98-4.89 (1H, m), 4.40 (1H, t, J = 6.3 Hz), 4.01 (1H,
20 dd, J = 5.5, 3.8 Hz), 3.85-3.78 (1H, m), 3.70-3.65 (2H, m), 3.30-
3.14 (2H, m), 3.08-3.00 (2H, m), 2.49-2.40 (1H, m), 2.36-2.25 (1H,
m), 1.97-1.88 (2H, m), 1.85-1.75 (1H, m), 1.60-1.50 (2H, m). LCMS
(ESI) m/z 578 [M+H]⁺.

[0574]

25 Example 120

4-Amino-5-[2-[2,6-difluoro-4-[(3R)-3-hydroxypyrrolidin-1-
yl]phenyl]ethynyl]-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidine

 The title compound was obtained as in step 10 of
30 Example 93, except that (3R)-1-(4-ethynyl-3,5-difluorophenyl)-
pyrrolidin-3-ol was used in place of 1-ethynylnaphthalene.

[0575]

¹H-NMR (CD₃OD) δ: 8.22 (1H, s), 7.55 (1H, s), 6.20 (2H, d, J =
11.0 Hz), 4.98-4.90 (1H, m), 4.55-4.51 (1H, m), 4.43-4.36 (1H, m),
35 4.01 (1H, dd, J = 5.5, 3.8 Hz), 3.51-3.42 (2H, m), 3.40-3.33 (1H,

m), 3.27-3.14 (3H, m), 2.48-2.40 (1H, m), 2.34-2.26 (1H, m), 2.20-2.09 (1H, m), 2.08-2.00 (1H, m), 1.84-1.75 (1H, m). LCMS (ESI) m/z 564 [M+H]⁺.

[0576]

5 Example 121

4-Amino-5-[2-[2,6-difluoro-4-[(3S)-3-hydroxypyrrolidin-1-yl]phenyl]ethynyl]-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidine
Step 1: Synthesis of (3S)-1-(4-ethynyl-3,5-difluorophenyl)-
10 pyrrolidin-3-ol

The title compound was obtained as in step 1 of Example 23, except that (S)-pyrrolidin-3-ol was used in place of morpholine.

[0577]

15 ¹H-NMR (CDCl₃) δ: 6.03 (2H, d, J = 10.5 Hz), 4.64-4.60 (1H, m), 3.51-3.43 (2H, m), 3.39 (1H, s), 3.34 (1H, dt, J = 3.2, 9.0 Hz), 3.22 (1H, d, J = 10.7 Hz), 2.22-2.12 (1H, m), 2.12-2.05 (1H, m). LCMS (ESI) m/z 224 [M+H]⁺

Step 2: Synthesis of example compound 121

20 The title compound was obtained as in step 10 of Example 93, except that (3S)-1-(4-ethynyl-3,5-difluorophenyl)-pyrrolidin-3-ol was used in place of 1-ethynylnaphthalene.

[0578]

¹H-NMR (CD₃OD) δ: 8.23 (1H, s), 7.55 (1H, s), 6.20 (2H, d, J = 10.7 Hz), 4.97-4.89 (1H, m), 4.54-4.49 (1H, m), 4.46-4.35 (1H, m), 4.03-3.96 (1H, m), 3.51-3.41 (2H, m), 3.40-3.33 (1H, m), 3.27-3.12 (3H, m), 2.48-2.39 (1H, m), 2.35-2.25 (1H, m), 2.19-2.09 (1H, m), 2.08-2.00 (1H, m), 1.84-1.74 (1H, m). LCMS (ESI) m/z 564 [M+H]⁺.

30 [0579]

Example 122

8-[2-[4-amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-7-fluoro-4-methyl-2,3-dihydro-1,4-benzoxazine

35 Step 1: The title compound was obtained as in step 10 of Example

93, except that 8-ethynyl-7-fluoro-4-methyl-2,3-dihydro-1,4-benzoxazine was used in place of 1-ethynylnaphthalene.

[0580]

¹H-NMR (DMSO-D₆) δ: 8.17-8.12 (2H, m), 7.84 (1H, s), 6.77-6.64 (3H, m), 6.53 (2H, s), 4.88 (1H, dd, J = 18.7, 8.4 Hz), 4.43 (2H, t, J = 4.2 Hz), 4.21 (1H, dd, J = 8.6, 5.3 Hz), 3.80 (1H, dd, J = 5.1, 3.3 Hz), 3.25 (2H, t, J = 4.2 Hz), 3.12-3.04 (1H, m), 2.96-2.89 (1H, m), 2.82 (3H, s), 2.24-2.19 (1H, m), 2.15-2.08 (1H, m), 1.56 (1H, dd, J = 20.9, 11.0 Hz). LCMS (ESI) m/z 532.3 [M+H]⁺.

10 [0581]

Step 2: Synthesis of 8-[2-[4-amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-7-fluoro-4-methyl-2,3-dihydro-1,4-benzoxazine hydrochloride

15 The title compound hydrochloride was obtained as in step 5 of Example 1.

[0582]

¹H-NMR (DMSO-D₆) δ: 8.45 (1H, s), 8.24 (1H, s), 6.81-6.74 (2H, m), 4.98 (1H, dd, J = 19.1, 8.8 Hz), 4.47 (2H, t, J = 4.2 Hz), 4.20 (1H, dd, J = 9.0, 5.3 Hz), 3.80 (1H, dd, J = 5.1, 2.9 Hz), 3.27 (2H, t, J = 4.4 Hz), 3.08 (1H, dd, J = 12.8, 6.6 Hz), 2.93 (1H, dd, J = 12.5, 7.3 Hz), 2.84 (3H, s), 2.29-2.22 (1H, m), 2.17-2.10 (1H, m), 1.58 (1H, dd, J = 20.7, 10.8 Hz). LCMS (ESI) m/z 532.4 [M+H]⁺

25 [0583]

Example 123

4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]-5-[2-(1,1-dioxo-3,4-dihydro-2H-thiochromen-8-yl)ethynyl]pyrrolo[2,3-d]pyrimidine

30 The title compound was obtained as in step 10 of Example 93, except that 8-ethynyl thiochroman 1,1-dioxide was used in place of 1-ethynylnaphthalene.

[0584]

¹H-NMR (CD₃OD) δ: 8.16 (1H, s), 7.73 (1H, s), 7.57 (1H, d, J = 7.7 Hz), 7.50 (1H, t, J = 7.7 Hz), 7.31 (1H, d, J = 7.7 Hz), 5.03-

4.89 (1H, m), 4.44-4.40 (1H, m), 4.04-4.02 (1H, m), 3.56-3.53 (2H, m), 3.30-3.25 (1H, m), 3.22-3.17 (1H, m), 3.09 (2H, t, J = 6.0 Hz), 2.50-2.39 (3H, m), 2.36-2.27 (1H, m), 1.87-1.79 (1H, m).
LCMS (ESI) m/z 547 [M+H].

5 [0585]

Example 124

4-Amino-5-[2-(2,6-difluorophenyl)ethynyl]-7-[(2R,4S,5R)-4-hydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

10 Step 1: Synthesis of (2R,3S,5R)-5-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(aminoethyl)tetrahydrofuran-3-ol

The title compound was obtained as in step 2 of Example 1, except that (2R,3S,5R)-5-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol was used
15 in place of [(3aR,4R,6R,6aR)-4-(4-amino-5-iodo-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol.

[0586]

¹H-NMR (CD₃OD) δ: 8.09 (1H, s), 7.48 (1H, s), 6.52 (1H, t, J = 7.0 Hz), 4.37 (1H, dt, J = 6.6, 4.0 Hz), 3.89 (1H, dt, J = 7.0, 4.0 Hz), 2.91 (1H, dd, J = 13.2, 4.0 Hz), 2.83 (1H, dd, J = 13.2, 7.0 Hz), 2.66-2.59 (1H, m), 2.33 (1H, ddd, J = 13.9, 7.0, 3.7 Hz).

LCMS (ESI) m/z 376 [M+H]⁺

Step 2: Synthesis of tert-butyl-N-[(2R,3S,5R)-5-(4-amino-5-iodo-pyrrolo[2,3-d]pyrimidin-7-yl)-3-hydroxy-tetrahydrofuran-2-yl]methyl sulfamoyl]carbamate
25

The title compound was obtained as in step 3 of Example 1, except that (2R,3S,5R)-5-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(aminoethyl)tetrahydrofuran-3-ol was used in
30 place of 7-((3aR,4R,6R,6aR)-6-(aminomethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-amine.

[0587]

¹H-NMR (DMSO-D₆) δ: 10.84 (1H, s), 8.09 (1H, s), 7.61 (1H, s), 6.76-6.61 (2H, brm), 6.35 (1H, dd, J = 8.8, 5.9 Hz), 5.33 (1H, d,

35

$J = 4.0$ Hz), 4.28-4.26 (1H, brm), 3.90-3.87 (1H, m), 3.16-3.10 (2H, m), 2.59-2.52 (1H, m), 2.11-2.06 (1H, m), 1.36 (9H, s). LCMS (ESI) m/z 555 $[M+H]^+$

Step 3: Synthesis of example compound 124

5 tert-Butyl-N-[[(2R,3S,5R)-5-(4-amino-5-iodo-pyrrolo[2,3-d]pyrimidin-7-yl)-3-hydroxy-tetrahydrofuran-2-yl]methyl sulfamoyl]carbamate (40 mg, 0.072 mmol), 2-ethynyl-1,3-difluorobenzene (15 mg, 0.11 mmol),
bis(triphenylphosphine)palladium (II) dichloride (10 mg, 0.014
10 mmol), copper iodide (2.7 mg, 0.014 mmol), and
diisopropylethylamine (0.030 mL, 0.18 mmol) were suspended in tetrahydrofuran (0.5 mL). The reaction solution was stirred at 70°C overnight. Thereafter, trifluoroacetic acid (0.5 mL) was added thereto at room temperature, followed by stirring at room
15 temperature overnight. After the solvent was distilled off, the residue was purified by silica gel column chromatography (developing solvent: methanol/chloroform), thereby obtaining the title compound (1.2 mg, 4%) as a white powder.

[0588]

20 $^1\text{H-NMR}$ (DMSO- D_6) δ : 8.18 (1H, s), 8.00 (1H, s), 7.53-7.47 (1H, m), 7.29-7.24 (1H, m), 7.18-7.15 (1H, m), 6.58 (2H, s), 6.43 (1H, dd, $J = 8.8, 5.6$ Hz), 5.35 (1H, d, $J = 4.1$ Hz), 4.39-4.35 (1H, brm), 3.98-3.94 (1H, brm), 3.18-3.03 (2H, brm), 2.66-2.59 (1H, m). LCMS (ESI) m/z 465 $[M+H]^+$.

25 [0589]

Example 125

4-Amino-7-[(2R,4S,5R)-4-hydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(1-naphthyl)ethynyl]pyrrolo[2,3-d]pyrimidine

30 The title compound was obtained as in step 3 of Example 124, except that 1-ethynylnaphthalene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0590]

$^1\text{H-NMR}$ (CD_3OD) δ : 8.39 (1H, d, $J = 8.4$ Hz), 8.35 (1H, s), 8.07 (1H, s), 7.96 (1H, brs), 7.94 (1H, brs), 7.85 (1H, d, $J = 7.3$ Hz),

35

7.67-7.46 (3H, m), 6.59 (1H, dd, J = 7.7, 6.2 Hz), 4.62-4.59 (1H, m), 4.18-4.15 (1H, m), 3.41-3.34 (2H, m), 2.77 (1H, ddd, J = 13.9, 7.7, 6.2 Hz), 2.45 (1H, ddd, J = 13.9, 6.2, 2.9 Hz). LCMS (ESI) m/z 479 [M+H]⁺.

5 [0591]

Example 126

4-[4-Amino-7-[(2R,4S,5R)-4-hydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
d]pyrimidin-5-yl]-2-(o-tolyl)thiazole

10 The title compound was obtained as in Example 2, except that tert-butyl-N-[[(2R,3S,5R)-5-(4-amino-5-iodo-pyrrolo[2,3-d]pyrimidin-7-yl)-3-hydroxy-tetrahydrofuran-2-yl]methyl sulfamoyl]carbamate was used in place of tert-butyl N-(((3aR,4R,6R,6aR)-6-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfamoyl carbamate.

15 [0592]

¹H-NMR (CD₃OD) δ: 8.37 (1H, s), 8.26 (1H, s), 8.15 (1H, s), 8.04-8.01 (1H, m), 7.66 (1H, d, J = 7.7 Hz), 7.49-7.35 (3H, m), 6.68
20 (1H, dd, J = 7.7, 6.2 Hz), 4.61-4.58 (1H, m), 4.16 (1H, dt, J = 5.9, 3.3 Hz), 3.44 (1H, dd, J = 13.6, 4.0 Hz), 3.39 (1H, dd, J = 13.6, 4.8 Hz), 2.72-2.65 (1H, m), 2.55 (3H, s), 2.47 (1H, ddd, J = 13.6, 6.2, 3.3 Hz). LCMS (ESI) m/z 502 [M+H]⁺.

[0593]

25 Example 127

4-Amino-5-[2-(2-ethoxy-6-fluoro-phenyl)ethynyl]-7-[(2R,4S,5R)-4-hydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 3 of Example 124, except that 1-ethoxy-2-ethynyl-3-fluorobenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

30 [0594]

¹H-NMR (DMSO-D₆) δ: 8.17 (1H, s), 7.88 (1H, s), 7.37 (1H, ddd, J = 8.8, 8.4, 7.0 Hz), 7.19 (1H, dd, J = 7.0, 5.5 Hz), 6.97 (1H, d, J = 8.4 Hz), 6.91 (1H, t, J = 8.8 Hz), 6.57 (2H, s), 6.42 (1H, dd,

J = 8.4, 5.5 Hz), 5.37 (1H, d, J = 4.0 Hz), 4.37 (1H, brs), 4.22 (2H, q, J = 7.0 Hz), 3.99-3.93 (1H, m), 3.22-3.04 (2H, m), 2.67-2.61 (1H, m), 2.17 (1H, dd, J = 13.6, 5.5 Hz), 1.37 (3H, t, J = 7.0 Hz). LCMS (ESI) m/z 491 [M+H]⁺.

5 [0595]

Example 128

4-Amino-5-[2-(2,6-difluorophenyl)ethynyl]-7-[(1R,4R,5S)-4,5-dihydroxy-3-[(sulfamoylamino)methyl]cyclopent-2-en-1-yl]pyrrolo[2,3-d]pyrimidine

10 Step 1: Synthesis of ((3aS,4R,6aR)-6-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-ol

(3aR,6aR)-6-(((tert-Butyldiphenylsilyl)oxy)methyl)-2,2-dimethyl-3aH-cyclopenta[d][1,3]dioxol-4(6aH)-one (1.0 g, 2.36 mmol) and cerium chloride heptahydrate (881 mg, 2.36 mmol) were suspended in methanol (5 mL), and sodium borohydride (92%, 146 mg, 3.54 mmol) was added thereto with stirring at 0°C. After the mixture was stirred at 0°C for 2 hours, water (20 mL) was added thereto. Acetic acid was then added thereto until the pH of the reaction liquid became about 5. After the reaction liquid was partitioned between ethyl acetate and water, the organic layer was separated. The obtained organic layer was sequentially washed with a saturated aqueous ammonium chloride solution and saturated saline, and dried over magnesium sulfate, followed by distilling off the solvent. The residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining the title compound (960 mg) as a colorless oil.

[0596]

¹H-NMR (CDCl₃) δ: 7.72-7.66 (4H, m), 7.45-7.37 (6H, m), 5.85 (1H, s), 4.88 (1H, d, J = 5.5 Hz), 4.76 (1H, dd, J = 6.2, 5.9 Hz), 4.58-4.55 (1H, brm), 4.39 (1H, d, J = 14.7 Hz), 4.29 (1H, d, J = 14.7 Hz), 1.37 (3H, s), 1.34 (3H, s), 1.08 (9H, s). LCMS (ESI) m/z 425 [M+H]⁺

Step 2: Synthesis of 7-((3aS,4R,6aR)-6-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyl-4,6a-dihydro-3aH-

cyclopenta[d][1,3]dioxol-4-yl)-4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine

(3aS,4R,6aR)-6-(((tert-Butyldiphenylsilyl)oxy)methyl)-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-ol (960 mg, 2.26 mmol), 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (632 mg, 2.26 mmol), and triphenylphosphine (889 mg, 3.39 mmol) were dissolved in tetrahydrofuran (7 mL). Then, diisopropyl azodicarboxylate (667 μ L, 3.39 mmol) was added thereto dropwise with stirring at 0°C. After the reaction liquid was stirred at room temperature for 14 hours, the reaction liquid was concentrated, and the residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining the title compound (1.33 g) as a colorless amorphous substance.

[0597]

¹H-NMR (CDCl₃) δ : 8.69 (1H, s), 7.72-7.69 (4H, m), 7.49-7.39 (6H, m), 7.15 (1H, s), 5.88-5.86 (1H, brm), 5.84-5.82 (1H, brm), 5.21 (1H, d, J = 5.5 Hz), 4.56 (1H, d, J = 5.5 Hz), 4.49 (2H, d, J = 14.7 Hz), 1.44 (3H, s), 1.31 (3H, s), 1.11 (9H, s). LCMS (ESI) m/z 687 [M+H]⁺

Step 3: Synthesis of ((3aR,6R,6aS)-6-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-6,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol

7-((3aS,4R,6aR)-6-(((tert-Butyldiphenylsilyl)oxy)methyl)-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)-4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (16.2 g, 23.6 mmol) was suspended in 1,4-dioxane (50 mL) and aqueous ammonia (28%, 50 mL), followed by heating with stirring at 100°C for 24 hours in a pressure-resistant container. After the solvent was distilled off, tetrahydrofuran (50 mL) was added to the residue, and tetrabutylammonium fluoride (a 1 M tetrahydrofuran solution, 47 mL) was added thereto with stirring at room temperature, followed by stirring at room temperature overnight. After the reaction solution was partitioned between ethyl acetate and water, the aqueous layer was separated, and

extracted with ethyl acetate. The organic layers were combined and washed with saturated saline, followed by distilling off the solvent. The residue was purified by silica gel column chromatography (developing solvent: methanol/chloroform), thereby obtaining the title compound (7.4 g) as a milky-white solid.

[0598]

¹H-NMR (DMSO-D₆) δ: 8.12 (1H, s), 7.18 (1H, s), 6.63 (2H, brs), 5.63-5.61 (1H, brm), 5.59-5.59 (1H, brm), 5.29 (1H, d, J = 5.5 Hz), 5.06 (1H, dd, J = 5.7, 5.5 Hz), 4.49 (1H, d, J = 5.9 Hz), 4.13 (2H, d, J = 5.9 Hz), 1.36 (3H, s), 1.25 (3H, s). LCMS (ESI) m/z 429 [M+H]⁺

Step 4: Synthesis of tert-butyl(((3aR,6R,6aS)-6-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-6,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methyl)sulfamoyl)carbamate

((3aR, 6R,6aS)-6-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-6,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol (100 mg, 0.233 mmol), tert-butyl sulfamoylcarbamate (60 mg, 0.30 mmol), and triphenylphosphine (92 mg, 0.35 mmol) were dissolved in tetrahydrofuran (1 mL). Then, diisopropyl azodicarboxylate (69 µL, 0.35 mmol) was added thereto dropwise with stirring at 0°C. After the reaction liquid was stirred for 3 hours under ice-cooling, methanol (1 mL) was added thereto, followed by stirring at room temperature for 10 minutes. The reaction liquid was concentrated, and the residue was purified by silica gel column chromatography (developing solvent: methanol/chloroform), thereby obtaining the title compound (60 mg) as a colorless amorphous substance.

[0599]

¹H-NMR (CDCl₃) δ: 8.22 (1H, s), 6.91 (1H, s), 6.36-6.07 (4H, brm), 5.81 (1H, brs), 5.69 (1H, brs), 5.32 (1H, d, J = 5.9 Hz), 4.66-4.52 (3H, m), 1.55 (9H, s), 1.48 (3H, s), 1.34 (3H, s). LCMS (ESI) m/z 607 [M+H]⁺

Step 5: Synthesis of example compound 128

tert-Butyl (((3aR,6R,6aS)-6-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-6,6a-dihydro-3aH-

cyclopenta[d][1,3]dioxol-4-yl)methyl)(sulfamoyl)carbamate (60 mg, 0.099 mmol), 2-ethynyl-1,3-difluorobenzene (27.3 mg, 0.198 mmol), bis(triphenylphosphine)palladium (II) dichloride (3.5 mg, 0.005 mmol), copper iodide (1 mg, 0.0053 mmol), and
5 diisopropylethylamine (0.034 mL, 0.19 mmol) were suspended in tetrahydrofuran (0.7 mL). After the reaction solution was stirred at 50°C for 1 hour, the reaction liquid was concentrated, and the residue was roughly purified by silica gel column chromatography (developing solvent: methanol/chloroform). The obtained residue
10 was dissolved at room temperature in acetonitrile (0.5 mL) and concentrated hydrochloric acid (0.2 mL), followed by stirring at room temperature overnight. After the reaction liquid was concentrated, the residue was purified by basic silica gel column chromatography (developing solvent: methanol/chloroform), thereby
15 obtaining the title compound (5.7 mg, 12%) as a white solid.

[0600]

¹H-NMR (CD₃OD) δ: 8.16 (1H, s), 7.56 (1H, s), 7.45-7.38 (1H, m), 7.11-7.05 (2H, m), 5.94 (1H, brs), 5.63 (1H, d, J = 5.5 Hz), 4.68 (1H, d, J = 5.5 Hz), 4.27 (1H, t, J = 5.5 Hz), 3.95 (1H, d, J =
20 16.5 Hz), 3.87 (1H, d, J = 16.5 Hz). LCMS (ESI) m/z 477 [M+H]⁺.

[0601]

Example 129

4-Amino-7-[(1R,4R,5S)-4,5-dihydroxy-3-
[(sulfamoylamino)methyl]cyclopent-2-en-1-yl]-5-[2-(2-ethoxy-6-
25 fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 5 of Example 128, except that 1-ethoxy-2-ethynyl-3-fluorobenzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0602]

¹H-NMR (CD₃OD) δ: 8.14 (1H, s), 7.45 (1H, s), 7.30 (1H, ddd, J = 8.8, 8.4, 6.6 Hz), 6.88 (1H, d, J = 8.4 Hz), 6.78 (1H, t, J = 8.8 Hz), 5.94 (1H, brs), 5.61 (1H, d, J = 4.8 Hz), 4.68 (1H, d, J = 5.5 Hz), 4.27 (1H, dd, J = 5.5, 4.8 Hz), 4.24 (2H, q, J = 7.0 Hz), 3.94 (1H, d, J = 16.1 Hz), 3.91 (1H, d, J = 16.1 Hz), 1.48 (3H, t,
35 J = 7.0 Hz). LCMS (ESI) m/z 503 [M+H]⁺.

[0603]

Example 130

4-Amino-7-[(1R,4R,5S)-4,5-dihydroxy-3-
[(sulfamoylamino)methyl]cyclopent-2-en-1-yl]-5-[2-(2-fluoro-6-
5 methylsulfanyl-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in step 5 of Example 128, except that 2-ethynyl-1-fluoro-3-methanesulfanyl-benzene was used in place of 2-ethynyl-1,3-difluorobenzene.

[0604]

10 ¹H-NMR (DMSO-D₆) δ: 8.17 (1H, s), 7.62 (1H, s), 7.41 (1H, ddd, J = 8.8, 8.8, 6.2 Hz), 7.15 (1H, d, J = 8.8 Hz), 7.11 (1H, t, J = 8.8 Hz), 6.80 (1H, t, J = 5.7 Hz), 6.64 (2H, s), 5.74 (1H, s), 5.56 (1H, brs), 5.10 (1H, d, J = 6.2 Hz), 5.01 (1H, d, J = 6.2 Hz), 4.48 (1H, t, J = 6.2 Hz), 4.11-4.06 (1H, m), 3.73-3.59 (2H, m),
15 2.55 (3H, s). LCMS (ESI) m/z 505 [M+H]⁺.

[0605]

Example 131

[(2R,3S,4R,5R)-5-[4-amino-5-(2-phenylethynyl)pyrrolo[2,3-
d]pyrimidin-7-yl]-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl
20 sulfamate

Step 1: Synthesis of ((3aR,4R,6R,6aR)-6-(4-amino-5-(phenylethynyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol

[(3aR,4R,6R,6aR)-4-(4-Amino-5-iodo-pyrrolo[2,3-
25 d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol (1 g, 2.3 mmol), phenylacetylene (354 mg, 3.5 mmol), bis(triphenylphosphine)palladium (II) dichloride (161 mg, 0.23 mmol), and copper iodide (44 mg, 0.23 mmol) were suspended in tetrahydrofuran (10 mL). Then, nitrogen purging was performed, and after diisopropylethylamine (0.78 mL, 4.6 mmol)
30 was added thereto, the reaction solution was stirred at 70°C for 2 hours. The reaction solution was filtered through a celite bed and washed with chloroform, followed by distilling off the solvent. The residue was purified by silica gel column
35 chromatography (developing solvent: ethyl acetate/hexane),

thereby obtaining the title compound (800 mg, 85%) as a yellow amorphous substance.

[0606]

¹H-NMR (CDCl₃) δ: 8.27 (1H, s), 7.51-7.49 (2H, m), 7.39-7.36 (3H, m), 7.27-7.25 (1H, m), 6.52 (1H, d, J = 10.7 Hz), 5.85-5.72 (2H, brs), 5.72 (1H, d, J = 5.1 Hz), 5.24 (1H, t, J = 5.5 Hz), 5.12-5.09 (1H, m), 4.52-4.50 (1H, brs), 4.00-3.96 (1H, m), 3.83-3.76 (1H, m), 1.64 (3H, s), 1.37 (3H, s). LCMS (ESI) m/z 407 [M+H]⁺
Step 2: Synthesis of ((3aR,4R,6R,6aR)-6-(4-amino-5-(phenylethynyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl sulfamate
((3aR,4R,6R,6aR)-6-(4-Amino-5-(phenylethynyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol (50 mg, 0.12 mmol) was dissolved in acetonitrile (0.5 mL). Then, triethylamine (0.084 mL, 0.59 mmol) was added thereto at room temperature, and sulfamoyl chloride (0.5 M acetonitrile solution, 0.27 mL) was added thereto in an ice bath. After the resulting mixture was stirred for 40 minutes in an ice bath, the solvent was distilled off. Then, chloroform and an aqueous sodium hydrogen carbonate solution were added thereto, and the aqueous layer was extracted with a liquid mixture of chloroform/methanol = 5/1. The organic layer was washed with saturated saline and dried over sodium sulfate, followed by distilling off the solvent. The residue was purified by silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining the title compound (39 mg, 67%) as a yellow amorphous substance.

[0607]

¹H-NMR (CDCl₃) δ: 8.29 (1H, s), 7.52-7.49 (2H, m), 7.37-7.36 (3H, m), 7.30 (1H, s), 6.08 (1H, d, J = 2.7 Hz), 5.72-5.68 (2H, brs), 5.35 (1H, dd, J = 6.3, 2.9 Hz), 5.13-5.11 (1H, m), 4.50-4.43 (3H, m), 1.62 (3H, s), 1.39 (3H, s). LCMS (ESI) m/z 486 [M+H]⁺

Step 3: Synthesis of example compound 131

((3aR,4R,6R,6aR)-6-(4-Amino-5-(phenylethynyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-

d][1,3]dioxol-4-yl)methyl sulfamate (380 mg, 0.79 mmol) was dissolved in tetrahydrofuran (4 mL), and a mixed solution (9.5 mL) of trifluoroacetic acid/water = 4/1 was added thereto, followed by stirring at room temperature for 8 hours. After the solvent was distilled off, methanol was added, and the solvent was distilled off again. The residue was purified by basic silica gel column chromatography (developing solvent: methanol/chloroform), thereby obtaining the title compound (323 mg, 92%) as a white powder.

[0608]

¹H-NMR (CD₃OD) δ: 8.15 (1H, s), 7.67 (1H, s), 7.55-7.52 (2H, m), 7.39-7.37 (3H, m), 6.22 (1H, d, J = 5.6 Hz), 4.90-4.80 (1H, m), 4.47-4.26 (4H, m). LCMS (ESI) m/z 446 [M+H]⁺.

[0609]

Example 132

[(2R,3S,4R,5R)-5-[4-Amino-5-[2-(2,6-difluorophenyl)ethynyl]pyrrolo[2,3-d]pyrimidin-7-yl]-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl sulfamate

The title compound was obtained as in Example 131, except that 2-ethynyl-1,3-difluorobenzene was used in place of phenylacetylene.

[0610]

¹H-NMR (DMSO-D₆) δ: 8.20 (1H, s), 7.97 (1H, s), 7.55-7.50 (1H, m), 7.31-7.25 (2H, m), 6.45-6.37 (2H, brs), 6.13 (1H, d, J = 5.9 Hz), 4.47-4.43 (1H, m), 4.28-4.23 (1H, m), 4.20-4.09 (5H, m). LCMS (ESI) m/z 482 [M+H]⁺.

[0611]

Example 133

[(2R,3S,4R,5R)-5-[4-Amino-5-[2-(1-naphthyl)ethynyl]pyrrolo[2,3-d]pyrimidin-7-yl]-3,4-dihydroxy-tetrahydrofuran-2-yl)methyl sulfamate

The title compound was obtained as in Example 131, except that 1-ethynyl-naphthalene was used in place of phenylacetylene.

[0612]

¹H-NMR (CD₃OD) δ: 8.41 (1H, d, J = 8.0 Hz), 8.19 (1H, s), 7.94-7.90 (2H, m), 7.86 (1H, s), 7.80 (1H, d, J = 4.0 Hz), 7.69-7.48 (3H, m), 6.29 (1H, d, J = 5.1 Hz), 4.87-4.80 (1H, m), 4.52-4.26 (4H, m). LCMS (ESI) m/z 496 [M+H]⁺.

5 [0613]

Example 134

[(2R,3S,5R)-5-[4-Amino-5-(2-phenylethynyl)pyrrolo[2,3-d]pyrimidin-7-yl]-3-hydroxy-tetrahydrofuran-2-yl]methyl sulfamate

The title compound was obtained as in Example 131,
10 except that (2R,3S,5R)-5-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol was used in place of [(3aR,4R,6R,6aR)-4-(4-amino-5-iodo-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol.

15 [0614]

¹H-NMR (CD₃OD) δ: 8.14 (1H, s), 7.67 (1H, s), 7.54-7.52 (2H, m), 7.39-7.36 (3H, m), 6.65 (1H, dd, J = 7.8, 6.1 Hz), 4.57-4.55 (1H, m), 4.32 (1H, dd, J = 11.0, 3.9 Hz), 4.29 (1H, dd, J = 11.0, 3.9 Hz), 4.18 (1H, dt, J = 3.2, 3.9 Hz), 2.60 (1H, ddd, J = 13.7, 7.8,
20 6.1 Hz), 2.39 (1H, ddd, J = 13.7, 6.1, 3.2 Hz). LCMS (ESI) m/z 430 [M+H]⁺.

[0615]

Example 135

[(2R,3S,5R)-5-[4-Amino-5-(1-benzylpyrazol-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-3-hydroxy-tetrahydrofuran-2-yl]methyl sulfamate
25 Step 1: Synthesis of (2R,3S,5R)-5-(4-amino-5-(1-benzyl-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol

(2R,3S,5R)-5-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol (100 mg,
30 0.265 mmol), tetrakis(triphenylphosphine)palladium(0) (15.3 mg, 0.013 mmol), and 1-benzyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (98 mg, 0.34 mmol) were suspended in a 2 M aqueous sodium carbonate solution (0.66 mL) and 1,2-dimethoxyethane (2 mL), followed by stirring at 100°C for 3 hours.
35

The reaction solution was partitioned between ethyl acetate and water, and the organic layer was washed with water, followed by concentration. The residue was purified by silica gel column chromatography (developing solvent: methanol/chloroform), thereby
5 obtaining the target product (66 mg, 61%) as a yellow oil.

[0616]

¹H-NMR (CDCl₃) δ: 8.18 (1H, brs), 7.59 (1H, s), 7.44 (1H, s),
7.38-7.32 (3H, m), 7.27-7.23 (2H, m), 6.90 (1H, s), 6.24 (1H, dd,
J = 8.8, 5.5 Hz), 5.42-5.38 (2H, m), 5.32 (2H, s), 4.71 (1H, d, J
10 = 4.0 Hz), 4.15 (1H, s), 3.91 (1H, d, J = 12.5 Hz), 3.75 (1H, d,
J = 12.5 Hz), 3.05-2.98 (1H, m), 2.25 (1H, dd, J = 12.8, 5.5 Hz).
LRMS (ESI) m/z 407 [M+H]⁺

Step 2: Synthesis of example compound 135

(2R,3S,5R)-5-(4-amino-5-(1-benzyl-1H-pyrazol-4-yl)-7H-
15 pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-
ol (53 mg, 0.13 mmol) was dissolved in acetonitrile (1 mL). Then,
1-aza-4-azoniabicyclo[2.2.2]octan-4-ylsulfonyl(tert-
butoxycarbonyl)azanido: 1,4-diazabicyclo[2.2.2]octane
monohydrochloride (Reference: Organic Letters, 2012, 10, 2626-
20 2629) (114 mg, 0.26 mmol) was added thereto at room temperature.
After the reaction solution was stirred at 40°C overnight,
trifluoroacetic acid (0.3 mL) was added to the reaction liquid,
followed by stirring at room temperature overnight. The reaction
solution was concentrated, and the residue was purified by silica
25 gel column chromatography (developing solvent:
methanol/chloroform), thereby obtaining the title compound (4.7
mg, 7%) as a milky-white solid.

[0617]

¹H-NMR (CD₃OD) δ: 8.12 (1H, s), 7.88 (1H, s), 7.69 (1H, s), 7.41
30 (1H, s), 7.37-7.28 (5H, m), 6.71 (1H, t, J = 7.0 Hz), 5.39 (2H,
s), 4.57-4.52 (1H, brm), 4.29-4.28 (2H, brm), 4.18-4.15 (1H, brm),
2.62-2.55 (1H, m), 2.39-2.35 (1H, m). LCMS (ESI) m/z 486 [M+H]⁺.

[0618]

Example 136

35 [(1R,2R,3S,4R)-4-[4-Amino-5-(1-benzylpyrazol-4-yl)pyrrolo[2,3-

d]pyrimidin-7-yl]-2,3-dihydroxy-cyclopentyl)methyl sulfamate

The title compound was obtained as in Example 135, except that ((3aR,4R,6R,6aS)-6-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-3aH-

5 cyclopenta[d][1,3]dioxol-4-yl)methanol was used in place of (2R,3S,5R)-5-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol.

[0619]

¹H-NMR (CD₃OD) δ: 8.10 (1H, s), 7.85 (1H, s), 7.66 (1H, s), 7.37-
10 7.21 (6H, m), 5.39 (2H, s), 5.07-4.98 (1H, m), 4.32 (1H, dd, J = 8.2, 5.7 Hz), 4.25 (2H, d, J = 4.9 Hz), 4.05 (1H, dd, J = 5.7, 3.5 Hz), 2.48-2.34 (2H, m), 1.82-1.76 (1H, m). LCMS (ESI) m/z 500 [M+H]⁺.

[0620]

15 Example 137

[(2R,3S,5R)-5-[4-Amino-5-[1-[(3,4-dimethylphenyl)methyl]pyrazol-4-yl]pyrrolo[2,3-d]pyrimidin-7-yl]-3-hydroxy-tetrahydrofuran-2-yl)methyl sulfamate

Step 1: Synthesis of 1-(3,4-dimethylbenzyl)-4-(4,4,5,5-

20 tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.0 g, 5.2 mmol), cesium carbonate (2.18 g, 6.7 mmol), and 3,4-dimethylbenzylchloride (0.98 mL, 6.7 mmol) were suspended in acetonitrile (10 mL). After the mixture was stirred at room
25 temperature overnight, the solid was filtered off through celite, and the filtrate was concentrated. The residue was purified by basic silica gel column chromatography (developing solvent: ethyl acetate/hexane), thereby obtaining the title compound (1.29 g, 80%) as a light-yellow oil.

30 [0621]

¹H-NMR (CDCl₃) δ: 7.80 (1H, s), 7.63 (1H, s), 7.14-6.97 (3H, m), 5.21 (2H, s), 2.25 (3H, s), 2.25 (3H, s), 1.29 (12H, s). LRMS (ESI) m/z 313 [M+H]⁺

Step 2: Synthesis of example compound 137

35 The title compound was obtained as in Example 135,

except that 1-(3,4-dimethylbenzyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole was used in place of 1-benzyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.

[0622]

5 ¹H-NMR (CD₃OD) δ: 8.12 (1H, s), 7.83 (1H, s), 7.66 (1H, s), 7.39 (1H, s), 7.11 (1H, d, J = 7.8 Hz), 7.09 (1H, s), 7.02 (1H, d, J = 7.8 Hz), 6.70 (1H, dd, J = 7.9, 6.2 Hz), 5.29 (2H, s), 4.57-4.52 (1H, m), 4.28 (2H, m), 4.16 (1H, m), 3.60 (1H, dd, J = 14.1, 7.1 Hz), 2.62-2.55 (1H, m), 2.40-2.34 (1H, m), 2.25 (3H, s), 2.23 (3H, s). LCMS (ESI) m/z 514 [M+H]⁺.

[0623]

Example 138

[(1R,2S,4R)-4-[4-Amino-5-[1-[(3,4-dimethylphenyl)methyl]pyrazol-4-yl]pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxy-cyclopentyl)methyl
15 sulfamate

Step 1: Synthesis of (1S,2R,4R)-4-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)cyclopentanol

The title compound was obtained as in step 2, step 5, and step 7 of Example 93, except that (1S,2R,4R)-4-amino-2-(hydroxymethyl)cyclopentanol was used in place of ((3aR,4R,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol.

[0624]

25 ¹H-NMR (DMSO-D₆) δ: 8.06 (1H, s), 7.54 (1H, s), 6.64 (2H, brs), 5.23-5.14 (1H, m), 4.73 (1H, brs), 4.61 (1H, brs), 4.01 (1H, m), 3.48-3.44 (1H, m), 3.41-3.36 (1H, m), 2.23-2.16 (1H, m), 2.08-2.01 (1H, m), 1.96-1.85 (2H, m), 1.58-1.50 (1H, m). LCMS (ESI) m/z 375 [M+H]⁺

Step 2: Synthesis of example compound 138

30 The title compound was obtained as in Example 135, except that (1S,2R,4R)-4-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)cyclopentanol and 1-(3,4-dimethylbenzyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole were used in place of (2R,3S,5R)-5-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-

(hydroxymethyl)tetrahydrofuran-3-ol and 1-benzyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.

[0625]

¹H-NMR (CD₃OD) δ: 8.10 (1H, s), 7.79 (1H, s), 7.64 (1H, s), 7.26
5 (1H, s), 7.10 (1H, d, J = 7.8 Hz), 7.09 (1H, s), 7.02 (1H, d, J =
7.8 Hz), 5.39-5.31 (1H, m), 5.29 (2H, s), 4.30-4.20 (3H, m),
2.53-2.46 (1H, m), 2.38-2.15 (3H, m), 2.24 (3H, s), 2.23 (3H, s),
1.87-1.79 (1H, m). LCMS (ESI) m/z 512 [M+H]⁺.

[0626]

10 Example 139

[(2R,3S,5R)-5-[4-Amino-5-[2-(o-tolyl)thiazol-4-yl]pyrrolo[2,3-
d]pyrimidin-7-yl]-3-hydroxy-tetrahydrofuran-2-yl)methyl sulfamate

The title compound was obtained as in Example 135,
except that 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(o-
15 tolyl)thiazole was used in place of 1-benzyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.

[0627]

¹H-NMR (CD₃OD) δ: 8.07 (1H, s), 8.04 (1H, s), 7.92 (1H, s), 7.67
(1H, d, J = 7.3 Hz), 7.42-7.36 (2H, m), 7.34-7.30 (1H, m), 6.75
20 (1H, t, J = 7.0 Hz), 4.62-4.59 (1H, m), 4.39 (1H, dd, J = 11.0,
3.2 Hz), 4.35 (1H, dd, J = 11.0, 3.2 Hz), 4.22 (1H, dd, J = 6.1,
3.2 Hz), 2.59-2.56 (1H, m), 2.56 (3H, s), 2.46-2.41 (1H, m). LCMS
(ESI) m/z 503 [M+H]⁺.

[0628]

25 Example 140

4-Amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-
ethylsulfonyl-6-fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine
Step 1: Synthesis of tert-butyl N-(((3aR,4R,6R,6aR)-6-(4-amino-5-
30 ((2-(ethylthio)-6-fluorophenyl)ethynyl)-7H-pyrrolo[2,3-
d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-
yl)methyl)sulfamoylcarbamate

tert-Butyl N-(((3aR,4R,6R,6aR)-6-(4-amino-5-iodo-7H-
pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-
35 d][1,3]dioxol-4-yl)methyl)sulfamoylcarbamate (39 mg, 0.064 mmol),

ethyl(2-ethynyl-3-fluorophenyl)sulfane (23 mg, 0.13 mmol), bis(triphenylphosphine)palladium (II) dichloride (4.5 mg, 0.0064 mmol), copper iodide (1.2 mg, 0.0064 mmol), and diisopropylethylamine (0.022 mL, 0.13 mmol) were suspended in tetrahydrofuran (1 mL). After the reaction solution was stirred at 50°C for 3 hours, the solvent was distilled off, and the residue was purified by silica gel column chromatography (developing solvent: methanol/chloroform), thereby obtaining the title compound (28 mg, 66%) as a yellow powder.

[0629]

¹H-NMR (CDCl₃) δ: 9.15 (1H, d, J = 8.1 Hz), 8.52 (1H, s), 7.31 (1H, s), 7.24-7.20 (1H, m), 7.06 (1H, d, J = 8.1 Hz), 6.91 (1H, t, J = 8.1 Hz), 6.74-6.59 (2H, brm), 5.68 (1H, d, J = 4.8 Hz), 5.30 (1H, dd, J = 6.2, 4.8 Hz), 5.11 (1H, dd, J = 6.2, 2.2 Hz), 4.51 (1H, d, J = 2.2 Hz), 3.72-3.66 (1H, m), 3.60 (1H, d, J = 12.8 Hz), 3.02 (3H, q, J = 7.3 Hz), 1.61 (3H, s), 1.45 (9H, s), 1.37 (3H, t, J = 7.3 Hz), 1.35 (3H, s).

Step 2: Synthesis of example compound 140

tert-Butyl N-(((3aR,4R,6R,6aR)-6-(4-amino-5-((2-(ethylthio)-6-fluorophenyl)ethynyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfamoylcarbamate (55 mg, 0.0829 mmol) was suspended with stirring under ice-cooling in 1,4-dioxane (0.5 mL) and water (0.5 mL) while oxone (102 mg, 0.166 mmol) was added thereto. After the reaction liquid was stirred at room temperature for 3 hours, the reaction solution was partitioned between ethyl acetate and water, and the organic layer was extracted. After the solvent was distilled off, acetonitrile (0.5 mL), water (0.1 mL), and trifluoroacetic acid (0.5 mL) were sequentially added to the residue, and the reaction solution was stirred at room temperature for 3 hours. The reaction liquid was concentrated, and the residue was purified by basic silica gel column chromatography (developing solvent: methanol/chloroform), thereby obtaining the title compound (20 mg) as a light-yellow solid.

[0630]

¹H-NMR (DMSO-D₆) δ: 8.16 (1H, s), 8.04 (1H, s), 7.82 (2H, d, J = 8.1 Hz), 7.77 (2H, t, J = 8.1 Hz), 7.70 (1H, dd, J = 8.1, 5.5 Hz), 7.35 (1H, dd, J = 7.7, 4.8 Hz), 6.58 (2H, s), 5.92 (1H, d, J = 7.0 Hz), 5.38 (1H, d, J = 6.2 Hz), 5.22 (1H, brs), 4.62-4.58 (1H, m), 4.09-4.07 (1H, brm), 4.05-4.02 (1H, m), 3.49 (2H, q, J = 7.3 Hz), 3.22-3.17 (1H, m), 3.14-3.06 (1H, m), 1.14 (3H, t, J = 7.3 Hz). LCMS (ESI) m/z 555 [M+H]⁺.

[0631]

10 Example 141

4-Amino-5-[2-(4-benzyloxy-2-methylsulfonyl-phenyl)ethynyl]-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-[(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidine
Step 1: (5-(Benzyloxy)-2-iodophenyl)(methyl)sulfane

15 The title compound was obtained as in step 1 of Example 76, except that 4-iodo-3-(methylsulfonyl)phenol was used in place of 2-bromopyrimidin-5-ol.

[0632]

¹H-NMR (CDCl₃) δ: 7.63 (1H, d, J = 8.6 Hz), 7.43-7.34 (5H, m), 6.74 (1H, d, J = 2.9 Hz), 6.51 (1H, dd, J = 8.6, 2.8 Hz), 5.06 (2H, s), 3.63 (3H, s). LCMS (ESI) m/z 356 [M+H]⁺

Step 2: Synthesis of (5-(benzyloxy)-2-ethynylphenyl)(methyl)sulfane

25 The title compound was obtained as in step 2 and step 3 of Example 76, except that (5-(benzyloxy)-2-iodophenyl)(methyl)sulfane was used in place of 5-(benzyloxy)-2-bromopyrimidine.

[0633]

¹H-NMR (CDCl₃) δ: 7.41-7.34 (6H, m), 6.76 (1H, d, J = 2.3 Hz), 6.69 (1H, dd, J = 8.4, 2.3 Hz), 5.08 (2H, s), 3.39 (1H, s), 2.45 (3H, s). LCMS (ESI) m/z 255 [M+H]⁺

Step 3: Synthesis of example compound 141

35 The title compound was obtained as in Example 140, except that (5-(benzyloxy)-2-ethynylphenyl)(methyl)sulfane was used in place of ethyl(2-ethynyl-3-fluorophenyl)sulfane.

[0634]

¹H-NMR (CD₃OD) δ: 8.20 (1H, s), 7.82 (1H, s), 7.73 (1H, d, J = 8.4 Hz), 7.67 (1H, d, J = 2.8 Hz), 7.47 (2H, d, J = 6.8 Hz), 7.42-7.32 (4H, m), 5.23 (2H, s), 5.05-4.95 (1H, m), 4.43-4.39 (1H, m),
5 4.03-4.00 (1H, m), 3.30 (3H, s), 3.27-3.12 (2H, m), 2.50-2.42 (1H, m), 2.32-2.28 (1H, m), 1.87-1.79 (1H, m). LCMS (ESI) m/z 627 [M+H].

[0635]

Example 142

10 4-Amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
[(sulfamoylamino)methyl]cyclopentyl]-5-[2-(2-ethylsulfonyl-6-fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in Example 140, except that tert-butyl N-(((3aR,4R,6R,6aS)-6-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methyl)sulfamoylcarbamate was used
15 in place of tert-butyl N-(((3aR,4R,6R,6aR)-6-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfamoylcarbamate.

20 [0636]

¹H-NMR (DMSO-D₆) δ: 8.13 (1H, s), 7.99 (1H, s), 7.81 (1H, d, J = 8.1 Hz), 7.76 (1H, t, J = 8.1 Hz), 7.68 (1H, dd, J = 8.1, 5.1 Hz), 6.63 (1H, t, J = 6.2 Hz), 6.50 (2H, s), 4.89 (2H, d, J = 7.0 Hz), 4.67 (1H, d, J = 4.4 Hz), 4.27-4.22 (1H, m), 4.08 (1H, q, J = 5.3
25 Hz), 3.79-3.76 (1H, m), 3.49 (2H, q, J = 7.3 Hz), 3.10-3.03 (1H, m), 2.94-2.87 (1H, m), 2.24-2.17 (1H, m), 2.12-2.06 (1H, m), 1.60-1.52 (1H, m), 1.14 (3H, t, J = 7.3 Hz). LCMS (ESI) m/z 553 [M+H]⁺.

[0637]

30 Example 143

4-Amino-5-[2-(2-ethylsulfonyl-6-fluoro-phenyl)ethynyl]-7-
[(2R,4S,5R)-4-hydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine

The title compound was obtained as in Example 140,
35 except that tert-butyl N-[[(2R,3S,5R)-5-(4-amino-5-iodo-

pyrrolo[2,3-d]pyrimidin-7-yl)-3-hydroxy-tetrahydrofuran-2-yl)methyl sulfamoyl]carbamate was used in place of tert-butyl N-(((3aR,4R,6R,6aR)-6-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)sulfamoylcarbamate.

[0638]

¹H-NMR (DMSO-D₆) δ: 8.18 (1H, s), 8.03 (1H, s), 7.87-7.83 (1H, m), 7.80-7.75 (1H, m), 7.73-7.68 (1H, m), 7.16 (1H, t, J = 5.9 Hz), 6.56 (2H, s), 6.43 (1H, dd, J = 8.7, 5.7 Hz), 4.37 (1H, brs), 3.97 (1H, dt, J = 2.0, 4.6 Hz), 3.50 (2H, q, J = 7.4 Hz), 3.20-3.14 (1H, m), 3.12-3.05 (1H, m), 2.71-2.62 (1H, m), 2.21-2.16 (1H, m), 1.15 (3H, t, J = 7.4 Hz). LCMS (ESI) m/z 539 [M+H]⁺.


[0639]

Comparative Example

N-[(1S)-1-indanyl]-7-[(1R)-3α-hydroxy-4α-(sulfamoyloxymethyl)cyclopentyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (MLN4924) was obtained by performing the synthesis in accordance with the method disclosed in Patent Document 1.

[0640]


20



[0641]













The following tables show the structural formulae of the example compounds of the present application.

[0642]














[0643]

Table 1

		X	Y	R ₁	R ₂	R ₃	R ₄	R ₅
Example 1	single	O	NH	OH	OH		bond	
Example 2	single	O	NH	OH	OH		bond	
Example 3	single	O	NH	OH	OH		bond	
Example 4	single	O	NH	OH	OH		bond	
Example 5	single	O	NH	OH	OH		bond	
Example 6	single	O	NH	OH	OH		bond	
Example 7	single	O	NH	OH	OH		-CH ₂ -	
Example 8	single	O	NH	OH	OH		bond	
Example 9	single	O	NH	OH	OH		bond	
Example 10	single	O	NH	OH	OH			











[0644]

Table 2

		X	Y	R ₁	R ₂	R ₃	R ₄	R ₅
Example 11	single	O	NH	OH	OH		bond	
Example 12	single	O	NH	OH	OH		bond	
Example 13	single	O	NH	OH	OH		bond	
Example 14	single	O	NH	OH	OH		bond	
Example 15	single	O	NH	OH	OH		bond	
Example 16	single	O	NH	OH	OH		bond	
Example 17	single	O	NH	OH	OH		bond	
Example 18	single	O	NH	OH	OH		bond	
Example 19	single	O	NH	OH	OH		bond	
Example 20	single	O	NH	OH	OH		bond	











[0645]

Table 3

	=====	X	Y	R ₁	R ₂	R ₃	R ₄	R ₅
Example 21	single	O	NH	OH	OH		bond	
Example 22	single	O	NH	OH	OH		bond	
Example 23	single	O	NH	OH	OH		bond	
Example 24	single	O	NH	OH	OH		bond	
Example 25	single	O	NH	OH	OH		bond	
Example 26	single	O	NH	OH	OH		bond	
Example 27	single	O	NH	OH	OH		bond	
Example 28	single	O	NH	OH	OH		bond	
Example 29	single	O	NH	OH	OH		bond	
Example 30	single	O	NH	OH	OH		bond	











[0646]

Table 4

	=====	X	Y	R ₁	R ₂	R ₃	R ₄	R ₅
Example 31	single	O	NH	OH	OH		-CH ₂ -	
Example 32	single	O	NH	OH	OH		bond	
Example 33	single	O	NH	OH	OH		bond	
Example 34	single	O	NH	OH	OH		bond	
Example 35	single	O	NH	OH	OH		bond	
Example 36	single	O	NH	OH	OH		-CH ₂ -	
Example 37	single	O	NH	OH	OH		bond	
Example 38	single	O	NH	OH	OH		bond	
Example 39	single	O	NH	OH	OH		bond	
Example 40	single	O	NH	OH	OH		bond	











[0647]

Table 5

	=====	X	Y	R ₁	R ₂	R ₃	R ₄	R ₅
Example 41	single	O	NH	OH	OH		bond	
Example 42	single	O	NH	OH	OH		bond	
Example 43	single	O	NH	OH	OH		bond	
Example 44	single	O	NH	OH	OH		bond	
Example 45	single	O	NH	OH	OH		bond	
Example 46	single	O	NH	OH	OH		bond	
Example 47	single	O	NH	OH	OH		bond	
Example 48	single	O	NH	OH	OH		bond	
Example 49	single	O	NH	OH	OH		bond	
Example 50	single	O	NH	OH	OH		-CH ₂ -	











[0648]

Table 6

		X	Y	R ₁	R ₂	R ₃	R ₄	R ₅
Example 51	single	O	NH	OH	OH		bond	
Example 52	single	O	NH	OH	OH		bond	
Example 53	single	O	NH	OH	OH		bond	
Example 54	single	O	NH	OH	OH		bond	
Example 55	single	O	NH	OH	OH		bond	
Example 56	single	O	NH	OH	OH		bond	
Example 57	single	O	NH	OH	OH		bond	
Example 58	single	O	NH	OH	OH		bond	
Example 59	single	O	NH	OH	OH		bond	
Example 60	single	O	NH	OH	OH		bond	











[0649]

Table 7

	-----	X	Y	R ₁	R ₂	R ₃	R ₄	R ₅
Example 61	single	O	NH	OH	OH		bond	
Example 62	single	O	NH	OH	OH		bond	
Example 63	single	O	NH	OH	OH		bond	
Example 64	single	O	NH	OH	OH		bond	
Example 65	single	O	NH	OH	OH		bond	
Example 66	single	O	NH	OH	OH		bond	
Example 67	single	O	NH	OH	OH		bond	
Example 68	single	O	NH	OH	OH		bond	
Example 69	single	O	NH	OH	OH		bond	
Example 70	single	O	NH	OH	OH		bond	










[0650]

Table 8

	=====	X	Y	R ₁	R ₂	R ₃	R ₄	R ₅
Example 71	single	O	NH	OH	OH		bond	
Example 72	single	O	NH	OH	OH		bond	
Example 73	single	O	NH	OH	OH		bond	
Example 74	single	O	NH	OH	OH		bond	
Example 75	single	O	NH	OH	OH		bond	
Example 76	single	O	NH	OH	OH		bond	
Example 77	single	O	NH	OH	OH		bond	
Example 78	single	O	NH	OH	OH		bond	
Example 79	single	O	NH	OH	OH		bond	
Example 80	single	O	NH	OH	OH		bond	











[0651]

Table 9

		X	Y	R ₁	R ₂	R ₃	R ₄	R ₅
Example 81	single	O	NH	OH	OH		bond	
Example 82	single	O	NH	OH	OH		bond	
Example 83	single	O	NH	OH	OH		bond	
Example 84	single	O	NH	OH	OH		bond	
Example 85	single	O	NH	OH	OH		bond	
Example 86	single	O	NH	OH	OH		bond	
Example 87	single	O	NH	OH	OH		bond	
Example 88	single	O	NH	OH	OH		bond	
Example 89	single	O	NH	OH	OH		bond	
Example 90	single	O	NH	OH	OH		bond	











[0652]

Table 10

	=====	X	Y	R ₁	R ₂	R ₃	R ₄	R ₅
Example 91	single	O	NH	OH	OH		bond	
Example 92	single	O	NH	OH	OH		bond	
Example 93	single	C	NH	OH	OH		bond	
Example 94	single	C	NH	OH	OH		bond	
Example 95	single	C	NH	OH	OH		bond	
Example 96	single	C	NH	OH	OH		bond	
Example 97	single	C	NH	OH	OH		bond	
Example 98	single	C	NH	OH	OH		bond	
Example 99	single	C	NH	OH	OH		bond	
Example 100	single	C	NH	OH	OH		bond	











[0653]

Table 11

	=====	X	Y	R ₁	R ₂	R ₃	R ₄	R ₅
Example 101	single	C	NH	OH	OH		bond	
Example 102	single	C	NH	OH	OH		bond	
Example 103	single	C	NH	OH	OH		bond	
Example 104	single	C	NH	OH	OH		bond	
Example 105	single	C	NH	OH	OH		bond	
Example 106	single	C	NH	OH	OH		bond	
Example 107	single	C	NH	OH	OH		bond	
Example 108	single	C	NH	OH	OH		bond	
Example 109	single	C	NH	OH	OH		bond	
Example 110	single	C	NH	OH	OH		bond	












[0654]

Table 12

	=====	X	Y	R ₁	R ₂	R ₃	R ₄	R ₅
Example 111	single	C	NH	OH	OH		bond	
Example 112	single	C	NH	OH	OH		bond	
Example 113	single	C	NH	OH	OH		bond	
Example 114	single	C	NH	OH	OH		bond	
Example 115	single	C	NH	OH	OH		bond	
Example 116	single	C	NH	OH	OH		bond	
Example 117	single	C	NH	OH	OH		bond	
Example 118	single	C	NH	OH	OH		bond	
Example 119	single	C	NH	OH	OH		bond	
Example 120	single	C	NH	OH	OH		bond	
















[0655]

Table 13

		X	Y	R ₁	R ₂	R ₃	R ₄	R ₅
Example 121	single	C	NH	OH	OH		bond	
Example 122	single	C	NH	OH	OH		bond	
Example 123	single	C	NH	OH	OH		bond	
Example 124	single	O	NH	OH	H		bond	
Example 125	single	O	NH	OH	H		bond	
Example 126	single	O	NH	OH	H		bond	
Example 127	single	O	NH	OH	H		bond	
Example 128	double	C	NH	OH	OH		bond	
Example 129	double	C	NH	OH	OH		bond	
Example 130	double	C	NH	OH	OH		bond	




[0656]

Table 14

		X	Y	R ₁	R ₂	R ₃	R ₄	R ₅
Example 131	single	O	O	OH	OH		bond	
Example 132	single	O	O	OH	OH		bond	
Example 133	single	O	O	OH	OH		bond	
Example 134	single	O	O	OH	H		bond	
Example 135	single	O	O	OH	H		-CH ₂ -	
Example 136	single	C	O	OH	OH		-CH ₂ -	
Example 137	single	O	O	OH	H		-CH ₂ -	
Example 138	single	C	O	OH	H		-CH ₂ -	
Example 139	single	O	O	OH	H		bond	
Example 140	single	O	NH	OH	OH		bond	

[0657]

Table 15

	-----	X	Y	R ₁	R ₂	R ₃	R ₄	R ₅
Example 141	single	C	NH	OH	OH		bond	
Example 142	single	C	NH	OH	OH		bond	
Example 143	single	O	NH	OH	H		bond	

[0658]

5 Test Example 1: Nedd8 conjugation inhibitory activity

A purified NAE (heterodimer of APPBP1 and UBA3) solution was prepared in the following manner. The human APPBP1 gene (NCBI Reference Sequence number: NM_003905) region corresponding to amino acids 1 to 534 of human APPBP1 protein

10 (NCBI Reference Sequence number: NP_003896, full length: 534 amino acids) was inserted in pBacPAK9 (produced by Clontech) to construct a plasmid pBacPAK9-APPBP1 for expressing APPBP1 full-length protein having a His tag and a TEV protease-recognition sequence at the N-terminus. Next, the human UBA3 gene (NCBI

15 Reference Sequence number: NM_003968) region corresponding to amino acids 1 to 463 of human UBA3 protein (NCBI Reference Sequence number: NP_003959, full length: 463 amino acids) was inserted in pBacPAK9 to construct a plasmid pBacPAK9-UBA3 for expressing UBA3 full-length protein. The pBacPAK9-APPBP1 or

20 pBacPAK9-UBA3, and BacPAK6 DNA were cotransfected into insect cells (Sf9, produced by Clontech) to produce a recombinant baculovirus containing APPBP1 or UBA3 gene. The APPBP1 gene recombinant baculovirus was mixed with the UBA3 gene recombinant baculovirus, and the resulting mixture was used to infect Sf9

25 cells. The baculovirus-infected Sf9 cells were incubated at 28°C with shaking for 72 hours in Grace's Insect Medium (produced by

Gibco), and the collected cells were suspended in a lysis buffer (50 mM Tris-HCl, 200 mM NaCl, and 10% glycerol (pH 7.4)), followed by sonication. The sonicated cell solution was centrifuged (40,000 x g, for 30 minutes) to obtain the supernatant as a crude extract. The crude extract was fractionated on a HisTrap HP column (produced by GE Healthcare) and a TALON Superflow column (produced by Clontech), followed by the addition of a TEV protease. Then, a His-tag cleavage reaction was performed at 4°C overnight. The resulting solution was subjected to TALON Superflow column chromatography, and the unadsorbed fraction was collected. This fraction was applied to a HiLoad 16/60 Superdex 75 prep grade column equilibrated with 50 mM Tris-HCl, 200 mM NaCl, and 10% glycerol (pH 7.4), and fractionated. A fraction containing an APPBP1/UBA3 complex was concentrated to obtain a purified NAE solution. The purification above was performed entirely at 4°C. The purified NAE solution was stored at -80°C until use.

[0659]

A purified GST-UBC12 solution was prepared in the following manner. The human UBC12 gene (NCBI Reference Sequence number: NM_003969) region corresponding to amino acids 1 to 183 of human UBC12 protein (NCBI Reference Sequence number: NP_003960, full length: 183 amino acids) was inserted in pGEX-4T-2 (produced by GE Healthcare) to construct a plasmid pGEX-UBC12 for expressing UBC12 full-length protein having a GST tag at the N-terminus. The pGEX-UBC12 was introduced into Escherichia coli (BL21 (DE3), produced by Stratagene), followed by culture at 37°C for 2 hours in the presence of 1 mM isopropyl-beta-D-thiogalactopyranoside (produced by Sigma-Aldrich). The collected Escherichia coli was suspended in PBS, followed by sonication. The sonicated cell solution was centrifuged (40,000 x g, for 5 minutes) to obtain the supernatant as a crude extract. A Glutathione Sepharose 4B carrier (produced by GE Healthcare) was added to the crude extract, and eluted with 50 mM Tris-HCl (pH 7.9), 150 mM NaCl, and a 10 mM reduced glutathione solution,

followed by dialysis with 50 mM HEPES (pH 7.5) and a 0.05% BSA solution to obtain a purified GST-UBC12 solution. The purified GST-UBC12 solution was divided and stored at -80°C until use.
[0660]

5 The Nedd8 conjugation inhibitory activity was measured using an AlphaScreen assay system. Each of the purified NAE solution and GST-UBC12 solution was diluted with an assay buffer (50 mM HEPES (pH 7.5), 5 mM MgCl₂, 1 mM DTT, 0.05% BSA) and added to a 384-well plate (#3673, produced by Corning) containing the
10 test compound. After reaction at room temperature for 30 minutes, a solution obtained by diluting ATP and Biotin-Nedd8 (produced by Boston Biochem) with the assay buffer was added thereto, followed by reaction for 90 minutes.
[0661]

15 Detection mix (50 mM HEPES (pH 7.5), 0.05% BSA, 0.04 mg/mL anti-GST Acceptor beads, 0.04 mg/mL Streptavidin Donor beads) (#6760603M, produced by Perkin Elmer) was added to each well in the same amount as that of the reaction solution. Then, after reaction in a dark place at room temperature for 1 hour,
20 the fluorescence intensity was measured using an EnVision (produced by Perkin Elmer) multilabel plate reader. The Neddylation inhibition rate (%) achieved by the compound of the present invention was determined by the equation (equation A) below using the fluorescence signal of a test compound-free group
25 as a positive control, and the fluorescence signal of the test compound- and ATP-free group as a negative control. The concentration at which the Nedd8 conjugation was reduced with the addition of each compound to 50% of the control was calculated (IC₅₀ (μM)) and used as a relative index of the Nedd8 conjugation
30 inhibitory activity.
[0662]

Inhibition rate (%) = $100 - (T-B)/(C-B) \times 100$ (equation A)

T: Signal in a well to which a test compound was added

C: Signal in a well to which a test compound was not added

35 B: Signal in a well to which a test compound and ATP were not

added

Table 16 below show the results.

[0663]

Table 16

	IC50 (μM)		IC50 (μM)		IC50 (μM)		IC50 (μM)
Example 1	≤0.0030	Example 42	0.0043	Example 75	≤0.0030	Example 114	≤0.0030
Example 2	0.0071	Example 43	0.0076	Example 76	0.0051	Example 115	0.004
Example 8	0.029	Example 44	0.029	Example 79	0.0032	Example 116	0.0051
Example 10	0.024	Example 46	0.013	Example 80	0.014	Example 117	0.0043
Example 11	0.0078	Example 47	0.0093	Example 81	0.0056	Example 118	0.0068
Example 16	0.0096	Example 49	0.018	Example 82	0.01	Example 119	0.0042
Example 17	0.0054	Example 51	0.0035	Example 83	0.019	Example 120	0.0043
Example 18	0.027	Example 52	0.008	Example 84	0.0097	Example 121	0.0062
Example 19	0.028	Example 54	0.0045	Example 86	0.0054	Example 122	0.02
Example 20	0.0091	Example 55	≤0.0030	Example 88	0.018	Example 123	0.0091
Example 21	0.015	Example 56	0.0053	Example 89	0.011	Example 127	0.019
Example 22	≤0.0030	Example 57	0.0058	Example 90	0.0056	Example 128	0.0033
Example 23	≤0.0030	Example 58	≤0.0030	Example 91	0.018	Example 129	≤0.0030
Example 24	≤0.0030	Example 59	0.0085	Example 94	0.021	Example 130	0.004
Example 25	0.0048	Example 60	0.0085	Example 95	0.013	Example 131	≤0.0030
Example 26	0.012	Example 61	0.0038	Example 96	0.0092	Example 132	≤0.0030
Example 29	0.0071	Example 62	0.016	Example 97	0.0088	Example 133	0.025
Example 30	0.027	Example 63	0.011	Example 98	0.0083	Example 134	0.018
Example 33	≤0.0030	Example 64	0.0094	Example 99	0.019	Example 136	0.012
Example 34	0.024	Example 66	0.0071	Example 101	0.0076	Example 137	0.019
Example 35	0.0041	Example 67	0.0085	Example 103	0.013	Example 138	0.0065
Example 37	0.011	Example 69	0.015	Example 104	0.0089	Example 139	0.017
Example 38	0.0035	Example 70	0.013	Example 106	0.028	Example 142	0.009
Example 39	≤0.0030	Example 71	0.014	Example 110	0.013	Example 143	0.024
Example 40	≤0.0030	Example 72	0.0044	Example 112	0.015	Comp. Example	0.033
Example 41	≤0.0030	Example 74	≤0.0030	Example 113	≤0.0030		

5

[0664]

These results show that the compounds of the present invention exhibited very excellent Nedd8 conjugation inhibitory activity, compared with the Comparative Example.

10

[0665]

Test Example 2: Cell growth inhibition 1

The ability of test compounds to inhibit cell growth was determined by quantifying ATP from viable cells using a CellTiter-Glo™ Luminescent Cell Viability Assay (#G7573, produced

by Promega, Inc.). The human acute T lymphoblastic leukemia CCRF-CEM cell lines (distributed by Dainippon Pharmaceutical Co., Ltd. (currently Sumitomo Dainippon Pharma Co., Ltd.)) were seeded in a 96-well plate (#165305, produced by Thermo Scientific Nunc) at a concentration of 1,000 cells/100 μ L medium per well. The cells were cultured in a 5% CO₂ incubator at 37°C overnight, and the test compound was added thereto, followed by culture for another 72 hours. A CellTiter-Glo™ Luminescent Cell Viability Assay reagent in an amount equal to the medium was added to each well, stirred for 5 minutes on a shaker under shading conditions, and then left to stand at room temperature for about 30 minutes. The luminescence intensity was measured using a microplate reader (EnSpire™ Multimode Plate Reader, produced by PerkinElmer Japan Co., Ltd.), and used as an index of the number of viable cells in each well. The cell growth inhibition rate (%) achieved by the compound of the present invention was determined by the following equation (equation B) by using the luminescence intensity of a drug untreated group (control) as a control. The concentration at which the number of cells are reduced with the addition of each compound to 50% of the control was calculated (IC₅₀ (μ M)).

[0666]

Inhibition rate (%) = (C-T)/C x 100 (equation B)

T: Luminescence intensity in a well to which a test compound was added

C: Luminescence intensity in a well to which a test substance was not added

Table 17 below shows the results.

[0667]

Table 17

	CCRF-CEM IC50 (μ M)		CCRF-CEM IC50 (μ M)
Example 1	0.0062	Example 66	0.0043
Example 24	0.0027	Example 70	0.015
Example 25	0.0017	Example 71	0.045
Example 29	0.004	Example 72	0.088
Example 31	0.6	Example 73	0.071
Example 32	2.5	Example 74	0.16

Example 33	0.037	Example 83	0.056
Example 34	0.0061	Example 84	0.23
Example 35	0.002	Example 85	0.038
Example 36	0.25	Example 86	0.0055
Example 37	0.006	Example 97	0.0031
Example 38	0.014	Example 98	0.0073
Example 39	0.0078	Example 120	0.035
Example 40	0.019	Example 122	0.0088
Example 43	0.0027	Example 123	0.097
Example 55	0.0022	Example 129	0.0021
Example 60	0.0051	Example 130	0.0032
Example 61	0.003	Example 132	0.0018
Example 64	0.0058	Comp. Example	0.089

[0668]

These results indicate that the compounds of the present invention inhibited the growth of human leukemia CCRF-CEM cell lines.

[0669]

Test Example 3: Carbonic anhydrase II enzyme activity inhibition

The carbonic anhydrase II enzyme activity inhibition was measured by measuring the esterase activity in which carbonic anhydrase II degrades 4-nitrophenyl acetate (4-NPA) (produced by Sigma-Aldrich). A purified carbonic anhydrase II solution (C6624, produced by Sigma-Aldrich) was diluted with an assay buffer (50 mM Tris-HCl (pH 7.5)) to 100 nM, and 50 μ L of the resulting solution was added to a 96-well plate (3695, produced by Costar) containing 40 μ L of the test substance. After reaction at room temperature for 10 minutes, 10 μ L of a 50 mM 4-NPA solution was added to each well, followed by incubation for 30 minutes at room temperature. The 50 mM 4-NPA solution was prepared by 10-fold dilution of a 500 mM 4-NPA solution, which was prepared at the time of use by dissolving the reaction product in DMSO, with the assay buffer. The absorbance at 405 nm was measured using a microplate reader (SpectraMax 250, produced by Molecular Devices). The activity level of the enzymatic hydrolysis reaction of ester was calculated using the following equation (equation C) by subtracting the absorbance in the well to which carbonic

anhydrase II was not added.

[0670]

Inhibition rate (%) = $100 - (T-B)/(C-B) \times 100$ (equation C)

T: Absorbance in a well to which a test compound was added

5 C: Absorbance in a well to which a test compound was not added

B: Absorbance in a well to which a test substance and carbonic anhydrase II were not added

Table 18 below shows the results.

[0671]

10 Table 18

	IC50 (μM)		IC50 (μM)
Example 1	>1.0	Example 60	>1.0
Example 2	>1.0	Example 61	0.79
Example 3	>1.0	Example 64	>1.0
Example 6	>1.0	Example 66	>1.0
Example 10	>1.0	Example 86	>1.0
Example 12	>1.0	Example 88	>1.0
Example 14	>1.0	Example 97	0.18
Example 24	0.4	Example 98	>1.0
Example 25	>1.0	Example 120	>1.0
Example 29	>1.0	Example 122	>1.0
Example 35	>1.0	Example 126	0.26
Example 36	>1.0	Example 127	0.34
Example 39	>1.0	Example 129	>1.0
Example 43	>1.0	Example 130	>1.0
Example 46	>1.0	Example 134	>1.0
Example 47	>1.0	Example 136	0.031
Example 49	>1.0	Example 138	0.12
Example 50	>1.0	Example 139	0.41
Example 52	>1.0	Example 143	>1.0
Example 55	>1.0	Comp. Example	0.012

[0672]

15 These results confirm that the compound of the Comparative Example exhibited inhibitory activity against carbonic anhydrase II, whereas the compounds of the Examples exhibited significantly reduced inhibitory activity.

[0673]

Test Example 4: Cell growth inhibition 2

The ability of test compounds to inhibit cell growth

was determined as in Test Example 2, except that the cell lines, the culture plate, and the number of cells seeded per well were as shown in Table 19. For the culture plate, a 384-well plate (#3571, produced by Corning) was used.

5 [0674]

Table 20 below shows the results.

[0675]

Table 19

Cell Name	Origin	Obtained from	Plate	Seeding number (per 1 well) (cells/ μ L medium)
HCT116	Colon cancer	ATCC	384 wells	250 cells/20 μ L
Capan-1	Pancreatic cancer	ATCC	384 wells	500 cells/20 μ L
A-427	Lung cancer	ATCC	384 wells	250 cells/20 μ L
MDA-MB-453	Breast cancer	ATCC	384 wells	500 cells/20 μ L
LNCaP.FGC	Prostate cancer	Dainippon Pharmaceutical Co., Ltd. (currently DS Parma Biomedical Co., Ltd.)	384 wells	500 cells/20 μ L
SJCRH30	Osteo- and soft tissue sarcoma	ATCC	384 wells	250 cells/20 μ L
U266B1	Multiple myeloma	ATCC	384 wells	3000 cells/20 μ L
A-431	Skin cancer	ATCC	384 wells	400 cells/20 μ L
MV-4-11	Acute leukemia	ATCC	384 wells	400 cells/20 μ L
DB	B-cell lymphoma	ATCC	384 wells	1500 cells/20 μ L

10 [0676]

Table 20

	HCT116	Capan-1	A-427	MDA-MB-453	LNCaP.FGC
Examples	IC50 (μ M)	IC50 (μ M)	IC50 (μ M)	IC50 (μ M)	IC50 (μ M)
1	0.016	0.73	0.022	0.46	0.65
25	0.0064	0.38	0.0054	0.48	0.5
55	0.012	0.87	0.007	0.094	0.26
130	0.012	0.21	0.0064	0.032	0.46
29	0.014	0.56	0.049	0.64	0.28
122	0.018	0.89	0.022	0.076	0.51
64	0.014	1.2	0.091	0.14	0.68
Comp. Example	0.089	1.5	0.18	1.9	0.41

	SJCRH30	U266B1	A-431	MV-4-11	DB
Examples	IC50 (μ M)	IC50 (μ M)	IC50 (μ M)	IC50 (μ M)	IC50 (μ M)
1	>10	0.11	0.73	0.021	0.26
25	5.1	0.22	0.12	0.011	0.12
55	0.55	0.031	0.48	0.0067	0.061
130	0.17	0.024	0.16	0.025	0.13
29	6.6	0.42	0.56	0.02	0.15
122	0.13	0.27	1.6	0.038	0.12

64	0.56	0.11	0.71	0.032	0.11
Comp. Example	>10	1.4	0.75	0.11	0.56

[0677]

According to the above results, these compounds of the present invention inhibited the growth of human colon cancer HCT116 cell line, human pancreatic cancer Capan-1 cell line, human lung cancer A-427 cell line, human breast cancer MDA-MB-453 cell line, human prostate cancer LNCAP.FGC cell line, human osteo- and soft tissue sarcoma SJCRH30 cell line, human multiple myeloma U266B1 cell line, human skin cancer A-431 cell line, human acute leukemia MV-4-11 cell line, and human diffuse large B-cell lymphoma DB cell line.

[0678]

Test Example 5: Antitumor effect on tumor cells transplanted into mice 1

Human colon cancer HCT-116 cell lines were washed in PBS and suspended at a concentration of 4×10^7 cells/mL. 0.1 mL of this cell suspension was subcutaneously implanted in the right chest of 6-week-old BALB/cAJcl-nu/nu mice (produced by CLEA Japan, Inc.).

[0679]

The length and the width of the implanted tumor and the body weight were measured. The tumor volume (TV) was calculated using the following equation (equation D).

[0680]

$TV \text{ (mm}^3\text{)} = (\text{length} \times \text{width}^2)/2$, wherein the unit of length and width is mm (equation D).

When the TV reached 100 to 300 mm³, the animals were assigned to each group in accordance with a stratified randomization procedure. The day was considered day 1, the TV on the day was considered TV1, and the body weight on the day was considered BW1.

[0681]

A required amount of the test compound was weighed to prepare an administration solution. The compound of Example 1 was intravenously administered in an amount of 5 mL per 1 kg of body weight on days 1, 4, 8, and 11, and the compound of the Comparative Example was intravenously administered in an amount of 10 mL per 1 kg of body weight on days 1, 4, 8, and 11.

[0682]

Thereafter, the length and the width of the tumor and the body weight (BW_n) on day n were measured over time in the same manner, and the TV_n of each mouse was calculated. Further, the relative tumor volume (RTV_n) was calculated based on the TV_n of each mouse using the following equation (equation E); the treatment/control (T/C) value (%) was calculated based on the mean RTV_n of each drug administration group using the following equation (equation F); and the weight change rate (BWC_n) was calculated using the following equation (equation G).

[0683]

$RTV_n = TV_n / TV_1$ (equation E)

$T/C_n(\%) = (\text{mean RTV of each drug administration group on the last day of the test}) / (\text{mean RTV of the control group on the last day of the test}) \times 100$ (equation F)

$BWC_n(\%) = (BW_n - BW_1) / BW_1 \times 100$ (equation G)

Figs. 1 and 2, and Table 21 below show the results.

[0684]

Table 21

Group	Dose (mg/kg/day)	Administration day	Number of mice	T/C15 (%)	BWC15 (%) Mean $\pm$ SD
Control	-	-	5	100	1.5 $\pm$ 3.7
Comp. Example	120	1,4,8,11	5	36	-14.3 $\pm$ 5.1
Example 1	50	1,4,8,11	5	23	-11.8 $\pm$ 4.7

[0685]

An RTV₁₅ comparison using Dunnett's test revealed that the RTV of the example compound and the comparative example compound was significantly lower than that of the control. Further, a comparison using Aspin-Welch's t-test revealed that the RTV of Example 1 was significantly lower than that of the

Comparative Example. The change of the body weight was within an acceptable degree, compared with the control.

[0686]

These results confirm the excellent tumor growth inhibitory effects of this compound of the present invention on human tumors.

[0687]

Test Example 6: Antitumor effect on tumor cells transplanted into mice 2

The tumor growth inhibitory effects on human tumors were evaluated as in Test Example 5, except that the hydrochloride compound obtained in Example 55 was used, and the animals were assigned to each group in accordance with a stratified randomization procedure when the TV reached 100 to 200 mm³.

[0688]

Figs. 3 and 4, and the following table (Table 22) show the results.

[0689]

Table 22

Group	Dose (mg/kg/day)	Administration day	Number of mice	T/C15 (%)	BWC15 (%) Mean $\pm$ SD
Control	-	-	5	100	0.9 $\pm$ 4.9
Comp. Example	120	1,4,8,11	5	51	-8.4 $\pm$ 3.2
Example 55	50	1,4,8,11	5	26	-11.0 $\pm$ 9.6

[0690]

An RTV15 comparison using Dunnett's test revealed that the RTV of the example compound and the comparative example compound was significantly lower than that of the control. Further, a comparison using Aspin-Welch's t-test revealed that the RTV of Example 55 was significantly lower than that of the Comparative Example. The change of the body weight was within an acceptable degree, compared with the control.

[0691]

These results confirm the excellent tumor growth inhibitory effects of this compound of the present invention on

human tumors.

[0692]

Test Example 7: Antitumor effect on tumor cells transplanted into mice 3

5 The tumor growth inhibitory effects on human tumors were evaluated as in Test Example 5, except that the compound hydrochloride obtained in Example 122, the compound hydrochloride (Example 64), and human acute lymphoblastic leukemia (ALL) CCRF-CEM cell lines were used, and the animals were assigned to each group in accordance with a stratified randomization procedure when the TV reached 140 to 380 mm³.

[0693]

 At this time, the cell lines were washed in PBS, and suspended in 50% PBS and 50% Matrigel basement membrane matrix (#356237; produced by BD Biosciences) at a concentration of 1 x 10⁸ cells/mL. 0.1 mL of this cell suspension was subcutaneously implanted to the right chest of 6-week-old BALB/cAJcl-nu/nu mice (nude mice) (produced by CLEA Japan, Inc.). The compound hydrochloride (Example 122) was intravenously administered in an amount of 5 mL per 1 kg of body weight on days 1 and 8, and the compound hydrochloride (Example 133) was intravenously administered in an amount of 5 mL per 1 kg of body weight on days 1 and 8. The administration solution of the Comparative Example was intravenously administered in an amount of 5 mL per 1 kg of body weight on days 1, 4, 8, and 11.

[0694]

Figs. 5 and 6, and Table 23 below show the results.

[0695]

Table 23

Group	Dose (mg/kg/day)	Administration day	Number of mice	T/C15 (%)	BWC15 (%) Mean ±SD
Control	-	-	5	100	7.8 ±3.2
Comp. Example	120	1,4,8,11	5	47	6.1 ±2.6
Example 64	50	1,8	5	8	4.1 ±1.6
Example 122	50	1,8	5	6	6.0 ±4.5

[0696]

An RTV comparison of Examples 120 and 133 was made using Dunnett's test on day 15. The results revealed that the RTV of Examples 120 and 133 on day 15 was significantly lower than that of the control. The change of the body weight was almost the same as that of the control.

[0697]

These results confirmed that these compounds of the Examples exhibited antitumor effects.

[0698]

An RTV15 comparison using Dunnett's test revealed that the RTV of the example compounds and the comparative example compound was significantly lower than that of the control. Further, the RTV of the compounds of Examples 122 and 64 was compared with the RTV of the compound of the Comparative Example using Dunnett's test. The results revealed that the RTV of Example 122 and Example 64 was significantly lower than that of the Comparative Example.

[0699]

These results confirm the excellent inhibitory effects of the compounds of the present invention on the growth of human tumors.

[0700]

It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.


[0701]

In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

CLAIMS

[Claim 1]

A compound or a salt thereof, represented by Formula (A) below:



wherein:

=====

is a single bond or a double bond;

X is -O-, -CH₂-, or -CH=;

Y is -NH- or -O-;

R₁ is hydrogen, fluorine, a hydroxy group, a cyano group, or an amino group;

R₂ is hydrogen, fluorine, a hydroxy group, a cyano group, or an amino group;

R₃ is a vinylene group, an ethynylene group, a C₆-C₁₄ arylene group, or a monocyclic or bicyclic heteroarylene group having at least one heteroatom selected from the group consisting of N, S, and O;

R₄ is a bond, a methylene group, or a C₃-C₇ cycloalkylidene group;

R₅ is a C₃-C₇ saturated cycloalkyl group that may have one or more R₆, a C₆-C₁₀ unsaturated cycloalkyl group that may

have one or more R_6 , or a monocyclic or bicyclic unsaturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more R_6 ;

5 R_6 is

halogen,

a hydroxy group,

a cyano group,

10 a C1-C6 alkyl group that may have one or more phenoxy group as a substituent,

a carbamoyl group,

a C1-C6 alkoxycarbonyl group,

15 a monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S, and O,

a monocyclic or bicyclic saturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more of either halogen, hydroxy group, carboxyl group, or C1-C6 alkyl group as a

20 substituent,

an amino group,

a mono- or di-(C1-C4 alkyl) amino group that may have one or more hydroxy group or phenyl group as a substituent,

25 a C1-C6 alkoxy group that may have one or more of either halogen, C3-C7 saturated cycloalkyl group, or monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S, and O as a substituent,

30 a benzyloxy group that may have one or more carbamoyl group as a substituent,

a C1-C6 alkylthio group,

a C1-C6 alkylsulfonyl group, or

an aminosulfonyl group,

35 when two or more R_6 are present, the plurality of R_6 may be the same or different.

[Claim 2]

The compound or a salt thereof according to Claim 1,
wherein in Formula (A), R₁ is hydrogen, fluorine, or a hydroxy
5 group;

R₂ is hydrogen, fluorine, or a hydroxy group; and

R₃ is an ethynylene group, or a monocyclic or bicyclic
heteroarylene group having 1 to 4 of at least one kind of
heteroatom selected from the group consisting of N, S, and O.

[Claim 3]

The compound or a salt thereof according to Claim 1 or
2, wherein in Formula (A), R₁ is a hydroxy group;

R₂ is hydrogen or a hydroxy group;

15 R₃ is an ethynylene group, or a monocyclic
heteroarylene group having 2 of at least one kind of heteroatom
selected from the group consisting of N, S and O;

R₅ is a C3-C7 saturated cycloalkyl group that may have
one or more R₆, a C6-C10 unsaturated cycloalkyl group that may
20 have one or more R₆, or a monocyclic or bicyclic unsaturated
heterocycloalkyl group that has at least one heteroatom selected
from the group consisting of N, S, and O, and that may have one
or more R₆; and

R₆ is halogen; a hydroxy group; a cyano group; a C1-C6
25 alkyl group that may have one or more phenoxy group as a
substituent; a carbamoyl group; a C1-C6 alkoxy carbonyl group; a
monocyclic or bicyclic unsaturated heterocycloalkyl group having
at least one heteroatom selected from the group consisting of N,
S and O; a monocyclic or bicyclic saturated heterocycloalkyl
30 group that has at least one heteroatom selected from the group
consisting of N, S, and O, and that may have one or more of
either halogen, hydroxy group, carboxyl group, or C1-C6 alkyl
group as a substituent; an amino group; a mono- or di-(C1-C4
alkyl) amino group that may have one or more hydroxy group or
35 phenyl group as a substituent; a C1-C6 alkoxy group that may have

one or more of either halogen, C3-C7 saturated cycloalkyl group, or monocyclic or bicyclic unsaturated heterocycloalkyl group having at least one heteroatom selected from the group consisting of N, S, and O as a substituent; a benzyloxy group that may have
5 one or more carbamoyl group as a substituent; a C1-C4 alkylthio group; a C1-C4 alkylsulfonyl group; or an aminosulfonyl group (when two or more R₆ are present, the plurality of R₆ may be the same or different).

10 [Claim 4]

A compound or a salt thereof according to any one of Claims 1 to 3, wherein, in Formula (A), R₁ is a hydroxy group;

R₂ is hydrogen or a hydroxy group;

R₃ is an ethynylene group, or a monocyclic
15 heteroarylene group having 2 of at least one kind of heteroatom selected from the group consisting of N, S and O;

R₅ is a C3-C7 saturated cycloalkyl group that may have one or more R₆; a C6-C10 unsaturated cycloalkyl group that may have one or more R₆, or a monocyclic or bicyclic unsaturated
20 heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S, and O, and that may have one or more R₆; and

R₆ is fluorine; chlorine; a hydroxy group; a cyano group; a C1-C6 alkyl group that may have one or more phenoxy
25 group as a substituent; a carbamoyl group; a C1-C6 alkoxy carbonyl group; a pyridinyl group; an azetidiny group; a hydroxy azetidiny group; a thiomorpholinyl group; a dioxide thiomorpholinyl group; a methyl piperazinyl group; a hydroxy piperidinyl group; an oxopiperidinyl group; a piperidinyl group;
30 a hydroxy pyrrolidinyl group; an oxopyrrolidinyl group; a pyrrolidinyl group; a carboxyl pyrrolidinyl group; a fluoro pyrrolidinyl group; a morpholinyl group; a 9-oxa-3-azabicyclo[3.3.1]nonan-3-yl group; a 3-oxa-8-azabicyclo[3.2.1]octan-8-yl group; an amino group; a methylamino
35 group; an ethylamino group; an isopropylamino group; a

hydroxyethylamino group; a dimethylamino group; a phenyl
methylamino group; a C1-C6 alkoxy group that may have one or more
of either halogen, C3-C7 saturated cycloalkyl group, or
monocyclic or bicyclic unsaturated heterocycloalkyl group having
5 at least one heteroatom selected from the group consisting of N,
S, and O as a substituent; a benzyloxy group that may have one or
more carbamoyl group as a substituent; a C1-C4 alkylthio group; a
C1-C4 alkylsulfonyl group; or an aminosulfonyl group (when two or
more R₆ are present, the plurality of R₆ may be the same or
10 different).

[Claim 5]

A compound or a salt thereof according to Claims 1 to
4, wherein, in Formula (A), R₁ is a hydroxy group;

15 R₂ is a hydroxy group;

R₃ is an ethynylene group;

R₄ is a bond;

R₅ is a C6-C10 unsaturated cycloalkyl group that may
have one or more R₆; or a monocyclic or bicyclic unsaturated
20 heterocycloalkyl group that has at least one heteroatom selected
from the group consisting of N, S, and O, and that may have one
or more R₆; and

R₆ is fluorine; chlorine; a hydroxy group; a cyano
group; a methyl group; a 3-fluoro pyrrolidinyl group; a
25 morpholinyl group; a thiomorpholinyl group; a 3-hydroxy
azetidiny group; an azetidiny group; an amino group; a N-
methylamino group; a C1-C6 alkoxy group that may have one or more
of either halogen or C3-C7 saturated cycloalkyl group as a
substituent; or a C1-C4 alkylthio group (when two or more R₆ are
30 present, the plurality of R₆ may be the same or different).

[Claim 6]

A compound or a salt thereof according to Claims 1 to
5, wherein in Formula (A), Y is -NH-;

35 R₁ is a hydroxy group;

R₂ is a hydroxy group;

R₃ is an ethynylene group;

R₄ is a bond;

5 R₅ is a phenyl group or a naphthyl group that may have one or more R₆; or a monocyclic or bicyclic unsaturated heterocycloalkyl group that has at least one heteroatom selected from the group consisting of N, S and O, and that may have one or more R₆;

10 R₆ is fluorine; a methyl group; a 3-fluoro pyrrolidinyl; a 3-hydroxy azetidiny; azetidiny; an amino group; a N-methylamino group; a C1-C6 alkoxy group that may have one or more cyclopropyl group; or a C1-C4 alkylthio group (when two or more R₆ are present, the plurality of R₆ may be the same or different).

15

[Claim 7]

The compound or a salt thereof according to any one of Claims 1 to 6, wherein the compound or a salt thereof is at least one member selected from the group consisting of: 4-amino-5-[2-
20 (2,6-difluoro phenyl)ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine;
4-amino-5-[2-(4-amino-2,6-difluoro-phenyl)ethynyl]-7-
[(2R,3R,4S,5R)-3,4-dihydroxy-5-
25 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine;
4-amino-5-[2-[2,6-difluoro-4-(methylamino)phenyl]ethynyl]-7-
[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
30 d]pyrimidine;
4-amino-5-[2-[2,6-difluoro-4-[(3R)-3-fluoro pyrrolidin-1-yl]phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
[(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-
d]pyrimidine;
35 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-

- [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-ethoxy-4,6-difluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
4-amino-5-[2-[2,6-difluoro-4-(3-hydroxy azetidin-1-yl)phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
- 5 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine;
4-amino-5-[2-[4-(azetidin-1-yl)-2,6-difluoro-phenyl]ethynyl]-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
- 10 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine;
4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
- [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-ethoxy-6-fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
- 15 [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-fluoro-6-propoxy-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
8-[2-[4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
- [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-7-fluoro-4-methyl-2,3-dihydro-1,4-
- 20 benzoxazine;
4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-
- [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]-5-[2-(2-ethylsulfanyl-6-fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
4-amino-5-[2-[2-(cyclopropyl methoxy)-6-fluoro-phenyl]ethynyl]-7-
- 25 [(2R,3R,4S,5R)-3,4-dihydroxy-5-
- [(sulfamoylamino)methyl]tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine;
4-amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
- [(sulfamoylamino)methyl]cyclopentyl]-5-[2-(2-fluoro-6-methylsulfanyl-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine;
- 30 8-[2-[4-amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-
- [(sulfamoylamino)methyl]cyclopentyl]pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-7-fluoro-4-methyl-2,3-dihydro-1,4-benzoxazine;
4-amino-7-[(1R,4R,5S)-4,5-dihydroxy-3-
- 35 [(sulfamoylamino)methyl]cyclopent-2-en-1-yl]-5-[2-(2-ethoxy-6-

fluoro-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine; and
4-amino-7-[(1R,4R,5S)-4,5-dihydroxy-3-
[(sulfamoylamino)methyl]cyclopent-2-en-1-yl]-5-[2-(2-fluoro-6-
methylsulfanyl-phenyl)ethynyl]pyrrolo[2,3-d]pyrimidine; and salts
5 of these compounds.

[Claim 8]

An NAE inhibitor comprising the compound or a salt
thereof according to any one of Claims 1 to 7, as an active
10 ingredient.

[Claim 9]

A pharmaceutical composition comprising the compound
or a salt thereof according to any one of Claims 1 to 7.
15

[Claim 10]

An antitumor agent comprising the compound or a salt
thereof according to any one of Claims 1 to 7.

20 [Claim 11]

A method of inhibiting NAE in a patient comprising
administering the compound or a salt thereof according to any one
of Claims 1 to 7 to the patient.

25 [Claim 12]

Use of the compound or a salt thereof according to any
one of Claims 1 to 7 in the preparation of a medicament for
inhibiting NAE.

30 [Claim 13]

A method for preventing or treating a tumor by
inhibiting NAE in a patient comprising administering the compound
or a salt thereof according to any one of Claims 1 to 7 to the
patient.
35

[Claim 14]

Use of the compound or a salt thereof according to any one of Claims 1 to 7 in the preparation of a medicament for preventing or treating a tumor by inhibiting NAE.

5

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

